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Research	  rationale	  	  
Background	  	  
In	  the	  course	  of	  the	  twentieth	  century,	  the	  ethical	  and	  regulatory	  stance	  towards	  medical	  
experiments	   involving	   children	  has	   changed	  dramatically.1	  Where	   initially	   the	   successes	  of	  
medical	   science	   had	   created	   a	   strong	   trust	   in	   the	   biomedical	   enterprise,	   the	   scandalous	  
research	   events	   that	   occurred	   during	   the	   Second	  World	  War	   and	   in	   its	   aftermath	   raised	  
considerable	  suspicion	  about	  the	  ethical	  acceptability	  of	  clinical	  research.	   In	  particular,	   the	  
discussion	   on	   the	   acceptability	   of	   conducting	   clinical	   research	   in	   vulnerable	   children	   has	  
provoked	   harsh	   controversy,2-­‐4	   since	   diverging	   standpoints	   have	   been	   defended	   by	  
prominent	  ethicists.5	  	  
The	  predicament	  	  
While	   medical	   ethicists	   quested	   for	   an	   appropriate	   ethical	   stance	   towards	   pediatric	  
clinical	   research,	   an	   overall	   reluctance	   to	   involve	   minors	   in	   clinical	   research	   rendered	  
innovations	  in	  the	  field	  of	  pediatric	  drug	  development	  scarce.	  As	  a	  result,	  a	  stringent	  lack	  of	  
licensed	   drugs	   that	   are	   labeled	   for	   pediatric	   use	   is	   tangible	   in	   pediatric	   practice	   to	   date,	  
resulting	  in	  a	  high	  rate	  of	  off-­‐label	  prescriptions.6-­‐9	  This	  predicament,	  however,	  cannot	  just	  
be	  attributed	  to	  a	  lack	  of	  consensus	  in	  the	  field	  of	  medical	  ethics.	  Quite	  the	  reverse,	  diverse	  
and	  complex	  causes,	  many	  of	  which	  are	  far	  removed	  from	  the	  work	  of	  bioethicists,	  render	  
pediatric	  clinical	  research	  a	  precarious	  enterprise.	  These	  causes	  can	  be	  related	  to	  individual	  
persons,	  and	  the	  pediatric	  population	  at	  large.	  	  
At	  the	  personal	   level,	  significant	  differences	  between	  minors	  and	  adults	  exist.	  Physically,	  
minors	  are	  not	  small	  adults	  because	  of	  major	  differences	  in	  the	  composition	  and	  functioning	  
of	  the	  body.	  This	  renders	  it	  impossible	  to	  extrapolate	  research	  data	  that	  have	  been	  obtained	  
in	  competent	  adults	  to	  the	  population	  of	  minors	  in	  a	  reliable	  way	  (e.g.,	  by	  dose	  recalculation	  
based	  on	  body	  weight	  or	  skin	  surface).10	  11	  Also	  psychologically,	  many	  differences	  between	  
minors	   and	   adults	   exist,	   for	   example	   with	   regard	   to	   understanding	   and	   maturity.	   At	   the	  
population	  level,	  at	  least	  four	  factors	  make	  that	  pediatric	  clinical	  research	  requires	  a	  specific	  
approach	  of	   scientific,	   ethical,	   legal,	   social,	   and	  economical	   issues.	   First,	   the	  population	  of	  
minors	  is	  relatively	  small	  and	  very	  heterogeneous,12	  which	  may	  complicate	  the	  recruitment	  
of	  an	  adequate	  number	  of	  eligible	   research	   subjects.13	   14	   In	  addition,	   the	   small	  population	  
indicates	   a	   small	   market,	   rendering	   the	   return	   on	   investment	   of	   pediatric	   clinical	   trials	  
uncertain	  under	  the	  regular	  market	  conditions.15	  Second,	  a	  number	  of	  diseases	  only	  occur	  in	  
minors,	  or	  prompt	  for	  diagnosis,	  prevention	  or	  treatment	  in	  early	  childhood	  (e.g.,	  in	  the	  case	  
of	  chronic	  diseases	  the	  pathology	  of	  which	  increases	  over	  time).	  In	  addition,	  children	  may	  be	  
in	  need	  of	  specific	  administration	  forms,	  different	  from	  those	  available	  to	  adults	  (e.g.,	  liquid	  
solution	   in	  stead	  of	  tablets).	  Third,	  pediatric	  clinical	  trials	  require	  specific	  research	  designs,	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including	   specific	   normal	   values	   and	   specific	   endpoints.	   Fourth,	   unique	   ethical,	   legal,	   and	  
social	   issues	   arise	   when	   minors	   are	   enrolled	   in	   clinical	   studies.	   In	   this	   respect,	   the	  
vulnerability	   of	   minors	   as	   a	   population	   has	   been	   emphasized	   strongly,	   and	   the	   ethical	  
acceptability	  of	  enrolling	  minors	  in	  clinical	  studies	  has	  been	  debated	  fiercely.	  
Because	   of	   the	   differences	   between	   minors	   and	   adults,	   both	   as	   persons	   and	   as	  
populations,	  there	  exists	  an	  unequivocal	  need	  to	  conduct	  clinical	  research	  in	  the	  population	  
of	   minors.	   Although	   Harry	   Shirkey	   reported	   already	   in	   1968	   that	   in	   absence	   of	   pediatric	  
clinical	   research	   minors	   would	   be	   turned	   into	   ‘therapeutic	   orphans’,16	   pediatric	   patients	  
have	   been	   ignored	   in	   clinical	   research	   for	   long	   and	   systematic	   efforts	   to	   encourage	   the	  
inclusion	  of	  minors	   in	  clinical	   studies	  only	  came	  decades	   later.17	   18	  Today,	   the	  urgent	  need	  
for	  pediatric	  clinical	  research	  in	  the	  population	  of	  minors	  continues	  to	  exist,	  even	  though	  it	  
has	   been	   generally	   recognized	   that	   pediatric	   clinical	   trials	   are	   indispensible	   to	   provide	  
minors	  with	  a	  gamut	  of	  safe	  and	  efficacious	  drugs	  that	  is	  equitable	  to	  that	  available	  to	  their	  
adult	  counterparts.	  In	  addition,	  the	  important	  differences	  between	  adults	  and	  minors	  make	  
that	  paradigms	  of	  clinical	  research,	  research	  ethics	  and	  research	  regulation	  that	  are	  grafted	  
on	   the	   competent	   adult	   do	   not	   adequately	   respond	   to	   the	   specifics	   of	   pediatric	   clinical	  
research.	  Therefore,	  specific	  attention	  must	  be	  paid	  to	  the	  ethical,	  legal,	  and	  social	  issues	  in	  
pediatric	  clinical	  research.	  In	  other	  words:	  one	  size	  does	  not	  fit	  all.	  
State	  of	  the	  art	  
Medical	  Ethics	  
Ethical	   refection	   frequently	   tends	   to	   focus	   on	   a	   canonical	   list	   of	   ethical	   issues	   that	   are	  
discussed	  in	  depth	  in	  literature.	  These	  discussions	  range	  from	  the	  exploration	  of	  conceptual	  
and	  semantic	  niceties	  to	  empirical-­‐ethical	  studies.	  Also	  with	  regard	  to	  the	  ethical,	  legal,	  and	  
social	   issues	   in	   pediatric	   research,	   a	   canonical	   list	   of	   ethical	   issues	   can	   easily	   be	   drafted.	  
Among	  others,	  such	  a	  list	  would	  definitely	  include	  the	  issues	  of	  (1)	  informed	  consent,	  assent,	  
and	  dissent,19-­‐25	   (2)	   the	  protection	  of	  vulnerable	  research	  subjects,1	   (3)	   risk	   thresholds,26-­‐29	  
and	  the	  (4)	  the	  payment	  of	  research	  subjects.30-­‐32	  	  
Notwithstanding	   the	   validity	   of	   canonical	   issues	   in	   pediatric	   research	   conduct,	   various	  
unique	   and	   important	   issues	   in	   pediatric	   clinical	   research	   exceed	   the	   traditional	   canonical	  
lists	  of	  ethical	  issues	  and	  have	  not	  or	  only	  insufficiently	  been	  addressed	  in	  literature	  thus	  far.	  
Other	   issues	   have	   been	   addressed	   extensively,	   but	   remain	   in	   search	   of	   an	   adequate	   and	  
realistic	  approach.	  	  
Health	  Law	  	  
In	  the	  course	  of	  the	  past	  two	  decades,	   important	  efforts	  have	  been	  made	  to	  encourage	  
the	   conduct	   of	   clinical	   research	   in	  minors.	   In	   the	   European	  Union,	   the	   establishment	   of	   a	  
harmonized	  legal	  framework	  to	  regulate	  the	  conduct	  of	  clinical	  research	  across	  the	  borders	  
of	  individual	  member	  states	  has	  been	  a	  milestone	  in	  this	  process.18	  33-­‐38	  The	  regulation	  that	  
currently	  governs	  pediatric	  clinical	   research,	  however,	   covers	   several	   legal	   systems	  and	  no	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less	   than	   22	   languages,	   which	   renders	   this	   legal	   framework	   difficult	   to	   access	   and	  
understand.	  In	  addition,	  diverse	  regulations,	  which	  have	  been	  issued	  by	  multiple	  legislative	  
bodies,	   coexist	   within	   the	   European	   legal	   landscape.	   As	   a	   result,	   the	   European	   legal	  
framework	   hosts	   a	   considerable	   diversity	   in	   its	   provisions,	   the	   clarity	   and	   consistency	   of	  
which	  have	  not	  been	  investigated	  properly	  to	  date.	  
Good	  clinical	  practice	  in	  pediatric	  research	  conduct	  
Pediatric	   clinical	   research	   must	   comply	   with	   ethical	   and	   regulatory	   requirements.	  
However,	   the	   ethical	   and	   regulatory	   frameworks	   that	   govern	   pediatric	   clinical	   research	   in	  
the	  EU	  are	  not	  ready	  to	  use	  instruments	  that	  can	  be	  implemented	  effortlessly	  into	  pediatric	  
research	  practice.	  Quite	  the	  reverse,	  it	  is	  to	  be	  expected	  that	  the	  applicable	  ethical	  and	  legal	  
requirements	  will	  sometimes	  prove	  hard	  to	  implement	  in	  clinical	  practice,	  given	  the	  need	  for	  
extensive	  interpretation	  and	  the	  potential	  for	  unclear	  or	  contradictory	  provisions.	  	  
To	  date,	  little	  is	  known	  about	  how	  ethical	  and	  regulatory	  requirements	  for	  the	  conduct	  of	  
pediatric	   clinical	   research	   are	   actually	   implemented	   into	   practice	   in	   EU	  member	   states.	   In	  
addition,	   it	   is	   not	   clear	   to	   what	   extent	   the	   current	   ethical	   and	   regulatory	   frameworks	  
respond	  to	  the	  major	  ethical	  issues	  that	  medical	  practitioners	  experience	  when	  they	  conduct	  
clinical	  research	  in	  the	  population	  of	  minors.	  	  
Objectives	  	  
Four	   research	   objectives	   are	   central	   to	   this	   dissertation:	   (1)	   the	   improvement	   of	   the	  
access	   to	   and	   insight	   in	   the	   European	   legal	   frameworks	   that	   govern	   pediatric	   clinical	  
research;	  (2)	  the	  comparative	  analysis	  of	  relevant	  regulation	  at	  the	  supranational	   level	  and	  
at	  the	  national	  level;	  (3)	  the	  enquiry	  of	  the	  operational	  implementation	  of	  legal	  good	  clinical	  
practice	   requirements	   in	   informed	   consent	   discussions;	   and	   (4)	   the	   ethical	   analysis	   of	  
specific	  issues	  in	  pediatric	  clinical	  research.	  	  
Improving	  the	  access	  to	  and	  insight	  in	  the	  European	  legal	  frameworks	  that	  govern	  pediatric	  
clinical	  research	  
Map	   the	   regulation	   governing	   pediatric	   clinical	   research	   in	   the	   EU,	   both	   at	   the	  
supranational	   level	   and	   at	   the	   level	   of	   individual	   EU	   Member	   States.	  	  
List,	  analyze,	  and	  address	  contingencies,	  inconsistencies,	  and	  contradictory	  provisions	  in	  the	  
European	  legal	  framework.	  	  
Comparative	  analysis	  of	  relevant	  regulation	  	  
Comparative	   analysis	   of	   the	   regulation	   governing	   pediatric	   clinical	   research	   at	   the	  
supranational	   level	   and	   at	   the	   level	   of	   individual	   EU	   member	   states.	   Identification	   and	  
analysis	  of	  unclear	  elements,	  inconsistencies,	  and	  contradictory	  provisions.	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Enquiry	   of	   the	   operational	   implementation	   of	   ethical	   and	   legal	   requirements	   in	   informed	  
consent	  discussions	  in	  clinical	  research	  
Explore	  and	  discuss	  the	  operational	  implementation	  of	  ethical	  and	  legal	  requirements	  in	  
pediatric	   clinical	   research.	   Discuss	   the	   adequacy	   of	   existing	   ethical	   and	   regulatory	  
frameworks	  to	  address	  the	  ethical	  issues	  that	  minors,	  their	  parents,	  and	  clinicians	  encounter	  
when	  minors	  are	  enrolled	  in	  clinical	  studies.	  	  
Ethical	  analysis	  of	  specific	  issues	  in	  pediatric	  clinical	  research	  
Identify	   and	   analyze	   specific	   ethical	   issues	   in	   the	   conduct	   of	   pediatric	   research.	  
Compound	  an	  inventory	  of	  key	  ethical	  issues	  that	  are	  either	  novel	  or	  in	  continuing	  search	  for	  
consensus.	   Analyze	   a	   limited	   number	   of	   ethical	   issues	   in	   depth,	   including:	   (1)	   non-­‐clinical	  
objectives	   in	   clinical	   research,	   (2)	   the	   regulation	   of	   trust,	   (3)	   patients’	   access	   to	  
investigational	  medicinal	  products,	  and	  (4)	  the	  fair	  allocation	  of	  resources	  to	  the	  prevention,	  
diagnosis,	  and	  treatment	  of	  rare	  diseases.	  	  
Scope	  and	  methodology	  	  
Bioethics	  is	  a	  relatively	  recent	  phenomenon	  that	  remains	  in	  search	  of	  a	  clear	  identity	  to	  
date.	   As	   a	   result,	   various	   views	   on	   the	   prospect,	   nature,	   and	  methodologies	   of	   bioethics	  
coexist.39	   This	   indicates	   an	   ontological	   and	   conceptual	   heterogeneity,	   that	   becomes	  
apparent	   in	   the	   many	   parallel	   approaches	   that	   coexist	   in	   contemporary	   bioethics,	   each	  
claiming	   their	   own	   validity	   (e.g.,	   utilitarianism,	   rights	   based	   approach,	   empirical	   ethics).40	  
While	   such	  parallel	   validity	  claims	  often	  generate	  exclusive	  and	  competing	  stances	   toward	  
particular	  ethical	  issues,	  the	  inherent	  ontological	  and	  conceptual	  heterogeneity	  of	  bioethics	  
can	   be	   approached	   differently.	   In	   this	   dissertation,	   efforts	   have	   been	   made	   to	   integrate	  
diverse	   theories	  of	  medical	  ethics,	  methodological	  approaches	  and	  heterogeneous	  data	  by	  
assembling	   three	   complementary	   tracks	   of	   ethical	   enquiry:	   contextual	   analysis,	   normative	  
qualification,	  and	  practical	  guidance.	  Contextual	  analysis	  drafts	  the	  state	  of	  the	  art	  of	  ethical,	  
legal,	   and	   social	   issues	   in	   pediatric	   clinical	   research,	   both	   in	   theory	   and	   in	   practice.	  
Normative	   qualification	   delineates	   the	   normative	   targets	   for	   ethical	   research	   conduct	   and	  
healthcare	   provision.	   Practical	   guidance	   aims	   at	   integrating	   ethical	   and	   legal	   guidance	  
towards	  the	  normatively	  qualified	  targets	  in	  the	  actual	  practice	  of	  pediatric	  clinical	  research.	  
Expressed	  commonsensical,	   these	  three	  tracks	  of	  enquiry	  address	  three	  questions	  that	  are	  
essential	   for	   the	   successful	   and	   responsible	   realization	   of	   any	   human	   enterprise,	  
respectively:	  (1)	  where	  do	  we	  stand,	  (2)	  where	  are	  we	  heading	  for,	  and	  (3)	  how	  can	  we	  get	  
there?	  	  
Contextual	  analysis	  	  
Ethical,	  legal,	  and	  social	  issues	  do	  not	  occur	  in	  a	  contextual	  void.	  They	  are	  shaped	  within	  
the	   specific	   social	   setting	   in	   which	   they	   occur,	   and	   by	   consequence	   ignoring	   the	   social	  
context	   of	   ethical	   and	   regulatory	   issues	   comes	   at	   the	   risk	   of	   short-­‐sighted	   reflection,	  
practical	   irrelevance	   or	   even	   the	   elucidation	   of	   merely	   fictive	   problems.	   To	   reduce	   these	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risks,	   it	   is	   essential	   that	   ethical,	   legal,	   and	   social	   issues	   in	   pediatric	   clinical	   research	   be	  
analyzed	  against	   the	  background	  of	   the	  social	  context	   in	  which	  they	  occur.	   In	   this	   respect,	  
contextual	  analysis	  aims	  at	  drafting	  the	  state	  of	  the	  art	  of	  ethical,	  legal,	  and	  social	  issues	  in	  
pediatric	  clinical	  research	  and	  the	  way	  in	  which	  these	  issues	  are	  addressed	  in	  medical	  ethics,	  
health	  law,	  and	  public	  policy.	  As	  such,	  contextual	  analysis	  is	  essential	  to	  provide	  an	  answer	  
to	  various	  questions	  that	  are	  highly	  relevant	  to	  our	  enquiry,	  for	  example:	  	  
• What	  ethical,	   legal,	  and	  social	   issues	  are	  deemed	  specific	  to	  pediatric	  clinical	  research?	  
What	  problems	  do	  these	  issues	  cause	  to	  practitioners,	  minors,	  and	  their	  parents?	  What	  
efforts	  are	  made	  to	  respond	  to	  these	  problems?	  	  
• Which	   regulation	   governs	   pediatric	   clinical	   research	   conduct?	   To	   what	   extent	   is	   this	  
regulation	   harmonized?	   What	   unclear	   provisions,	   inconsistencies,	   and	   contradictory	  
requirements	  exist	   in	   law?	  What	  contradictory	  stances	  coexist	   in	  medical	  ethics?	  What	  
ethical	  and	  regulatory	  issues	  need	  to	  be	  addressed?	  	  
• How	   do	   medical	   practitioners,	   minors,	   and	   their	   parents	   deal	   with	   ethical,	   legal,	   and	  
social	  issues?	  How	  do	  they	  interpret	  and	  implement	  the	  ethical	  and	  legal	  requirements?	  
Are	  the	  ethical,	  legal,	  and	  social	  issues	  that	  they	  experience	  addressed	  in	  ethics	  and	  law?	  	  
Normative	  qualification	  	  
Addressing	   ethical,	   legal,	   and	   social	   issues	   in	   pediatric	   clinical	   research	   is	   not	  merely	   a	  
matter	  of	  technique,	  but	  also	  a	  precarious	  exercise	  to	  provide	  normative	  orientation.	  Such	  
orientation	   can	   be	   provided	   in	   two	   ways.	   First,	   it	   can	   be	   aspired	   to	   prevent,	   avoid,	   and	  
condemn	   what	   is	   considered	   to	   be	   unethical.	   Myriad	   historical	   examples	   illustrate	   this	  
process,	   since	  many	  major	   ethical	   and	   legal	   regulations	   have	   been	   issued	   in	   response	   to	  
research	   scandals.2	   Second,	   it	   can	   be	   aspired	   to	   pursue	  what	   is	   considered	   to	   be	   ethical.	  
Here,	   the	  good	   that	   is	  aspired	  needs	  not	   to	  be	  an	   invariable	  and	   irrefutable	  entity.	  This	   is	  
clearly	   illustrated	   by	   the	   concept	   of	   good	   clinical	   practice,	   a	   set	   of	   requirements	   that	   is	  
generally	   accepted,	   though	   open	   to	   evolution	   and	   change	   (as	   the	   many	   revisions	   of	   the	  
Declaration	   of	   Helsinki	   illustrate).41	   In	   addition,	   it	   must	   be	   acknowledged	   that	   several	  
concepts	  of	  the	  good	  coexist:	  individual	  concepts	  of	  the	  good	  (such	  as	  personal	  values),	  and	  
social	  concepts	  of	  the	  good	  (such	  as	  norms	  and	  regulations).	  	  
Different	  types	  of	  normative	  reflection	  provide	  normative	  qualification	  to	  the	  objectives	  
that	   are	   aspired	   in	   human	   enterprises,	   each	   having	   specific	   assets	   and	   demerits.42	   For	  
example,	   academic	   theoretical	   reflection	   is	   an	   excellent	   way	   to	   dismantle	   unsound	  
reasoning,	   but	   has	   been	   extensively	   criticized	   for	   its	   limited	   practical	   problem-­‐solving	  
capacities.	  Indeed,	  dealing	  with	  ethical	  issues	  at	  a	  theoretical	  level	  by	  no	  means	  guarantees	  
an	  adequate	  approach	  of	  these	  issues	  in	  practice.	  Alternately,	  clinical	  ethics	  may	  be	  praised	  
for	   its	   capacity	   to	  adequately	  address	  ethical	   issues	  on	  a	   case-­‐by-­‐case	  basis,	  but	   can	  been	  
criticized	   for	   its	   normative	   impurity.	   Necessarily,	   a	   case-­‐by-­‐case	   approach	   will	   lack	   the	  
general	   validity	   that	   is	   characteristic	   to	   theoretical	   normative	   reflection.	   In	   turn,	   empirical	  
ethics	   opens	   up	   new	   potential	   to	   design	  more	   realistic	   approaches	   to	   ethical	   issues,	   and	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enables	  to	  identify	  ethical	  issues	  that	  traditionally	  do	  no	  receive	  any	  attention.	  However,	  the	  
way	   in	   which	   empirical	   data	   and	   normative	   reflection	   are	   to	   relate	   remains	   a	   source	   of	  
controversy	  to	  date,43	  and	  empirical	  data	  do	  not	  demonstrate	  what	  is	  ethical	  in	  itself.	  
With	  regard	  to	  pediatric	  clinical	   research,	  normative	  qualification	   is	  essential	   to	  provide	  
an	  answer	  to	  various	  questions	  that	  are	  highly	  relevant	  to	  our	  enquiry,	  for	  example:	  
• What	  research	  do	  children	  need?	  	  
• What	  legitimate	  claim	  to	  safe	  and	  efficacious	  drugs	  do	  children	  have?	  	  
• What	  research	  is	  deemed	  unethical	  in	  children?	  	  
• What	  pursuit	  of	  health	  is	  considered	  to	  be	  ethical?	  	  
• What	  is	  society’s	  duty	  towards	  children?	  	  
• What	  are	  the	  implications	  of	  the	  vulnerability	  of	  children?	  	  
• What	  constitutes	  “Good	  Clinical	  Practice”?	  	  
• How	   do	   personal	   values,	   ethical	   norms	   and	   legal	   rules	   relate?	  What	   is	   their	   role	   and	  
righteous	  place	  in	  medical	  decision-­‐making?	  
Practical	  guidance	  
The	  combination	  of	  a	   sound	  awareness	  of	   the	  social	   context	   in	  which	  ethical,	   legal	  and	  
social	  issues	  are	  shaped	  and	  the	  clear	  normative	  qualification	  of	  the	  endpoints	  we	  pursue	  in	  
our	  reasoning	  and	  action	  does	  not	  constitute,	  support,	  or	  direct	  ethical	  conduct	  in	  itself.	  In	  
other	  words,	  knowing	  where	  we	  stand	  and	  where	  we	  are	  heading	  for,	  does	  not	  discharge	  us	  
from	  navigating	  through	  a	  complex	  landscape,	  seeking	  orientation	  and	  surpassing	  obstacles	  
along	  the	  road.	  	  
Throughout	   the	   recent	  history	  of	  medical	  ethics	  and	  health	   law,	  ethical	  principles	   (e.g.,	  
the	   four	  major	   principles	   of	   biomedical	   ethics44)	   have	   played	   a	   key	   role	   in	   the	   search	   for	  
practical	  guidance.	  Although	  it	  must	  be	  emphasized	  that	  ethical	  principles	  are	  not	  an	  end	  in	  
itself	   but	   a	  means	   to	   another	   normative	   end,	   principles	   do	   enable	   to	   graft	   reasoning	   and	  
action	   to	   normatively	   qualified	   endpoints.	   Nonetheless,	   ethical	   principles	   have	   also	   been	  
harshly	   criticized	   for	   their	   limited	   practical	   problem	   solving	   capacity.45	   Against	   this	  
background,	  alternate	  ways	  to	  provide	  normative	  guidance	  have	  been	  explored	  and	  remain	  
in	  need	  of	  further	  exploration.	  	  
With	   regard	   to	   pediatric	   clinical	   research,	   practical	   guidance	   is	   essential	   to	   provide	   an	  
answer	  to	  various	  questions	  that	  are	  highly	  relevant	  to	  our	  enquiry,	  for	  example:	  
• Which	  normative	  orientation	  is	  provided	  to	  pediatric	  clinical	  research?	  	  
• How	  can	  efficacious	  operational	  guidance	  be	  integrated	  into	  pediatric	  clinical	  research?	  	  
• How	  can	  we	  deal	  with	  conflicting	  values,	  norms,	  and	  rules	  in	  practice?	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Multidisciplinary	  approach	  
In	  this	  dissertation,	  we	  have	  integrated	  three	  types	  of	  data	  and	  three	  methods	  of	  analysis	  
in	   a	   single,	  multidisciplinary	   approach,	   using	   a	   newly	   designed	   conceptual	   framework	   (cf.	  
chapter	   1),	   covering	   (1)	   literature	   review,	   (2)	   comparative	   law	   study,	   and	   (3)	   qualitative	  
empirical	  research.	  	  	  
The	  literature	  study	  covers	  scientific	  literature	  with	  regard	  to	  the	  general	  ethical	  concerns	  
and	  the	  specific	  ethical	  issues	  that	  are	  analyzed	  in	  this	  dissertation.	  	  
The	   comparative	   law	   study	   comprises	   the	   supranational	   and	   national	   regulation	   that	  
governs	   pediatric	   clinical	   research	   across	   the	   borders	   of	   individual	   EU	  member	   states.	   In	  
addition,	  the	  Belgian	  regulatory	  framework	  has	  been	  analyzed	  in	  greater	  detail.	  	  
For	   the	   qualitative	   empirical	   analysis,	   empirical	   data	   have	   been	   generated	   through	  
observational	  research.	  By	  its	  design,	  the	  observational	  study	  covers	  different	  age	  subgroups	  
in	   pediatrics	   and	   comprises	   both	   patients	   and	   a	   limited	   number	   of	   healthy	   volunteers.	  
Diverse	  types	  of	  pediatric	  wards,	  clinical	  trials,	  and	  diseases	  are	  covered	  in	  the	  analysis.	  	  
Research	  results:	  Outline	  of	  the	  doctoral	  dissertation	  
Chapter	  1:	  Supranational	  regulation	  in	  the	  EU	  
Pinxten,	   W.,	   Dierickx,	   K.,	   Nys,	   H.	   (2009).	   Ethical	   principles	   and	   legal	   requirements	   for	  
pediatric	   research	   in	   the	   EU:	   an	   analysis	   of	   the	   European	   normative	   and	   legal	   framework	  
surrounding	  pediatric	  clinical	  trials.	  European	  Journal	  of	  Pediatrics,	  168(10),	  1225-­‐1234.	  
Abstract:	   In	   this	   chapter,	   the	   European	   legal	   framework	   surrounding	   pediatric	   clinical	  
trials	   is	   analyzed	   from	   the	  perspective	  of	   the	  major	  ethical	   concerns	   in	  pediatric	   research.	  
The	  four	  principles	  of	  biomedical	  ethics	  will	  be	  used	  as	  a	  conceptual	  framework	  (1)	  to	  map	  
the	  ethical	  issues	  addressed	  in	  the	  European	  legal	  framework,	  (2)	  to	  study	  how	  these	  issues	  
are	   commonly	   handled	   in	   competent	   adults,	   (3)	   to	   detect	   workability	   problems	   of	   these	  
paradigmatic	  approaches	  in	  the	  specific	  setting	  of	  pediatric	  research,	  and	  (4)	  to	  illustrate	  the	  
strong	  urge	  to	  differentiate,	  specify,	  or	  adjust	  these	  paradigmatic	  approaches	  to	  guarantee	  
their	  successful	  operation	   in	  pediatric	  research.	   In	  addition,	  a	  concise	  comparative	  analysis	  
of	  the	  European	  regulation	  is	  made.	  To	  conclude	  the	  analysis,	  the	  findings	  are	  integrated	  in	  
the	  existing	  ethical	  discussions	  on	  issues	  specific	  to	  pediatric	  clinical	  research.	  
Chapter	  2:	  Domestic	  regulation	  in	  individual	  EU	  Member	  States	  
Pinxten,	  W.,	   Dierickx,	   K.,	   Nys,	   H.	   (2010)	   Diversified	  Harmony,	   Supranational	   and	   domestic	  
regulation	   of	   pediatric	   clinical	   trials	   in	   the	   European	   Union.	   Journal	   of	   Cystic	   Fibrosis	  
[Accepted].	  	  
Abstract:	  In	  this	  chapter,	  the	  regulation	  that	  currently	  governs	  pediatric	  clinical	  research	  
conduct	  at	  the	  supranational	  level	  of	  the	  EU	  and	  at	  the	  level	  of	  individual	  EU	  member	  states	  
is	  analyzed.	  The	  analysis	   focuses	  on	   the	  way	   in	  which	   the	  national	  and	  supranational	   legal	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frameworks	   address	   five	   ethical	   issues	   that	   are	   specific	   to	   pediatric	   clinical	   research:	  	  
(a)	   informed	   consent,	   (b)	   the	   necessity	   to	   conduct	   research	   in	   minor	   subjects,	   (c)	   the	  
interests	  of	  the	  subject	  concerned,	  (d)	  the	  risks	  and	  burdens	  involved,	  and	  (e)	  the	  pediatric	  
expertise	  of	  protocol	  review	  committees.	  The	  chapter	  is	  concluded	  with	  a	  discussion	  of	  the	  
harmonization	   and	   diversification	   of	   the	   legal	   requirements	   that	   govern	   pediatric	   clinical	  
research	  in	  the	  EU.	  
Chapter	  3:	  The	  Belgian	  law	  	  
Pinxten,	  W.,	  Dierickx,	  K.,	  Nys,	  H.	   (2008).	   The	   implementation	  of	  Directive	  2001/20/EC	   into	  
Belgian	   law	   and	   the	   specific	   provisions	   on	   pediatric	   research.	   European	   Journal	   of	   Health	  
Law,	  15(2),	  153-­‐61.	  
Abstract:	  This	  chapter	  provides	  an	  overview	  of	  the	  requirements	  for	   involving	  minors	   in	  
medical	  experiments	  that	  are	  captured	  in	  the	  Law	  of	  7	  May	  2004	  concerning	  experiments	  on	  
the	  human	  person	  (LEH),	  and	  analyzes	  the	  dissimilarities	  between	  the	  LEH	  and	  the	  European	  
Directive.	  
Chapter	  4:	  Beyond	  regulation	  	  	  
Pinxten,	  W.,	  Nys,	  H.,	  Dierickx,	  K.	  (2008).	  Regulating	  trust	  in	  pediatric	  clinical	  trials.	  Medicine,	  
health	  care,	  and	  philosophy,	  11(4),	  439-­‐444.	  
Abstract:	   In	   this	  chapter,	   it	   is	  analyzed	  how	  the	  enrollment	  of	  minors	   in	  clinical	   trials	   is	  
negotiated	   within	   relationships	   of	   mutual	   trust	   between	   clinicians,	   minors,	   and	   their	  
parents.	  After	  a	  brief	  description	  of	  the	  problems	  associated	  with	  involving	  minors	  in	  clinical	  
research,	  it	  is	  considered	  how	  existing	  ‘‘relationships	  of	  trust’’	  can	  be	  used	  as	  a	  place	  where	  
the	   concerns	  of	   research	   subjects	   can	  be	  more	   fully	  discussed	  and	  addressed.	  Building	  on	  
the	   tacit	   recognition	   of	   trust	   found	   in	   The	   European	   Clinical	   Trials	   Directive,	   policy	  
recommendations	   are	   made	   to	   allow	   for	   clearer,	   more	   ethically	   informed	   guidelines	   for	  
enrolling	  minors	  in	  clinical	  research.	  
Chapter	  5:	  Essentials	  for	  the	  ethical	  and	  regulatory	  agenda	  
Pinxten,	  W.,	  Nys,	  H.,	  Dierickx,	  K.	  (2010).	  Frontline	  ethical	  issues	  in	  pediatric	  clinical	  research.	  
Ethical	   and	   regulatory	   aspects	   of	   seven	   current	   bottlenecks	   in	   pediatric	   clinical	   research.	  	  
European	  Journal	  of	  Pedatrics	  169(12),1541-8.	  	  
Abstract:	   This	   chapter	   explores	   seven	   bottlenecks	   in	   the	   ethical	   guidance	   and	   legal	  
regulation	   that	   currently	   governs	   govern	   pediatric	   clinical	   research:	   (1)	   the	   integration	   of	  
research	  in	  therapy,	  (2)	  the	  education	  of	  clinicians,	  (3)	  the	  empowerment	  of	  families,	  (4)	  the	  
harmonization	   of	   protocol	   review,	   (5)	   the	   assessment	   non-­‐clinical	   research	   objectives,	   (6)	  
the	   control	   of	   placebo	   use,	   and	   (7)	   the	   provision	   of	   fair	   incentives	   for	   pediatric	   research	  
conduct.	   For	   all	   of	   these	   issues,	   a	   clear	   view	  on	   the	  way	   forward	   is	   largely	   lacking,	   either	  
because	  these	  issues	  have	  not	  been	  discussed	  in	  depth	  to	  date,	  date	  or	  because	  the	  existing	  
debates	  have	  failed	  to	  generate	  a	  generally	  supported	  consensus.	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Chapter	   6:	   Current	   controversies	   in	   search	   of	   normative	   orientation:	   access	   to	  
investigational	  medicinal	  products	  for	  minors	  	  
Pinxten,	  W.,	   Nys,	   H.,	   Dierickx,	   K.	   (2010).	   Access	   to	   investigational	   medicinal	   products	   for	  
minors.	   Ethical	   and	   regulatory	   issues	   in	   negotiating	   children's	   access	   to	   investigational	  
medicines.	  Journal	  of	  Medical	  Ethics	  36:	  791-­‐794.	  
Abstract:	  The	  quest	  for	  access	  to	  investigational	  drugs	  is	  particularly	  relevant	  to	  pediatric	  
practice,	  where	  a	  significant	  share	  of	  the	  drugs	  prescribed	  has	  never	  been	  tested	  in	  children	  
or	   labeled	   for	  use	   in	   the	  pediatric	  population.	   In	   this	   chapter,	   the	  ethical	   concerns	   in	   two	  
potential	  tracks	  of	  seeking	  access	  to	  investigational	  medicinal	  products	  (IMP)	  for	  minors	  are	  
explored:	   access	   on	   an	   individual	   basis,	   and	   collective	   access,	   via	   patient	   organizations.	   In	  
the	   discourse,	   several	   unique	   ethical	   and	   regulatory	   concerns	   related	   to	   the	   direct	  
negotiation	   of	   access	   to	   IMP	   for	   minor	   patients	   are	   identified,	   with	   a	   focus	   on	   product	  
safety,	  the	  recruitment	  of	  research	  subjects,	  the	  unnoticed	  entry	  of	  market	  mechanisms	  in	  
the	   recruitment	  of	   research	  subjects,	  and	   the	  sidelining	  of	   third	  parties	   in	   the	   recruitment	  
process.	  The	  chapter	  is	  concluded	  with	  a	  concise	  reflection	  on	  the	  way	  forward.	  	  
Chapter	   7:	   Current	   controversies	   in	   search	   of	   normative	   orientation:	  	  
non-­‐clinical	  research	  objectives	  
Pinxten,	  W.,	  Nys,	  H.,	  Dierickx,	  K.	   (2009).	  Ethical	  and	   regulatory	   issues	   in	  pediatric	   research	  
supporting	  the	  non-­‐clinical	  application	  of	  fMR	  imaging.	  American	  Journal	  of	  Bioethics,	  9(1),	  
21-­‐23.	  
Abstract:	   Over	   the	   past	   decades,	   important	   efforts	   have	   been	   made	   to	   regulate	   the	  
involvement	   of	   children	   in	   clinical	   trials.	   However,	   current	   ethical	   and	   legal	   procedures	  
surrounding	  clinical	  trials	  in	  minors	  (US/EU)	  are	  not	  designed	  to	  consider	  and	  assess	  the	  non-­‐
clinical	  use	  of	  medical	  technologies	  such	  as	  fMRI,	  while	  non-­‐clinical	  applications	  of	  pediatric	  
fMRI	  cannot	  be	  developed	  without	  conducting	  clinical	  trials	  in	  children.	  In	  this	  chapter,	  the	  
diverse	  ethical	  issues	  related	  to	  the	  non-­‐clinical	  applications	  of	  fMRI	  are	  discussed	  from	  the	  
perspective	  of	  pediatric	  clinical	  trial	  regulation	  	  
Chapter	   8:	   Current	   controversies	   in	   search	   of	   normative	   orientation:	  
distributive	  justice:	  funding	  the	  development	  and	  supply	  of	  orphan	  drugs	  	  
Pinxten,	  W.,	  Denier	  Y.,	  Dooms	  M.,	  Dierickx,	  K.	   (2010).	  A	  fair	  share	  for	  the	  orphans.	  Justice,	  
rationality	   and	   arbitrariness	   in	   the	   allocation	   of	   limited	   healthcare	   resources	   to	   the	  
prevention	  and	  treatment	  of	  rare	  diseases.	  [Unpublished	  manuscript]	  
Abstract:	  For	  a	   significant	  number	  of	  patients,	  no	  or	  only	  poor	   interest	   in	  developing	  a	  
treatment	  for	  their	  disease	  or	  condition	  exists.	  Especially	  with	  regard	  to	  rare	  conditions,	  the	  
lack	   of	   commercial	   interest	   in	   drug	   development	   is	   a	   burning	   issue.	   This	   is	   particularly	  
relevant	  to	  pediatrics,	  where	  rare	  diseases	  have	  a	  relatively	  high	  prevalence.	  	  
To	   address	   the	   commercial	   disinterest	   in	   these	   conditions,	   several	   interventions	   have	  
been	   made	   in	   the	   regulatory	   field.	   However,	   existing	   regulations	   mainly	   focus	   on	   the	  
provision	   of	   incentives	   to	   the	   sponsors	   of	   clinical	   trials	   of	   orphan	   drugs,	   and	   leave	   the	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overarching	  question	  on	  the	  righteous	  place	  of	  orphan	  drugs	  in	  resource	  allocation	  systems	  
unanswered.	  	  
In	  this	  chapter,	  major	  ethical	  issues	  in	  the	  development	  and	  supply	  of	  treatments	  for	  rare	  
conditions	  are	  analyzed.	  Subsequently,	  an	  ethical	   framework,	  which	  can	  help	  health	  policy	  
makers	   in	   moving	   forward	   in	   the	   difficult	   issue	   of	   justly	   allocating	   resources	   to	   the	  
prevention	  and	  treatment	  of	  rare	  diseases	  is	  presented.	  	  
Chapter	   9:	   Empirical	   exploration	   of	   the	   implementation	   of	   ethical	   and	   legal	   guidance	   in	  
pediatric	  clinical	  research	  
Pinxten,	  W.,	  Nys,	  H.,	  Dierickx,	  K.,	  Van	  Geet,	  C.	  (2010).	  The	  implementation	  of	  the	  European	  
Good	  Clinical	  Practice	  Directive	  in	  informed	  consent	  discussions	  [Submitted	  for	  review].	  
Abstract:	  Objectives:	   In	   this	   chapter,	   practical	   issues	   in	   implementing	   ethical	   and	   legal	  
requirements	   in	  pediatric	   research	  practice	  are	  empirically	   explored.	   The	   findings	   that	   are	  
presented	   serve	   as	   a	   first	   illustration	   of	   how	   empirical	   enquiry	   can	   be	   integrated	   in	   the	  
analysis	   of	   ethical,	   legal,	   and	   social	   aspects	   of	   pediatric	   clinical	   research,	   using	   the	  
conceptual	   framework	   that	   has	   been	   developed	   in	   this	   doctoral	   thesis	   (cf.	   chapter	   1).	   In	  
addition,	   the	   findings	   that	   are	   presented	   in	   this	   chapter	   aim	   at	   informing	   the	   normative	  
discussion	   of	   major	   tensions	   in	   pediatric	   research	   practice	   empirically	   (cf.	   general	  
discussion).	  The	  analysis	  in	  this	  chapter	  focuses	  on	  the	  implementation	  of	  the	  national	  and	  
supranational	   legal	   frameworks	   governing	   pediatric	   clinical	   research	   in	   informed	   consent	  
discussions.	  	  
Methods:	   	   Practical	   issues	   in	   the	   operational	   implementation	   of	   ethical	   and	   legal	  
requirements	   in	   pediatric	   research	   practice	   are	   empirically	   explored	   by	   means	   of	   an	  
observational	  study	  of	  23	  informed	  consent	  discussions.	  Recognizing	  that	  the	  European	  legal	  
framework	  imposes	  a	  single	  set	  of	  legal	  requirements	  to	  a	  large	  diversity	  of	  pediatric	  clinical	  
trials,	  consent	  discussions	  were	  observed	   for	  a	   large	  variety	  of	  studies,	  diseases,	  sponsors,	  
and	   study	   designs.	   The	   discussions	   were	   audio	   taped,	   transcribed,	   coded	   and	   analyzed	  
qualitatively,	   linking	   the	   content	   of	   the	   informed	   consent	   discussions	   to	   three	   major	  
concerns	   in	   the	   European	   legal	   framework.	   Only	   oral	   communication	   was	   taken	   account,	  
even	   though	   additional	   written	   information	   was	   provided	   to	   the	   parents	   and/or	   minor	  
subjects.	  	  
Against	  the	  background	  of	  the	  modest	  objectives	  of	  this	  empirical	  exploration,	  the	  limited	  
sample	  size,	   the	  explicit	  choice	   to	  study	  pediatric	  clinical	   research	   in	   its	   full	  heterogeneity,	  
and	  concerns	  to	  protect	  the	  anonymity	  of	  the	  clinicians,	  minors,	  and	  their	  parents	  involved,	  
some	  types	  of	  analysis	  have	  been	  abandoned.	  In	  this	  respect,	  no	  links	  between	  observations	  
and	   specific	   studies	   have	   been	   made,	   and	   no	   counts	   of	   the	   number	   of	   cases	   in	   which	  
particular	  observations	  were	  present	  are	  given,	  since	  this	  type	  of	  analysis	  is	  likely	  to	  create	  a	  
deceptive	  view	  given	  the	  small	  and	  heterogeneous	  sample	  of	  cases.	  	  
It	  is	  fully	  acknowledged	  that	  the	  analysis	  does	  not	  generate	  any	  generalizable	  knowledge,	  
and	  that	  the	  findings	  presented	  in	  this	  chapter	  could	  not	  be	  saturated	  in	  within	  the	  limits	  of	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this	   empirical	   exploration.	   Nonetheless,	   the	   findings	   in	   this	   chapter	   suggest	   a	   number	   of	  
issues	   that	   are	   highly	   relevant	   to	   analyze	   and	   discuss	   the	   operational	   implementation	   of	  
ethical	  and	  legal	  requirements	  in	  pediatric	  research	  practice.	  As	  such,	  this	  analysis	  serves	  as	  
a	  first	  inventory	  of	  practical	  issues	  that	  can	  inform	  (1)	  pragmatic	  decision-­‐making	  and	  (2)	  the	  
design	  of	  further,	  more	  comprehensive	  clinical	  research.	  
Results:	  From	  the	  observed	  consent	  discussions,	  there	  are	  few	  indications	  that	  European	  
legal	   good	  clinical	  practice	   (GCP)	   requirements	  are	   systematically	   implemented.	  We	   found	  
no	  indications	  that	  the	  European	  legal	  framework	  offers	  strong	  impetuses	  for	  the	  realization	  
of	  legal	  GCP-­‐requirements	  at	  the	  interpersonal	  level	  of	  addressing	  ethical	  issues.	  	  
In	   addition,	   our	   analysis	   sheds	   a	   new	   light	   on	   five	   important	   ethical	   tensions:	   (1)	  
harmonization	  versus	  heterogeneity	   (2)	   informed	  consent	  versus	  documented	  consent,	   (3)	  
assent	  versus	  procedure	  compliance,	  (4)	  direct	  benefit	  versus	  valid	  research	  results,	  and	  (5)	  
risk-­‐benefit	  ratio	  versus	  risk-­‐risk	  ratio.	  	  
Conclusion:	  It	  is	  both	  relevant	  and	  important	  to	  define	  and	  support	  the	  tasks,	  roles,	  and	  
interests	   of	   minors,	   parents,	   and	   researchers	   in	   the	   informed	   consent	   process.	   Our	  
observations	   draft	   a	   background	   against	   which	   these	   tasks,	   roles,	   and	   interests	   can	   be	  
explored.	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Abstract	  	  
The	   involvement	  of	  minors	   in	  clinical	   research	   is	   inevitable	   to	  catch	  up	  with	   the	   lack	  of	  
drugs	   labeled	   for	   pediatric	   use.	   To	   encourage	   the	   responsible	   conduct	   of	   pediatric	   clinical	  
trials	   in	  the	  EU,	  an	  extensive	   legal	  framework	  has	  been	  developed	  over	  the	  past	  decade	  in	  
which	   the	   practical,	   ethical,	   legal,	   social,	   and	   commercial	   issues	   in	   pediatric	   research	   are	  
addressed.	  In	  this	  article,	  the	  European	  legal	  framework	  surrounding	  pediatric	  clinical	  trials	  
is	  analyzed	  from	  the	  perspective	  of	  the	  major	  ethical	  concerns	  in	  pediatric	  research.	  The	  four	  
principles	  of	  biomedical	  ethics	  will	  be	  used	  as	  a	  conceptual	  framework	  (1)	  to	  map	  the	  ethical	  
issues	   addressed	   in	   the	   European	   legal	   framework,	   (2)	   to	   study	   how	   these	   issues	   are	  
commonly	   handled	   in	   competent	   adults,	   (3)	   to	   detect	   workability	   problems	   of	   these	  
paradigmatic	  approaches	  in	  the	  specific	  setting	  of	  pediatric	  research,	  and	  (4)	  to	  illustrate	  the	  
strong	  urge	  to	  differentiate,	  specify,	  or	  adjust	  these	  paradigmatic	  approaches	  to	  guarantee	  
their	  successful	  operation	   in	  pediatric	  research.	   In	  addition,	  a	  concise	  comparative	  analysis	  
of	  the	  European	  regulation	  will	  be	  made.	  To	  conclude	  our	  analysis,	  we	  integrate	  our	  findings	  
in	  the	  existing	  ethical	  discussions	  on	  issues	  specific	  to	  pediatric	  clinical	  research.	  
Introduction	  
The	  safety	  and	  efficacy	  of	  a	  large	  number	  of	  the	  drugs	  used	  in	  pediatric	  practice	  has	  not	  
been	  demonstrated	  for	  the	  specific	  use	   in	  children.1	  Because	  children	  are	  not	  simply	  small	  
adults,	   results	   of	   clinical	   trials	   in	   adults	   cannot	   often	   be	   reliably	   extrapolated	   to	  minors.2	  
Therefore,	  there	  is	  an	  urgent	  need	  to	  perform	  clinical	  trials	  on	  children.	  
At	  present,	  it	  is	  widely	  recognized	  that	  it	  is	  not	  possible	  to	  provide	  children	  with	  a	  variety	  
of	   safe	   and	   efficacious	   drugs	   comparable	   to	   those	   available	   to	   adults	   without	   involving	  
minors	   in	   clinical	   trials.	   To	   catch	   up	   with	   the	   lack	   of	   licensed	   drugs	   that	   are	   labeled	   for	  
pediatric	  use,	  regulatory	  efforts	  have	  focused	  on	  facilitating,	  encouraging,	  and	  rewarding	  the	  
conduct	  of	  clinical	  research	  in	  minors.	  Nonetheless,	  the	  development	  of	  safe	  and	  efficacious	  
drugs	  for	  use	  in	  children	  remains	  a	  precarious	  enterprise.3	  Several	  constraints	  work	  against	  
the	   marketing	   of	   drugs	   tested	   in	   children	   and	   labeled	   for	   pediatric	   use,	   among	   which	  
practical	   difficulties	   (e.g.,	   recruitment	   issues)4	   5,	   strict	   ethical	   and	   legal	   requirements	   (e.g.,	  
restrictive	  policy	  concerning	  non-­‐beneficial	  research,	  cf.	  infra),	  and	  economic	  issues	  (e.g.,	  the	  
limited	  potential	  for	  return	  on	  investment	  in	  pediatric	  trials).6	  In	  the	  EU,	  this	  predicament	  is	  
addressed	  in	  an	  extensive	  legal	  framework	  that	  has	  been	  developed	  over	  the	  past	  decade.	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In	  this	  article,	  the	  European	  legal	  framework	  surrounding	  pediatric	  trials	  is	  analyzed	  from	  
the	  perspective	  of	   the	  major	   ethical	   concerns	   in	  pediatric	   research.	   First,	   the	   content	   and	  
implementation	  of	   the	  European	   legal	   framework	  will	  be	  presented	  and	  clarified	  using	  the	  
four	  principles	  of	  biomedical	  ethics.7	  The	  well-­‐known	  principles	  of	  justice,	  non-­‐maleficence,	  
beneficence,	   and	   autonomy	  will	   be	   used	   as	   a	   starting	   point	   (1)	   to	  map	   the	   ethical	   issues	  
addressed	   in	   the	   European	   legal	   framework,	   (2)	   to	   study	   how	   these	   issues	   are	   commonly	  
handled	   in	   competent	   adults,	   (3)	   to	   detect	   workability	   problems	   of	   these	   paradigmatic	  
approaches	  in	  the	  specific	  setting	  of	  pediatric	  research,	  and	  (4)	  to	  illustrate	  the	  strong	  urge	  
to	   differentiate,	   specify,	   or	   adjust	   these	   paradigmatic	   approaches	   to	   guarantee	   their	  
successful	   operation	   in	   pediatric	   research.	   Second,	   a	   concise	   comparative	   analysis	   of	   the	  
European	  regulation	  will	  be	  made.	  To	  conclude	  our	  analysis,	  we	  will	   integrate	  our	   findings	  
with	  the	  existing	  ethical	  discussions	  on	  issues	  specific	  to	  pediatric	  clinical	  research.	  
The	  European	  legal	  framework	  
The	  urgent	  need	  to	  conduct	  clinical	  research	  in	  minors	  has	  called	  for	  legislative	  action.	  In	  
Europe,	   various	   regulations	   have	   been	   promulgated	   by	   diverse	   legislative	   bodies	   over	   the	  
past	   decade,	   aiming	   at	   the	   facilitation	   and	   promotion	   of	   pediatric	   research	   and	   the	  
harmonization	  of	  standards	  of	  good	  clinical	  practice.	  
In	  this	  article,	  three	  criteria	  are	  used	  to	  determine	  the	  scope	  of	  relevant	  legislation.	  First,	  
the	  scope	  is	   limited	  to	  legislation	  issued	  at	  the	  European	  level	  (i.e.,	  the	  European	  Union	  or	  
Council	   of	   Europe).	   Domestic	   legislation	   of	   individual	   countries	   is	   thus	   not	   taken	   into	  
account.	  Second,	  the	  scope	  is	  limited	  to	  legal	  provisions	  that	  are	  related	  to	  ethical	  concerns	  
in	   the	   conduct	   of	   pediatric	   clinical	   trials.	   By	   consequence,	   regulation	   focusing	   on	  
administrative	   or	   technical	   issues	   such	   as	   the	   production	   of	   investigational	   medicinal	  
products	  or	  the	  labeling	  of	  drugs	  falls	  outside	  the	  scope	  of	  this	  article.	  Third,	  only	  provisions	  
specifically	  addressing	  the	  involvement	  of	  minors	  in	  clinical	  trials	  fall	  within	  the	  scope	  of	  this	  
article.	  General	  provisions	   regulating	   the	   involvement	  of	   competent	  adults	   in	   research	  are	  
not	  discussed	  exhaustively,	  although	  these	  provisions	  may	  also	  apply	  to	  the	  involvement	  of	  
minors	  in	  clinical	  trials.	  In	  accordance	  to	  these	  criteria,	  the	  European	  Convention	  on	  Human	  
Rights	   and	  Biomedicine,	   the	  European	  Clinical	   Trial	  Directive,	   and	   the	  Pediatric	  Regulation	  
fall	  within	  the	  scope	  of	  this	  article.	  
European	  Convention	  on	  human	  rights	  and	  biomedicine	  
In	   1997,	   the	   Council	   of	   Europe	   promulgated	   the	   European	   Convention	   (European	  
Convention	  for	  the	  Protection	  of	  Human	  Rights	  and	  Dignity	  of	  the	  Human	  Being	  with	  Regard	  
to	   the	  Application	   of	   Biology	   and	  Medicine).8	   In	   2005,	   this	   convention	  was	   supplemented	  
with	  an	  additional	  protocol	  on	  biomedical	   research	   (Additional	  Protocol	   to	   the	  Convention	  
on	  Human	  Rights	  and	  Biomedicine,	  Concerning	  Biomedical	  Research,	  Strasbourg,	  25	  January	  
2005).9	   To	  date,	   the	  European	  Convention	   is	  binding	  upon	   the	  13	  EU	  member	   states	   (and	  
eight	   countries	   outside	   the	   EU)	   that	   signed	   and	   ratified	   it,	   and	   its	   additional	   protocol	   is	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binding	  upon	  the	  four	  EU	  member	  states	  (and	  one	  country	  outside	  the	  EU)	  that	  signed	  and	  
ratified	  it.i	  
The	  European	  Convention	  specifically	  addresses	  the	  issue	  of	  pediatric	  research	  in	  article	  
17.	  Also,	  articles	  6	  and	  16	  are	  of	  some	  relevance,	  as	  they	  provide	  details	  on	  the	  protection	  of	  
persons	  not	  able	  to	  consent	  (be	  it	  not	  specifically	  in	  the	  setting	  of	  clinical	  research)	  and	  the	  
protection	  of	  persons	  undergoing	  research	   (be	   it	  not	  specifically	  minors),	   respectively.	  The	  
additional	  protocol	  on	  biomedical	   research	   touches	  on	  the	  subject	  of	  pediatric	   research	   in	  
article	  17.	  
European	  clinical	  trial	  directive	  
The	   European	   Directive	   (Directive	   2001/20/EC	   of	   the	   European	   Parliament	   and	   of	   the	  
Council	   of	   4	   April	   2001	   on	   the	   approximation	   of	   laws,	   regulations	   and	   administrative	  
provisions	  of	  the	  member	  states	  in	  relation	  to	  the	  implementation	  of	  good	  clinical	  practice	  in	  
the	   conduct	   of	   clinical	   trials	   on	   medicinal	   products	   for	   human	   use)10	   mainly	   aims	   at	   a	  
harmonization	   of	   the	   provisions	   regarding	   good	   clinical	   practice	   and	   the	   facilitation	   of	  
multicenter	  clinical	  trials	  across	  the	  borders	  of	  individual	  EU	  member	  states.	  All	  EU	  member	  
states	  were	   bound	   to	   implement	   this	   directive	   into	   national	   law	  before	   the	   deadline	   of	   1	  
May	   2004.	   In	   the	   national	   implementation	   of	   the	   European	   Directive,	   EU	  member	   states	  
were	  free	  to	  adopt	  stricter	  provisions	  than	  those	  set	  down	  in	  the	  European	  Directive,	  as	  long	  
as	  the	  standards	  of	  protection	  and	  time	  limits	  captured	  in	  the	  European	  Directive	  were	  not	  
violated	   (article	   3,1).	   The	   European	   Directive	   specifically	   addresses	   the	   issue	   of	   involving	  
minors	  in	  research	  in	  article	  4.	  
In	   addition	   to	   the	   provisions	   of	   the	   European	  Directive,	   the	   scientific	   guidelines	   of	   the	  
European	  Medicines	  Agency	  (EMEA)	  must	  be	  followed.	  In	  this	  respect,	  the	  guideline	  “Ethical	  
Considerations	   for	   Clinical	   Trials	   on	   Medicinal	   Products	   Conducted	   with	   the	   Paediatric	  
Population”11	  was	   recently	   issued	  by	   EMEA	   to	   guide	   the	   implementation	   of	   the	   European	  
Directive	  in	  pediatric	  research	  practice.	  
Pediatric	  Regulation	  
Even	   though	   the	  European	  Directive	  was	  a	  milestone	   in	   the	   facilitation	  of	   clinical	   trials,	  
further	  legislative	  initiatives	  were	  needed	  to	  address	  the	  lack	  of	  interest	  in	  developing	  drugs	  
for	  the	  young.	  To	  correct	  the	  disinterest	  of	  the	  industry	  in	  developing	  and	  marketing	  drugs	  
for	  children,	  the	  Pediatric	  Regulation	  (EU	  Regulation	  1901/2006	  of	  the	  European	  Parliament	  
and	   of	   the	   Council	   of	   12	   December	   2006	   on	   Medicinal	   Products	   for	   Pediatric	   Use	   and	  
Amending	   Regulation	   (EEC)	   No.	   1768/92,	   Directive	   2001/20/EC,	   Directive	   2001/83/EC	   and	  
Regulation	   (EC)	   No.	   726/2004)12	   requires	   that	   clinical	   trials	   in	   minors	   be	   planned	   and	  
conducted	   for	   all	   new	  products	   entering	   the	  market.	   In	   addition,	   the	   Pediatric	   Regulation	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i	  A	  list	  of	  countries	  that	  signed	  and/or	  ratified	  the	  convention	  can	  be	  consulted	  at:	  
http://conventions.coe.int/Treaty/Commun/ChercheSig.	  asp?NT=164&CM=&DF=&CL=ENG.	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offers	   considerable	   rewards	   for	   the	   conduct	   of	   clinical	   trials	   in	   minors,	   in	   the	   form	   of	  
prolongation	   of	   market	   exclusivity.	   In	   contrast	   to	   the	   European	   Convention	   and	   the	  
European	   Directive,	   the	   Pediatric	   Regulation	   is	   entirely	   dedicated	   to	   clinical	   research	   in	  
minors.	  
Ethical	  principles	  and	  pediatric	  clinical	  research	  conduct	  
Various	  types	  of	  bioethical	  reflection	  can	  be	  used	  to	   identify,	  clarify,	  and	  discuss	  ethical	  
issues	   in	   pediatric	   research.	   In	   this	   paper,	   a	   principle-­‐based	   approach	   will	   be	   used	   as	   a	  
conceptual	   framework	   to	   interconnect	   (1)	   the	   main	   ethical	   issues	   in	   involving	   human	  
persons	  in	  research,	  (2)	  the	  common	  approaches	  of	  these	  issues	  in	  competent	  adults,	  (3)	  the	  
workability	  problems	  these	  paradigmatic	  approaches	  have	  in	  the	  pediatric	  research	  setting,	  
and	  (4)	  the	  regulatory	  answers	  to	  these	  workability	  problems.	  
Although	   principles	   are	   a	  well-­‐validated	   tool	   for	   ethical	   reflection,	   their	   generality	  may	  
render	  them	  somewhat	  difficult	  to	  apply	  directly	  to	  specific	  ethical	  issues.	  Therefore,	  in	  this	  
article,	  the	  four	  principles	  of	  biomedical	  ethics—justice,	  non-­‐maleficence,	  beneficence,	  and	  
autonomy7—	   will	   be	   tailored	   to	   the	   specific	   issues	   of	   involving	   minors	   in	   research	   by	  
describing	  them	  in	  terms	  of	  four	  fields	  of	  social,	  scientific,	  and	  regulatory	  action.	  Obviously,	  
overlap	   between	   these	   four	   fields	   of	   action	   will	   exist,	   as	   the	   four	   principles	   cannot	   be	  
distinguished	  strictly	  from	  each	  other	  in	  content	  and	  scope.	  
Justice	  
The	  formal	  principle	  of	  justice	  can	  be	  set	  forth	  in	  several	  ways:	  to	  each	  person	  an	  equal	  
share	   or	   a	   share	   according	   to	   (1)	   need,	   (2)	   effort,	   (3)	   contribution,	   (4)	  merit,	   and	   (5)	   free	  
market	  exchanges.7	  
Obviously,	   the	   unmet	   medical	   needs	   of	   minors	   are	   a	   major	   reason	   to	   encourage	   the	  
development	  of	   safe	   and	  efficacious	  drugs	   for	   the	   young.	   Free	  market	  exchanges	  are	  also	  
relevant	  to	  the	  development	  and	  provision	  of	  safe	  and	  efficacious	  drugs	  for	  children,	  as	  the	  
pharmaceutical	  industry	  is	  a	  key	  player	  in	  this	  process.	  In	  contrast,	  effort,	  contribution,	  and	  
merit	   are	   not	   commonly	   cited	   as	   motives	   to	   develop	   and	   distribute	   drugs	   for	   pediatric	  
patients.	   Therefore,	   in	   this	   article,	   the	   principle	   of	   justice	   will	   be	   referred	   to	   as	   a	   “share	  
according	  to	  need”	  and	  a	  “share	  according	  to	  free	  market	  exchanges.”	  
Main	  issues	  in	  clinical	  research	  and	  paradigmatic	  approach	  in	  competent	  adults	  
To	  respond	  to	  existing	  therapeutic	  needs,	  safe	  and	  efficacious	  drugs	  must	  be	  developed	  
and	   made	   available	   to	   patients	   who	   can	   benefit	   from	   them.	   The	   development,	   safety,	  
efficacy,	  and	  availability	  of	  drugs	  all	  entail	  ethical	  issues.	  
The	  current	  paradigmatic	  approach	   leaves	  the	  development	  and	  distribution	  of	  drugs	   in	  
large	   part	   to	   the	   market.	   Requirements	   for	   obtaining	   marketing	   authorization	   seek	   to	  
guarantee	  that	  drugs	  are	  safe	  and	  efficacious.	  According	  to	  these	  requirements,	  the	  terms	  of	  
use	   must	   be	   captured	   in	   the	   corresponding	   license	   that	   provides	   details	   of	   the	   patients,	  
Supranational	  regulation	  in	  the	  EU	  ⏐	  31	  
ages,	   indications,	   dosages,	   routes	  of	   administration,	   and	   contraindications	   associated	  with	  
each	  drug.13	  
Workability	   problems	   of	   the	   paradigmatic	   approach	   in	   competent	   adults	   in	   pediatric	  
healthcare	  and	  implementation	  of	  the	  principle	  of	  justice	  
While	   requirements	   for	   obtaining	   marketing	   authorization	   are	   effective	   to	   assure	   the	  
safety	   and	  efficacy	  of	   drugs	   that	   enters	   the	  market,	   these	   requirements	   fail	   to	   supply	   the	  
population	  of	  minors	  with	  an	  equitable	  variety	  of	  drugs.	  
Due	   to	   the	   high	   complexity	   of	   testing	   drugs	   in	   children,	   the	   costs	   of	   testing	   a	   drug	   in	  
minors	   may	   well	   exceed	   the	   potential	   return	   on	   investment	   and,	   therefore,	   render	   it	  
economically	  unattractive	  to	  label	  drugs	  for	  pediatric	  use.	  As	  a	  result,	  there	  is	  a	  dearth	  lack	  
of	  drugs	  for	  use	  in	  children,	  and	  in	  many	  instances,	  pediatricians	  have	  no	  therapeutic	  options	  
apart	   from	   using	   drugs	   off-­‐license	   or	   off-­‐label.14	   The	   high	   rate	   of	   off-­‐license	   and	   off-­‐label	  
drug	   prescriptions	   in	   pediatric	   practice	   is	   disturbing,	   as	   it	   entails	   experimental	   drug	   use	  
outside	  of	  the	  controlled	  conditions	  of	  a	  clinical	  trial.15	  
In	  the	  ongoing	  efforts	  to	  develop	  and	  provide	  drugs	  for	  the	  young,	  the	  principle	  of	  justice	  
is	  made	  operational	  in	  the	  pediatric	  research	  setting	  as	  the	  provision	  of	  safe	  and	  efficacious	  
treatments	  for	  minors.	  
Non-­‐maleficence	  
The	   principle	   of	   non-­‐maleficence	   intimates	   that	   biomedical	   interventions	   should	   not	  
intentionally	   inflict	   harm	   on	   the	   subjects	   of	   these	   interventions.	   This	   principle	   is	   often	  
formulated	  as	  “first	  do	  no	  harm”	  (primum	  non	  nocere).	  
Main	  issues	  in	  clinical	  research	  and	  paradigmatic	  approach	  in	  competent	  adults	  
The	  numerous	   incidences	  of	  unethical	   research	   conduct	   that	  have	  occurred	   in	   the	  past	  
century	  indicate	  that	  research	  can	  be	  unsafe,	  disrespectful	  of	  established	  ethical	  guidelines,	  
and	  lacking	  in	  scientific	  quality.16	  
Central	   to	   the	   current	   paradigmatic	   approach	   of	   unethical	   research	   is	   the	   review	   of	  
research	  protocols	  by	  ethics	   committees.	  This	  procedure	   seeks	   to	  guard	   that	   research	  has	  
added	  value,	   is	   safe	  and	  scientifically	   sound,	  and	  pays	  sufficient	  attention	   to	  ethical	   issues	  
such	  as	  the	  provision	  of	  information	  and	  the	  protection	  of	  the	  research	  subjects.	  
Workability	   problems	   of	   the	   paradigmatic	   approach	   in	   competent	   adults	   in	   pediatric	  
healthcare	  and	  implementation	  of	  the	  principle	  of	  non-­‐maleficence	  
In	  pediatric	  research,	  the	  desire	  to	  prevent	  unethical	  research	  can	  obstruct	  or	  prevent	  the	  
development	  of	  drugs	  for	  pediatric	  use,	  as	  the	  act	  of	  balancing	  the	  protection	  of	  minors	  and	  
the	   promotion	   of	   medical	   progress	   has	   proven	   to	   be	   complicated	   in	   the	   past	   several	  
decades.17	  Therefore,	  pediatric	  expertise	  in	  ethics	  committees	  is	  essential	  in	  addressing	  the	  
specific	  complexities	  of	  involving	  minors	  in	  clinical	  trials.	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In	   the	   specific	   setting	   of	   pediatric	   research,	   the	   principle	   of	   non-­‐maleficence	   is	   made	  
operational	   in	   the	  well-­‐organized	   efforts	   to	   prevent	   unethical	   research,	   among	  which	   the	  
review	  of	  research	  protocols	  by	  an	  ethics	  committee.	  
Beneficence	  
While	   the	   principle	   of	   non-­‐maleficence	   requires	   that	   biomedical	   interventions	   do	   not	  
inflict	   harm	   on	   the	   persons	   undergoing	   these	   interventions,	   the	   principle	   of	   beneficence	  
requires	  that	  biomedical	   interventions	  contribute	  to	  the	  welfare	  of	  these	  persons.	  This	  can	  
be	   achieved	   in	   two	   ways.	   First,	   biomedical	   interventions	   can	   generate	   benefits	   in	   the	  
research	   subjects	   themselves.	   Second,	   the	   drawbacks	   of	   biomedical	   interventions	   can	   be	  
balanced	  with	  a	  newly	  generated	  benefit,	  either	  directly	  to	  the	  minor	  research	  subject	  or	  to	  
another	  beneficiary.	  
Main	  issues	  in	  clinical	  research	  and	  paradigmatic	  approach	  in	  competent	  adults	  
The	   principle	   of	   beneficence	   is	   not	   easily	   applicable	   to	   research	   in	   humans.	   While	   a	  
medical	   intervention	   that	   is	   not	   intended	   to	   cause	   a	   direct	   benefit	   to	   the	   individual	  
concerned	  would	  be	  considered	  futile	  in	  the	  context	  of	  a	  treatment,	  the	  situation	  is	  clearly	  
different	  in	  the	  context	  of	  research.	  Research	  does	  not	  necessarily	  aim	  at	  generating	  a	  direct	  
benefit	   to	   the	   research	   subject.	   In	   the	   absence	   of	   a	   benefit,	   however,	   there	   is	   no	  
counterbalance	  for	  the	  risks	  and/or	  burdens	  involved	  in	  research.	  
Paradigmatically,	   competent	   persons	   are	   considered	   to	   be	   capable	   of	   voluntarily	  
accepting	  the	  risks	  and/or	  burdens	  involved	  in	  research.	  Therefore,	  the	  absence	  of	  a	  benefit	  
need	  not	  be	  a	  hurdle	  to	  conducting	  valuable	  non-­‐beneficial	  research.	  
Workability	   problems	   of	   the	   paradigmatic	   approach	   in	   competent	   adults	   in	   pediatric	  
healthcare	  and	  implementation	  of	  the	  principle	  of	  beneficence	  
Most	  minors	   are	   incapable	   of	   informed	   consent.	   As	   a	   consequence,	   a	   third	   party	   (the	  
parents	  or	  another	  legal	  representative)	  has	  to	  decide	  upon	  the	  participation	  of	  a	  minor	  in	  a	  
clinical	  trial.	  This	  proxy	  decision	  maker	  must	  serve	  the	  interests	  of	  the	  minor.	  When	  there	  is	  
no	  benefit	  to	  counterbalance	  the	  risks	  and	  burdens	  involved	  in	  participating	  in	  the	  research,	  
the	   interests	   of	   the	  minor	   in	   participation	  may	  be	  hard	   to	  demonstrate	   and	   the	   risks	   and	  
burdens	  involved	  may	  be	  difficult	  to	  justify.	  
Given	  the	  strong	  emphasis	  on	  risks	  in	  research	  participation,	  the	  principle	  of	  beneficence	  
is	  made	  operational	  in	  pediatric	  research	  in	  the	  efforts	  to	  counterbalance	  risks	  and	  burdens	  
involved	  in	  research	  participation.	  
Autonomy	  
The	   principle	   of	   autonomy	   is	   closely	   related	   to	   the	   capacity	   for	   self-­‐governance	   of	  
competent	  human	  beings.	  This	  capacity	  enables	   individuals	  to	  make	  autonomous	  decisions	  
that	  should	  be	  respected	  by	  others.	  
Supranational	  regulation	  in	  the	  EU	  ⏐	  33	  
Main	  issues	  in	  clinical	  research	  and	  paradigmatic	  approach	  in	  competent	  adults	  
In	   clinical	   research,	   autonomous	   decision	   makers	   are	   often,	   paradoxically,	   highly	  
dependent	  upon	  others,	  as	  they	  need	  information	  provided	  by	  experts	  to	  make	  rational	  and	  
informed	   decisions.18	   However,	   the	   information	   provided	   can	   be	   biased,	   deceptive,	   or	  
misunderstood	  (e.g.,	  in	  case	  of	  therapeutic	  misconception,	  see.19	  20	  As	  a	  result,	  autonomous	  
decision-­‐making	  may	  be	  compromised.	  
In	  competent	  adults,	  the	  ethical	  and	  legal	  doctrine	  of	  voluntary	  and	  informed	  consent	  is	  
used	   as	   a	   paradigm	   for	   autonomous	   decision-­‐making.	   According	   to	   this	   doctrine,	   valid	  
decisions	  to	  participate	  in	  research	  must	  be	  made	  voluntarily	  by	  competent	  persons	  (or	  their	  
representatives)	  after	  being	  duly	  informed	  of	  the	  nature,	  significance,	  implications,	  and	  risks	  
involved	  in	  the	  research.	  As	  a	  general	  rule,	  informed	  consent	  for	  research	  participation	  must	  
be	  provided	  in	  writing.	  The	  doctrine	  of	  voluntary	  and	  informed	  consent	  is	  well	  validated	  in	  
ethics	  and	  law.	  
Workability	   problems	   of	   the	   paradigmatic	   approach	   in	   competent	   adults	   in	   pediatric	  
healthcare	  and	  implementation	  of	  the	  principle	  of	  autonomy	  
In	   the	  pediatric	   setting,	  most	   research	   subjects	  are	  not	   capable	  of	  making	  autonomous	  
decisions	  because	  they	  do	  not	  comply	  with	  the	  ethical	  and	  legal	  requirements	  to	  do	  so.	  The	  
fact	   that	   most	   minors	   are	   incapable	   of	   giving	   a	   legally	   valid	   consent,	   however,	   does	   not	  
preclude	   them	   from	  having	  certain	  decision-­‐making	   skills,	   such	  as	  understanding	  what	   the	  
decision	  is	  about,	  assessing	  information,	  and	  making	  rational	  decisions.	  
In	   decisions	   to	   enroll	   a	   minor	   in	   clinical	   a	   study,	   different	   participants	   negotiate	   their	  
varying	  interests	  and	  concerns	  The	  role	  minors	  can	  and	  should	  play	  in	  these	  decisions	  may	  
be	   hard	   to	   determine	   due	   to	   the	   constantly	   evolving	   capacities	   and	   maturity	   of	   minors.	  
However,	  the	  principle	  of	  respect	  for	  minors	  implies	  that	  minors	  are	  appropriately	  involved	  
in	  decisions	  about	   research	  participation.	   Therefore,	   in	  pediatric	   research,	   the	  principle	  of	  
autonomy	  is	  made	  operational	  in	  pediatric	  research	  as	  respect	  for	  the	  minor	  by	  means	  of	  a	  
fair	  distribution	  of	  power	  and	  responsibility	  in	  research	  participation	  decisions.	  
Ethical	  concerns	  addressed	  in	  the	  European	  legal	  framework	  
All	   four	  ethical	   concerns	   in	  pediatric	   research	  discussed	  above	  are	  addressed	   in	  various	  
documents	   of	   the	   European	   legal	   framework.	   We	   will	   now	   explore	   how	   these	   ethical	  
concerns	  are	  addressed	  in	  the	  content	  of	  the	  European	  legal	  framework.	  
The	  European	  Convention	  on	  human	  rights	  and	  biomedicine	  
The	   European	   Convention’s	   provisions	   regarding	   the	   involvement	   of	   minors	   in	   clinical	  
research	   are	   related	   to	   the	   ethical	   concerns	   of	   counterbalancing	   risks	   and	   burdens,	  
preventing	   unethical	   research,	   and	   distributing	   decision-­‐making	   power	   and	   responsibility	  
fairly.	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Counterbalancing	  risks	  and	  burdens	  
As	  a	  general	  rule,	  article	  17,1ii	  of	  the	  European	  Convention	  provides	  that	  research	  on	  a	  
person	   without	   the	   capacity	   to	   consent	   may	   only	   be	   undertaken	   if	   “the	   results	   of	   the	  
research	  have	  the	  potential	  to	  produce	  real	  and	  direct	  benefit	  to	  his	  or	  her	  health.”	   In	  the	  
absence	  of	  a	   real	   and	  direct	  benefit,	   the	   risks	  and	  burdens	  are	  only	  deemed	  acceptable	   if	  
two	  additional	  requirements	  are	  met.	  First,	  the	  research	  must	  aim	  at	  generating	  benefit	  to	  
persons	  sharing	  the	  same	  age	  category,	  disease,	  disorder,	  or	  condition	  with	  the	  participating	  
research	  subject	   (article	  17,2i).	  Second,	   research	  may	  only	  entail	  minimal	   risk	  and	  minimal	  
burden	  to	  the	  research	  subject	  involved	  (article	  17,2i).	  In	  the	  additional	  protocol,	  the	  terms	  
“minimal	  risk”	  and	  “minimal	  burden”	  are	  clarified.	  According	  to	  article	  17	  of	  the	  additional	  
protocol,	  a	  research	  intervention	  only	  entails	  minimal	  risk	  if	  the	  results	  of	  that	  intervention	  
generate,	   at	   the	  most,	   a	   very	   slight	   and	   temporary	   negative	   impact	   on	   the	   health	   of	   the	  
person	   concerned	   and	   it	   entails	   only	   minimal	   burden	   if	   it	   is	   to	   be	   expected	   that	   the	  
discomfort	   to	  the	  research	  participant	  will	  be,	  at	   the	  most,	   temporary	  and	  very	  slight.	  The	  
explanatory	   report	   illustrates	   minimal	   risk	   as	   taking	   a	   single	   blood	   sample	   from	   a	   child	  
(Explanatory	  Report,	  section	  111).	  
The	  double	  requirement	  of	  generating	  a	  group	  benefit	  and	  limiting	  risks	  and	  burdens	  to	  
no	  more	   than	  “minimal”	  puts	  strong	  boundaries	  on	  pediatric	   research.	   In	  accordance	  with	  
the	   European	   Convention,	   several	   research	   interventions,	   such	   as	   clinical	   trials	   in	   early	  
stages	  of	  drug	  development,	  are	  not	  permitted	  in	  children.	  
Preventing	  unethical	  research	  
The	  prevention	  of	  unethical	  research	  is	  also	  addressed	  in	  the	  European	  Convention.	  First,	  
the	  convention	  states	  that	  minors	  should	  only	  take	  part	  in	  clinical	  research	  if	  similar	  results	  
cannot	  be	  obtained	  without	  their	  involvement,	  i.e.,	  by	  research	  not	  involving	  humans	  (article	  
16,i)	   or	   by	   research	   involving	   individuals	   capable	   of	   informed	   consent	   (article	   17,1iii).	  
Second,	   article	   17,1iv	   requires	   that	   authorization	   must	   be	   provided	   specifically	   and	   in	  
writing.	  
Fair	  distribution	  of	  decisional	  power	  and	  responsibilities	  
The	  European	  Convention	  requires	   in	  article	  17,1iv	  that	  the	  representative	  of	  the	  minor	  
must	   grant	   his	   or	   her	   informed	   consent	   for	   the	   involvement	   of	   a	  minor	   in	   a	   clinical	   trial.	  
Although	  the	  European	  Convention	  requires	  that	  the	  opinion	  of	  minors	  must	  be	  taken	  into	  
consideration	  as	  an	  increasingly	  determining	  factor	  in	  relation	  to	  age	  and	  degree	  of	  maturity	  
regarding	   therapeutic	   interventions	   (article	   6,2),	   this	   provision	   does	   not	   occur	   in	   the	  
provisions	  on	  research	  participation.	  However,	  the	  active	  participation	  of	  minors	  in	  decisions	  
is	   not	   hereby	   precluded.	  On	   the	   contrary,	   the	   European	   Convention	   grants	  minors	   a	   veto	  
right,	   as	   it	   is	   provided	   in	   article	   17,1v,	   that	   research	   can	   only	   be	   carried	   out	   if	   the	  minor	  
research	  subject	  does	  not	  object.	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The	  European	  clinical	  trial	  directive	  
Like	   the	   European	   Convention,	   the	   European	   Directive	   delineates	   specific	   provisions	  
regarding	  the	  involvement	  of	  minors	  in	  clinical	  research	  (article	  4)	  and	  touches	  on	  the	  ethical	  
concerns	   of	   counterbalancing	   risks	   and	   burdens,	   preventing	   unethical	   research,	   and	   fairly	  
distributing	  decision-­‐making	  power	  and	  responsibility.	  
Counterbalancing	  risks	  and	  burdens	  
The	  European	  Directive	  provides	  for	  a	  counterbalance	  to	  the	  risks	  and	  burdens	  involved	  
in	  pediatric	  research	  by	  requiring	  that	  the	  research	  generate	  a	  direct	  benefit.	   In	  article	  4e,	  
this	  direct	  benefit	  is	  defined	  broadly	  as	  “some	  direct	  benefit”	  that	  can	  be	  either	  an	  individual	  
benefit	  (to	  the	  research	  subject)	  or	  a	  group	  benefit	  (to	  the	  group	  of	  patients).	  In	  the	  case	  of	  
a	  group	  benefit,	  no	  additional	  requirements	  are	  applicable.	  
Along	  with	  the	  requirement	  that	  research	  generate	  a	  benefit,	  the	  European	  Directive	  also	  
sets	   forth	   a	   preventive	  measure	   in	   article	   4g,	   requiring	   that	   clinical	   trials	   be	   designed	   to	  
“minimize	  pain,	  discomfort,	   fear,	   and	  any	  other	   foreseeable	   risk	   in	   relation	   to	   the	  disease	  
and	   developmental	   stage.”	   The	   requirement	   that	   the	   degree	   of	   distress	   and	   risk	   be	  
constantly	  monitored,	   as	   stated	   in	   the	   same	   article,	   demonstrates	   the	   importance	   of	   this	  
provision,	  as	  conformity	  with	  most	  requirements	  in	  the	  European	  Directive	  is	  only	  assessed	  
at	  a	  single	  point	  in	  time.	  
Prevention	  of	  unethical	  research	  
The	   protection	   of	   minor	   research	   subjects	   is	   extensively	   addressed	   in	   the	   European	  
Directive.	   Aiming	   at	   the	   harmonization	   of	   already	   existing	   guidelines	   on	   good	   clinical	  
practice,	   the	   directive	   integrates	   the	  myriad	   principles	   captured	   in	   the	   historical	   codes	   of	  
research	  ethics	   in	  which	   the	  protection	  of	   research	  subjects	  has	  consequently	  been	  a	  vast	  
priority.	  
First,	   the	   well-­‐known	   general	   principle	   that	   the	   interests	   of	   the	   patient	   always	   prevail	  
over	   those	  of	   science	  and	  society	   is	  adopted	   in	  article	  4i	  of	   the	  directive.	  This	  provision	   is	  
notably	  subsumed	  in	  the	  specific	  provisions	  on	  clinical	  trials	  on	  minors.	  
Second,	  the	  European	  Directive	  states	  that	  minors	  should	  only	  be	  involved	  in	  research	  if	  
there	  is	  a	  necessity	  to	  do	  so.	  Consequently,	  minors	  should	  not	  be	  involved	  in	  research	  when	  
similar	   results	   can	   be	   obtained	   by	   research	   in	   competent	   adults	   or	   by	   other	   research	  
methods,	  as	  provided	  in	  article	  4e.	  In	  addition,	  this	  article	  requires	  that	  research	  be	  related	  
directly	  to	  “a	  clinical	  condition	  from	  which	  the	  minor	  concerned	  suffers	  or	  be	  of	  such	  nature	  
that	  it	  can	  only	  be	  carried	  out	  on	  minors.”	  
Third,	  article	  4a	  of	  the	  European	  Directive	  requires	  that	  consent	  for	  research	  participation	  
is	  given	  by	  the	  parents	  or	  a	  legal	  representative.	  It	  is	  specified	  that	  consent	  “must	  represent	  
the	  presumed	  will	  of	  the	  minor,	  and	  may	  be	  revoked	  at	  any	  time	  without	  repercussions	  to	  
the	  minor.”	  
36	  ⏐	  Chapter	  1	  
Fourth,	   according	   to	   article	   4d	   of	   the	   European	   Directive,	   incentives	   or	   financial	  
inducements	  to	  stimulate	  research	  participation,	  except	  for	  compensation,	  are	  prohibited.	  
Finally,	   article	   4h	   of	   the	   European	   Directive	   requires	   that	   an	   ethics	   committee	   with	  
pediatric	  expertise	  (“or	  after	  taking	  advice	   in	  clinical,	  ethical,	  and	  psychosocial	  problems	  in	  
the	   field	   of	   pediatrics”)	   endorse	   the	   research	   protocol.	   This	   ethics	   committee	   faces	   the	  
challenging	   task	  of	  assessing	  whether	   the	  design	  of	   the	   research	  project	   sufficiently	   fulfills	  
the	  ethical	  requirements	  captured	  in	  the	  European	  Directive.	  
Distributing	  decision-­‐making	  power	  and	  responsibilities	  fairly	  
The	   European	   Directive	   serves	   the	   involvement	   of	   minors	   in	   decisions	   on	   research	  
participation	   by	   stating	   in	   article	   4b	   that	  minors	  must	   receive	   information	   “regarding	   the	  
trial,	   the	   risks,	   and	   the	   benefits	   of	   the	   trial,”	   in	   accordance	   with	   their	   capacity	   for	  
understanding	   and	   provided	   by	   staff	   with	   experience	   with	   minors.	   In	   addition,	   article	   4c	  
provides	   that	   the	   (principal)	   investigator	   must	   consider	   the	   explicit	   wish	   to	   refuse	   or	  
discontinue	  participation	  formulated	  by	  a	  minor	  who	  is	  capable	  of	  assessing	  information	  and	  
forming	  an	  opinion.	  
The	   guideline	   on	   the	   implementation	   of	   the	   European	   Directive	   issued	   by	   the	   EMEA	  
(Ethical	   Considerations	   for	   Clinical	   Trials	   on	   Medicinal	   Products	   Conducted	   with	   the	  
Paediatric	   Population)	   provides	   additional	   guidance	   in	   the	   fair	   distribution	   of	   power	   and	  
responsibilities	   among	   decision	   makers.	   This	   guideline	   addresses	   a	   number	   of	   important	  
issues	  in	  the	  involvement	  of	  minors	  in	  clinical	  trials.	  First,	  assent,	  a	  term	  that	  is	  not	  used	  in	  
the	  European	  Directive,	   is	   recommended	   in	   the	  additional	   guidance	  as	   a	  means	   to	  enable	  
the	  participation	  of	  minors	  in	  decisions.	  Notwithstanding	  this	  provision,	  the	  responsibility	  of	  
parents	  to	  protect	  the	  interests	  of	  their	  child	  is	  emphasized.	  
Second,	   the	   gray	   zone	   between	   legal	   capacity	   to	   consent	   and	   factual	   capacity	   is	  
addressed.	   It	   is	   acknowledged	   that	   certain	   minors	   are	   mature	   enough	   to	   provide	   valid	  
consent,	  even	  when	  they	  have	  not	  reached	  the	  legal	  age	  cutoff.	  In	  this	  respect,	  the	  guideline	  
acknowledges	   that	   “emancipated	   minors”	   must	   give	   written	   consent	   to	   participation	   in	  
research	  and	  that	  the	  consent	  of	  the	  parents	  or	  another	  legal	  representative	  is	  not	  required	  
for	  mature	  minors.	  Notwithstanding	  this	  provision,	  it	  is	  emphasized	  that	  mature	  minors	  can	  
be	  vulnerable	  and	  may	  require	  additional	  discussions	  and	  explanations.	  
The	  pediatric	  regulation	  
The	  Pediatric	  Regulation	  solely	  addresses	  the	  issue	  of	  involving	  minors	  in	  clinical	  research	  
and	   focuses	   on	   the	   issue	   of	   facilitating	   the	   development	   of	   safe	   and	   efficacious	   are	   for	  
minors	   of	   all	   ages.	   In	   article	   2,1	   of	   the	   regulation,	   minors	   are	   defined	   as	   the	   population	  
between	  birth	  and	  18	  years	  of	  age.	  
The	  provision	  of	  safe	  and	  efficacious	  treatments	  to	  children	  
To	  encourage	  pediatric	  research	  aiming	  at	  the	  development	  of	  new	  drugs,	   the	  Pediatric	  
Regulation	   requires	   that,	   for	   every	   request	   for	   marketing	   authorization,	   a	   Pediatric	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Investigation	  Plan	  (PIP)	  be	  negotiated	  early	   in	  the	  research	  (article	  7).	  This	  PIP	   is	  to	  ensure	  
that	  the	  data	  necessary	  to	  use	  a	  drug	  in	  all	  subsets	  of	  the	  pediatric	  population	  are	  gathered	  
in	   the	   clinical	   research	   preceding	   the	   marketing	   authorization.	   However,	   waivers	   and	  
deferrals	   to	   this	   general	   rule	   are	   possible	   under	   certain	   conditions.	   In	   addition,	   pediatric	  
research	  is	  encouraged	  by	  means	  of	  strong	  incentives,	  as	  drugs	  tested	  in	  children	  obtain	  an	  
extension	  of	  market	  exclusivity	  of	  6	  months	  (article	  36).	  Also,	  for	  off-­‐patent	  drugs,	  research	  
in	  minors	  is	  rewarded	  by	  means	  of	  the	  “pediatric	  use	  marketing	  authorization.”	  
To	   arrange	   the	   assessment	   of	   PIPs,	   waivers,	   and	   deferrals,	   article	   3	   of	   the	   Pediatric	  
Regulation	  mandates	  the	  establishment	  of	  a	  Pediatric	  Committee,	  whose	  main	  tasks	  are	  the	  
assessment	   of	   PIPs,	  waivers,	   and	   deferrals	   and	   the	   support	   and	   advice	   of	   the	   agency	   and	  
commission.	  
Comparative	  analysis	  of	  the	  legal	  framework	  
The	   European	   legal	   framework	   surrounding	   pediatric	   clinical	   trials	   addresses	   various	  
ethical	   issues.	   However,	   none	   of	   the	   individual	   documents	   that	   constitute	   the	   framework	  
addresses	  the	  major	  issues	  in	  pediatric	  research	  in	  a	  systematic	  and	  exhaustive	  way.	  While	  
the	  European	  Convention	  and	  the	  European	  Directive	  mainly	  focus	  on	  the	  counterbalancing	  
of	   risks	   and	   burdens,	   the	   prevention	   of	   unethical	   research,	   and	   the	   fair	   distribution	   of	  
powers	   and	   responsibilities	   in	   decision	   making	   of	   research	   participation,	   the	   Pediatric	  
Regulation	   focuses	   almost	   exclusively	   on	   the	   development	   and	   provision	   of	   safe	   and	  
efficacious	  drugs	  for	  minors.	  
Unfortunately,	   the	   European	   legal	   framework	   lacks	   internal	   consistency	   in	   certain	  
matters.	   A	   comparative	   analysis	   of	   the	   three	   main	   documents	   of	   the	   European	   legal	  
framework	   reveals	   contradictory	   provisions	   among	   the	   different	   documents,	   such	   as	   the	  
provisions	   regarding	  non-­‐beneficial	   research	  and	   the	  veto	  power	  of	  minors	   in	  decisions	  of	  
research	  participation.	   In	   the	  area	  of	  non-­‐beneficial	   research,	  article	  17,2	  of	   the	  European	  
Convention	   requires	   that,	   in	   the	   absence	   of	   a	   direct	   benefit	   to	   the	   individual	   research	  
participant,	  a	  minor	  can	  be	   involved	   in	  research	   if	   the	  study	  only	  entails	  minimal	  risks	  and	  
minimal	   burden,	   while	   article	   4e	   of	   the	   European	   Directive	   simply	   requires	   “some	   direct	  
benefit”	   to	  the	  research	  subject	  or	  a	  related	  group	  of	  beneficiaries.	  This	   indicates	  that	   the	  
European	   Convention	   endorses	   a	   more	   restrictive	   policy	   than	   the	   European	   Directive.	  
Consequently,	   early	   stage	  drug	  development	  may	  be	   compromised	   in	  member	   states	   that	  
have	  signed	  and	  ratified	  the	  European	  Convention.	  
In	  relation	  to	  the	  power	  of	  a	  minor	  to	  veto	  participation	  in	  clinical	  research,	  contradictory	  
provisions	   also	   exist.	  While	   article	   4c	   of	   the	   European	  Directive	   states	   that	   the	   (principal)	  
investigator	  must	  consider	  the	  explicit	  wish	  of	  a	  minor	  to	  refuse	  or	  discontinue	  participation	  
(given	   that	   the	  minor	   is	   capable	   of	   assessing	   information	   and	   forming	   an	   opinion),	   article	  
17,1v	  of	   the	  European	  Convention	   states	   that	  minors	   cannot	  be	   involved	   in	  a	   study	  when	  
they	   object	   to	   research	   participation.	   Thus,	   the	   European	   Convention	   theoretically	   grants	  
minors	  more	  extensive	  decision-­‐making	  power	  than	  the	  European	  Directive	  does.	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In	   addition	   to	   these	   contradictory	   provisions,	   the	   European	   legal	   framework	   contains	  
numerous	   contingencies	   that	   require	  extensive	   interpretation.	   It	   is	   not	   clear,	   for	   example,	  
what	   must	   be	   understood	   to	   be	   an	   acceptable	   risk–	   benefit	   ratio,	   what	   it	   means	   to	  
“consider”	  the	  explicit	  dissent	  of	  a	  minor,	  how	  the	  capacity	  of	  minors	  to	  make	  decision	  can	  
be	   assessed,	   or	   why	   the	   European	   Directive	   refers	   to	   minor	   research	   participants	   as	  
“patients”	  and	   links	  benefits	   to	   the	  “group	  of	  patients.”	  The	   fact	   that	  many	   terms	  are	  not	  
clearly	   defined	   is	   likely	   to	   negatively	   affect	   the	   implementation	   of	   the	   European	   legal	  
framework	  and	  creates	  the	  need	  for	  accurate	  guidance	  and	  support.	  
The	  interpretation	  and	  application	  of	  principles	  and	  requirements	  are	  largely	  left	  to	  those	  
active	   in	   the	   field	  of	  pediatric	   research	  practice.	  Although	   it	   is	   true	   that	  efforts	  have	  been	  
made	  to	  provide	  additional	  guidance	  in	  the	  interpretation	  and	  implementation	  of	  the	  legal	  
framework,	  little	  practical	  support	  is	  offered	  to	  those	  responsible	  for	  implementing	  the	  law.	  
Discussion:	  ethical	  concerns	  in	  regulating	  clinical	  trials	  
Up	  to	  this	  point,	  we	  have	  integrated	  the	  (1)	  ethical	  issues	  in	  clinical	  research,	  (2)	  common	  
approaches	   to	   these	   issues	   in	   competent	   adults,	   (3)	   workability	   problems	   of	   these	  
paradigmatic	   approaches	   in	   the	   pediatric	   research	   setting,	   and	   (4)	   regulatory	   answers	   to	  
these	   problems.	   Now,	   we	   will	   discuss	   the	   regulation	   of	   the	   ethical	   concerns	   in	   pediatric	  
research	  and	  to	  relate	  our	  analysis	  of	  the	  European	  legal	  framework	  to	  specific	  discussions	  in	  
bioethics.	  
The	  development	  of	  safe	  and	  efficacious	  healthcare	  for	  minors	  
Throughout	  this	  article,	  it	  has	  been	  clarified	  that	  the	  lack	  of	  commercial	  interest	  in	  testing	  
drugs	   in	   minors	   must	   be	   corrected	   in	   order	   to	   guarantee	   the	   marketing	   of	   an	   equitable	  
variety	  of	  drugs	  for	  pediatric	  use.	  Such	  a	  correction	  has	  been	  effected	  in	  the	  European	  legal	  
framework,	  as	  the	  Pediatric	  Regulation	  offers	  an	  extension	  of	  market	  exclusivity	  as	  a	  reward	  
for	  the	  conduct	  of	  pediatric	  clinical	  trials.	  
This	  incentive	  provided	  for	  in	  the	  Pediatric	  Regulation,	  however,	  is	  open	  to	  discussion	  on	  
two	   counts.	   First,	   it	   is	   questionable	   whether	   the	   extension	   of	   market	   exclusivity	   is	   a	  
reasonable	   and	   fair	   incentive.	   While	   the	   extension	   of	   market	   exclusivity	   seeks	   to	  
compensate	  the	  high	  costs	  of	  pediatric	  trials,	  the	  actual	  profits	  generated	  as	  a	  result	  of	  this	  
incentive	   are	   highly	   variable;	   in	   some	   cases,	   the	   extension	   of	   exclusivity	   not	   even	  
compensates	   for	   the	   costs	   of	   conducting	   the	   trial,	   while	   in	   other	   cases,	   the	   conduct	   of	  
pediatric	   trials	   is	  a	   lucrative	  enterprise.ii	   This	  highly	  variable	  compensation	   for	   the	  costs	  of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ii	   Similar	   to	   the	   Pediatric	   Regulation,	   US	   Legislation	   offers	   (already	   since	   1997)	   a	   6-­‐month	   extension	   of	  
marketing	  exclusivity	  as	  a	  reward	  for	  the	  conduct	  of	  pediatric	  clinical	  trials.	  A	  study	  of	  the	  economic	  return	  of	  
the	   Pediatric	   Exclusivity	   Program	   in	   the	   US	   shows	   that	   the	   economic	   return	   of	   the	   6-­‐month	   exclusivity	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conducting	  pediatric	  trials	  challenges	  the	  fairness	  and	  effectiveness	  of	  this	  incentive.	  Second,	  
an	   extension	   of	   market	   exclusivity	   may	   also	   work	   against	   the	   quality	   of	   research.	   As	   the	  
extended	   exclusivity	   is	   granted	   regardless	   of	   the	   results	   of	   pediatric	   research	   (and	   the	  
marketing	  of	  a	  drug	  for	  use	  in	  pediatrics),	  pediatric	  trials	  may	  be	  more	  economically	  oriented	  
than	  healthcare	  oriented.	  Care	  must	  be	  taken	  to	  ensure	  that	  the	  incentives	  provided	  for	  in	  
the	  Pediatric	  Regulation	  encourage	  the	  actual	  marketing	  of	  drugs	  for	  use	  in	  children	  and	  do	  
not	  result	   in	  the	  pro	  forma	  conducting	  of	  pediatric	  trials,	  which	  are	  aimed	  at	  acquiring	  the	  
reward	  than	  actually	  marketing	  drugs.	  
Counterbalancing	  risks	  and	  burdens	  
To	  prevent	   the	   interests	  of	  minors	   from	  being	  harmed	   in	   the	  process	  of	  proxy	   consent	  
provided	  by	  the	  parents	  or	  another	  legal	  representative,	  the	  freedom	  to	  accept	  the	  risks	  and	  
burdens	  of	  voluntarily	  participation	  in	  research	  is	  strongly	  restricted	  in	  pediatric	  research	  (cf.	  
supra).	  The	  main	  restriction	  of	  this	  freedom	  is	  the	  fact	  that	  research	  in	  minors	  must	  aim	  at	  
generating	  a	  benefit	  for	  the	  research	  participant	  or	  for	  a	  related	  group	  of	  beneficiaries.	  This	  
strong	  emphasis	  on	  benefit	  engenders	  several	  ethical	  issues.	  
First,	  even	  though	  children	  have	  an	  understanding	  of	  the	  risks	  and	  benefits	  of	  research,21	  
it	   is	   hard	   to	   measure	   benefit,	   risk,	   and	   burdens	   in	   a	   reliable	   way	   or	   to	   assess	   their	  
proportionality.	   Although	   risks	   may	   be	   determined	   using	   objective	   toxicity	   criteria,	   the	  
benefits,	  risks,	  and	  burdens	  in	  research	  are	  not	  entirely	  objective	  standards.	  On	  the	  contrary,	  
the	   experience	   and	   interpretation	   of	   risks,	   burdens,	   and	   benefits	   is	   highly	   personal	   and	  
related	   to	   the	   condition,	   disease,	   and	   personal	   experience	   of	   the	   participant.	   Due	   to	   this	  
subjective	   nature,	   it	   is	   not	   clear	   how	   risks,	   burdens,	   and	   benefits	   can	   be	   assessed	   in	   a	  
reliable	  way	   and	   how	   the	   proportionality	   between	   risks	   and	   burdens	   can	   be	   determined.	  
Second,	  the	  strong	  emphasis	  on	  benefit	  blurs	  the	  distinction	  between	  research	  and	  therapy.	  
While	  the	  distinction	  between	  research	  and	  therapy	  was	  already	  flawed	  in	  pediatric	  practice	  
due	   to	   the	   high	   rate	   of	   off-­‐label	   treatments	   (which	   constitutes,	   to	   a	   certain	   extent,	   an	  
experimental	  use	  of	  drugs),	  the	  strong	  emphasis	  on	  the	  necessity	  of	  a	  therapeutic	  benefit	  in	  
pediatric	  research	  gives	  the	  impression	  that	  research	  is	  a	  kind	  of	  a	  pseudotherapy.	  This	  may	  
result	  in	  a	  therapeutic	  misconception	  in	  the	  minds	  of	  minors	  and	  their	  parents.	  
Third,	   the	   requirement	   that	   research	   should	   generate	   a	   benefit	   imposes	   strong	  
boundaries	  on	  altruistic	  behavior	  in	  minors.	  While	  it	  is	  commonly	  rejected	  that	  minors	  have	  
a	   duty	   to	   participate	   in	   research,	   minors	   may	   be	   willing	   to	   participate	   in	   research	   for	  
altruistic	   motives.	   However,	   the	   strong	   emphasis	   on	   benefit	   and	   the	   restrictions	   on	   non-­‐	  
beneficial	   research	  may	  constitute	  a	  hurdle	   to	  altruistic	  behavior	   in	   research	  participation.	  
Therefore,	  one	  could	   reasonably	  ask	  whether	  pediatric	   research	   should	  not	  be	  opened	  up	  
for	   altruistic	   behavior	   by	   (healthy)	   volunteers	   or	   patients	   not	   belonging	   to	   the	   group	   of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
extension	   is	   highly	   variable	  with	   net	   return-­‐to-­‐cost	   ratios	   ranging	   from	  −0.84	   (i.e.,	   a	   loss	   of	   $11,088,214)	   to	  
73.63	  (i.e.,	  a	  profit	  of	  $507,899,374)	  (see	  Li	  et	  al.	  [23]).	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expected	   beneficiaries.22	   Enabling	   minors	   to	   decide	   upon	   voluntary	   participation	   in	   non-­‐
beneficial	  research	  themselves,	  however,	  remains	  ethically	  contested.23	  
Fourth,	   incentives	   continue	   to	   be	   a	   sensitive	   issue.24	   25	  While	   it	   is	   generally	   recognized	  
that	   no	   financial	   incentives	   other	   than	   compensation	   for	   the	   costs	   involved	   in	   research	  
participation	   is	   ethically	   acceptable,	   it	   is	   not	   clear	   how	   difficulties	   in	   the	   recruitment	   of	  
research	  subjects	  can	  be	  addressed	  without	  using	  incentives.	  In	  pediatric	  research,	  there	  is	  
the	  additional	  complexity	  that	  a	  reasonable	  compensation	  of	  costs	  may	  appear	  to	  be	  a	  large	  
amount	  of	  money	  to	  a	  minor.	  
The	  prevention	  of	  unethical	  research	  
The	   prevention	   of	   unethical	   research	   is	   arranged	   effectively.	   The	   numerous	   historical	  
incidences	  of	  unethical	   research	   in	  human	  beings	   in	  general	  and	  minors	   in	  particular	  have	  
called	  for	  response	  in	  court	  trials	  (e.g.,	  the	  Nuremberg	  Trials),	  self-­‐regulatory	  efforts	  of	  the	  
medical	   community	   (e.g.,	   the	   World	   Medical	   Association’s	   Declaration	   of	   Helsinki),	  
harmonized	   guidelines	   on	   good	   clinical	   practice	   (e.g.,	   International	   Conference	   on	  
Harmonization	   (ICH)	   E6,	   E11),	   and	   legal	   regulation	   (e.g.,	   European	   Convention,	   European	  
Directive).	  
The	   fair	   distribution	   of	   power	   and	   responsibilities	   in	   decision	   making	   on	   research	  
participation	  
Central	   to	   research	  participation	   is	   the	   voluntary	   and	   informed	   consent	   granted	  by	   the	  
research	   participant.	   In	   pediatric	   research,	   however,	   such	   consent	   most	   often	   cannot	   be	  
obtained,	   as	   most	   minors	   are	   incapable	   of	   legally	   valid	   consent.	   The	   problems	   of	  
implementation	  that	  the	  ethical	  and	  legal	  doctrine	  of	  voluntary	  and	  informed	  consent	  face	  in	  
the	   setting	   of	   pediatric	   research	   are	   commonly	   addressed	   by	   diversifying	   the	   process	   of	  
informed	   consent.	   This	   diversification	   may	   entail	   proxy	   consent	   given	   by	   the	   parents	   or	  
another	  legal	  representative,	  assent	  or	  dissent	  by	  the	  child,	  and	  the	  provision	  of	  appropriate	  
information	  to	  minors.26	  27	  
While	   the	  diversification	  of	  consent	  successfully	   tailors	   the	   legal	  dimension	  of	   informed	  
consent	   to	   the	   pediatric	   setting,	   it	   fails	   to	   address	   the	   ethical	   dimension	   of	   consent	   in	   a	  
satisfactory	  way,	  as	  the	  ethical	  principle	  of	  respect	  for	  persons	  that	  underpins	  the	  doctrine	  
of	   informed	  consent	   is	  eroded	  by	  such	  a	  diversification.	  Transferring	  the	  power	  to	  consent	  
from	  the	  research	  subject	  to	  a	  third	  party	  distracts	  the	  attention	  from	  the	  central	  position	  of	  
the	  minor	  in	  decisions	  on	  research	  participation,	  while	  there	  is	  no	  reason	  to	  compromise	  the	  
principle	  of	  respect	  for	  persons	  in	  the	  pediatric	  setting.28	  Therefore,	  the	  active	  involvement	  
of	  the	  minor	  in	  decisions	  to	  participate	  in	  research	  should	  not	  be	  an	  affirmation	  of	  a	  decision	  
that	  was	  already	  made	  by	  the	  parents	  (as	  is	  the	  case	  in	  parental	  consent	  and	  assent	  of	  the	  
child),	  but	  the	  starting	  point	  of	  decisions	  on	  research	  participation	  whenever	  possible	  (which	  
may	  not	  be	  the	  case	  in	  small	  children).	  
Although	   the	   European	   legal	   framework	   recognizes	   that	   minors	   develop	   a	   growing	  
capacity	  to	  understand	  and	  assess	  information	  and	  make	  informed	  decisions,	  the	  exact	  role	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that	   is	   attributed	   to	  minors	   in	   decisions	   on	   research	   participation	   often	   remains	   unclear.	  
While	  the	  right	  of	  minors	  to	  be	  informed	  and	  to	  dissent	  is	  taken	  very	  seriously,	  there	  is	  no	  
clarity	   concerning	   the	   active	   role	   that	  minors	   can	   and	   should	   play	   in	   the	   actual	   decision-­‐
making	   process	   apart	   from	   affirming	   or	   refusing	   participation.	   In	   addition,	   it	   is	   hard	   to	  
determine	  the	  decision-­‐making	  capacities	  of	  individual	  minors.29	  Therefore,	  practical	  support	  
for	  the	  active	  involvement	  of	  minors	  in	  decisions	  on	  research	  participation	  could	  be	  of	  great	  
help	   in	  making	   the	   principle	   of	   respect	   for	   persons	   operational	   in	   the	   setting	   of	   pediatric	  
research.	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Abstract	  
Over	   the	   past	   decades,	   considerable	   legislative	   effort	   has	   been	  made	   to	   facilitate	   and	  
encourage	  clinical	  research	  in	  the	  European	  Union	  (EU).	  Hereby,	  specific	  attention	  has	  been	  
paid	   to	   the	  urgent	  need	   to	   conduct	   research	   in	  minors.	   In	   this	   article,	  we	  will	   analyze	   the	  
regulation	   that	   currently	   governs	   pediatric	   clinical	   research	   conduct	   at	   the	   supranational	  
level	  of	  the	  EU	  and	  at	  the	  level	  of	  individual	  EU	  member	  states.	  Our	  analysis	  will	  focus	  on	  the	  
way	   in	   which	   the	   national	   and	   supranational	   legal	   frameworks	   address	   five	   ethical	   issues	  
that	   are	   specific	   to	   pediatric	   clinical	   research:	   (a)	   informed	   consent,	   (b)	   the	   necessity	   to	  
conduct	  research	  in	  minor	  subjects,	  (c)	  the	  interests	  of	  the	  subject	  concerned,	  (d)	  the	  risks	  
and	   burdens	   involved,	   and	   (e)	   the	   pediatric	   expertise	   of	   protocol	   review	   committees.	  We	  
conclude	  by	  discussing	  the	  harmonization	  and	  diversification	  of	  the	  legal	  requirements	  that	  
govern	  pediatric	  clinical	  research	  in	  the	  EU.	  
Introduction	  
Safe	  and	  efficacious	  drugs	  cannot	  be	  provided	   to	   those	   in	  need	  without	   the	  conduct	  of	  
clinical	   research.	   Over	   the	   past	   decades,	   considerable	   legislative	   effort	   has	   been	  made	   to	  
facilitate	  and	  encourage	  the	  conduct	  of	  clinical	  research	  in	  the	  European	  Union	  (EU).	  Hereby,	  
specific	   attention	   has	   been	   paid	   to	   the	   urgent	   need	   to	   conduct	   research	   in	   small	   and	  
vulnerable	  populations	  in	  general	  and	  minors	  in	  particular.	  
At	   present,	   pediatrics	   is	   still	   hampered	   by	   a	   stringent	   lack	   of	   licensed	   drugs	   that	   are	  
labeled	   for	   pediatric	   use.	   Although	   minors	   have	   been	   designated	   as	   therapeutic	   orphans	  
ever	  since	  this	  phenomenon	  was	  first	  described	  in	  1968,1	  the	  gamut	  of	  approved	  medicines	  
for	  use	  in	  children	  remains	  considerably	  smaller	  than	  that	  available	  to	  adults.2-­‐4	  Nonetheless,	  
catching	  up	  with	  pediatric	  research	  is	  a	  precarious	  enterprise,	  and	  several	  constraints	  render	  
the	  conduct	  of	  clinical	  studies	  in	  minor	  subjects	  complicated	  and	  expensive.5	  	  
In	  the	  specific	  case	  of	  cystic	  fibrosis,	  the	  conduct	  of	  clinical	  research	  in	  minor	  subjects	  is	  
particularly	   valuable	   for	   several	   reasons.	   First,	   starting	   with	   preventive	   and	   therapeutic	  
measures	   at	   an	  early	   stage	  of	   the	  disease	   is	   an	   important	   asset	  because	   the	  pathology	  of	  
cystic	   fibrosis	  develops	  over	   time.	  Therefore,	   the	  disease	  will	  have	  caused	   less	   irreversible	  
damage	  to	   the	  body	   in	  young	  children	  than	   in	  adults,	  and	  early	   intervention	  may	  open	  up	  
additional	  therapeutic	  opportunities.	  Second,	  the	  treatment	  of	  CF	  involves	  considerable	  drug	  
intake,	   also	   for	   minors.	   The	   availability	   of	   safe	   and	   efficacious	   drugs	   is	   thus	   of	   great	  
importance	  to	  minors	  suffering	  from	  CF.	  In	  addition,	  clinical	  trials	  may	  result	  in	  a	  reduction	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of	   the	  number	  of	  drugs	   that	  CF-­‐patients	  need	   to	   take,	  and	   thus	   reduce	   the	  burden	  of	   the	  
often	  harsh-­‐	   therapeutic	   scheme.	  Third,	   the	  number	  of	  patients	  with	  CF	   is	   relatively	   large,	  
rendering	  the	  population	  a	  good	  candidate	  for	  the	  conduct	  of	  pediatric	  clinical	  research.	  The	  
population	  of	  CF	  minors	   is	  not	   too	  small	   to	  compound	  representative	  samples	  of	   research	  
subjects,	  and	  the	  market	  for	  newly	  tested	  medicines	  can	  be	  large	  enough	  to	  make	  research	  
financially	  viable.	  	  
Obviously,	   the	   conduct	   of	   clinical	   research	   in	   the	   vulnerable	   population	   of	   minors	  
generates	   abundant,	   diverse,	   and	   specific	   ethical	   issues.	   Nonetheless,	   these	   issues	   have	  
increasingly	   been	   addressed	   in	   the	   ethical	   and	   legal	   frameworks	   that	   currently	   govern	  
clinical	  research	  in	  the	  EU.5	  	  
In	   this	   article,	   we	   will	   analyze	   the	   regulation	   that	   currently	   governs	   pediatric	   clinical	  
research	   conduct	   at	   the	   supranational	   level	   of	   the	   EU	   and	   at	   the	   level	   of	   individual	   EU	  
member	  states.	  Our	  analysis	  will	  focus	  on	  the	  way	  in	  which	  the	  national	  and	  supranational	  
legal	  frameworks	  address	  five	  ethical	  issues	  that	  are	  specific	  to	  pediatric	  clinical	  research:	  (a)	  
informed	  consent,	  (b)	  the	  necessity	  to	  conduct	  research	  in	  minor	  subjects,	  (c)	  the	  interests	  
of	  the	  subject	  concerned,	  (d)	  the	  risks	  and	  burdens	  involved,	  and	  (e)	  the	  pediatric	  expertise	  
in	   committees	   that	   review	   research	  protocols	   for	  pediatric	   studies.	  Our	  analysis	   concludes	  
with	   a	   discussion	   of	   the	   harmonization	   and	   diversification	   of	   the	   legal	   requirements	   that	  
govern	  pediatric	  clinical	  research	  in	  the	  European	  Union.	  	  
Scope,	  Materials	  and	  Methods	  
In	   this	   article,	   the	   supranational	   and	   national	   legal	   frameworks	   that	   govern	   pediatric	  
clinical	   research	   in	   the	   EU	   are	   investigated.	   Several	   criteria	   were	   used	   to	   determine	   the	  
scope	  of	  our	  analysis.	   First,	  our	  analysis	   is	   limited	   to	   legislation	   that	  was	   issued	  under	   the	  
responsibility	  of	  either	  the	  European	  Union,	  the	  Council	  of	  Europe,	  or	  by	  a	  legislative	  body	  of	  
an	   individual	  EU	  Member	  State.	  Second,	  only	   legal	   regulations	   fall	  within	   the	  scope	  of	  our	  
analysis.	   Ethical	   codes	   that	   were	   not	   promulgated	   by	   a	   legislative	   body,	   such	   as	   the	  
Declaration	  of	  Helsinki,	  are	  thus	  not	  taken	  into	  account,	  even	  though	  these	  codes	  may	  have	  
considerable	  (moral)	  authority.	  Third,	  to	  be	  part	  of	  our	  analysis,	  regulation	  must	  concern	  the	  
ethics	  of	  pediatric	  research	  conduct,	  and	  thus	  be	  related	  to	  good	  clinical	  practice	  in	  pediatric	  
research	   conduct	   or	   the	   encouragement	   and	   facilitation	   of	   pediatric	   clinical	   research.	  
Therefore,	   purely	   administrative	   requirements	   fall	   outside	   the	   scope	  of	   our	   analysis,	   even	  
when	   they	   are	   specific	   to	   pediatric	   research.	   Likewise,	   the	   general	   requirements	   for	   good	  
clinical	  practice	  in	  research	  conduct	  that	  are	  also	  applicable	  to	  other	  patient	  populations	  will	  
not	  explicitly	  be	  part	  of	  our	  analysis,	  even	  though	  these	  requirements	  are	  often	  applicable	  to	  
research	   in	   minor	   subjects.	   Also	   the	   general	   procedures	   of	   protocol	   approval	   by	   ethics	  
committees	  or	  competent	  authorities	  in	  individual	  EU	  member	  states	  will	  not	  be	  the	  subject	  
of	  our	  analysis,	  as	  such	  analysis	  was	  already	  published	  elsewhere.6	  7	  	  
At	   the	   supranational	   level,	   the	   Clinical	   Trial	   Directive	   (Directive	   2001/20/EC	   of	   the	  
European	   Parliament	   and	   of	   the	   Council	   of	   4	   April	   2001	   on	   the	   approximation	   of	   laws,	  
regulations	   and	   administrative	   provisions	   of	   the	   member	   states	   in	   relation	   to	   the	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implementation	   of	   good	   clinical	   practice	   in	   the	   conduct	   of	   clinical	   trials	   on	   medicinal	  
products	  for	  human	  use)	  functions	  as	  the	  centerpiece	  of	  a	  wider	  regulatory	  framework.8	  In	  
addition	   to	   the	   Clinical	   Trial	   Directive,	   the	   Pediatric	   Regulation	   (Regulation	   (EC)	   No	  
1901/2006	   of	   the	   European	   Parliament	   and	   of	   the	   Council	   of	   12	   December	   2006	   on	  
medicinal	  products	  for	  paediatric	  use	  and	  amending	  Regulation	  (EEC)	  No	  1768/92,	  Directive	  
2001/20/EC,	  Directive	  2001/83/EC	  and	  Regulation	   (EC)	  No	  726/2004)	   is	  highly	   relevant	   for	  
the	  conduct	  of	  pediatric	  clinical	  research	  in	  EU	  Member	  states.9	  This	  regulation	  discusses	  the	  
conduct	   of	   ethical	   research	   and	   aims	   to	   encourage	   and	   reward	   the	   conduct	   of	   pediatric	  
clinical	  research.	  Third,	  the	  Council	  of	  Europe	  Convention	  on	  Human	  Rights	  and	  Biomedicine	  
(European	  Convention	  for	  the	  protection	  of	  Human	  Rights	  and	  dignity	  of	   the	  human	  being	  
with	  regard	  to	  the	  application	  of	  biology	  and	  medicine,	  Oviedo	  1997,	  further	  the	  European	  
Convention)10	  is	  binding	  upon	  the	  EU	  member	  states	  that	  respectively	  signed	  and	  ratified	  the	  
Convention.i	   In	   2005,	   the	   European	   Convention	   was	   supplemented	   with	   an	   additional	  
protocol	   on	   biomedical	   research	   (Additional	   Protocol	   to	   the	   Convention	   on	  Human	  Rights	  
and	  Biomedicine,	  concerning	  Biomedical	  Research,	  Strasbourg,	  25.I.2005),11	  which	  is	  binding	  
upon	  the	  member	  states	  that	  signed	  and	  ratified	  this	  additional	  protocol.ii	  	  
In	   addition	   to	   our	   analysis	   of	   supranational	   regulation,	   we	   analyzed	   the	   domestic	  
legislation	  that	  implements	  the	  Clinical	  Trial	  Directive	  into	  the	  national	  law	  of	  individual	  EU	  
member	  states.	  Table	  1	  offers	  an	  overview	  of	  national	   laws	   implementing	  the	  Clinical	  Trial	  
Directive.	  The	  original	   texts	  of	  domestic	   laws,	  acts,	  decrees,	  or	  regulations	  that	   implement	  
the	   Clinical	   Trial	   Directive	   into	   national	   law	   entail	   different	   legal	   systems	   (civil	   law	   and	  
common	   law)	   and	   are	   issued	   in	   no	   less	   than	   22	   different	   languages.	   Our	   analysis	   covers	  
original	   texts	   in	   four	   languages	   (English,	   French,	   German,	   and	   Dutch).	   In	   addition,	   (most	  
often	  unauthorized)	  English	  translations	  of	  national	  laws	  were	  consulted,	  and	  in	  one	  case,	  a	  
native	  speaker	  was	  called	  upon	  to	  gather	  information	  where	  no	  translation	  was	  accessible.iii	  
For	  24	  EU	  Member	  States,	  the	  text	  of	  the	  national	  law	  that	  implements	  the	  Clinical	  Trial	  
Directive	   could	   be	   analyzed	   in	   its	   original	   language	   or	   via	   an	   (unauthorized)	   English	  
translation.	  Specific	   regulations	  arranging	   the	  operational	   implementation	  of	  national	   laws	  
(e.g.,	  (royal)	  decrees,	  orders,	  circulars),	  however,	  were	  often	  difficult	  or	  impossible	  to	  access	  
in	   English.	   Therefore,	   these	   documents	   will	   not	   exhaustively	   be	   part	   of	   the	   analysis	  
presented	  in	  this	  article.	  For	  three	  countries,	  there	  was	  no	  English	  translation	  of	  the	  national	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i	  For	  an	  overview	  of	  countries	  that	  signed	  and	  ratified	  the	  European	  Convention,	  see:	  
http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?NT=164&CM=&DF=&CL=ENG	  (accessed:	  1	  
December	  2009)	  
ii	  For	  an	  overview	  of	  countries	  that	  signed	  and	  ratified	  the	  European	  Convention’s	  Additional	  Protocol	  
concerning	  Biomedical	  Research,	  see:	  
http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?NT=195&CM=7&DF=03/12/2009&CL=ENG	  
(accessed:	  1	  December	  2009)	  
iii	  The	  authors	  are	  grateful	  to	  Zuzanna	  Osewska	  for	  the	  analysis	  and	  translation	  of	  the	  Polish	  law.	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law	   implementing	   the	   European	   Clinical	   Trial	   Directive	   available	   (Cyprus,	   Hungary,	   and	  
Slovenia).	  For	  these	  countries,	  the	  analysis	  in	  this	  article	  is	  based	  on	  secondary	  sources,	  in	  so	  
far	  that	  such	  information	  could	  be	  traced.	  	  
	  
Table	  1:	  	  
Overview	  of	  the	  national	  laws	  implementing	  the	  European	  Clinical	  Trial	  Directive	  
Country	   Domestic	  implementation	  of	  Directive	  2001/20/ECiv	   Article	  
Austria	   Drug	  Law	  (1983,	  amended	  29	  April	  2004	  to	  implement	  Directive	  
2001/20/EC)	  
§42(1)	  
Belgium	   Law	   concerning	   experiments	   on	   the	   human	   person	   (7	   May	  
2004)	  	  
Art.	  7	  
Bulgaria	   Medicinal	  Products	  in	  Human	  Medicine	  Act	  (13	  April	  2007).	  	   Art	  97,	  100	  




Cyprus	  	   -­‐	   	  
Czech	  Republic	   Act	  on	  Pharmaceuticals	  and	  on	  Amendments	  to	  Some	  Related	  
Acts	  (the	  Act	  on	  Pharmaceuticals,	  6	  December	  2007).	  	  
Section	  52	  	  
	  
Decree	   on	   good	   clinical	   practice	   and	   detailed	   conditions	   of	  
clinical	  trials	  on	  medicinal	  products	  (23	  June	  2008).	  	  
Section	  8	  (5)	  
Denmark	   Act	   on	   a	   Scientific	   Ethical	   Committee	   System	   and	   the	  
Processing	  of	  Biomedical	  Research	  Projects	  (28	  May	  2003).	  	  
Art.	  17	  	  
Art.	  19	  	  
Estonia	   Medicinal	  Products	  Act	  (16	  December	  2004).	  	   §91	  	  
Germany	   Medicinal	  Products	  Act	  (12	  December	  2005).	   Chapter	   6,	   Section	  
40(4)	  and	  41(2)	  	  
Finland	   Medical	  Research	  Act	  No.	  488/1999	  (23	  April	  2004).	  	   Section	  8	  	  
France	   Law	   no.	   2004-­‐806	   of	   9	   August	   2004	   concerning	   public	   health	  
policy	  	  
1121-­‐1122	  
Greece	   Law	   n°	   DYG	   3/89292	   on	   the	   harmonization	   of	   the	   Hellenic	  
Legislation	   to	   the	   respective	   Community	   legislation	   in	  
compliance	  with	  Directive	  2001/20/EC	  of	  4	  April	  2001	  “on	  the	  
approximation	  of	  the	   legislative,	  regulatory	  and	  administrative	  
provisions	  of	  the	  Member	  States	  regarding	  the	  implementation	  
of	   Good	   Clinical	   Practice	   (GCP)	   in	   clinical	   trials	   on	   medicinal	  
products	  for	  human	  use”.	  (12	  December	  2005).	  
Art.	  4	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
iv	  The	  document	  named	   in	   the	   list	   is	   the	  main	   law,	  act	  or	   regulation	   implementing	   the	  Clinical	  Trial	  Directive	  
into	  the	  national	  law	  of	  the	  member	  state	  concerned,	  that	  has	  explicitly	  been	  drafted	  to	  implement	  the	  Clinical	  
Trial	  Directive.	  It	   is	   important	  to	  acknowledge	  that	  other	  laws,	  acts	  or	  regulations	  that	  are	  complementary	  to	  
the	  named	  document(s)	  in	  the	  regulation	  of	  pediatric	  research	  may	  exist.	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Hungary	   Health	   Ministry	   Decree	   EüM24/2002	   on	   the	   clinical	   trial	   of	  
medicinal	   products	   for	   human	   use	   and	   on	   Good	   Clinical	  
Practice	  
	  
Ireland	  	   Statutory	   Instrument	  No.	  190	  of	  2004	  (European	  Communities	  
(Clinical	   Trials	   on	   Medicinal	   Products	   for	   Human	   Use)	  
Regulations	  (29	  April	  2004).	  
Part	  4	  
	  
Italy	   Legislative	   Decree	   no.	   211	   concerning	   the	   transposition	   of	  
Directive	   2001/20/EC	   relating	   to	   the	   implementation	   of	   good	  
clinical	   practice	   in	   the	   conduct	   of	   clinical	   trials	   on	   medicinal	  
products	  for	  clinical	  use	  (24	  June	  2003)	  
Section	  4	  
Latvia	   Cabinet	  Regulation	  No	  172	  Regulations	  on	  Conducting	  Clinical	  
Trials	   and	   Non-­‐interventional	   studies	   and	   Labeling	   of	  
Investigational	   Medicinal	   Products,	   and	   Procedure	   for	  
Conducting	   Inspections	  on	  Compliance	  with	   the	  Requirements	  
of	  Good	  Clinical	  Practice	  (28	  February	  2006).	  	  
Art.	  30	  	  
Lithuania	   Health	   Care	   Ministry	   Decree	   on	   the	   Implementation	   of	   the	  
Rules	   of	   Good	   Clinical	   Practice,	   which	   implemented	   Directive	  
2001/20/EC	  (11	  May	  2004).	  
	  
Law	  on	  Ethics	  of	  Biomedical	  Research	  (11	  May	  2000).	  	   Art.	  7	  
Luxembourg	   Grand	   Ducal	   Regulation	   concerning	   the	   application	   of	   good	  
clinical	  practice	  in	  the	  conduct	  of	  clinical	  trials	  of	  medicines	  for	  




Malta	   Amended	  Medicines	  Act	   (Medicines	  act	   to	  make	  provision	   for	  
matters	   connected	   with	   the	   manufacture,	   preparation	   and	  
assembly,	   wholesale	   distribution,	   storage,	   destruction,	  
disposal,	   advertising	   and	   authorization	   of	   medicinal	   products	  
and	  any	  activity	  connected	  therewith	  and	  the	  regulation	  of	  the	  
sale	   of	   medicinal	   products,	   pharmacies	   and	   related	  
pharmaceutical	   activities	   and	   for	   any	   other	   matters	   ancillary	  
thereto	  or	  connected	  therewith,	  21	  November	  2003)	  
Art.	  18.2.	  
Netherlands	   Amended	   Medicinal	   Research	   involving	   Human	   Subjects	   Act	  




Poland	   Resolution	  of	   the	  Senate	  of	   the	  Republic	  of	  Poland	  of	  16	  April	  
2004,	   amending	   the	   Pharmaceutical	   Law	   and	   the	   Act	   on	   the	  
Profession	  of	  the	  Medical	  Doctor	  
	  
Portugal	   Law	   no.	   46/2004	   concerning	   Clinical	   Trials	   on	   Medicinal	  
Products	  for	  Human	  Use	  (19	  August	  2004).	  
Art.	  7	  
Romania	   Ministry	   of	   Health	   order	   No.	   904/25.07.2006	   on	   approval	   of	  
rules	  relating	  to	  the	  implementation	  of	  good	  clinical	  practice	  in	  
the	   conduct	  of	   clinical	   trials	  on	  medicinal	  products	   for	  human	  
use	  	  
	  
Slovakia	   Ministerial	  Decree	  on	  clinical	  trials	  and	  Good	  Clinical	  Practice	  (1	  
May	  2004).	  	  
Art.	  15b	  	  
Slovenia	   -­‐	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Spain	   Royal	  Decree	  223/2004	  regulating	  clinical	   trials	  with	  medicinal	  
products	  (6	  February	  2004).	  	  
Art.	  4	  	  
Art.	  7,3	  	  
Sweden	   Act	   concerning	   the	   Ethical	   Review	   of	   Research	   Involving	  
Humans	  (5	  June	  2003).	  	  
Section	  18	  	  
United	  Kingdom	   Medicines	   for	   Human	   Use	   (Clinical	   Trials)	   Regulations	  
(Statutory	  Instrument	  2004	  No.	  1031,	  31	  March	  2004).	  	  
Part	  4	  	  
1.	  Ethical	  issues	  addressed	  in	  the	  legal	  frameworks	  	  
Five	   major	   ethical	   issues	   in	   pediatric	   clinical	   research	   conduct	   are	   addressed	   in	   the	  
European	   legal	   frameworks	   governing	   pediatric	   research:	   (a)	   informed	   consent,	   (b)	   the	  
necessity	  to	  conduct	  research	  in	  minors,	  (c)	  the	  interests	  of	  the	  research	  subject	  in	  the	  study	  
concerned,	   (d)	   the	   risks	   and	   burdens	   involved,	   and	   (e)	   the	   pediatric	   expertise	   of	   ethics	  
committees	  reviewing	  protocols	  for	  clinical	  studies	  in	  minors.	  	  
1.1	  Informed	  consent	  	  
Ever	   since	   the	   research	   scandals	   during	   the	   Second	  World	  War	   and	   its	   aftermath,	   the	  
principle	  of	  respect	  for	  persons	  has	  been	  adopted	  steadfastly	  in	  influential	  ethical	  guidelines	  
and	   legal	   regulations.	  Traditionally,	   this	  principle	  has	  been	  made	  operational	   in	   the	  ethical	  
and	  legal	  doctrine	  of	  informed	  consent.	  	  
The	  current	  paradigm	  of	  informed	  consent	  for	  research	  participation	  is	  voluntary	  consent	  
provided	  by	  a	  legally	  competent	  adult	  after	  being	  duly	  informed	  about	  all	  relevant	  aspects	  of	  
the	   clinical	   trial	   concerned.	   For	   several	   reasons,	   this	   paradigm	   has	   serious	   workability	  
problems	  in	  the	  case	  of	  pediatric	  clinical	  studies.	  First,	  due	  to	  age	  restrictions,	  most	  minors	  
are	  not	  capable	  of	  granting	   legally	  valid	  consent,	  as	  they	  may	  not	  have	  reached	  the	  age	  of	  
medical	  majority	  (which	  is	  not	  necessarily	  the	  same	  as	  the	  age	  of	  legal	  majority).12	  Second,	  
the	   capacity	   to	   understand	   and	   assess	   information	   is	   often	   still	   underdeveloped	   in	  minor	  
research	  subjects.	  As	  a	  result,	  minors	  may	  lack	  the	  competence	  necessary	  to	  make	  rational	  
decisions	   and	   it	   may	   be	   difficult	   to	   inform	   minors	   duly.	   Third,	   most	   minors	   are	   largely	  
dependent	  upon	  their	  parents	  in	  numerous	  aspects	  of	  their	  lives.	  It	  is	  widely	  recognized	  that	  
parents	  enjoy	  considerable	  discretion	  in	  educational	  matters,	  and	  therefore	  they	  may,	  to	  a	  
large	   extent,	   decide	   autonomously	   whether	   and	   to	   what	   extent	   their	   minor	   children	   can	  
participate	  in	  decisions	  about	  clinical	  trial	  participation.	  	  
Due	   to	   the	   incompetence	   of	   minors	   to	   provide	   legally	   valid	   informed	   consent,	   the	  
involvement	   of	   a	   competent	   adult	   acting	   as	   a	   surrogate	   decision	   maker	   is	   most	   often	  
required	  to	  enroll	  a	  minor	  in	  a	  clinical	  trial.	  Obviously,	  such	  involvement	  of	  a	  proxy	  does	  not	  
preclude	  minors	   from	   playing	   an	   active	   role	   in	   decisions	   about	   clinical	   trial	   participation.	  
Quite	  the	  reverse,	  several	  decision	  making	  strategies,	  including	  (i)	  dual	  consent,	  (ii)	  consent	  
by	   the	   proxy	   and	   assent	   by	   the	   child,	   and	   (iii)	   respect	   for	   the	   dissent	   of	   the	   child,	   aim	   at	  
encouraging	  shared	  decision	  making	  and	  a	  fair	  differentiation	  of	  decision	  authority	  between	  
the	  proxy	  decision	  maker	  and	  the	  minor	  research	  subject.	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1.2	  Necessity	  to	  involve	  minors	  	  
Minors	  are	  widely	  regarded	  as	  a	  vulnerable	  population	  that	  deserve	  extensive	  protection	  
against	  harm	  and	  abuse.	  Therefore,	   it	   is	  a	  generally	  accepted	  principle	   that	  minors	   should	  
not	  be	  exposed	  to	  the	  risks	  to	  harm	  and	  abuse	  that	  are	  inherent	  to	  any	  clinical	  trial,	  unless	  
this	  is	  strictly	  required	  to	  generate	  relevant	  research	  results	  that	  will	  be	  of	  benefit	  to	  minor	  
patients.	  In	  this	  respect,	  the	  large	  majority	  of	  ethical	  codes	  and	  legal	  rules	  prohibit	  research	  
from	  being	  conducted	  in	  minors	  whenever	  alternative	  research	  methods	  or	  (non-­‐vulnerable)	  
populations	  are	  available.	  	  
1.3	  Interest	  in	  the	  research	  	  
To	  preclude	  human	   subjects	  who	  participate	   in	   clinical	   trials	   being	   used	   as	   a	  means	   to	  
procure	   a	   scientific	   end,	   two	   principles	   of	   research	   conduct	   are	   generally	   adopted	   in	   the	  
ethical	   codes	  and	   legal	   regulations	   governing	   clinical	   research.	   First,	   the	  principle	   that	   the	  
interests	   of	   science	   and	   society	   never	   prevail	   over	   the	   interests	   of	   individual	   research	  
subjects	   is	  widely	   endorsed	   in	   ethics	   and	   law.	   Second,	   it	   is	  widely	   assumed	   that	   research	  
should	   comply	   with	   the	   interests	   of	   the	   subjects	   involved.	   However,	   it	   is	   important	   to	  
emphasize	  that	  these	  interests	  can	  be	  very	  broad	  and	  diverse,	  as	  they	  may	  range	  from	  mere	  
altruism	   to	   becoming	   one	   of	   the	   very	   first	   beneficiaries	   of	   a	   newly	   developed	   safe	   and	  
efficacious	  treatment.	  
In	   the	   specific	   case	   of	   pediatric	   research,	   there	   exists	   a	   considerable	   consensus	   that	  
clinical	   research	   in	   the	   pediatric	   population	   should	   only	   be	   undertaken	   in	   so	   far	   that	   the	  
research	  serves	  the	  interests	  of	  minors,	  either	  by	  generating	  a	  direct	  benefit	  for	  the	  minor	  
research	   subject	   concerned,	   or	   by	   yielding	   an	   indirect	   benefit	   to	   a	   larger	   group	   of	  
beneficiaries,	  such	  as	  the	  population	  of	  minors	  or	  the	  group	  of	  patients	  to	  which	  the	  minor	  
belongs.	  	  
1.4	  Risks	  and	  burdens	  
Research	  participation	  never	  comes	  without	  burdens,	  and	  most	  often	  accepting	  a	  certain	  
degree	   of	   risk	   is	   essentially	   part	   of	   participating	   in	   a	   clinical	   trial.	   Deciding	   upon	   the	  
acceptability	  of	  the	  risks	  and	  burdens	  inherent	  to	  research	  participation,	  however,	  is	  often	  a	  
complex	   and	   difficult	   issue,	   particularly	   when	   research	   is	   conducted	   in	   a	   vulnerable	  
population	  such	  as	  minors.	  	  
Throughout	   the	   recent	   history	   of	   pediatric	   clinical	   research,	   the	   ethical	   acceptability	   of	  
research	  risks	  has	  been	  the	  subject	  of	  considerable	  debate.13	  Excluding	  minors	  from	  research	  
participation	  altogether	  may	  be	  considered	  the	  most	  effective	  way	  to	  protect	  minors	   from	  
research	   risks.	  However,	   the	  practical	  outcome	  of	   such	  a	   stance	   is	  devastating,	  because	   it	  
leads	  minors	  to	  become	  therapeutic	  orphans.1	  Therefore,	  alternate	  ways	  have	  been	  sought	  
to	  keep	  minors	  from	  unacceptable	  research	  risks.	  At	  the	  present	  time,	  risk	  thresholds	  often	  
play	   a	   prominent	   role	   in	   the	   assessment	   of	   the	   ethical	   acceptability	   of	   pediatric	   clinical	  
trials.14-­‐17	   As	   a	   general	   rule,	   research	   in	   minors	   will	   increasingly	   be	   considered	   to	   be	  
acceptable	  as	  the	  risks	  involved	  decrease.	  In	  addition,	  it	  is	  a	  widely	  supported	  premise	  that,	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to	   a	   considerable	   extent,	   the	   benefits	   generated	   by	   clinical	   research	   justify	   the	   risks	  
involved.	  	  
Several	   principles	   guide	   the	   assessment	   of	   this	   risk-­‐benefit	   ratio.	   First,	   a	   principle	   of	  
proportionality	  is	  used	  to	  determine	  whether	  the	  risks	  inherent	  to	  a	  clinical	  trial	  are	  deemed	  
acceptable.	   The	   greater	   the	   benefit	   to	   a	   person	   or	   group	   of	   individuals	   the	   research	   is	  
expected	  to	  yield,	  the	  more	  the	  risk	  will	  be	  considered	  acceptable.	  Second,	  a	  direct	  benefit	  
to	  the	  subject	  concerned	  is	  preferred	  over	  a	  benefit	  to	  more	  remote	  beneficiaries,	  such	  as	  
the	  population	  of	  minors,	   the	  group	  of	  patients	  to	  which	  the	  minor	  belongs,	  or	  a	  group	  of	  
future	  patients.	  As	  a	  result,	  the	  more	  remote	  the	  beneficiary,	  the	  higher	  the	  risk	  threshold.	  
Third,	  also	  the	  physical	  condition	  of	  research	  subjects	  relates	  to	  the	  acceptability	  of	  research	  
risks.	   The	   worse	   the	   condition	   of	   a	   patient,	   the	   higher	   the	   risk	   that	   will	   be	   deemed	  
acceptable.	   In	   severe	   conditions,	   such	   as	   life	   threatening	   diseases	   at	   an	   advanced	   stage,	  
decision-­‐makers,	  including	  ethics	  committees,	  clinicians,	  parents,	  or	  a	  minor	  subject	  will	  be	  
generally	  prepared	  to	  accept	  higher	  risks	  in	  research	  participation.	  	  
1.5	  Pediatric	  expertise	  of	  ethics	  committees	  
Before	  research	  in	  minor	  subjects	  can	  start,	  the	  research	  protocol	  must	  be	  reviewed	  and	  
endorsed	  by	  the	  competent	  authority	  and	  at	  least	  one	  ethics	  committee.v	  To	  guarantee	  an	  
adequate	  assessment	  of	  issues	  that	  are	  specifically	  related	  to	  the	  conduct	  of	  clinical	  research	  
in	  minors,	  ethics	  committees	  require	  expertise	  to	  assess	  rigorously	  research	  protocols.	  This	  
pediatric	   expertise	   can	   be	   achieved	   in	   various	   ways,	   such	   as	   fostering	   pediatric	   expertise	  
within	   the	   ethics	   committee	   (e.g.,	   by	   having	   a	   pediatrician	   among	   the	   committees	  
members),	  or	  by	  consulting	  external	  expertise.	  	  
2.	  Regulation	  at	  the	  supranational	  level	  
At	   present,	   clinical	   research	   is	   to	   a	   considerable	   extent	   regulated	   at	   the	   supranational	  
level.	  At	  the	  European	  supranational	   level,	  the	  European	  Convention	  on	  Human	  Rights	  and	  
Biomedicine,	   the	   European	   Clinical	   Trial	   Directive,	   and	   the	   Pediatric	   Regulation	   together	  
constitute	  the	  legal	  framework	  governing	  pediatric	  clinical	  trials.	  	  
2.1	  European	  Convention	  on	  Human	  Rights	  and	  Biomedicine	  	  
In	  1997,	  the	  European	  Convention	  was	  denounced	  by	  the	  Council	  of	  Europe.	  In	  2005,	  this	  
Convention	  was	  supplemented	  with	  an	  additional	  protocol	  on	  biomedical	  research.	  To	  date,	  
the	   European	   Convention	   is	   binding	   upon	   the	   14	   EU	   Member	   States	   (and	   10	   countries	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
v	  Depending	  upon	  the	  EU	  member	  state	  in	  which	  the	  research	  is	  conducted,	  the	  intervention	  of	  one	  or	  several	  
ethics	  committees	  may	  be	  required	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outside	  the	  EU)	  that	  signed	  and	  ratified	  it,	  and	  its	  additional	  protocol	  is	  binding	  upon	  the	  4	  
EU	  Member	  States	  (and	  1	  country	  outside	  the	  EU)	  that	  signed	  and	  ratified	  it.vi	  	  
The	  European	  Convention	  specifically	  addresses	  the	  issue	  of	  pediatric	  research	  in	  art.	  17	  
(Box	  1).	  Also	  art.	  6	  and	  16	  are	  of	  some	  relevance,	  as	  they	  provide	  details	  on	  the	  protection	  of	  
persons	  not	  able	  to	  consent	  (be	  it	  not	  specifically	  in	  the	  setting	  of	  clinical	  research),	  and	  the	  
protection	  of	  persons	  undergoing	  research	   (be	   it	  not	  specifically	  minors),	   respectively.	  The	  
additional	  protocol	  on	  biomedical	  research	  touches	  the	  subject	  of	  pediatric	  research	  in	  art.	  
17.	  
The	  European	  Convention’s	  provisions	  on	  the	   involvement	  of	  minors	   in	  clinical	   research	  
are	   related	   to	   the	   provision	   of	   informed	   consent,	   the	   necessity	   to	   involve	   minors,	   the	  
interest	  of	  the	  research	  subject	  and	  the	  risks	  and	  burdens	  involved	  in	  the	  study.	  	  
	  	  
Box	  1:	  
European	  Convention	  on	  Human	  Rights	  and	  Biomedicine	  
Article	  17	  –	  Protection	  of	  persons	  not	  able	  to	  consent	  to	  research	  
	  
1. Research	  on	  a	  person	  without	  the	  capacity	  to	  consent	  as	  stipulated	  in	  Article	  5	  may	  be	  undertaken	  only	  
if	  all	  the	  following	  conditions	  are	  met:	  
i. the	  conditions	  laid	  down	  in	  Article	  16,	  sub-­‐paragraphs	  i	  to	  iv,	  are	  fulfilled;	  
ii. the	  results	  of	  the	  research	  have	  the	  potential	  to	  produce	  real	  and	  direct	  benefit	  to	  his	  or	  her	  
health;	  
iii. research	   of	   comparable	   effectiveness	   cannot	   be	   carried	   out	   on	   individuals	   capable	   of	   giving	  
consent;	  
iv. the	   necessary	   authorisation	   provided	   for	   under	   Article	  6	   has	   been	   given	   specifically	   and	   in	  
writing;	  and	  
v. the	  person	  concerned	  does	  not	  object.	  
2. Exceptionally	   and	  under	   the	  protective	   conditions	  prescribed	  by	   law,	  where	   the	   research	  has	  not	   the	  
potential	  to	  produce	  results	  of	  direct	  benefit	  to	  the	  health	  of	  the	  person	  concerned,	  such	  research	  may	  
be	  authorised	  subject	  to	  the	  conditions	  laid	  down	  in	  paragraph	  1,	  sub-­‐paragraphs	  i,	   iii,	   iv	  and	  v	  above,	  
and	  to	  the	  following	  additional	  conditions:	  
i. the	   research	   has	   the	   aim	   of	   contributing,	   through	   significant	   improvement	   in	   the	   scientific	  
understanding	  of	  the	  individual's	  condition,	  disease	  or	  disorder,	  to	  the	  ultimate	  attainment	  of	  
results	  capable	  of	  conferring	  benefit	  to	  the	  person	  concerned	  or	  to	  other	  persons	  in	  the	  same	  
age	  category	  or	  afflicted	  with	  the	  same	  disease	  or	  disorder	  or	  having	  the	  same	  condition;	  
ii. the	  research	  entails	  only	  minimal	  risk	  and	  minimal	  burden	  for	  the	  individual	  concerned.	  
Informed	  Consent	  	  
The	  European	  Convention	  provides	  in	  art	  17,1iv	  that	  the	  representative	  of	  the	  minor	  must	  
grant	  his	  or	  her	  informed	  consent	  for	  the	  enrollment	  of	  a	  minor	  subject	  in	  a	  clinical	  trial.	  This	  
authorization	   must	   be	   provided	   specifically	   and	   in	   writing.	   According	   to	   the	   European	  
Convention,	   it	   is	   not	   required	   that	   minor	   research	   subjects	   provide	   informed	   consent	   or	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
vi	   In	  Finland,	   that	   recently	   signed	  and	   ratified	   the	  European	  Convention,	   the	  European	  Convention	  will	   enter	  
into	  force	  at	  1	  March	  2010.	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assent	   in	   addition	   to	   the	   proxy	   consent	   provided	   by	   the	   parents	   or	   another	   legal	  
representative.	   However,	   the	   active	   participation	   of	   minors	   in	   decisions	   is	   hereby	   not	  
precluded.	  Quite	  the	  reverse,	  the	  European	  Convention	  does	  not	  create	  any	  hurdles	  to	  the	  
active	  participation	  of	  minors	  in	  consent	  discussions,	  and	  even	  grants	  minors	  clear	  decision-­‐
making	  powers	   in	  the	  form	  of	  a	  veto	  right,	  as	  art	  17,1v	  provides	  that	  research	  can	  only	  be	  
carried	   out	   if	   the	   minor	   research	   subject	   does	   not	   object.	   In	   addition,	   the	   European	  
Convention	   provides	   that	   the	   opinion	   of	   minors	   must	   be	   taken	   into	   consideration	   as	   an	  
increasingly	  important	  factor	  in	  relation	  to	  age	  and	  degree	  of	  maturity	  regarding	  therapeutic	  
interventions	   (art.	   6,2).	   Although	   this	   requirement	   is	   provided	  with	   regard	   to	   therapeutic	  
interventions	  and	  is	  not	  highlighted	  in	  the	  section	  on	  research	  intervention,	  respect	  for	  this	  
requirement	  is	  recommended	  in	  the	  research	  setting.	  
Necessity	  to	  involve	  minors	  	  
The	   European	   Convention	   endorses	   the	   principle	   that	   minors	   should	   only	   take	   part	   in	  
clinical	   research	   if	   similar	   results	   cannot	   be	   obtained	   without	   their	   involvement,	   i.e.	   by	  
research	   not	   involving	   humans	   (art.	   16,i)	   or	   research	   in	   individuals	   capable	   of	   informed	  
consent	  (art.	  17,1iii).	  	  
Interest	  of	  the	  research	  subject	  	  
As	   a	   general	   rule,	   art.	   17,1ii	   of	   the	   European	   Convention	   provides	   that	   research	   on	   a	  
person	  who	   lacks	   the	   capacity	   to	   provide	   legally	   valid	   consent	  may	   only	   be	   undertaken	   if	  
“the	  results	  of	  the	  research	  have	  the	  potential	  to	  produce	  real	  and	  direct	  benefit	  to	  his	  or	  her	  
health”.	  In	  absence	  of	  a	  real	  and	  direct	  benefit	  to	  the	  research	  subject	  concerned,	  the	  risks	  
and	   burdens	   are	   only	   deemed	   acceptable	   if	   two	   additional	   requirements	   are	   met.	   First,	  
research	  must	  aim	  at	  generating	  benefit	  to	  persons	  sharing	  the	  same	  age	  category,	  disease,	  
disorder,	  or	  condition	  with	   the	  participating	   research	  subject	   (art.	  17,2i).	  Second,	   research	  
may	   only	   entail	   a	  minimal	   risk	   and	  minimal	   burden	   to	   the	   research	   subject	   involved	   (art.	  
17,2i).	  
Risks	  and	  burdens	  	  
The	   European	   Convention	   explicitly	   links	   the	   acceptability	   of	   risks	   and	   burdens	   to	   the	  
benefit	  involved.	  In	  the	  absence	  of	  a	  direct	  benefit	  to	  the	  research	  subject,	  only	  minimal	  risk	  
and	  minimal	   burden	   are	   deemed	   acceptable.	   The	   additional	   protocol	   clarifies	   the	   notions	  
‘minimal	   risk’	   and	   ‘minimal	   burden’,	   as	   according	   to	   art.	   17	   of	   the	   additional	   protocol,	   a	  
research	  intervention	  only	  entails	  minimal	  risk	  if	  the	  results	  of	  that	  intervention	  generate	  at	  
most	   a	   very	   slight	   and	   temporary	  negative	   impact	  on	   the	  health	  of	   the	  person	   concerned	  
and	  entails	  only	  minimal	  burden	   if	   it	   is	  to	  be	  expected	  that	  the	  discomfort	  to	  the	  research	  
participants	  will	   be,	   at	  most,	   temporary	   and	   very	   slight.	   The	  explanatory	   report	   illustrates	  
minimal	  risk	  as	  taking	  a	  single	  blood	  sample	  from	  a	  child	  (Explanatory	  Report,	  §111),	  which	  
implies	  that	  many	  clinical	  trials,	  especially	  those	  with	  investigational	  medicinal	  products	  and	  
in	  relatively	  early	  stage	  of	  the	  research,	  are	  outlawed	  by	  the	  European	  Convention.	  	  
Domestic	  regulation	  of	  EU	  Member	  States	  ⏐	  55	  
2.	  2	  Clinical	  Trial	  Directive	  	  
The	  Clinical	   Trial	  Directive	  mainly	   aims	   at	   the	   harmonization	  of	   the	   provisions	   on	   good	  
clinical	   practice	   and	   the	   facilitation	   of	   multicentre	   clinical	   trials	   across	   the	   borders	   of	  
individual	  EU	  Member	  States.	  All	  EU	  Member	  States	  were	  bound	  to	  implement	  this	  directive	  
into	  national	  law	  before	  the	  deadline	  of	  1	  May	  2004.	  In	  the	  national	  implementation	  of	  the	  
European	  Directive,	  EU	  Member	  States	  were	  free	  to	  adopt	  stricter	  provisions	  than	  those	  set	  
down	   in	   the	   European	   Directive,	   as	   long	   as	   the	   standards	   of	   protection	   and	   time	   limits	  
captured	   in	   the	  Clinical	  Trial	  Directive	  were	  not	  violated	   (art.	  3,1).	  As	  a	   result,	   there	  exists	  
considerable	  diversity	  in	  the	  national	  provisions	  on	  the	  conduct	  of	  pediatric	  clinical	  research	  
across	   the	   EU.	   Nevertheless,	   several	   EU	   member	   states	   opted	   for	   an	   almost	   verbatim	  
implementation	   of	   the	   text	   of	   the	   Directive.vii	   The	   Clinical	   Trial	   Directive	   addresses	   the	  
specific	  issues	  of	  pediatric	  research	  in	  its	  article	  4	  (box	  2).	  	  
	  
Box	  2:	  
Clinical	  Trial	  Directive	  (Directive	  2001/20/EC)	  
Article	  4	  –	  Clinical	  trials	  on	  minors	  
In	  addition	  to	  any	  other	  relevant	  restriction,	  a	  clinical	  trial	  on	  minors	  may	  be	  undertaken	  only	  if:	  
(a) the	  informed	  consent	  of	  the	  parents	  or	  legal	  representative	  has	  been	  obtained;	  consent	  must	  represent	  
the	  minor's	  presumed	  will	  and	  may	  be	  revoked	  at	  any	  time,	  without	  detriment	  to	  the	  minor;	  
(b) the	   minor	   has	   received	   information	   according	   to	   its	   capacity	   of	   understanding,	   from	   staff	   with	  
experience	  with	  minors,	  regarding	  the	  trial,	  the	  risks	  and	  the	  benefits;	  
(c) the	   explicit	   wish	   of	   a	  minor	   who	   is	   capable	   of	   forming	   an	   opinion	   and	   assessing	   this	   information	   to	  
refuse	   participation	   or	   to	   be	   withdrawn	   from	   the	   clinical	   trial	   at	   any	   time	   is	   considered	   by	   the	  
investigator	  or	  where	  appropriate	  the	  principal	  investigator;	  
(d) no	  incentives	  or	  financial	  inducements	  are	  given	  except	  compensation;	  
(e) some	   direct	   benefit	   for	   the	   group	   of	   patients	   is	   obtained	   from	   the	   clinical	   trial	   and	   only	  where	   such	  
research	  is	  essential	  to	  validate	  data	  obtained	  in	  clinical	  trials	  on	  persons	  able	  to	  give	  informed	  consent	  
or	  by	  other	  research	  methods;	  additionally,	  such	  research	  should	  either	  relate	  
(f) directly	  to	  a	  clinical	  condition	  from	  which	  the	  minor	  concerned	  suffers	  or	  be	  of	  such	  a	  nature	  that	  it	  can	  
only	  be	  carried	  out	  on	  minors;	  
(g) the	  corresponding	  scientific	  guidelines	  of	  the	  Agency	  have	  been	  followed;	  
(h) clinical	   trials	  have	  been	  designed	   to	  minimise	  pain,	  discomfort,	   fear	  and	  any	  other	   foreseeable	   risk	   in	  
relation	  to	  the	  disease	  and	  developmental	  stage;	  both	  the	  risk	  threshold	  and	  the	  degree	  of	  distress	  have	  
to	  be	  specially	  defined	  and	  constantly	  monitored;	  
(i) the	  Ethics	  Committee,	  with	  paediatric	  expertise	  or	  after	  taking	  advice	  in	  clinical,	  ethical	  and	  psychosocial	  
problems	  in	  the	  field	  of	  paediatrics,	  has	  endorsed	  the	  protocol;	  and	  
(j) the	  interests	  of	  the	  patient	  always	  prevail	  over	  those	  of	  science	  and	  society.	  
In	   addition	   to	   the	   provisions	   of	   the	   European	  Directive,	   the	   scientific	   guidelines	   of	   the	  
European	  Medicines	  Agency	  (EMEA)	  have	  to	  be	  followed.	   In	  this	  respect,	  specific	  guidance	  
on	   the	   implementation	   of	   the	   Clinical	   Trial	   Directive	   in	   pediatric	   research	   practice	   was	  
provided	   in	   the	   guideline	   “Ethical	   Considerations	   for	   Clinical	   Trials	   on	  Medicinal	   Products	  
Conducted	   with	   the	   Paediatric	   Population”.18	   This	   guideline	   addresses	   a	   number	   of	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
vii	  Italy,	  Luxembourg,	  Malta,	  Portugal	  and	  Romania	  opted	  for	  a	  (nearly)	  verbatim	  implementation	  of	  the	  text	  of	  
the	  Clinical	  Trial	  Directive.	  	  
56	  ⏐	  Chapter	  2	  
important	   issues	   involving	   minors	   in	   clinical	   trials.	   First,	   the	   participation	   of	   minors	   in	  
decisions	  on	  their	  enrollment	  in	  clinical	  research	  is	  addressed.	  In	  this	  respect,	  assent,	  a	  term	  
that	   is	   not	   used	   in	   the	   European	   Directive,	   is	   recommended	   as	   a	   means	   to	   enable	   the	  
participation	   of	   minors	   in	   decisions.	   Notwithstanding	   this	   provision,	   the	   responsibility	   of	  
parents	  to	  protect	  the	  interests	  of	  their	  child	  is	  emphasized.	  	  
Second,	   the	   grey	   zone	   in	   between	   legal	   incapacity	   to	   consent	   and	   factual	   capacity	   to	  
consent	  is	  addressed.	  It	  is	  acknowledged	  that	  certain	  minors	  are	  mature	  enough	  to	  provide	  
valid	  consent,	  even	  when	  they	  have	  not	  reached	  the	  legal	  minimum	  age.	  In	  this	  respect,	  the	  
guideline	  acknowledges	   that	   “emancipated	  minors”	  must	  give	  written	  consent	   to	   research	  
participation,	   and	   that	   the	   consent	   of	   the	   parents	   or	   another	   legal	   representative	   is	   not	  
required	   for	  mature	  minors.	   Notwithstanding	   this	   provision,	   it	   is	   emphasized	   that	  mature	  
minors	  can	  be	  vulnerable,	  and	  may	  require	  additional	  discussions	  and	  explanations.	  	  
Like	  the	  European	  Convention,	  the	  Clinical	  Trial	  Directive	  captures	  specific	  provisions	  on	  
the	   involvement	   of	   minors	   in	   clinical	   research	   (art.	   4),	   in	   which	   the	   ethical	   concerns	   of	  
informed	  consent,	   the	  necessity	  of	   involving	  minors,	   the	   interests	  of	   the	   research	   subject,	  
the	  risks	  and	  burdens	  involved,	  and	  the	  review	  of	  research	  protocols	  are	  addressed.	  	  
Informed	  Consent	  	  
Art.	  4a	   of	   the	   Clinical	   Trial	   Directive	   requires	   that	   consent	   for	   research	   participation	   is	  
given	  by	   the	  parents	  or	  a	   legal	   representative.	   It	   is	   specified	   that	  consent	  “must	   represent	  
the	  presumed	  will	  of	  the	  minor,	  and	  may	  be	  revoked	  at	  any	  time	  without	  repercussions	  to	  the	  
minor”.	   In	   addition,	   the	   Clinical	   Trial	   Directive	   serves	   to	   involve	   minors	   in	   decisions	   on	  
research	  participation	  by	  stating	  in	  art.	  4b	  that	  minors	  must	  receive	  information	  “regarding	  
the	   trial,	   the	   risks,	   and	   the	   benefits	   of	   the	   trial”,	   in	   accordance	   with	   their	   capacity	   of	  
understanding	  and	  provided	  by	  staff	  with	  experience	  with	  minors.	  Further,	  art.	  4c	  provides	  
that	   the	   (principal)	   investigator	   must	   consider	   the	   explicit	   wish	   to	   refuse	   or	   discontinue	  
participation	  formulated	  by	  a	  minor	  who	  is	  capable	  of	  assessing	  information	  and	  forming	  an	  
opinion.	  In	  the	  Dutch	  version	  of	  the	  Directive,	  however,	  it	  is	  stated	  that	  the	  will	  of	  the	  minor	  
to	  discontinue	  participation	  must	  be	  respected	  by	  the	  principal	  investigator.19	  
Necessity	  to	  involve	  minors	  	  
The	   Clinical	   Trial	   Directive	   provides	   in	   art.	   4e	   that	   minors	   should	   not	   be	   involved	   in	  
research	  whenever	   similar	   results	   can	  be	  obtained	  by	   research	   in	   competent	   adults	   or	   by	  
other	  research	  methods.	  	  
Interests	  of	  the	  research	  subject	  
The	  Clinical	  Trial	  Directive	  requires	  that	  the	  research	  generates	  a	  direct	  benefit.	  In	  art.	  4e,	  
this	  direct	  benefit	  is	  defined	  broadly	  as	  “some	  direct	  benefit”	  that	  either	  can	  be	  an	  individual	  
benefit	   (to	  the	  research	  subject)	  or	  a	  group	  benefit	   (to	  the	  group	  of	  patients).	   In	  case	  of	  a	  
group	   benefit,	   no	   additional	   requirements	   are	   applicable.	   In	   addition,	   this	   article	   requires	  
that	   research	   is	   related	   directly	   to	   “a	   clinical	   condition	   from	   which	   the	   minor	   concerned	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suffers	   or	   be	   of	   such	   nature	   that	   it	   can	   only	   be	   carried	   out	   on	  minors”.	   The	   Clinical	   Trial	  
Directive	  explicitly	  guards	  minors	  and	  their	  parents	  against	  financial	  persuasions,	  as	  art.	  4d	  
prohibits	  all	   incentives	  or	  financial	   inducements	  to	  stimulate	  research	  participation,	  except	  
for	  compensation.	  
Risks	  and	  burdens	  	  
In	   art.	   4g,	   the	   Clinical	   Trial	   Directive	   provides	   that	   clinical	   trials	   must	   be	   designed	   to	  
“minimize	  pain,	  discomfort,	  fear,	  and	  any	  other	  foreseeable	  risk	  in	  relation	  to	  the	  disease	  and	  
developmental	  stage”.	  The	  requirement	  that	  the	  degree	  of	  distress	  and	  risk	  threshold	  have	  
to	  be	  constantly	  monitored,	  captured	   in	  the	  same	  article,	  demonstrates	  the	   importance	  of	  
this	   provision,	   as	   conformity	  with	  most	   requirements	   in	   the	   Clinical	   Trial	   Directive	   is	   only	  
assessed	  at	  a	  single	  moment	  in	  time.	  In	  addition,	  the	  well-­‐known	  general	  principle	  that	  the	  
interests	  of	  the	  patient	  always	  prevail	  over	  those	  of	  science	  and	  society	  is	  adopted	  in	  art.	  4i	  
of	  the	  Directive.	  Somewhat	  notable,	  this	  provision	  is	  subsumed	  in	  the	  specific	  provisions	  on	  
clinical	  trials	  on	  minors.	  
Pediatric	  Expertise	  	  
According	  to	  art.	  4h	  of	  the	  Clinical	  Trial	  Directive,	  ethics	  committees	  that	  assess	  studies	  
involving	  minor	   research	  subjects	  must	   include	  a	  member	  with	  pediatric	  expertise,	  or	  gain	  
advice	  about	  the	  clinical,	  ethical,	  and	  psychosocial	  problems	  in	  the	  field	  of	  pediatrics	  before	  
deciding	  upon	  the	  research	  protocol.	  	  
2.3	  Pediatric	  regulation	  	  
Even	  though	  the	  Clinical	  Trial	  Directive	  was	  a	  milestone	  in	  the	  facilitation	  of	  clinical	  trials,	  
further	   legislative	   initiatives	  were	  needed	  to	  address	  the	  poor	   interest	   in	  developing	  drugs	  
for	  the	  young.	  To	  correct	  the	  disinterest	  of	   industry	   in	  developing	  and	  marketing	  drugs	  for	  
children,	   the	   Pediatric	   Regulation	   requires	   that	   clinical	   trials	   in	   minors	   are	   planned	   and	  
conducted	   for	   all	   new	  products	   entering	   the	  market.	   In	   addition,	   the	   Pediatric	   Regulation	  
offers	   considerable	   rewards	   for	   the	   conduct	   of	   clinical	   trials	   in	   minors,	   in	   the	   form	   of	  
prolongation	  of	  market	  exclusivity.	  
In	   contrast	   to	   the	   European	   Convention	   and	   the	   European	   Directive,	   the	   Pediatric	  
Regulation	   is	  entirely	  dedicated	  to	  clinical	  research	   in	  minors.	   In	  art.	  2,1	  of	  the	  Regulation,	  
minors	  are	  defined	  as	  the	  population	  aged	  between	  birth	  and	  18	  years	  of	  age.	  	  
The	   Pediatric	   Regulation	   does	   not	   specifically	   address	   ethical	   issues	   related	   to	   the	  
involvement	   of	   minor	   subjects	   in	   clinical	   research,	   but	   focuses	   on	   facilitation	   and	  
encouragement	   of	   pediatric	   drug	   development.	   The	   regulation	   requires	   that	   for	   every	  
request	  for	  marketing	  authorization,	  a	  Pediatric	  Investigation	  Plan	  (PIP)	  is	  negotiated	  early	  in	  
research	  (art.	  7).	  This	  PIP	  is	  to	  ensure	  that	  the	  necessary	  data	  to	  use	  a	  drug	  in	  all	  subsets	  of	  
the	   pediatric	   population	   are	   gathered	   in	   the	   clinical	   research	   preceding	   marketing	  
authorization.	  However,	  waivers	  and	  deferrals	  to	  this	  general	  rule	  are	  possible	  under	  certain	  
conditions.	   In	   addition,	   the	   conduct	   of	   pediatric	   research	   is	   stimulated	   with	   strong	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incentives,	   as	   drugs	   tested	   in	   children	   obtain	   an	   extension	   of	   market	   exclusivity	   of	   six	  
months	  (art.	  36).	  Also	  for	  off-­‐patent	  drugs,	  research	  in	  minors	  is	  rewarded	  by	  means	  of	  the	  
‘pediatric	  use	  marketing	  authorization’	  (PUMA).	  To	  organize	  the	  assessment	  of	  PIPs,	  waivers,	  
and	  deferrals,	  art.	  3	  of	  the	  Pediatric	  Regulation	  mandated	  the	  establishment	  of	  a	  Pediatric	  
Committee	  (PDCO),	  having	  as	  its	  main	  tasks	  the	  assessment	  of	  PIPs,	  waivers,	  and	  deferrals,	  
and	  to	  support	  and	  advise	  the	  Agency	  and	  Commission.	  	  
3.	  Regulation	  at	  the	  national	  level	  of	  EU	  member	  states	  
At	   the	   level	   of	   EU	  member	   states,	   national	   regulation	   set	   out	   the	   conditions	   in	   which	  
pediatric	   clinical	   research	  can	  be	  conducted	   in	   the	   territory	  of	   the	  nation	   in	  question.	  The	  
requirements	   captured	   in	   the	   national	   legislation	   of	   an	   EU	   member	   state,	   however,	   can	  
diverge	   from	  the	   requirements	  captured	   in	   the	   regulatory	   framework	  at	   the	  supranational	  
level	  or	  be	  applicable	  supplementary	  to	  the	  provisions	  in	  the	  directive.	  
The	  analysis	  of	  domestic	  regulatory	  requirements	  will	  focus	  on	  the	  implementation	  of	  the	  
Clinical	  Trial	  Directive	  in	  the	  national	  legislation	  of	  EU	  member	  states.	  Like	  the	  analysis	  of	  the	  
regulation	  at	  the	  supranational	  level,	  the	  analysis	  of	  the	  domestic	  legislation	  of	  EU	  Member	  
States	  will	  focus	  on	  the	  five	  major	  ethical	  issues	  in	  pediatric	  clinical	  trials	  that	  are	  regulated:	  
(a)	   informed	   consent,	   (b)	   the	   necessity	   to	   involve	   minors	   in	   research	   to	   obtain	   relevant	  
results,	   (c)	   the	   interests	   of	   minors	   in	   research	   participation,	   (d)	   the	   potential	   risks	   and	  
burdens	   related	   to	   clinical	   trial	   participation,	   and	   (e)	   the	   pediatric	   expertise	   of	   ethics	  
committees.	  
3.1	  Informed	  Consent	  	  
Article	  4	  of	  the	  Clinical	  Trial	  Directive	  addresses	  the	  specific	  issue	  of	  informed	  consent	  to	  
enroll	   a	  minor	   in	   a	   clinical	   study	   and	   sets	   down	   several	   requirements	   for	   the	   consent	   to	  
enroll	   a	  minor	   in	   a	   clinical	   trial.	   First,	   proxy	   consent	  must	   be	   provided	   by	   the	   parents	   or	  
another	   legal	   representative.	   This	   consent	  may	   be	   revoked	   at	   any	   time	   without	   negative	  
consequences	  to	  the	  minor	  concerned,	  and	  must	  represent	  the	  presumed	  will	  of	  the	  minor.	  
Second,	  the	  minor	  concerned	  must	  receive	  information	  regarding	  the	  trial,	  the	  risks	  and	  the	  
benefits,	   appropriate	   to	   his/her	   capacity	   of	   understanding,	   and	   provided	   by	   staff	   with	  
experience	  with	  minors.	  Third,	  the	  explicit	  dissent	  to	  start	  or	  continue	  research	  participation	  
expressed	  by	  a	  minor	  who	   is	  capable	  of	   forming	  an	  opinion	  and	  assessing	   the	   information	  
relevant	   to	   participation	   in	   the	   clinical	   trial,	   must	   be	   considered	   by	   the	   (principal)	  
investigator	   at	   any	   time.	   Fourth,	   no	   incentives	   or	   financial	   inducements	  may	   be	   provided	  
except	  for	  compensation.	  	  
Among	   the	   different	   domestic	   laws	   that	   implement	   the	   Clinical	   Trial	   Directive	   into	   the	  
national	  law	  of	  individual	  member	  states,	  diversity	  exists	  regarding	  all	  four	  requirements	  for	  
valid	  informed	  consent.	  In	  addition,	  several	  EU	  Member	  States	  specifically	  define	  age	  criteria	  
or	  an	  age	  cut-­‐off	  with	  regard	  to	  the	  decision-­‐making	  capabilities	  of	  minor	  research	  subjects.	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Age	  criteria	  	  
The	  Clinical	  Trial	  Directive	  does	  not	  specify	  an	  age	  cut-­‐off	  for	  medical	  majority.	  However,	  as	  
a	  general	  rule,	  all	  individuals	  who	  have	  not	  reached	  the	  age	  of	  18	  years	  can	  be	  regarded	  as	  
minors	  in	  decisions	  concerning	  their	  participation	  in	  a	  clinical	  trial.	  Nonetheless,	  several	  EU	  
member	   states	   define	   specific	   age	   criteria	   that	   deviate	   from	   this	   general	   rule.	   (Table	   2	  
provides	  an	  overview	  of	  the	  age	  cut-­‐offs	  that	  are	  applicable	  in	  different	  EU	  Member	  States).	  
For	  example,	  in	  Ireland,	  Lithuania	  and	  the	  United	  Kingdom,	  all	  individuals	  who	  have	  not	  yet	  
reached	  the	  age	  of	  16	  years	  are	  considered	  minors.	  Alternately,	  several	  EU	  Member	  States	  
distinguish	  between	  two	  age	  groups,	  each	  of	  which	  is	  subjected	  to	  specific	  requirements	  for	  
informed	   consent.	   The	   age	   criterion	   that	   is	   used	   to	   distinguish	   age	   groups	   varies	  
significantly,	  ranging	  from	  7	  to	  15	  years	  of	  age.	  For	  example,	  in	  Estonia,	  the	  group	  of	  minors	  
up	  to	  6	  years	  of	  age	  is	  differentiated	  from	  minors	  aged	  7-­‐17	  years.	   In	  the	  Netherlands	  and	  
Spain,	   the	   age	   of	   12	   is	   used	   as	   an	   age	   cut-­‐off.	   The	   Bulgarian	   act	   differentiates	   between	  
“children”	  (being	  minors	  up	  to	  14	  years	  of	  age)	  and	  “young	  persons”	  (being	  minors	  aged	  14	  
to	   18	   years	   old).	   Also	   in	  Hungary,	   an	   age	   cut-­‐off	   of	   14	   years	   of	   age	   is	   applicable.	   Persons	  
under	  the	  age	  of	  14	  are	  considered	  as	  legally	  incompetent,	  persons	  aged	  14	  and	  older	  have	  a	  
“limited	   competency”,	   similar	   to	   adults	   that	   are	   placed	   under	   limited	   guardianship.6	   The	  
Finnish	  act	  distinguishes	  minors	  up	  to	  14	  years	  of	  age	  from	  minors	  aged	  15	  and	  older.	  Also	  
Denmark	  distinguishes	  minors	  under	  the	  age	  of	  15	  from	  minors	  aged	  15	  to	  17	  years	  old.	  In	  
Poland,	  the	  age	  of	  16	  is	  used	  as	  an	  age	  cut-­‐off.	  
	  
Table	  2:	  	  
Overview	  of	  Age	  Criteria	  in	  the	  National	  Laws	  implementing	  the	  Clinical	  Trials	  Directive	  
	   Age	  
cut-­‐off	  	  
For	   minors	   in	   aged	   younger	   than	  
the	  age	  criterion:	  
Minors	  aged	  older	  than	  the	  age	  criterion:	  
Bulgaria	   14	   consent	  must	  be	  provided	  by	  both	  
parents	  or	  the	  legal	  representative	  
must	   grant	   their	   consent	   in	   addition	   to	   the	  
consent	  provided	  by	   the	  parents	  or	   another	  
legal	  guardian	  
Denmark	   15	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
can	   in	   some	   instances	   consent	   to	   research	  
participation	  without	   consent	   provided	  by	   a	  
parent	  or	  another	  legal	  representative,	  if	  the	  
ethics	   committee	   grants	   an	   exception	  
hereto.	  	  	  
Estonia	   7	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
must	   grant	   their	   consent	   in	   addition	   to	   the	  
consent	  provided	  by	   the	  parents	  or	   another	  
legal	  guardian	  
Finland	   15	   consent	   must	   be	   provided	   by	   the	  
parents	   or	   legal	   representative.	   In	  
the	  case	  minors	  who	  are	  capable	  of	  
understanding	   the	   importance	   of	  
the	  research	  procedure,	   they	  must	  
provide	  written	  consent	  in	  addition	  
to	  the	  parents	  
can	   consent	   for	   clinical	   research	  
participation.	   The	   parents	   or	   another	   legal	  
representative	   must	   be	   informed,	   but	   not	  
consent,	   provided	   that	   the	  minor	   is	   capable	  
of	   understanding	   the	   important	   of	   the	  
research	   procedure,	   and	   the	   research	   is	   of	  
direct	  benefit.	  	  
Hungary	   14	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
must	   not	   provide	   consent.	   The	   consent	   of	  
the	   parents	   or	   legal	   representative	   is	  
sufficient.	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Ireland	  	   16	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
are	   regarded	   as	   competent	   adults	   in	  
decisions	  on	  clinical	  research	  participation	  
Lithuania	   16	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  and	  
the	   children’s	   rights	   protection	  
agency	  of	  a	  district	  or	  a	  city	  
are	   regarded	   as	   competent	   adults	   in	  
decisions	  on	  clinical	  research	  participation	  
Netherlands	   12	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
must	   grant	   their	   consent	   in	   addition	   to	   the	  
consent	  provided	  by	   the	  parents	  or	   another	  
legal	  guardian	  
Poland	   16	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
must	   grant	   their	   consent	   in	   addition	   to	   the	  
consent	  provided	  by	   the	  parents	  or	   another	  
legal	  guardian	  
Spain	   12	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  	  
must	   grant	   their	   consent	   in	   addition	   to	   the	  




16	   consent	   must	   be	   provided	   by	   the	  
parents	  or	  legal	  representative	  
are	   regarded	   as	   competent	   adults	   in	  
decisions	  on	  clinical	  research	  participation	  	  
Proxy	  consent	  representing	  the	  presumed	  will	  of	  the	  minor	  
The	   Clinical	   Trial	   Directive	   requires	   that	   proxy	   consent	   has	   been	   obtained	   from	   the	  
parents	  or	  another	   legal	   representative	  prior	   to	  enrolling	  a	  minor	  subject	   in	  a	  clinical	   trial.	  
This	   consent	   can	   be	   withdrawn	   at	   any	   time	   without	   detriment	   to	   the	   minor	   (e.g.,	   by	   a	  
decrease	  in	  the	  current	   level	  of	  care),	  and	  must	  represent	  the	  presumed	  will	  of	  the	  minor.	  
This	  last	  requirement,	  however,	  is	  very	  confusing,	  as	  it	  is	  neither	  clear	  what	  constitutes	  the	  
presumed	   will	   of	   the	   minor,	   nor	   how	   this	   presumed	   will	   (or	   violations	   to	   it)	   can	   be	  
determined.	  
Within	   the	   domestic	   law	   of	   EU	  Member	   States,	   considerable	   variation	   in	   requirements	  
regarding	  proxy	   consent	   representing	   the	  presumed	  will	   of	   the	  minor	   can	  be	   found.	   First,	  
several	   member	   states	   specify	   who	   must	   grant	   informed	   consent.	   The	   Bulgarian	   act	  
emphasizes	  that	  consent	  must	  be	  provided	  by	  bothviii	  parents	  or	  the	   legal	  guardians	  of	  the	  
subject.	  Also	  in	  France,	  both	  parents	  must	  grant	  their	  consent,	  except	  in	  the	  case	  that	  (a)	  the	  
research	   only	   entails	   minimal	   risk	   and	  minimal	   burden	   without	   detriment	   to	   the	  medical	  
treatment	   of	   the	   minor,	   (b)	   the	   research	   is	   conducted	   on	   the	   occasion	   of	   medical	  
treatments,	   or	   (c)	   one	   of	   the	   parents	   cannot	   give	   his/her	   authorization	  within	   time	   limits	  
compatible	  with	  the	  methodological	   requirements	  of	   the	  trial	  concerned.	  According	  to	  the	  
Italian	  decree,	  the	  informed	  consent	  of	  one	  of	  the	  parents	  or	  a	  legal	  representative	  must	  be	  
obtained.	  However,	  when	  both	  parents	  are	  present	  they	  both	  have	  to	  grant	  their	  informed	  
consent.	   In	   Latvia,	   the	   informed	   consent	   of	   (at	   least	   one	   of)	   the	   parents	   or	   a	   legal	  
representative	  is	  required.	  In	  Lithuania,	  informed	  consent	  must	  be	  given	  by	  both	  parents	  or	  
another	  legally	  acceptable	  representative	  of	  the	  minor,	  and	  the	  children’s	  rights	  protection	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
viii	  One	  parent	  suffices	  when	  one	  of	  the	  parents	  is	  unknown,	  deceased	  or	  deprived	  of	  parental	  rights	  or,	  when	  in	  
the	  case	  of	  divorce	  no	  such	  rights	  have	  been	  assigned.	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agency	   of	   a	   district	   or	   a	   city.	   However,	   when	   the	   parents	   of	   a	   minor	   are	   divorced,	   the	  
consent	  of	  one	  of	  the	  parents	  or	  of	  the	  legally	  acceptable	  representative	  and	  of	  the	  district	  
or	  city	  children’s	  rights	  protection	  agency	  suffices.	  
Depending	  on	  the	  age	  cut-­‐off	  defined	  in	  domestic	  legislation,	  the	  consent	  of	  a	  minor	  may	  
be	   required	   in	   addition	   to	   the	   proxy	   consent	   granted	   by	   the	   parents.	   According	   to	   the	  
Estonian	  implementation	  of	  the	  Clinical	  Trial	  Directive,	  minors	  aged	  7	  to	  17	  years	  old	  must	  
grant	  their	  consent	  in	  addition	  to	  the	  consent	  of	  the	  legal	  representative	  before	  entering	  a	  
clinical	   trial.	   In	   the	  Netherlands,	  minors	   aged	   at	   least	   12	   years	  must	   grant	   their	   informed	  
consent	  complementary	  to	  the	  consent	  of	  the	  parents	  or	  another	  legal	  guardian,	  unless	  the	  
minor	   subject	   cannot	   be	   deemed	   capable	   of	   reasonably	   assessing	   his	   or	   her	   interests	   in	  
participating	   in	  the	  clinical	   trial.	  Also	   in	  Spain,	  minors	  aged	  twelve	  or	  older	  must	  give	  their	  
consent	  to	  take	  part	   in	  the	  trial.	   In	  Bulgaria,	  young	  persons	  (aged	  14	  to	  18	  years	  old)	  must	  
provide	  their	   informed	  consent	   in	  addition	  to	   (both)	  parents	  or	   the	  custodian.	   In	  Hungary,	  
minors	  with	  limited	  competency	  (aged	  14	  and	  older)	  must	  not	  grant	  their	  informed	  consent	  
in	  addition	  to	  the	  consent	  provided	  by	  a	  close	  relative	  or	  a	  legal	  guardian.	  Thus,	  the	  age	  cut-­‐
off	   used	   in	  Hungary	   to	  discern	   incompetent	  minors	   from	  minors	  with	   limited	   competency	  
does	  not	  have	  any	   impact	  on	  the	  consent	  process.6	   In	  Finland,	  minors	  under	  the	  age	  of	  15	  
years	  who	   are	   capable	   of	   understanding	   the	   importance	   of	   the	   research	   procedure	   to	   be	  
carried	  out	  on	  them	  must	  provide	  written	  consent	  in	  addition	  to	  the	  proxy	  consent	  given	  by	  
their	  guardian	  or	  legal	  representative.	  For	  minors	  aged	  15	  and	  older	  surrogate	  consent	  is	  not	  
required,	   provided	   that	   the	   minor	   is	   capable	   of	   understanding	   the	   importance	   of	   the	  
research	  procedure	  (taking	  account	  of	  the	  age	  and	  maturity	  of	  the	  minor)	  and	  the	  research	  
is	  likely	  to	  be	  of	  direct	  benefit	  to	  the	  minor’s	  health.	  Here,	  the	  written	  consent	  of	  the	  minor	  
is	  sufficient,	  although	  the	  guardian	  must	  be	  informed	  about	  the	  participation	  of	  the	  minor	  in	  
the	   clinical	   trial.	   In	  Denmark,	   the	   ethics	   committee	  may	   grant	   exemptions	   from	   surrogate	  
consent	  for	  minors	  aged	  15	  and	  older.	  It	  is	  emphasized	  that	  this	  exemption	  shall	  be	  granted	  
with	   due	   regard	   to	   the	   nature,	   risk	   and	   harmfulness	   of	   the	   project.	   The	   exemption	   of	  
surrogate	  consent	  does	  not	  rule	  out	  the	  holder	  of	  the	  custody,	  as	  it	  is	  emphasized	  that	  the	  
holder	   of	   the	   custody	   must	   receive	   the	   same	   information	   and	   must	   be	   involved	   in	   the	  
decision	   of	   the	  minor.	   In	   Poland,	  minors	   aged	   16	   or	   older	  must	   grant	   written	   consent	   in	  
addition	   to	   the	   consent	   of	   the	   parents	   or	   another	   legal	   representative,	   in	   so	   far	   that	   the	  
minor	   concerned	   is	   capable	   of	   expressing	   a	   conscious	   opinion	   about	   participation	   in	   the	  
research	  concerned.	  	  
The	  Greek	  law	  does	  not	  use	  a	  fixed	  age	  cut-­‐off,	  but	  requires	  that	  minors	  who	  are	  capable	  
of	  comprehending	  the	  essence	  of	  the	  clinical	  trial	  grant	  their	  written	  consent	  in	  addition	  to	  
the	   consent	   of	   the	   parents	   or	   the	   legal	   representative.	   This	   is	   also	   the	   case	   in	   Germany,	  
where	  minors	  who	  are	  capable	  of	  understanding	  the	  nature,	  significance	  and	  implications	  of	  
the	  clinical	  trial	  and	  who	  are	  capable	  of	  forming	  a	  rational	  opinion	  regarding	  participation	  in	  
the	  trial	  must	  grant	  their	  informed	  consent	  in	  addition	  to	  the	  proxy	  consent	  granted	  by	  the	  
legal	  representative.	  In	  addition,	  the	  German	  law	  clarifies	  that	  consent	  must	  only	  represent	  
the	   presumed	   will	   of	   the	   minor	   whenever	   such	   a	   will	   can	   be	   ascertained.	   In	   the	   Czech	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implementation	  of	  the	  Clinical	  Trial	  Directive,	  it	  is	  stated	  that	  consent	  must	  be	  respectful	  to	  
the	  minor’s	  age	  and/or	  intellectual	  capacity.	  	  
The	  Austrian	  act	  requires	  that	  consent	  has	  been	  obtained	  from	  minor	  research	  subjects	  in	  
so	  far	  the	  minor	  concerned	  is	  capable	  of	  making	  rational	  decisions	  and	  of	  understanding	  the	  
importance,	   scope,	   and	   risks	   of	   the	   trial.	   This	   consent	   is	   complementary	   to	   the	   consent	  
provided	   by	   the	   legal	   guardian.	   In	   France,	   minors	   must	   be	   consulted	   according	   to	   their	  
capacity	  of	  understanding	  and	  their	  assent	  for	  research	  participation	  must	  be	  sought.	  Finally,	  
the	  Estonian	  Act	  provides	  that	  proxy	  consent	  must	  not	  always	  be	  respected.	  For	  minors	  who	  
have	  not	  reached	  the	  age	  of	  7,	  the	  proxy	  consent	  to	  enroll	  the	  minor	  in	  a	  clinical	  study	  must	  
not	  be	  adhered	  to	  by	  researchers	  if	  the	  decision	  of	  the	  legal	  representative	  clearly	  violates	  
the	  interests	  of	  the	  child	  concerned.	  This	  provision	  however,	  seems	  completely	  redundant,	  
as	   there	   are	   no	   valid	   reasons	   for	   involving	   minors	   in	   research	   that	   clearly	   violates	   their	  
interests,	  even	   if	   the	  parents	  would	  be	  prepared	   to	  consent	   to	   such	   research.	   In	  addition,	  
parental	   consent	   never	   obliges	   researchers	   to	   enroll	   a	  minor	   in	   a	   study,	   since	   there	   is	   no	  
such	  thing	  as	  a	  generally	  recognized	  right	  to	  be	  in	  a	  clinical	  trial.	  	  
Information	  provided	  to	  the	  minor	  	  
The	  Clinical	  Trial	  Directive	   stipulates	   that	  minors	  must	   receive	   information	  according	   to	  
their	  capacity	  of	  understanding,	  from	  staff	  with	  experience	  with	  minors,	  regarding	  the	  trial,	  
the	  risks	  and	  the	  benefits.	  Obviously,	  this	  general	  formulation	  leaves	  much	  to	  the	  discretion	  
of	  those	  implementing	  the	  provisions	  of	  the	  Clinical	  Trial	  Directive,	  including	  the	  legislators	  
of	   the	  27	  EU	  member	  states.	  Member	  states	  vary	  considerably	  with	  regard	  to	  age	  criteria,	  
the	  content	  of	  the	  information,	  the	  person	  providing	  the	  information	  and	  the	  verification	  of	  
understanding.	  	  
First,	  several	  EU	  Member	  states	  relate	  requirements	  to	  provide	  information	  to	  the	  age	  of	  
minor	   subjects.	   In	   Estonia,	   children	   aged	   6	   or	   younger	   must,	   to	   a	   reasonable	   extent,	   be	  
informed	  about	  the	  clinical	  trial	  and	  the	  decisions	  made.	   In	  the	  Netherlands,	  minors	  under	  
the	   age	   of	   twelve	   and	   other	   minors	   that	   are	   not	   capable	   of	   consenting	   to	   research	  
participation	  must	  be	  told	  what	  is	  to	  happen	  in	  a	  way	  they	  are	  able	  to	  understand.	  According	  
to	   Swedish	   law,	   minor	   subjects	   who	   have	   reached	   the	   age	   of	   15	  must	   be	   provided	   with	  
information	  about	  the	  trial	  and	  consent	  to	  research	  participation	  in	  so	  far	  that	  they	  realize	  
what	  their	  part	  in	  the	  research	  entails.	  
Second,	   several	   EU	  member	   states	  provide	  detailed	   requirements	  about	   the	   content	  of	  
the	  information	  provided.	  In	  Germany,	  both	  minors	  and	  their	  legal	  representative	  should	  be	  
offered	  a	  counseling	  session	  with	  an	  investigator	  about	  conditions	  surrounding	  the	  conduct	  
of	   the	  clinical	   trial.	  According	   to	   the	   Irish	   statutory	   instrument,	   informed	  consent	  must	  be	  
preceded	   by	   an	   interview	   with	   the	   investigator	   (or	   another	   member	   of	   the	   investigating	  
team)	   in	   which	   he	   or	   she	   has	   been	   given	   the	   opportunity	   to	   understand	   the	   nature,	  
objectives,	   risks	  and	   inconveniences	  of	   the	   trial	  and	  the	  conditions	  under	  which	   it	   is	   to	  be	  
conducted.	   In	   Ireland	  and	   the	  UK,	   the	  person	  with	  parental	   responsibility	  must	  have	  been	  
provided	  with	   a	   contact	   point	  where	   further	   information	   about	   the	   trial	   can	   be	   obtained	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prior	  to	  granting	  informed	  consent.	  The	  Czech	  Decree	  on	  Good	  Clinical	  Practice	  specifies	  that	  
the	  information	  provided	  to	  the	  minor	  must	  include	  information	  about	  possible	  discomfort	  
and	   potential	   problems,	   be	   provided	   in	  writing	   and	   be	   specifically	   tailored	   to	   the	   level	   of	  
understanding	  of	  the	  minor	  whenever	  possible.	  	  
Third,	   details	   on	   the	   person	   providing	   the	   information	   are	   given	   in	   the	   domestic	  
implementation	  of	   the	  Clinical	  Trial	  Directive	  of	  several	  EU	  member	  states.	   In	   this	   respect,	  
the	  Danish	  law	  stipulates	  that	  the	  information	  be	  provided	  by	  a	  person	  that	  is	  familiar	  with	  
the	  trial	  and	  possesses	  the	  educational	  qualifications	  to	  communicate	  with	  minors	  of	  the	  age	  
group	  in	  question.	  The	  Irish	  legislation	  requires	  that	  consent	  is	  given	  in	  consultation	  with	  the	  
registered	  medical	  practitioner	  who	  has	  been	  treating	  the	  minor.	  	  
Finally,	   several	   EU	   member	   states	   require	   that	   the	   understanding	   of	   information	   is	  
verified.	  In	  the	  Netherlands,	  the	  party	  conducting	  the	  research	  must	  ensure	  that	  the	  person	  
from	  whom	   consent	   is	   requested	   is	   informed	   of	   (a)	   the	   aim,	   nature	   and	   duration	   of	   the	  
research,	   (b)	   the	   risk	   of	   participating	   in	   the	   trial	   and	   of	   withdrawing	   participation	  
prematurely,	   and	   (c)	   the	   burdens	   involved	   in	   research	   participation	   before	   the	   consent	   is	  
granted.	   In	   addition,	   this	   information	   must	   be	   provided	   in	   such	   a	   way	   that	   there	   is	   no	  
reasonable	  doubt	   that	   it	  has	  been	  understood	  by	   the	   recipient,	  and	   the	   recipient	  must	  be	  
given	  sufficient	  time	  to	  consider	  the	  information	  properly	  and	  to	  reach	  a	  reasoned	  decision.	  
According	  to	  the	  Slovak	  implementation	  of	  the	  Clinical	  Trial	  Directive,	  the	  investigator	  must	  
verify	   that	   (a)	   the	  minor	   has	   expressed	   the	  will	   to	   participate	   in	   the	   trial	   and	   is	   aware	   of	  
his/her	  right,	  (b)	  is	  capable	  of	  forming	  an	  opinion	  and	  evaluating	  the	  information	  provided,	  
and	   (c)	   is	   aware	   of	   the	   right	   to	   refuse	   or	   withdraw	   participation	   at	   any	   time,	   without	  
negative	  consequences.	  	  
Explicit	  Dissent	  	  
According	   to	   article	   4(c)	   of	   the	   Clinical	   Trial	   Directive,	   the	   explicit	   wish	   of	   a	   minor	   to	  
refuse	   participation	   in	   a	   clinical	   trial	   or	   to	   be	   withdrawn	   from	   a	   clinical	   trial	   is	   to	   be	  
considered	   at	   any	   time	   during	   the	   trial	   by	   the	   (principal)	   investigator,	   in	   so	   far	   the	  minor	  
concerned	   is	   capable	   of	   forming	   an	   opinion	   and	   assessing	   the	   information	   provided.	  
Obviously,	   the	  obligation	   to	   ‘consider’	   the	   explicit	   dissent	   of	   the	  minor	   is	   open	   to	   various	  
interpretations.	  Several	  EU	  Member	  States,	  however,	  narrow	  this	  broad	  formulation.	  	  
In	  Belgium,	  the	  Czech	  Republic,	  Germany,	  France,	  Finland,	  Greece,	  the	  Netherlands,	  and	  
Sweden,	   the	   explicit	   dissent	   of	   a	  minor	  must	   be	   considered	   and	   respected.	   However,	   the	  
Finnish	   law	  nuances	  that	  the	  age	  and	  maturity	  of	  the	  minor	  must	  be	  taken	  into	  account	   in	  
this	   matter.	   The	   Swedish	   law	   explicitly	   adds	   that	   the	   dissent	   of	   a	   minor	   must	   also	   be	  
respected	  in	  the	  case	  that	  informed	  consent	  has	  been	  obtained	  from	  the	  minor’s	  guardians.	  	  
The	  Bulgarian	  law	  requires	  that	  the	  expressed	  dissent	  of	  young	  persons	  (i.e.	  minors	  aged	  
14	   to	   18	   years	   old)	   is	   taken	   into	   account	   by	   the	   (principal)	   investigator.	   However,	   since	  
according	  to	  the	  Bulgarian	  law,	  young	  persons	  must	  provide	  their	  informed	  consent	  prior	  to	  
research	  participation,	  the	  function	  of	  this	  provision	  is	  unclear.	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No	  incentives	  other	  than	  compensation	  
The	   EU	   has	   a	   clear	   policy	   with	   regard	   to	   the	   payment	   of	   minor	   research	   subjects.	   In	  
conformity	   with	   article	   4(d)	   of	   the	   Clinical	   Trial	   Directive,	   no	   incentives	   or	   financial	  
inducements	  except	  for	  compensation	  may	  be	  granted	  to	  reward	  research	  participation.	  This	  
requirement	   is	   adopted	   (nearly)	   verbatim	   in	   all	   domestic	   implementations	   of	   the	   Clinical	  
Trial	  Directive.	  	  
Latvia	   adds	   in	   its	   domestic	   implementation	   of	   article	   4(d)	   of	   the	   Directive	   that	   also	  
compensation	  in	  the	  event	  of	   injury	  or	  death	  attributable	  to	  research	  participation	  may	  be	  
provided	   to	   the	  minor.	  However,	   such	   compensation	   cannot	   be	   regarded	   as	   an	   incentive,	  
and	   therefore	   this	   addition	   is	   not	   relevant	   and	   rather	   confusing.	   Likewise,	   in	   the	   Slovak	  
implementation	   of	   article	   4(d)	   of	   the	   Clinical	   Trial	   Directive,	   it	   is	   stipulated	   that	   financial	  
motives,	  financial	  or	  other	  material	  advantages	  apart	  from	  indemnification	  are	  forbidden.	  
3.2	  Necessity	  to	  involve	  minors	  	  
Minors	  are	  widely	  regarded	  as	  a	  vulnerable	  population	  that	  deserve	  extensive	  protection	  
against	  harm	  and	  abuse.	  Therefore,	  minors	  should	  not	  be	  exposed	  to	  the	  risks	  to	  harm	  and	  
abuse	   that	   are	   inherent	   to	   any	   clinical	   trial,	   unless	   this	   is	   strictly	   required	   to	   generate	  
relevant	  research	  results	  for	  the	  benefit	  of	  minor	  patients	  (cf.	  infra).	  	  
In	   article	   4(e),	   the	   Clinical	   Trial	   Directive	   requires	   that	   the	   involvement	   of	   minors	   be	  
absolutely	   necessary	   to	   validate	   data	   obtained	   in	   clinical	   trials	   on	   persons	   able	   to	   give	  
informed	  consent	  or	  by	  other	  research	  methods,	  and	  that	  research	  in	  minor	  subjects	  either	  
relates	  directly	  to	  a	  clinical	  condition	  from	  which	  the	  minor	  concerned	  suffers,	  or	  be	  of	  such	  
a	  nature	  that	  it	  can	  only	  be	  carried	  out	  on	  minors.	  	  
Although,	   theoretically,	   necessity	   is	   a	   term	   that	   is	   open	   to	   various	   interpretations,	   the	  
term	   appears	   to	   be	   understood	   uniformly	   in	   the	   European	   legislative	   landscape,	   as	   no	  
significant	   variation	   in	   domestic	   provisions	   regarding	   the	   necessity	   of	   involving	  minors	   in	  
clinical	  research	  can	  be	  found	  in	  the	  legislation	  of	  individual	  EU	  member	  states.	  	  
3.3	  Interests	  of	  minor	  research	  subjects	  
Two	   provisions	   of	   the	   Clinical	   Trial	   Directive	   incorporate	   the	   requirement	   to	   serve	   the	  
interests	  of	  minor	  research	  subjects.	  First,	  it	  is	  required	  that	  the	  clinical	  research	  generates	  
“some	   direct	   benefit	   for	   the	   group	   of	   patients”.	   The	   interpretation	   of	   this	   puzzling	  
requirement	   is	   hampered	   by	   the	   many	   ambiguities	   it	   entails,	   as	   a	   direct	   benefit	   is	   by	  
definition	  a	  benefit	  to	  the	  research	  subject	  concerned	  and	  thus	  not	  to	  a	  group	  of	  individuals,	  
and	  because	  research	  subjects	  are	  not	  necessarily	  patients,	  and	  patients	  are	  not	  necessarily	  
minors.19	   Unfortunately,	   these	   ambiguities	   are	   not	   cleared	   up	   in	   the	   domestic	  
implementations	  of	   the	  Clinical	  Trial	  Directive	  of	  EU	  member	   states.	  Second,	   it	   is	   required	  
that	  research	  either	  relates	  directly	  to	  a	  clinical	  condition	  from	  which	  the	  minor	  concerned	  
suffers,	  or	  be	  of	  such	  nature	  that	  it	  can	  only	  be	  carried	  out	  on	  minors.	  	  
Several	  member	  states	  specify	  the	  requirements	  captured	  in	  the	  Clinical	  Trial	  Directive.	  In	  
Austria,	  investigational	  medicinal	  products	  must	  be	  used	  in	  accordance	  with	  the	  latest	  state	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of	   the	   art	   of	  medical	   science,	   diagnose,	   cure,	   alleviate,	   or	   prevent	  minors	   from	   illnesses.	  
Likewise,	  the	  Bulgarian	  act	  stipulates	  that	  the	  tested	  medicinal	  product	  must	  be	  designed	  for	  
diagnosis,	  treatment	  or	  prevention	  of	  diseases	  that	  is	  specific	  to	  children	  and	  young	  persons.	  
The	   Czech	   Health	   Act	   provides	   that	   research	   in	   minors	   must	   be	   expected	   to	   generate	  
preventive	   or	   therapeutic	   benefits	   for	   the	   participating	   subjects	   and	   generate	   a	   direct	  
benefit	   for	   a	   group	  of	   patients.	  According	   to	   the	   French	  Public	  Health	  Code,	   research	   can	  
only	  be	  conducted	  in	  minors	  when	  the	  expected	  benefit	  to	  the	  participating	  subjects	  is	  likely	  
to	   justify	   the	   foreseeable	   risks.	  Alternately,	  also	  a	  benefit	   for	  other	  minors	  may	   justify	   the	  
risk	  that	  the	  research	  entails.	  In	  Germany,	  medicinal	  products	  can	  only	  be	  tested	  in	  minors	  if	  
they	  are	  intended	  to	  facilitate	  diagnosis	  or	  prevention	  of	  diseases	  in	  minors.	  In	  addition,	  the	  
German	  act	  requires	  that	   investigational	  medicinal	  products	  are	   indicated	  according	  to	  the	  
findings	  of	  medical	  science	  to	  save	  the	   life	  of	   the	  person	  concerned,	   to	  restore	  a	  subject’s	  
health,	  or	  to	  alleviate	  his	  or	  her	  suffering,	  unless	  the	  trial	  is	  of	  direct	  benefit	  to	  the	  group	  of	  
patients	  suffering	  from	  the	  same	  disease	  as	  the	  subject	  concerned.	  
In	   Estonia,	   the	  broad	   and	  unclear	   requirement	   to	   generate	   some	  direct	   benefit	   for	   the	  
group	   of	   patients	   is	   narrowed	   as,	   according	   to	   the	   Estonian	   act,	   pediatric	   clinical	   trials	   of	  
investigational	   medicinal	   products	   must	   be	   expected	   to	   generate	   a	   direct	   benefit	   to	   the	  
research	  subject.	  Also	  in	  Lithuania,	  it	  is	  required	  that	  the	  research	  results	  have	  the	  potential	  
to	  produce	  a	  real	  and	  direct	  benefit	  to	  the	  health	  of	  the	  research	  subjects	  themselves,	  rather	  
than	   a	   group	   of	   patients.	   In	   the	   Netherlands	   and	   Hungary,	   clinical	   research	   may	   not	   be	  
conducted	   in	  minors	  under	   18	   years	  of	   age	  unless	   the	   research	   is	   of	   direct	   benefit	   to	   the	  
subjects.	  However,	   the	   requirement	   to	  generate	  a	  direct	  benefit	   is	   linked	   to	  a	   specific	   risk	  
threshold:	   research	   with	   negligible	   risks	   and	   minimal	   burden	   for	   the	   minor	   subject	  
concerned	  may	  be	  conducted,	  also	  in	  the	  absence	  of	  a	  direct	  benefit	  to	  the	  research	  subject.	  
3.4	  Risks	  and	  burdens	  	  
In	  article	  4(g),	  the	  Clinical	  Trial	  Directive	  requires	  that	  clinical	  trials	  must	  be	  designed	  to	  
minimize	  pain,	  discomfort,	  fear,	  and	  any	  other	  foreseeable	  risk	  in	  relation	  to	  the	  disease	  and	  
developmental	  stage.	  In	  addition,	  the	  risk	  threshold	  and	  degree	  of	  distress	  must	  be	  specially	  
defined	  and	  constantly	  monitored.	  	  
Several	   EU	  member	   states	   provide	   additional	   details	   concerning	   the	   risks	   and	   burdens	  
involved	  in	  pediatric	  clinical	  research.	  In	  this	  respect,	  the	  Belgian	  law	  provides	  that	  research	  
risks	   may	   not	   be	   disproportionate	   to	   the	   expected	   benefits.	   More	   generally,	   the	   Finnish	  
Medical	  Research	  Act	  requires	  that	  the	  risks	   involved	   in	  research	  are	   limited.	  Likewise,	  the	  
Lithuanian	  law	  requires	  that	  biomedical	  research	  does	  not	  pose	  risks	  to	  the	  health	  or	  life	  of	  
vulnerable	  research	  subjects.	  
Germany	  has	   a	  more	   restrictive	  policy	   than	   the	  Clinical	   Trial	  Directive.	   The	  German	  act	  
specifies	  that	  clinical	  research	  may	  only	  cause	  minimal	  risk	  and	  minimal	  burden	  to	  the	  minor	  
concerned.	  Moreover,	  the	  German	  act	  stipulates	  that	  a	  research	  intervention	  only	  entails	  (i)	  
minimal	   risk	   if	   this	   intervention	   will	   result,	   at	   most,	   in	   a	   very	   slight	   and	   temporary	  
impairment	  of	  the	  minors’	  health,	  and	  (ii)	  minimal	  burden	  when	  it	  is	  to	  be	  expected	  that	  the	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discomfort	  for	  the	  minor	  will	  be,	  at	  most,	  temporary	  and	  very	  slight.	  Also	  in	  the	  Netherlands,	  
pediatric	   clinical	   research	   that	   does	   not	   generate	   a	   direct	   benefit	   to	   the	   subjects	  
participating	  in	  the	  trial	  may	  not	  cross	  the	  thresholds	  for	  minimal	  risk	  and	  minimal	  burden.	  
The	   Austrian	   act	   requires	   that	   the	   benefits	   to	   the	   subject	   concerned	   outweigh	   the	   risks	  
involved,	   unless	   when	   the	   trial	   (i)	   aims	   at	   generating	   a	   substantial	   progress	   in	   scientific	  
understanding	   of	   the	   condition,	   disease,	   or	   disorder	   from	   which	   the	   minor	   suffers	   and	  
therefore	  is	  likely	  to	  benefit	  the	  patient	  or	  group	  of	  patients	  to	  which	  the	  minor	  belongs,	  and	  
(ii)	  only	  entails	  minimal	  risk	  and	  minimal	  burden.	  	  
3.5	  Pediatric	  expertise	  of	  Ethics	  Committees	  
The	   legislator	  has	  assigned	  research	  ethics	  committees	  an	  essential	  task	   in	  checking	  the	  
compliance	  of	  research	  protocols	  with	  the	  ethical	  legal	  requirements	  captured	  in	  the	  Clinical	  
Trial	   Directive.	   For	   the	   assessment	   of	   pediatric	   research	   protocols,	   the	   Clinical	   Trials	  
Directive	   explicitly	   requires	   in	   art.	   4(h)	   that	   ethics	   committees	   either	   have	   pediatric	  
expertise,	   or	   take	   advice	   in	   clinical,	   ethical	   and	   psychosocial	   problems	   in	   the	   field	   of	  
pediatrics.	  	  
Several	   EU	   member	   states	   provide	   specific	   requirements	   with	   regard	   to	   this	   pediatric	  
expertise.	   In	  France,	  pediatric	  expertise	   in	  ethics	  committees	   is	   required	   in	  so	   far	   research	  
concerns	  subjects	  aged	  16	  years	  or	  less,	  and	  only	  when	  the	  ethics	  committee	  concerned	  has	  
no	  pediatrician	  among	  its	  members.	  In	  Italy,	   it	   is	  required	  that	  ethics	  committees	  include	  a	  
pediatrician	  among	   their	  members.	  The	  Belgian	   law	  stipulates	   that	  Ethics	  committees	   that	  
assess	   and	   endorse	   pediatric	   protocols	   must	   include	   at	   least	   two	   doctor-­‐specialists	   in	  
pediatrics,	  or	  take	  advice	  from	  two	  doctor-­‐specialists	  in	  pediatrics	  on	  the	  clinical,	  ethical,	  and	  
psychosocial	   aspects	   of	   the	   protocol.	   In	   Bulgaria,	   the	   consultation	   of	   external	   experts	   in	  
pediatrics	   by	   the	   ethics	   committee	   is	  mandatory	   for	   all	   clinical	   trials	   in	   children	   or	   young	  
persons.	  Likewise,	  in	  Denmark,	  it	  is	  required	  that	  ethics	  committees	  that	  assess	  protocols	  for	  
pediatric	   clinical	   trials	   take	   advice	   from	   an	   expert	   in	   pediatrics.	   The	   Czech	   Decree	   Good	  
Clinical	   Practice	   requires	   that	   ethics	   committees	   perform	   their	   supervision	   in	   at	   least	   six-­‐
monthly	   intervals.	   Ethics	   committees	   lacking	   experience	   in	   pediatrics	   must	   involve	   a	  
specialist	   qualified	   in	   pediatrics	   for	   the	  purposes	   of	   this	   supervision.	   Four	  member	   states,	  
Finland,	   Slovakia,	   the	   Netherlands,	   and	   Italy,	   have	   ethics	   committees	   that	   are	   specifically	  
devoted	  to	  minors.7	  
Discussion	  
Throughout	  the	  past	  decades,	  considerable	  effort	  has	  been	  made	  to	  harmonize	  the	  legal	  
framework	  governing	  clinical	  trials	  in	  the	  EU.	  Hereby,	  attention	  has	  been	  paid	  to	  the	  specific	  
issues	  in	  pediatric	  research.	  Particularly	  the	  European	  Clinical	  Trial	  Directive	  is	  a	  milestone	  in	  
the	  harmonization	  of	  good	  clinical	  practice	  guidelines	  and	  legal	  requirements	  for	  conducting	  
clinical	   research	   in	   minors.	   As	   such,	   the	   European	   Clinical	   Trial	   Directive	   is	   an	   important	  
instrument	  in	  efforts	  to	  facilitate	  pan-­‐European	  multicentre	  pediatric	  research.	  Nonetheless,	  
the	  harmonizing	  capacity	  of	  the	  European	  Clinical	  Trial	  Directive	  is	  profoundly	  compromised	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by	  three	  factors.	  First,	  apart	  from	  the	  Clinical	  Trial	  Directive,	  also	  the	  European	  Convention	  
and	  the	  Pediatric	  Regulation	  govern	  the	  conduct	  of	  pediatric	  clinical	  trials	   in	  Europe	  at	  the	  
supranational	   level.	   This	   supranational	   legal	   framework	   in	   its	   entirety,	   however,	   contains	  
various	  unclear	  and	  contradictory	  provisions,	  which	  complicate	   the	   implementation	  of	   this	  
legal	   framework.	   Second,	   a	   Directive,	   in	   contrast	   to	   a	   European	   Regulation,	   must	   be	  
implemented	  into	  domestic	  law	  by	  all	  EU	  Member	  States.	  As	  such	  an	  implementation	  is	  not	  
necessarily	  a	   servile	  copy	  of	   the	  original	   text	  of	   the	  Directive,	   the	   implementation	  process	  
may	  create	  diversity	  within	  the	  European	  legal	  landscape.	  Third,	  not	  everything	  in	  the	  law	  is	  
arranged	  by	  law,	  and	  the	  legal	  frameworks,	  both	  at	  supranational	  and	  at	  national	  level,	  leave	  
a	   lot	   of	   the	   interpretation	   and	   implementation	   of	   the	   legal	   frameworks	   to	   those	  who	   are	  
actually	  involved	  in	  the	  conduct	  of	  pediatric	  research.	  	  
First,	   a	   comparative	   analysis	   of	   the	   three	   main	   documents	   of	   the	   European	   legal	  
framework	  at	  the	  supranational	  level	  reveals	  that	  this	  framework	  lacks	  internal	  consistency.	  
Contradictory	   provisions	   between	   the	   different	   documents,	   for	   example	   with	   regard	   to	  
provisions	   on	   the	   conduct	   of	   non-­‐beneficial	   research	   and	   the	   veto-­‐power	   of	   minors	   in	  
decisions	   about	   research	   participation,	   render	   it	   difficult	   to	   interpret	   and	   implement	   the	  
European	  supranational	  legal	  framework.	  Regarding	  non-­‐beneficial	  research,	  art.	  17,2	  of	  the	  
European	   Convention	   requires	   that	   in	   the	   absence	   of	   a	   direct	   benefit	   to	   the	   individual	  
research	   participant,	   a	   minor	   can	   only	   be	   involved	   in	   research	   if	   the	   study	   only	   entails	  
minimal	   risks	   and	   minimal	   burden,	   while	   art.	   4e	   the	   Clinical	   Trial	   Directive	   only	   requires	  
”some	   direct	   benefit’”	   to	   the	   research	   subject	   or	   a	   related	   group	   of	   beneficiaries.	   This	  
indicates	   that	   the	   European	   Convention	   endorses	   a	   more	   restrictive	   policy	   than	   the	  
European	  Directive.	  As	  a	  consequence,	  early	  stage	  drug	  development	  may	  be	  compromised	  
in	  Member	  States	  that	  have	  signed	  and	  ratified	  the	  European	  Convention.	  Also	  in	  relation	  to	  
the	  power	  of	  a	  minor	  to	  veto	  participation	  in	  clinical	  research,	  contradictory	  provisions	  exist.	  
While	   art.	   4c	   of	   the	   Clinical	   Trial	   Directive	   provides	   that	   the	   (principal)	   investigator	  must	  
consider	  the	  explicit	  wish	  of	  a	  minor	  to	  refuse	  or	  discontinue	  participation	  (in	  the	  case	  of	  a	  
minor	   that	   is	   capable	   of	   assessing	   information	   and	   forming	   an	   opinion),	   art.	   17,1v	   of	   the	  
European	   Convention	   provides	   that	  minors	   cannot	   be	   involved	   in	   a	   study	  whenever	   they	  
object	  to	  research	  participation.	  Thus,	  theoretically,	  the	  European	  Convention	  grants	  minors	  
more	  extensive	  decision	  making	  powers	   than	   the	  European	  Directive.	   In	   addition	   to	   these	  
contradictory	   provisions,	   the	   European	   legal	   framework	   also	   contains	   numerous	  
contingencies	  that	  require	  extensive	  interpretation.	  It	  is	  for	  example	  not	  clear	  what	  must	  be	  
understood	   as	   an	   acceptable	   risk-­‐benefit	   ratio,	   what	   it	   means	   to	   ‘consider’	   the	   explicit	  
dissent	  of	  a	  minor,	  how	  the	  capacity	  of	  minors	  to	  make	  decisions	  can	  be	  assessed,	  or	  why	  
the	   Clinical	   Trial	   Directive	   designates	   minor	   research	   participants	   as	   ‘patients’	   and	   links	  
benefits	  to	  the	  ‘group	  of	  patients’.	  	  
Second,	   to	   a	   certain	   extent,	   the	   domestic	   implementation	   of	   the	   clinical	   trial	   directive	  
works	   against	   harmonization,	   as	   Member	   States	   are	   free	   to	   vary	   the	   original	   text	   and	  
stipulate	  additional	  legal	  requirements,	  provided	  the	  standards	  of	  protection	  and	  time	  limits	  
captured	  in	  the	  European	  Clinical	  Trial	  Directive	  are	  not	  violated.	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The	   analysis	   of	   the	   domestic	   implementation	   of	   the	   Clinical	   Trial	   Directive	   in	   the	   27	  
member	  states	  of	  the	  EU	  presented	  in	  this	  article	  shows	  that	  the	  domestic	  implementation	  
creates	   considerable	   legislative	   diversity.	   However,	   despite	   these	   variations	   in	   national	  
provisions,	  few	  of	  the	  domestic	  implementations	  of	  the	  Clinical	  Trial	  Directive	  appear	  to	  be	  a	  
major	  obstacle	   to	  pediatric	   clinical	   trials.	   In	   general,	   research	  protocols	   can	  be	   tailored	   to	  
comply	  with	  national	   legal	  requirements	  of	  a	  Member	  State	  relatively	  easily,	  provided	  that	  
one	   takes	   notice	   of	   the	   domestic	   provisions	   of	   an	   individual	  Member	   State.	   Nonetheless,	  
there	  is	  still	  a	   long	  way	  to	  go	  in	  making	  all	  national	  requirements	  of	   individual	  EU	  member	  
states	  accessible,	  due	  to	  a	  lack	  of	  authorized	  translations	  and	  easily	  accessible	  compilations	  
of	  all	  legal	  requirements.	  
Third,	   not	   everything	   in	   the	   law	   is	   arranged	   by	   law.	   Particularly	   the	   role	   of	   individual	  
decision	  makers	  in	  the	  interpretation	  and	  implementation	  of	  European	  legal	  frameworks	  can	  
hardly	   be	   overestimated.	   These	   decision	  makers	   can	   be	   institutional	   bodies	   (for	   example	  
ethics	  committees,	  or	  competent	  authorities)	  or	  persons	  (for	  example	  clinicians,	  minors	  and	  
their	  parents	  or	  legal	  representatives).	  	  
As	  the	  European	  legal	  framework	  leaves	  considerable	  discretion	  in	  the	  interpretation	  and	  
application	   of	   regulatory	   requirements	   individual	   and	   institutional	   decision-­‐makers,	   the	  
implementation	  of	  this	  legal	  framework	  becomes	  largely	  dependent	  upon	  the	  bodies	  and/or	  
individuals	  who	  actually	  decide	  on	  the	  involvement	  of	  an	  individual	  minor	  in	  a	  clinical	  trial.	  
Applying	  the	  same	  set	  of	  rules	  does	  not	  guarantee	  a	  similar	  interpretation	  or	  application	  of	  
these	   rules,	   and	   therefore	   the	   discretionary	   freedom	   of	   decision-­‐makers	   in	   the	   setting	   of	  
pediatric	  clinical	  research	  provokes	  a	  certain	  diversification	  of	  the	  regulatory	  landscape.	  The	  
diversity	   in	   implementation	   of	   regulatory	   requirements,	   however,	   entails	   harsher	  
consequences	  than	  the	  diversity	  of	   legal	  provisions	   itself	  because	  of	  their	  practical	   impact.	  
Rendering	   the	   implementation	   of	   regulation	   dependent	   upon	   the	   discretion	   of	   individuals	  
that	  decide	  upon	  the	  accessibility	  and	  execution	  of	  a	  research	  protocol,	  tends	  to	  make	  the	  
implementation	   of	   legal	   requirements	   a	   poorly	   intelligible	   process,	   the	   outcome	   of	  which	  
often	  appears	  hard	  to	  predict.	  
While	  it	  is	  true	  that	  the	  European	  legal	  frameworks	  that	  govern	  pediatric	  clinical	  research	  
by	   their	   nature	   generate	   a	   considerable	   diversity	   in	   their	   actual	   interpretation	   and	  
implementation,	   this	   diversity	   need	   not	   become	   an	   enemy	   to	   be	   defeated.	   Quite	   the	  
reverse,	   the	   diversity	   in	   interpretation	   and	   application	   of	   the	   legal	   frameworks	   governing	  
pediatric	  clinical	  research	  can	  be	  regarded	  as	  a	  considerable	  asset	  for	  several	  reasons.	  First,	  
research	  is	  not	  an	  impersonal	  enterprise.	  Taking	  the	  personal	  concerns	  of	  clinicians,	  minors	  
and	  their	  parents	  seriously,	  however,	  can	  hardly	  be	  done	  in	  a	  regulatory	  environment	  that	  
fails	  to	  tolerate	  a	  certain	  level	  of	  diversity.	  Second,	  research	  is	  not	  a	  universal	  enterprise.	  The	  
demographic,	   institutional,	   economic,	   and	   cultural	   particularities	   of	   individual	   member	  
states	   are	   relevant	   to	   the	   design	   and	   conduct	   of	   pediatric	   clinical	   studies.	   Apparently	  
uncomplicated	  environmental	  factors,	  such	  as	  research	  infrastructure	  may	  deeply	  affect	  the	  
conduct	  of	  pediatric	  research.	  Consequently,	  locality	  matters.	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Therefore,	  the	  way	  forward	  in	  pediatric	  clinical	  research	  rather	  seems	  one	  of	  dealing	  with	  
diversity	   than	   one	   of	   seeking	   further	   operational	   harmonization.	   Nonetheless,	   certain	  
contradictory	  provisions	  should	  be	  rectified	  urgently.	   In	  particular,	   the	  contradiction	   in	  the	  
stance	  towards	  non-­‐beneficial	  research	  between	  the	  European	  Convention	  and	  the	  Clinical	  
Trials	   Directive	   should	   be	   resolved.	   This	   should	   be	   feasible,	   because	   now	   that	   the	   Clinical	  
Trial	  Directive	  has	  been	  governing	  pediatric	  clinical	  trials	  for	  more	  than	  five	  years,	  we	  should	  
be	   able	   to	   assess	   whether	   the	   more	   tolerant	   approach	   of	   the	   Clinical	   Trial	   Directive	   in	  
comparison	  to	  the	  European	  Convention	  has	  permitted	  unethical	  research	  conduct.	  To	  our	  
knowledge,	   no	   incidences	   have	   been	   reported	   in	   this	   respect.	   Therefore,	   it	   is	   doubtful	  
whether	   abolishing	   the	  minimal	   risk	   and	  minimal	   burden	   thresholds	   would	   impair	   ethical	  
research	  conduct	  or	  decrease	  the	  level	  of	  protection	  of	  research	  subjects.	  If	  the	  minimal	  risk	  
and	  minimal	  burden	  threshold,	  however,	  do	  not	  contribute	  to	  increased	  ethical	  standards	  in	  
pediatric	   clinical	   research,	   they	  may	  be	  considered	  an	  obstacle	   that	  works	  against	   the	  key	  
objective	  of	  encouraging	  and	  facilitating	  clinical	  studies	  in	  children.	  	  
Although	   further	   harmonization	   can	   solve	   certain	   issues,	   handling	   diversity	   will	   be	  
indispensible	   in	   a	   landscape	   as	   diverse	   as	   the	   EU.	   Operational	   strategies	   to	   manage	   this	  
diversity,	  however,	  remain	  largely	  unexplored	  to	  date.	  	  
Recommendations	   for	   the	   conduct	   of	   clinical	   trials	   in	   minor	   CF-­‐
patients	  
A	  shared	  responsibility	  	  
The	   ethical	   conduct	   of	   clinical	   research	   is	   a	   shared	   commitment	   of	   all	   those	   involved.	  
Obviously,	   the	  approval	  of	  a	   research	  protocol	   is	  by	  no	  means	  a	   full	   guarantee	   for	   clinical	  
research	   to	   be	   ethically	   sound.	   Therefore,	   all	   parties	   involved	   have	   a	   responsibility	   in	  
assessing	   the	   acceptability	   and	   appropriateness	   of	   the	   research,	   in	   general,	   and	   for	   the	  
subject	  concerned,	  from	  their	  own,	  unique	  perspective.	  	  
Although	  the	  European	  legal	  framework	  only	  draws	  explicit	  attention	  to	  permission	  in	  the	  
form	   of	   protocol	   approval	   and	   informed	   consent,	   clinicians	   have	   an	   important	   role.	   They	  
must	   assess	   whether	   research	   participation	   is	   medically	   recommendable	   to	   the	   subject	  
concerned.	   When	   the	   researcher	   is	   also	   the	   patient’s	   physician,	   their	   knowledge	   of	   the	  
patients’	  medical	  and	  personal	  background	  aids	  greatly	  this	  assessment.	  	  
Walking	  the	  thin	  line	  
The	  regulations	  that	  govern	  pediatric	  clinical	  research	  in	  the	  EU	  address	  ethical	  issues	  in	  
research	   participation	   detached	   from	   the	   therapeutic	   context	   in	   which	   clinical	   trial	  
participation	  is	  often	  discussed.	  In	  practice,	  however,	  the	  dividing	  line	  between	  research	  and	  
therapy	  is	  often	  extremely	  thin.	  Therefore,	  dealing	  with	  the	  ambiguous	  distinction	  between	  
research	  and	  therapy	  is	  essential	  for	  good	  clinical	  practice.	  	  
While	  framing	  clinical	  research	  in	  the	  therapeutic	  context	  of	  the	  minor	  concerned	  offers	  
unique	   opportunities	   to	   clarify	   the	   relevance	   of	   the	   proposed	   research	   for	   the	   individual	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minor,	   integrating	   research	   in	   a	   therapeutic	   framework	   may	   at	   the	   same	   time	   blur	   the	  
dividing	  line	  between	  research	  and	  therapy.	  Therefore,	  it	  is	  of	  key	  importance	  that	  research	  
is	   also	   distinguished	   from	   therapy,	   even	   when	   it	   is	   discussed	   against	   a	   therapeutic	  
background.	  In	  this	  respect,	  it	   is	  particularly	  important	  to	  communicate	  what	  the	  patient	  is	  
to	  expect	  after	  the	  trial	  has	  been	  terminated.	  	  
It’s	  all	  about	  the	  minor	  
Conducting	   research	   in	   minors	   is	   all	   about	   minors.	   Therefore,	   minors	   who	   are	   eligible	  
research	   subjects	   should	  have	  a	   central	   position	  and	   sometimes	  also	   an	  active	   role	   in	   the	  
consent	   discussion,	   reflecting	   their	   personal	   desire	   to	   take	   part	   in	   the	   decision,	   and	   their	  
maturity	  and	  developmental	  stage.	  	  
Notwithstanding	  this	  central	  role	  of	  the	  minor,	  the	  main	  responsibilities	  in	  deciding	  upon	  
the	  enrollment	  of	  a	  minor	  in	  a	  clinical	  trial	  are	  in	  the	  hands	  of	  the	  adults	  surrounding	  them.	  
These	   are	   in	   the	   first	   place	   the	   parents	   or	   legal	   guardians	   that	   hold	   the	   legal	   capacity	   to	  
grant	   informed	   consent	   for	   research	   participation,	   but	   also	   their	   physicians	   and	   the	  
researchers	   that	   invite	   them	  to	  participate	   in	   the	  clinical	   trial.	  All	   involved	  should	  strive	   to	  
move	  beyond	  their	  personal	  convictions,	  and	  aspire	  to	  decide	  in	  the	  interests	  of	  the	  minor	  
concerned.	  	  
Validate	  experience	  
In	  the	  specific	  case	  of	  clinical	  research	  on	  CF	  patients,	  it	  should	  be	  taken	  into	  account	  that	  
due	   to	   the	  chronic	  nature	  of	   this	  disorder	  and	   its	   impact	  on	   their	   lives,	   young	  CF	  patients	  
may	   already	  have	  developed	  above-­‐average	  decision-­‐making	   skills.	   Therefore,	   they	   should	  
not	  be	  underestimated	  in	  their	  capacity	  to	  participate.	  Moreover,	  the	  experience	  that	  minor	  
patients	  already	  have	  and	  will	  create	  in	  the	  near	  future	  should	  be	  taken	  into	  account.	  	  
It	  should	  be	  acknowledged	  that	  throughout	  the	  years,	  CF	  patients	  are	  frequently	  invited	  
to	   participate	   in	   studies.	   Clinicians	   should	   therefore	   guard	   against	   individual	   CF	   patients	  
participating	   too	   frequently	   in	   clinical	   studies	   to	   prevent	   them	   from	   becoming	   research	  
guinea	   pigs.	   On	   the	   other	   hand,	   inordinate	   enthusiasm	   for	   clinical	   trials	   may	   create	   the	  
impression	   that	   research	   subjects	   are	   elected	   to	   be	   the	   first	   beneficiaries	   of	   novel	   and	  
important	  medical	  breakthroughs.	  This	  should	  also	  be	  avoided.	  	  
In	  between	  the	  lines	  
The	   supranational	  and	  national	   legal	   frameworks	   that	  govern	  pediatric	   clinical	   trials	   set	  
down	  general	  requirements	  for	  the	  conduct	  of	  studies	  in	  minor	  research	  subjects.	  To	  a	  large	  
extent,	   the	   interpretation	   and	   implementation	   of	   these	   frameworks,	   however,	   is	   not	  
arranged	  by	  law	  but	  left	  to	  the	  discretion	  of	  those	  who	  are	  directly	  involved	  in	  the	  conduct	  
of	   clinical	   trials.	   Here,	   obviously,	   clinicians	   hold	   an	   expertise	   and	   experience	   that	   is	  
disproportionately	  large	  in	  comparison	  to	  that	  of	  minors	  and	  their	  parents.	  Therefore,	  they	  
have	  a	  vital	  role	  in	  the	  realization	  of	  good	  clinical	  practice.	  	  
Giving	   shape	   to	   poorly	   defined	   ethical	   and	   legal	   requirements	   is	   a	   complex	   task,	   that	  
should	   not	   be	   reduced	   to	   the	   responsibility	   of	   a	   single	   individual.	   Therefore,	   it	   is	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recommended	   that	   ethical	   issues	   in	   the	   conduct	   of	   clinical	   research	   are	   discussed	   among	  
colleagues,	   and	   that	   the	   created	   expertise	   in	   dealing	   with	   these	   issues	   is	   shared	   over	  
individual	  trials.	  	  
Incorporate	  trust	  
The	   fact	   that	   clinicians,	  minors,	   and	   their	   parents	   (or	   another	   legal	   representative)	   are	  
assigned	   a	   considerable	   role	   in	   the	   interpretation	   and	   implementation	   of	   the	   legal	  
framework	  renders	  the	  relationships	  between	  these	  actors	  of	  vital	  importance.	  Within	  these	  
relationships,	   trust	   is	  essential,	   from	  the	  moment	  of	  recruitment	  to	  the	  termination	  of	  the	  
trial,	   to	   bridge	   the	   asymmetry	   in	   knowledge,	   expertise,	   and	   commitment	   of	   the	   different	  
parties	  involved.	  
However,	   despite	   the	   fundamental	   importance	   of	   trust	   in	   the	   mutual	   relationships	  
between	   clinicians,	   minors,	   and	   their	   parents	   (or	   other	   legal	   representative),	   also	   the	  
downside	  of	  trust	  must	  be	  acknowledged.	  Trust	  is	  not	  infallible,	  can	  be	  very	  naïve,	  and	  may	  
open	   minor	   research	   subjects	   to	   the	   possibility	   of	   coercion	   and	   abuse.	   Therefore,	   it	   is	  
necessary	  that	  safeguards	  against	   inordinate	   loyalty,	  deception,	   therapeutic	  misconception	  
and	   other	   ethical	   digressions	   are	   incorporated	   in	   clinical	   practice.	   Rather	   than	   having	  
outsiders	   bringing	   in	   such	   safeguards,	   expertise	   should	   be	   created	   both	   in	   clinicians	   who	  
communicate	   about	   the	   trial	   and	   in	   minors	   and	   parents	   who	   consider	   enrollment	   into	   a	  
clinical	  trial.	  	  
Pediatric	  Expertise	  
The	   ethical	   and	   legal	   frameworks	   that	   govern	   pediatric	   research	   in	   the	   EU	   formally	  
require	  that	  ethics	  committees	  foster	  pediatric	  expertise,	  either	  by	   including	  a	  pediatrician	  
among	   their	  members	   or	   by	   calling	   in	   external	   advice.	   Although	   it	   is	   clear	   that	   individual	  
pediatricians	   are	   to	   embody	   this	   pediatric	   expertise	   (who),	   it	   is	   neither	   clear	   what	   such	  
pediatric	  expertise	  entails	  contentwise	  (what),	  nor	  what	  added	  value	  such	  expertise	  should	  
bring	   to	   the	  assessment	  of	   research	  protocols	   (why).	   Therefore,	  both	   the	  content	  and	   the	  
aims	  of	  pediatric	  expertise	   in	  pediatric	   research	  should	  be	  cleared	  out.	  Hereby,	   it	  must	  be	  
acknowledged	  that	  the	  individual	  pediatricians	  who	  embody	  the	  pediatric	  expertise	  of	  ethics	  
committees	   may	   lack	   specific	   knowledge	   on	   certain	   ethical	   and	   legal	   aspects	   of	   their	  
practice,	   no	  matter	   how	  experienced	   they	   are.	   Therefore,	   it	   is	   essential	   that	   pediatricians	  
who	  act	  as	  an	  expert	  in	  ethics	  committees	  are	  provided	  with	  up	  to	  date,	  clear	  and	  relevant	  
research	  results	  on	  the	  ethical,	  legal,	  and	  social	  issues	  in	  pediatric	  clinical	  research	  practice.	  	  
Previous	  Publication	  of	  Results	  
Part	   of	   the	   results	   in	   this	   paper	   (analysis	   of	   legislation	   at	   the	   supranational	   level)	   have	  
been	   previously	   published	   in:	   Pinxten	   W,	   Dierickx	   K,	   Nys	   H.	   Ethical	   principles	   and	   legal	  
requirements	   for	  pediatric	   research	   in	   the	  EU:	  an	  analysis	  of	   the	  European	  normative	  and	  
legal	  framework	  surrounding	  pediatric	  clinical	  trials.	  Eur	  J	  Pediatr	  2009	  Oct;168(10):1225-­‐34.	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Abstract	  	  
The	  European	  Clinical	  Trial	  Directive	  (2001/20/EC)	  was	  implemented	  into	  the	  Belgian	  legal	  
system	  by	  the	  Law	  of	  7	  may	  2004	  concerning	  experiments	  on	  the	  human	  person	  (LEH).	  Apart	  
from	  implementing	  the	  European	  Directive,	  this	  law	  also	  broadens	  the	  scope	  of	  the	  Directive	  
from	  interventional	  clinical	  trials	  to	  all	  medical	  experiments	  involving	  human	  persons.	  	  
This	   article	   offers	   an	   overview	   of	   the	   requirements	   for	   involving	   minors	   in	   medical	  
experiments	   that	  are	  captured	   in	   the	  LEH,	   illustrates	   the	  process	  of	  protocol	   review	  by	  an	  
ethics	   committee,	   and	   discusses	   the	   dissimilarities	   between	   the	   LEH	   and	   the	   European	  
Directive.	  	  
The	  implementation	  of	  Directive	  2001/20/EC	  into	  Belgian	  law	  
Directive	  2001/20/EC	  of	  the	  European	  Parliament	  and	  the	  Council	  of	  4	  April	  2001	  on	  the	  
approximation	  of	  the	  laws,	  regulations	  and	  administrative	  provisions	  of	  the	  Member	  States	  
relating	   to	   the	   implementation	  of	   good	   clinical	   practice	   in	   the	   conduct	  of	   clinical	   trials	   on	  
medicinal	  products	  for	  human	  use	  (further:	  the	  European	  Directive)	  was	  implemented	  in	  the	  
Belgian	   legal	   system	   by	   the	   Law	   of	   7	   may	   2004	   concerning	   experiments	   on	   the	   human	  
person	   (further:	   the	  LEH).	  Three	  Royal	  Decrees	  arrange	  the	  operational	   implementation	  of	  
this	  law,	  and	  several	  circulars	  offer	  help	  in	  interpretation	  and	  practical	  arrangements.i	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i	  Royal	  Decree	  of	  30	  June	  2004	  providing	  for	   implementation	  measures	  of	  the	  Law	  of	  7	  may	  2004	  concerning	  
experiments	   on	   the	   human	   person	   with	   regard	   to	   clinical	   trials	   with	   medicinal	   products	   for	   human	   use,	  
modified	  by	  the	  Royal	  Decree	  of	  18	  may	  2006.	  (MB/BS	  26	  May	  2006)	  
Royal	   Decree	   of	   15	   July	   2004	   establishing	   the	   retributions	   to	   be	   paid	   in	   the	   context	   of	   an	   application	   for	   a	  
clinical	  trial	  or	  an	  experiment.	  (MB/BS	  16	  July	  2004)	  
Royal	  Decree	  of	  27	  April	  2007	  providing	  the	  fees	  to	  be	  paid	  in	  the	  context	  of	  Article	  30,	  §6	  of	  the	  LEH.	  (MB/BS	  
22	  May	  2007)	  
Royal	   Decree	   of	   15	   July	   2004	   establishing	   the	   retributions	   to	   be	   paid	   in	   the	   context	   of	   an	   application	   for	   a	  
clinical	  trial	  or	  an	  experiment.	  (MB/BS	  16	  July	  2004)	  
76	  ⏐	  Chapter	  3	  
Scope	  	  
As	   the	   title	   of	   the	   LEH	   indicates,	   its	   scope	   is	   significantly	   broader	   than	   that	   of	   the	  
Directive.	   All	   medical	   experiments	   conducted	   on	   human	   persons,	   and	   thus	   not	   only	  
interventional	   clinical	   trials,	   are	   covered	   by	   the	   LEH.	   Art.	   2,11°	   of	   the	   LEH	   defines	   an	  
experiment	  as:	  
‘Any	  trial,	  study	  or	  investigation	  carried	  out	  on	  the	  human	  person	  with	  the	  aim	  of	  
developing	  knowledge	  particular	   to	   the	  exercising	  of	  health	   care	  professions	  as	  
referred	  to	   in	  Royal	  Decree	  No.	  78	  of	  10	  November	  1967	  concerning	  the	  health	  
care	  professions.’	  
This	   definition	   is	   clearly	   broader	   than	   the	  definition	  of	   a	   clinical	   trial	   in	   art.	   2(a)	   of	   the	  
European	  Directive.	  	  
‘Any	   investigation	   in	   human	   subjects	   intended	   to	   discover	   or	   verify	   the	   clinical,	  
pharmacological,	   and/or	   other	   pharmacodynamic	   effects	   of	   one	   or	   more	  
investigational	  medicinal	   product(s),	   and/or	   to	   identify	   any	   adverse	   reaction	   to	  
one	   or	   more	   investigational	   product(s)	   an/or	   to	   study	   absorption,	   distribution,	  
metabolism	  of	  one	  or	  more	   investigational	  medicinal	  product(s)	  with	   the	  object	  
of	  ascertaining	  its	  (their)	  safety	  an/or	  efficacy’.	  
Also	   the	   definition	   of	   ‘human	   person’	   is	   more	   comprehensive	   than	   that	   of	   ‘research	  
subject’.	  While	  the	  European	  Directive	  defines	  a	  subject	  as	  ‘an	  individual	  who	  participates	  in	  
a	   clinical	   trial	   as	   either	   a	   recipient	   of	   the	   investigational	   medicinal	   product	   or	   a	   control’,	  	  
(art.	  2(i))	  the	  LEH	  defines	  a	  human	  person	  as	  ‘a	  born,	  living,	  and	  viable	  person’	  	  (art.	  2,23°).	  
According	   to	   this	   definition,	   the	   LEH	   is	   not	   applicable	   in	   research	   with	   human	   material	  
already	  separated	  from	  the	  body,	  embryos	  in	  vitro,	  or	  corpses.	  Also	  retrospective	  research	  is	  
excluded	  from	  the	  scope	  of	  the	  law.	  	  
The	  broader	  scope	  of	  the	  LEH	  does	  not	  imply	  that	  all	  experiments	  on	  human	  persons	  are	  
subjected	   to	   the	   same	   requirements.	   Several	  provisions	  are	  not	  applicable	   in	   case	  of	  non-­‐
interventional	  experiments	  or	  experiments	  not	  involving	  medicinal	  products.	  In	  addition,	  the	  
LEH	  makes	  a	  distinction	  between	  commercial	  and	  non-­‐commercial	  research,	  and	  addresses	  
hereby	  a	  frequently	  formulated	  point	  of	  criticism	  in	  the	  appraisal	  of	  the	  European	  Directive.	  	  
Requirements	  for	  the	  conduct	  of	  pediatric	  medical	  experiments	  	  
Pediatric	   clinical	   trials	   are	   subjected	   to	   the	   general	   requirements	   valid	   in	   research	   in	  
competent	  adults	  and	   to	  additional	   requirements	   specific	   to	   the	   involvement	  of	  minors	   in	  
research.	  The	  specific	  provisions	  on	  the	   involvement	  of	  minors	   in	  research	  captured	   in	  the	  
European	   Directive	   and	   the	   LEH	   are	   related	   to	   (1)	   the	   specific	   design	   of	   the	   pediatric	  
research,	  (2)	  the	  approval	  of	  the	  protocol	  by	  an	  ethics	  committee,	  (3)	  the	  informed	  consent	  
to	  enroll	  a	  minor	  in	  research,	  and	  (4)	  the	  absence	  of	  incentives	  or	  financial	  inducements.	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Scientific	  design	  of	  the	  research	  	  
Research	  in	  minors	  can	  only	  be	  conducted	  if	  certain	  standards	  related	  to	  the	  design	  of	  the	  
research	  project	   are	  met.	   First,	   the	  necessity	   to	   involve	  minors	   in	   a	   clinical	   trial	   to	   obtain	  
relevant	  results	  must	  be	  demonstrated.	  According	  to	  both	  the	  European	  Directive	  (art.	  4(e))	  
and	   the	   LEH	   (art.	   7,3°),	   it	   is	   not	   permitted	   to	   conduct	   research	   in	   minors	   if	   comparable	  
results	  can	  be	  obtained	  by	  using	  other	  research	  methods	  (e.g.,	  laboratory	  research	  or	  animal	  
models)	   or	   by	   conducting	   research	   in	   other	   populations	   capable	   of	   valid	   consent	   (e.g.,	  
competent	  adults),	  as	   it	   is	   required	   that	  “the	  experiment	  must	  be	  essential	   to	  validate	   the	  
data	  obtained	  in	  experiments	  on	  persons	  able	  to	  give	  consent	  or	  by	  other	  research	  methods”	  
(Art.	  4(e)	  European	  Directive	  and	  art.	  7,3°	  LEH).	  Second,	  it	  is	  required	  that	  research	  is	  related	  
to	   the	   participating	   minor.	   In	   this	   respect,	   art.	   7,2°	   LEH	   and	   art.	   4(e)	   of	   the	   European	  
Directive	  specify	  that	  research	  should	  either	  relate	  directly	  to	  a	  clinical	  condition	  from	  which	  
the	  participating	  minor	  concerned	  suffers	  or	  be	  of	  such	  a	  nature	  that	  it	  can	  only	  be	  carried	  
out	  on	  minors.	  Third,	   it	   is	  provided	  that	  research	   in	  minors	  must	  generate	  an	  added	  value	  
benefiting	  the	  minor	  research	  participant	  or	  a	  related	  group	  of	  beneficiaries.	  In	  this	  respect,	  
art.	   7,3°	   LEH	   attempts	   to	   implement	   art.	   4(e)	   of	   the	   Directive	   that	   states:	   “some	   direct	  
benefit	   for	   the	   group	   of	   patients	   is	   obtained	   from	   the	   clinical	   trial	   and	   only	   where	   such	  
research	   is	   essential	   to	   validate	   data	   obtained	   in	   clinical	   trials	   on	   persons	   able	   to	   give	  
informed	   consent	   or	   by	   other	   research	   methods;	   (…)”.	   Art.	   7,3°	   LEH	   and	   art.	   4(e)	   of	   the	  
European	  Directive	   thus	   both	   require	   that	   research	   generates	   some	  direct	   benefit	   for	   the	  
group	  of	  patients	  to	  which	  the	  minor	  research	  participant	  belongs.	  However,	   it	   is	  not	  clear	  
how	   this	   requirement	   of	   a	   group	   benefit	   must	   be	   interpreted.	   Especially	   the	   expression	  
‘group	   of	   patients’	   in	   art	   7,3°	   LEH	   -­‐adopted	   verbatim	   from	   art.	   4(e)	   of	   the	   European	  
Directive-­‐	   is	   tangling,	  as	   it	  does	  not	  necessarily	  restrict	  research	  to	  participants	  who	  are	  at	  
the	   same	   time	   patients.	   In	   the	   light	   of	   the	   explanatory	   memorandum	   of	   the	   European	  
Directive,	   the	   notion	   ‘group	   of	   patients’	   can	   be	   interpreted	   as	   the	   group	   of	   minors	   in	  
general.1	   In	   addition,	   also	   the	   specification	   of	   a	   ‘group	   benefit’	   as	   a	   ‘direct	   benefit’	   is	  
confusing,	   as	   the	   ‘direct’	   character	   of	   a	   benefit	   implies	   that	   the	   beneficiary	   is	   the	  
participating	   individual.	   Fourth,	   whenever	   a	   research	   design	   requires	   the	   involvement	   of	  
minors	  in	  research,	  provisions	  must	  be	  made	  to	  minimize	  the	  risks	  and	  burdens	  involved	  in	  
research	   participation.	   In	   this	   respect,	   art.	   4(g)	   of	   the	   European	   Directive	   is	   adopted	  
verbatim	  in	  art.	  7.6°	  of	  the	  LEH,	  reading:	  
‘the	  experiment	  has	  been	  designed	   to	  minimize	  pain,	   discomfort,	   fear,	   and	  any	  
other	   foreseeable	   risk	   in	   relation	   to	   the	  disease	  and	  developmental	   stage;	  both	  
the	   risk	   threshold	   and	   the	   degree	   of	   distress	   have	   to	   be	   specially	   defined	   and	  
permanently	  monitored.’	  
In	   addition	   to	   this	  minimization	   of	   risks	   and	   burdens,	   art.	   7.4°	   of	   the	   LEH	   provides	   (in	  
accordance	   to	   art.	   3,2a	   of	   the	   European	  Directive)	   that	   the	   risks	   taken	  by	  minor	   research	  
participants	  (and	  the	  foreseeable	  risks	  according	  to	  the	  current	  state	  of	  scientific	  knowledge)	  
may	  not	  be	  disproportionate	  to	  the	  anticipated	  benefits	  for	  that	   individual.	   It	   is	  difficult	  to	  
see	  how	  this	  requirement	  can	  be	  met	  in	  the	  case	  that	  the	  experiment	  has	  only	  some	  direct	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benefit	  for	  the	  groups	  of	  patients	  the	  participant	  belongs	  to	  (cf.	  supra)	  and	  not	  directly	  for	  
the	  participating	  minor.	  	  
Protocol	  endorsement	  by	  an	  ethics	  committee	  
Both	  the	  European	  Directive	  and	  the	  LEH	  require	  that	  the	  research	  protocol	  is	  endorsed	  
by	   an	   ethics	   committee	   before	   research	   commences.	   The	   Directive	   introduces	   three	  
important	   innovations	   in	   relation	   to	   obtaining	   ethics	   approval:	   (a)	   the	   provision	   of	   single	  
ethics	   opinion	   in	   multicentre	   trials,	   (b)	   the	   requirement	   of	   pediatric	   expertise	   in	   ethics	  
committees	   that	   review	   protocols	   of	   pediatric	   studies,	   and	   (c)	   the	   determination	   of	   strict	  
time	  limits	  for	  protocol	  review	  by	  an	  ethics	  committee.	  	  
Single	  opinion	  in	  multicentre	  trials	  	  
Art.	  7	  of	  the	  European	  Directive	  provides	  that	  Member	  States	  must	  establish	  a	  procedure	  
for	  obtaining	   ‘single	  opinion’	   in	  multicentre	   trials	   for	   that	  Member	  State.	  Correspondingly,	  
the	  protocol	  of	  a	  multicentre	  trial	  now	  needs	  to	  be	  endorsed	  by	  only	  one	  ethics	  committee	  
per	  Member	  State,	  whereas	  formerly	  approval	  needed	  to	  be	  obtained	  from	  every	  site.	  As	  a	  
result,	   researchers	   are	   less	   often	   confronted	   with	   diverging	   opinions	   of	   different	   Ethics	  
Committees.	  	  
In	  correspondence	  with	  art.	  7	  of	  the	  European	  Directive,	  the	  practical	  organization	  of	  the	  
provision	  of	  single	  ethics	  opinion	  in	  multicentre	  research	  is	  left	  to	  the	  freedom	  of	  individual	  
Member	  States.	  In	  this	  respect,	  the	  Belgian	  legislator	  opted	  to	  organize	  the	  provision	  of	  the	  
single	  opinion	  within	  the	  existing	  network	  of	  ethics	  committees,	  rather	  than	  creating	  a	  new	  
national	   body	   to	   perform	   this	   task.	   In	   practice,	   a	   limited	   number	   of	   Belgian	   ethics	  
committees	  are	  authorized	  to	  provide	  single	  opinion	  in	  multicentre	  trials.	  	  
However,	  also	  the	  ethics	  committees	  that	  are	  not	  authorized	  to	  provide	  single	  opinion	  in	  
multicentre	   trials	   take	  part	   in	   the	   review	  of	  protocols	  of	  multicentre	  experiments,	   as	   they	  
report	  to	  the	  ethics	  committee	  providing	  single	  opinion	  on	  elements	  specific	  to	  a	  particular	  
site	  These	  elements	  include	  the	  suitability	  of	  the	  local	  investigator	  and	  supporting	  staff,	  the	  
quality	   and	   adequacy	   of	   local	   facilities,	   and	   the	   adequacy	   and	   completeness	   of	   written	  
patient	  information	  and	  consent	  form	  in	  the	  local	  language.	  	  
Summarizing,	   ethics	   committees	   can	   act	   in	   two	   complementary	   roles	   when	   research	  
protocols	   for	  multicentre	   trials	   are	   reviewed.	   First,	   if	   they	   are	   authorized	   to	   do	   so,	   ethics	  
committees	  can	  act	  as	  a	  so	  called	  ‘leading	  ethics	  committee’	  providing	  single	  ethics	  opinion	  
in	  multicentre	  trials.	  Second,	  all	  ethics	  committees	  can	  act	  as	  a	  so	  called	  ‘non	  leading	  ethics	  
committee’,	  reporting	  on	  issues	  specific	  to	  the	  site	  where	  a	  part	  of	  the	  experiment	  will	  take	  
place.	  
The	  authorization	  to	  provide	  single	  opinion	  committee	   is	  granted	  for	  one	  year	  to	  ethics	  
committees	   that	   acted	   as	   a	   non-­‐leading	   committee	   in	   at	   least	   20	   multicentre	   research	  
protocols	   or	   as	   a	   leading	   committee	   in	   at	   least	   5	   multicentre	   research	   protocols	   in	   the	  
course	   of	   the	   past	   year.	   According	   to	   the	  most	   recent	   list	   published	   in	   the	   Belgian	   State	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Gazette,	  35	  ethics	  committees	  are	  authorized	  to	  provide	  single	  opinion	  in	  multicentre	  trials,	  
on	  an	  estimated	  total	  of	  235	  ethics	  committees	  in	  Belgium.ii	  	  
With	  at	  present	  35	  Belgian	  ethics	  committees	  being	  authorized	  to	  provide	  single	  opinion	  
in	  multicentre	  trials,	  a	  clear	  trend	  towards	  centralization	  can	  be	  observed.2	  While	  in	  2006	  a	  
total	   of	   162	   Belgian	   ethics	   committeesiii	   assessed	   3997	   protocols,	   over	   2353	   of	   these	  
protocols	  were	  assessed	  by	  9	  committees	  reviewing	  more	  than	  100	  protocols.	  This	  indicates	  
a	   de	   facto	   centralization	   of	   protocol	   assessment	   to	   ethics	   committees	   with	   sufficient	  
scientific	  background	  to	  provide	  sound	  advice.2	  
While	  it	  is	  evident	  that	  a	  single	  opinion	  in	  multicentre	  experiments	  has	  to	  be	  provided	  by	  
a	   leading	   ethics	   committee,	   also	   for	   monocentre	   experiments	   ethics	   approval	   must	   be	  
provided	  by	  a	  leading	  ethics	  committee.	  As	  a	  consequence,	  monocentre	  studies	  initiated	  at	  a	  
particular	  site	  disposing	  of	  a	  non-­‐leading	  ethics	  committee	  must	  be	  endorsed	  by	  a	   leading	  
ethics	  committee	  at	  another	  site.	  	  
Pediatric	  expertise	  	  
The	  European	  Directive	  provides	   in	  art.	  7(h)	  that	  ethics	  committees	  reviewing	  protocols	  
of	  research	  in	  minors	  must	  have	  pediatric	  expertise	  or	  take	  advise	  in	  the	  clinical,	  ethical,	  and	  
psychosocial	  field	  of	  pediatrics.	  This	  is	  implemented	  into	  Belgian	  law	  by	  means	  of	  art.	  7.6°	  of	  
the	   LEH,	   requiring	  Belgian	  Ethics	   committees	   to	   include	  at	   least	   two	  medical	   specialists	   in	  
pediatrics	   or	   take	   advice	   from	   two	   medical	   specialists	   in	   pediatrics	   whenever	   assessing	  
protocols	  of	  experiments	  involving	  minors.	  	  
In	   2006,	   4%	   of	   the	   studies	   reported	   to	   the	   Belgian	   Advisory	   Committee	   on	   Bioethics	  
(n=70)	   were	   pediatric	   studies.	   No	   less	   than	   10%	   of	   all	   research	   participants	   (n=190),	  
however,	  were	  minors.	  	  
Time	  limits	  	  
The	  European	  Directive	   sets	   clear	   time	   limits	   for	   the	  provision	  of	   ethics	  opinion	  by	   the	  
Ethics	  Committee	  reviewing	   the	  protocol.	   In	   this	   respect,	  art.	  6,5	  of	   the	  Directive	  provides	  
that	  Ethics	  Committees	  must	  give	  their	  reasoned	  opinion	  to	  within	  60	  days	  from	  the	  date	  of	  
receipt	  of	  a	  valid	  application.	  In	  contrast,	  the	  LEH	  adopts	  stricter	  time	  limits	  than	  those	  set	  
forth	   in	   the	  European	  Directive.	  Art.	   11	  of	   the	   LEH	   reduces	   the	   time	   limit	   captured	   in	   the	  
European	  Directive	  to	  15	  days	  in	  case	  of	  a	  monocentre	  phase	  I	  trial,	  and	  28	  days	  for	  all	  other	  
experiments.iv	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ii	  Belgian	  State	  Gazette,	  11	  July	  2007	  	  
iii	  Ethics	  Committees	  that	  did	  not	  assess	  any	  research	  protocols	  in	  2006	  were	  not	  taken	  into	  account	  
iv	   In	   case	   of	   gene	   therapy	  or	   somatic	   cell	   therapy,	   an	   extension	  of	   the	   time	   limit	  with	   30	   days	   (+90	  days)	   is	  
possible.	  In	  case	  of	  xenogenetic	  cell	  therapy,	  no	  time	  limits	  are	  applicable.	  (European	  Directive	  art.	  6,7)	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This	  fast	  review	  of	  protocols	  by	  ethics	  committees	  makes	  Belgium	  an	  attractive	  locus	  for	  
the	  conduct	  of	  clinical	  research.	  Today	  Belgium	  has	  the	  second	  highest	  rate	  of	  research	  sites	  
for	  industry	  sponsored	  research	  per	  million	  habitants	  in	  Europe	  after	  Denmark.3	  However,	  it	  
is	  doubtful	  whether	  such	  a	  shortened	  time	  limit	  is	  compatible	  with	  the	  Directive’s	  provision	  
that	  the	  Directive	  ‘shall	  apply	  without	  prejudice	  to	  the	  national	  provisions	  on	  the	  protection	  
of	  clinical	  trial	  subjects	  if	  they	  are	  more	  comprehensive	  than	  the	  provisions	  of	  this	  Directive	  
and	   consistent	   with	   the	   procedures	   and	   time-­‐scales	   specified	   herein’	   (art.	   3,1).	   One	   may	  
wonder	   whether	   a	   stricter	   time	   limit	   is	   “consistent”	   with	   the	   timescales	   specified	   in	   the	  
European	  Directive.	  While	  it	  could	  be	  argued	  that	  a	  stricter	  timing	  than	  that	  required	  by	  the	  
Directive	   is	   not	   unlawful	   as	   such,	   art.	   3	   of	   the	   Directive	  mandates	   that	   the	   protection	   of	  
research	   participants	   must	   be	   enhanced	   by	   doing	   so.	   Obviously,	   this	   is	   not	   the	   case.	  
Although	   increased	   time	   pressure	   will	   not	   necessarily	   result	   in	   a	   decreased	   level	   of	  
participant	   protection,	   it	   cannot	   be	   argued	   that	   it	   generates	   an	   extended	   protection	   of	  
human	  subjects	  participating	  in	  medical	  experiments.	  	  
Informed	  consent	  	  
Apart	  from	  a	  sound	  research	  design	  and	  the	  endorsement	  of	  the	  research	  protocol	  by	  an	  
ethics	   committee,	   voluntary	   and	   informed	   consent	   must	   be	   obtained	   before	   research	  
commences.	  	  
As	   a	   general	   rule,	   consent	   for	   research	   participation	   must	   be	   granted	   by	   the	   subject	  
participating	  in	  research.	  However,	  most	  minors	  cannot	  provide	  legally	  valid	  consent	  due	  to	  
their	   factual	   limited	   capability	   of	   understanding	   information	   and	   making	   responsible	  
decisions	   or	   to	   an	   age	   criterion	   captured	   in	   law.	   As	   a	   result,	   the	   process	   of	   obtaining	  
informed	   consent	   in	  minors	  encompasses	   a	  number	  of	   complexities	   that	   are	   addressed	   in	  
the	  European	  Directive	  and	  the	  LEH.	  	  
First,	  for	  pediatric	  research,	  art.	  7.1°	  of	  the	  LEH	  provides	  that	  consent	  to	  enroll	  a	  minor	  in	  
research	  must	   be	   granted	  by	   the	  parents	   of	   the	  minor	  or	   another	   legal	   representative.	   In	  
principle,	  parental	  consent	  is	  granted	  by	  both	  parents.	  As	  this	  may	  be	  difficult	  to	  achieve	  in	  
practice,	   however,	   the	   consent	   of	   the	   second	   parent	   is	   assumed.v	   Parental	   consent	  must	  
represent	   the	   presumed	   will	   of	   the	   minor	   and	   may	   be	   withdrawn	   at	   any	   time,	   without	  
repercussions	  to	  the	  minor.	  Art.7,1°	  LEH	  implements	  art.4	  (a)	  of	  the	  European	  Directive	  and	  
is	   formulated	   in	   exactly	   the	   same	   terms.	   It	   is	   unclear	   on	   which	   elements	   the	   will	   of	   an	  
incapacitated	  person	  who	  never	  was	   competent	   before	   can	  be	  presumed.	   The	   consent	   of	  
the	   parents	   or	   legal	   representative	   of	   the	   minor	   must	   be	   obtained	   in	   accordance	   to	   all	  
requirements	  applicable	  to	  consent	  provided	  by	  competent	  adults	  that	  are	  captured	  in	  art.	  6	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
v	  Art	  373	  of	  the	  Belgian	  Civil	  Code	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of	  the	  LEH,	  providing	  that	  consent	  must	  be	  granted	  in	  writingvi	  and	  be	  preceded	  by	  specific	  
and	   comprehensible	   written	   information	   on	   ‘the	   nature,	   significance,	   objectives,	  
implications,	   anticipated	   benefits,	   and	   risks	   of	   the	   experiments,	   the	   circumstances	   under	  
which	  it	  is	  conducted,	  the	  identification	  and	  opinion	  of	  the	  competent	  ethics	  committee	  (…)’	  
(art.	  6,§2).	  
Second,	  art.	  7,1°	  of	  the	  LEH	  also	  explicitly	  provides	  that	  the	  minor	  must	  be	  involved	  in	  the	  
exercise	   of	   the	   right	   to	   consent.	   The	  measure	   of	   involvement	   of	   the	  minors,	   however,	   is	  
dependent	  on	  the	  age	  and	  degree	  of	  maturity	  of	   the	  minor.	  To	  enable	  the	   involvement	  of	  
minors	   in	   decisions	   on	   their	   participation	   in	   medical	   experiments,	   the	   provision	   of	  
appropriate	  information	  is	  essential.	  In	  this	  respect,	  the	  LEH	  provides	  that	  information	  must	  
be	  geared	  to	   the	  minor’s	  capacity	  of	  understanding	  and	  provided	  by	  pedagogically	   trained	  
staff.	  	  
In	  addition,	  the	  involvement	  of	  minors	  is	  more	  decisive	  in	  the	  LEH	  than	  in	  the	  European	  
Directive.	  Unlike	  the	  European	  Directive,	  the	  LEH	  provides	  that	  the	  explicit	  wish	  of	  a	  minor	  
capable	  of	  forming	  an	  opinion	  and	  assessing	  information	  concerning	  participation	  to	  refuse	  
participation	   or	   withdraw	   it	   must	   not	   only	   be	   considered	   (as	   provided	   in	   art.4,c	   of	   the	  
European	  Directive)	  but	  also	  be	  respected:	  art.	  7,1°	  of	  the	  LEH	  reads:	  	  
‘The	  explicit	  wish	  of	  a	  minor	  who	  is	  capable	  of	  forming	  an	  opinion	  and	  assessing	  
this	   information	   with	   regard	   to	   his	   participation	   in	   an	   experiment,	   to	   refuse	  
participation	   or	   to	   be	   withdrawn	   from	   the	   experiment	   at	   any	   time	   is	   also	  
considered	  and	  respected	  by	  the	  investigator.’	  
Like	  the	  Directive,	  the	  LEH	  does	  not	  impose	  fixed	  age	  criteria	  for	  consent	  or	  as	  a	  threshold	  
for	  a	  certain	  level	  of	  participation	  in	  the	  consent	  procedure.	  
No	  incentives	  or	  financial	  inducements	  
To	  prevent	  that	  financial	  profit	  would	  persuade	  minors	  and/or	  their	  parents	  to	  consent	  to	  
research	   participation	   art.	   4,7°	   of	   the	   LEH	   provides	   in	   accordance	   with	   art.	   4(d)	   of	   the	  
European	   Directive	   that	   no	   incentives	   or	   financial	   inducements	   except	   compensation	   are	  
permitted.	  	  
Conclusion	  
The	  European	  Directive	  is	  implemented	  in	  Belgian	  law	  by	  the	  LEH.	  This	  law	  shows	  several	  
important	   dissimilarities	   with	   the	   European	   Directive.	   First,	   the	   scope	   of	   the	   LEH	   is	  
significantly	   broader	   than	   that	   of	   the	   Directive,	   as	   it	   is	   applicable	   to	   all	   experiments	   on	  
human	  persons	  and	  thus	  not	  limited	  to	  interventional	  clinical	  trials.	  Second,	  to	  intensify	  the	  
attractiveness	  of	  Belgium	  as	  a	  locus	  for	  the	  conduct	  of	  clinical	  trials,	  the	  time	  limits	  for	  ethics	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
vi	  If	  individuals	  are	  unable	  to	  write	  because	  of	  physical	  reasons,	  oral	  consent	  is	  valid	  if	  given	  in	  the	  presence	  of	  
at	  least	  one	  witness	  of	  legal	  age	  who	  is	  independent	  from	  the	  sponsor	  and	  the	  investigator.	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approval	  are	  shortened.	  The	  provision	  of	  time	  limits	  in	  the	  LEH	  that	  are	  shorter	  than	  those	  
captured	  in	  European	  Directive,	  however,	  is	  not	  in	  accordance	  with	  the	  requirements	  of	  the	  
European	  Directive,	  as	   it	   is	  clearly	   implausible	   that	  shortened	  time	   limits	  would	  result	   in	  a	  
more	   extensive	   protection	   of	   minor	   research	   subject.	   Third,	   the	   LEH	   provides	   a	   more	  
extensive	  involvement	  of	  minors	  in	  the	  informed	  consent	  process	  than	  that	  provided	  in	  the	  
European	  Directive.	  While	  as	  a	  general	  rule	  the	  capacity	  to	  consent	  to	  research	  enrollment	  
of	  a	  minor	   is	  granted	  to	  the	  parents	  or	  another	   legal	   representative	  of	   the	  minor,	   the	  LEH	  
explicitly	   grants	   minors	   –in	   so	   far	   they	   are	   capable	   of	   forming	   an	   opinion	   and	   assessing	  
information-­‐	   considerable	   decisional	   power	   in	   the	   form	   of	   dissent.	   This	   means	   that	   the	  
explicitly	  expressed	   refusal	  of	   (continuation	  of)	  participation	  by	  a	  minor	  who	   is	   capable	  of	  
forming	  an	  opinion	  and	  assessing	   information	  must	  not	  only	  be	  considered	  (as	  provided	   in	  
the	  European	  Directive)	  but	  also	  be	  respected.	  Like	  the	  Directive,	  the	  LEH	  does	  not	  impose	  
fixed	   age	   criteria	   for	   consent	   or	   as	   a	   threshold	   for	   a	   certain	   level	   of	   participation	   in	   the	  
consent	  procedure.	  
In	   the	   review	   of	   research	   protocols	   of	   experiments,	   35	   Belgian	   ethics	   committees	   are	  
authorized	   to	   endorse	   the	   protocol.	   In	   practice,	   there	   is	   a	   clear	   tendency	   towards	  
centralization,	   as	   a	   small	   number	   of	   ethics	   committees	   review	   the	   large	   majority	   of	  
protocols.	   This	   tendency	   supports	  a	  professionalization	  of	  ethics	   committees,	  which	  might	  
entail	   important	  opportunities	  to	  increase	  the	  pediatric	  expertise	  that	  is	  currently	  available	  
in	  ethics	  committees.	  	  
Little	   is	   known	   about	   the	   practical	   impact	   of	   the	   LEH	   on	   pediatric	   research	   practice.	  
However,	   it	   is	   certain	   that	   both	   the	   European	   Directive	   and	   the	   LEH	   leave	   the	   practical	  
organization	   of	   many	   important	   issues	   (e.g.,	   the	   practical	   involvement	   of	   minors	   in	  
decisional	  processes,	  the	  assessment	  of	  the	  maturity	  and	  understanding	  of	  minors)	  to	  those	  
in	   the	   field.	   Not	   everything	   is	   thus	   arranged	   by	   law.	   This	   entails	   both	   an	   opportunity,	   as	  
medical	   practitioners	   enjoy	   a	   great	   deal	   of	   freedom	   to	   deal	   with	   the	   complexities	   of	   the	  
case,	  and	  a	  challenge,	  as	  little	  support	  exists	  to	  help	  practitioners	  to	  translate	  the	  generally	  
formulated	   requirements	   captured	   in	   the	   LEH	   to	   pediatric	   research	  practice.	   The	  practical	  
implementation	  of	  the	  European	  Directive	  and	  its	  Belgian	  implementation	  in	  the	  LEH	  would	  
certainly	  benefit	  from	  some	  further	  clarification,	  especially	  in	  relation	  to	  the	  requirement	  of	  
generating	  ‘some	  direct	  group	  benefit’	  in	  pediatric	  research.	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Abstract	  
The	   participation	   of	   minors	   in	   clinical	   trials	   is	   essential	   to	   provide	   safe	   and	   effective	  
medical	  care	  to	  children.	  Because	  few	  drugs	  have	  been	  tested	  in	  children,	  pediatricians	  are	  
forced	   to	  prescribe	  medications	  off-­‐label	  with	  uncertain	  efficacy	  and	  safety.	   In	   this	  article,	  
we	  analyze	  how	  the	  enrollment	  of	  minors	  in	  clinical	  trials	  is	  negotiated	  within	  relationships	  
of	  mutual	  trust	  between	  clinicians,	  minors,	  and	  their	  parents.	  After	  a	  brief	  description	  of	  the	  
problems	   associated	   with	   involving	   minors	   in	   clinical	   research,	   we	   consider	   how	   existing	  
‘‘relationships	  of	  trust’’	  can	  be	  used	  as	  a	  place	  where	  the	  concerns	  of	  research	  subjects	  can	  
be	  more	  fully	  discussed	  and	  addressed.	  Building	  on	  the	  tacit	  recognition	  of	  trust	  found	  in	  The	  
European	  Clinical	   Trials	  Directive	  we	  make	  policy	   recommendations	   that	   allow	   for	   clearer,	  
more	  ethically	  informed	  guidelines	  for	  enrolling	  minors	  in	  clinical	  research.	  
Introduction:	  issues	  in	  involving	  minors	  in	  clinical	  research	  
In	   the	   course	   of	   the	   twentieth	   century,	   it	   became	   increasingly	   clear	   that	   results	   from	  
laboratory	  research,	  animal	  experimentation	  and	  research	   in	  adults	  could	  not	  offer	  proper	  
data	   to	   develop	   safe	   and	   effective	   drugs	   for	   use	   in	   pediatric	   practice.	   Because	   adults	   and	  
children	   differ	   significantly	   in	   pharmacodynamics	   (the	   way	   a	   drug	   affects	   the	   body)	   and	  
pharmacokinetics	  (the	  way	  the	  body	  responds	  to	  the	  drug),	  results	  obtained	  in	  adults	  cannot	  
easily	  be	  transposed	  to	  minors.	  A	  mere	  recalculation	  of	  drug	  dosages	  used	   in	  adults	  based	  
on	  a	   child’s	  weight	  or	   skin	   surface	   is	  not	   reliable.1	   2	  As	  a	   consequence	   there	  are	  no	  viable	  
alternatives	  to	  using	  minors	  in	  clinical	  trials.	  
In	  the	  aftermath	  of	  the	  Nazi	  experiments	  and	  a	  series	  of	  research	  scandals	  in	  the	  US3	  and	  
the	  UK4	  minors	  were	  excluded	  from	  clinical	  trials.	  This	  was	  thought	  to	  be	  an	  efficient	  way	  to	  
protect	  minors,	  but	  this	  strategy	  was	  eventually	  judged	  untenable.	  Denying	  minors	  access	  to	  
clinical	  studies	  makes	  children	   ‘therapeutic	  orphans’5	  and	  results	   in	  a	  high	  rate	  of	  off-­‐label	  
prescriptions	   (the	  prescribing	  of	  drugs	  not	   tested	   in	   children	  and	  not	   labeled	   for	  pediatric	  
use).i	   As	   Ross7	   notes,	   in	   the	   absence	   of	   tested	   drugs	   every	   treatment	   becomes	   an	  
experiment.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i	  It	  is	  estimated	  that	  between	  7	  and	  60%	  of	  prescriptions	  in	  pediatric	  hospital	  wards	  are	  off-­‐label.	  (6.	  Pandolfini	  
C,	  Bonati	  M.	  A	  literature	  review	  on	  off-­‐label	  drug	  use	  in	  children.	  Eur	  J	  Pediatr	  2005;164(9):552-­‐8.)	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The	  involvement	  of	  minors	  in	  clinical	  studies,	  however,	   is	  a	  precarious	  enterprise.	  There	  
at	  least	  three	  reasons	  for	  this.	  
1) The	   limited	  (and	  varied)	   level	  of	  maturity	  of	  children	  generates	  a	  plethora	  of	  ethical	  
and	  legal	  issues.	  	  
2) The	   small	   number	   of	   pediatric	   patients	  makes	   research	   on	   the	   diseases	   of	   children	  
commercially	   less	   interesting	   (and	   hence	   less	   likely)	   than	   research	   on	   adult	  	  
diseases.2	  8	  ii	  
3) Clinical	   trials	   in	   children	  are	  practically	  difficult.	   The	   limited	  pool	  of	   children	  eligible	  
and	  willing	  to	  participate	  in	  a	  clinical	  trial	  makes	  it	  difficult	  for	  physicians	  to	  recruit	  a	  
sufficient	  number	  of	  research	  subjects.12	  
Negotiating	  the	  involvement	  of	  minors	  in	  clinical	  trials	  
Obtaining	  authorization	  to	  enroll	  minors	  in	  clinical	  research	  
In	   order	   to	   enroll	   minors	   in	   clinical	   research,	   researchers	  must	   gain	   the	   approval	   of	   a	  
research	   ethics	   committee	   (REC)	   and	   obtain	   valid	   permission—including	   consent	   from	  
parents	  and,	  when	  possible,	  assent	  from	  their	  child—	  to	  participate	  in	  a	  study.	  
Authorization	  to	  conduct	  research	  	  
RECs	  weigh	  three	  issues	  in	  evaluating	  research	  proposals	  that	  involve	  children:	  necessity,	  
safety,	  and	  consent.	  Research	  with	  minors	  will	  be	  approved	  only	  if:	  (1)	  there	  is	  no	  other	  way	  
to	  gain	  the	  needed	  information,	  (2)	  the	  risk	  of	  harm	  is	  in	  proportion	  to	  the	  expected	  benefits	  
and	   procedures	   exist	   for	   reporting	   harm	   and	   for	   stopping	   a	   clinical	   trial	   if	   the	   safety	   of	  
subjects	  is	  threatened,	  and	  (3)	  parental	  consent	  that	  respects	  the	  child’s	  presumed	  interests	  
is	  granted	  and	  children	  are	  informed	  and	  involved—to	  the	  extent	  possible—in	  the	  decision.	  
Permission	  to	  enroll	  individual	  minors	  	  
In	  the	  European	  normative	  framework,	  the	  paradigmatic	  research	  subject	  is	  a	  competent	  
adult.	   This	   fact,	   together	   with	   age	   standards	   and	   other	   criteria	   for	   legally	   valid	   consent,	  
make	   gaining	   valid	   consent	   from	   minors	   problematic.	   Given	   the	   legal	   impossibility	   of	  
obtaining	  consent	  from	  minors,	  other	  methods	  to	  protect	  children	  involved	  in	  research	  have	  
been	   developed.	   Most	   common	   is	   the	   use	   of	   parental	   consent,	   where	   the	   parent	   (or	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ii	   To	   correct	   the	   commercial	   disinterest	   in	   pediatric	   drug	   development,	   incentives	   stimulating	   the	  
pharmaceutical	  industry	  to	  conduct	  pediatric	  trials	  were	  adopted	  in	  US	  and	  EU	  legislation.(See:	  Rodriguez	  WJ,	  
Roberts	   R,	   Murphy	   D.	   Current	   regulatory	   policies	   regarding	   pediatric	   indications	   and	   exclusivity.	   J	   Pediatr	  
Gastroenterol	   Nutr	   2003;37	   Suppl	   1:S40-­‐5;	   Food	   and	   Drug	   Administration	   Modernization	   Act	   of	   1997.	  
http://www.fda.gov/cder/guidance/s830enr.txt	   (accessed:	   31	   July	   2007);	   European	   Parliament	   and	   of	   the	  
Council,	  Regulation	  (EC)	  No.	  1901/2006	  of	  the	  European	  Parliament	  and	  of	  the	  Council	  of	  12	  December	  2006	  
on	  medicinal	  products	   for	  paediatric	  use	  and	  amending	  Regulation	   (EEC)	  No.	  1768/92,	  Directive	  2001/20/EC,	  
Directive	  2001/83/EC	  and	  Regulation	  (EC)	  No.	  726/2004.) 
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parents)	  of	  a	  minor	  make	  decisions	  about	  the	  child’s	  clinical	  trial	  participation.	  This	  strategy,	  
while	   practical,	   is	   not	   completely	   satisfactory.	   Simply	   ignoring	   minors	   in	   decisions	   about	  
participation	   in	   research	   overlooks	   their	   decisional	   capacity	   and	   threatens	   to	   erode	   the	  
ethical	  standards	  used	  for	  research	  with	  adults.	  
If	   parental	   consent	   is	   to	   be	   held	   to	   the	   same	   ethical	   standard	   as	   informed	   consent	  
provided	  by	  a	  competent	  adult,	  the	  child	  who	  is	  participating	  in	  research	  must	  somehow	  be	  
involved	   in	   the	  decision-­‐making	  process.	  This	   can	  be	  accomplished	  by	  means	  of	   ‘assent’—
the	   affirmative	   agreement	   of	   a	  minor	   to	   participate	   in	   research	   (45	   CFR	   46	   subpart	   D).13	  
Specification	  of	  the	  need	  for	  assent	  is	  a	  step	  toward	  more	  informed	  participation	  of	  children	  
in	  research	  but	  it	  does	  not	  clearly	  define	  the	  role	  and	  position	  of	  minors	  in	  the	  decision	  to	  
participate	   in	   research.	   As	   Olechnowicz	   et	   al.14	   observed,	   assent	   can	   be	   implemented	   in	  
different	  ways:	   clinicians	   can	  opt	   for	   a	   ‘‘patient-­‐centered’’	   (clinicians	  begin	  by	   seeking	   the	  
agreement	  of	  the	  child),	  a	  ‘‘parent-­‐centered’’	  (clinicians	  begin	  by	  seeking	  the	  permission	  of	  
the	   parents),	   or	   a	   ‘‘joint	   patient-­‐parent	   approach	   in	   decision	   making’’	   (clinicians	   invite	  
children	  and	  their	  parents	  to	  decide	  upon	  participation).	  
Three	  basic	  concerns	  when	  enrolling	  children	  as	  research	  subjects	  
Decisions	  to	  involve	  a	  minor	  in	  a	  clinical	  trial	  are	  complex.	  Gaining	  permission	  to	  enroll	  a	  
child	  in	  a	  study	  is	  not	  a	  linear	  process	  where	  subjects	  provide	  their	  consent	  (or	  assent)	  at	  a	  
distinguishable	  moment	   in	   time,	   i.e.	  when	  a	  document	   is	   signed.15	   16	  Decisions	   to	  enroll	   a	  
minor	   in	   a	   clinical	   trial	   are	   ‘‘stretched	   out’’	   and	   require	   the	   cooperation	   of	   the	   multiple	  
parties.	   Communication	   and	   information	   are	   essential	   in	   this	   procedure.2	   12	   From	   the	  
patient’s	  perspective,	  three	  concerns	  are	  central.	  
Opportunities	  	  
First,	  the	  child	  and	  parents	  must	  be	  convinced	  that	  it	  is	  worthwhile	  to	  enroll	  in	  a	  clinical	  
trial.	  The	  opportunities	  presented	  by	  research	  participation	  are	  diverse	  and	  may	  not	  provide	  
benefit	  to	  the	  participant.	  Participation	  in	  research	  that	  contributes	  to	  the	  health	  and	  well-­‐
being	  of	  other	  minors,	  or	   future	  patients,	  or	   to	  the	  progress	  of	  science	   in	  general,	  may	  be	  
judged	  worthwhile	  even	  when	  direct	  benefit	  to	  the	  participant	  is	  unlikely.	  Lacking	  some	  form	  
of	   opportunity	   for	   the	   participant—be	   it	   direct	   or	   altruistic—the	   necessity	   of	   research	   is	  
difficult	  to	  justify.	  
Feasibility	  	  
Second,	   the	   child	   and	   his	   or	   her	   parents	   must	   assess	   the	   feasibility	   of	   research	  
participation.	   Research	  participation	   involves	   a	   considerable	   burden	   for	   both	  minors	   (e.g.,	  
taking	  drugs,	  blood	  sampling,	  hospitalization,	   follow	  up,	  physical	   inconveniences)	  and	  their	  
parents	  (e.g.,	  travel	  for	  study	  participation	  and	  follow	  up,	  drug	  administration,	  log	  keeping,	  
reporting	  adverse	  events).	  The	  decision	  to	  assume	  these	  burdens	  must	  be	  shared	  by	  parents	  
and	  their	  child.	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Decisional	  freedom	  	  
Third,	  the	  involvement	  of	  minors	  in	  decisions	  to	  participate	  in	  clinical	  trails	  rests	  upon	  the	  
decisional	  strategy	  used	  by	  the	  family.	  Parents	  have	  considerable	  autonomy	  in	  the	  way	  they	  
involve	   their	   children	   in	   decision	   making	   processes.	   Snethen	   et	   al.16	   identify	   four	   ways	  
minors	  may	  be	  involved	  in	  decisions	  about	  study	  participation:	  exclusionary	  decision-­‐making	  
(no	  involvement	  of	  the	  child),	  informative	  decision-­‐making	  (the	  child	  is	  informed	  but	  has	  no	  
decisional	  power),	  collaborative	  decision-­‐making	  (the	  child	   is	  at	  the	  center	  of	  the	  decision-­‐
making	  process,	  but	  decisional	  power	  and	  responsibilities	  remain,	  for	  the	  most	  part,	  with	  the	  
parents),	   and	   delegated	   decision-­‐making	   (the	   decision	   is	   delegated	   to	   the	   child).	   The	  
decisional	  strategy	  used	  varies	  by	  family	  type	  and	  culture.	  
Difficulties	  in	  addressing	  patient	  concerns	  in	  research	  participation	  
Clarity	   of	   information	   and	   decisional	   autonomy	   are	   essential	   to	  making	   good	   decisions	  
about	  the	  involvement	  of	  minors	  in	  clinical	  trials.	  Unfortunately,	  the	  many	  contingencies	  and	  
dependencies	  involved	  in	  research	  with	  minors	  make	  it	  difficult	  to	  ensure	  good	  information	  
and	  unconstrained	  choice.	  
Contingencies	  	  
The	  setting	  of	  pediatric	  clinical	  research	  is	  rife	  with	  contingencies.	  The	  benefits	  and	  risks	  
of	  participation	  in	  a	  clinical	  trial	  are	  difficult	  to	  determine	  resulting	  in	  ambiguous	  information	  
and	  uncertain	  prognoses.	  Further,	  the	  provision	  of	   information	  is	  not	  an	  unbiased	  process.	  
Physicians	   (or	   other	   clinicians)	   who	   invite	   minors	   and	   their	   parents	   to	   consider	   research	  
participation	  provide	  reasons	  to	  enroll	   in	  a	  study,	  and	  in	  some	  cases	  these	  reasons	  are	  not	  
health	  related.	  Simon	  observed	  that	  most	  of	  the	  altruistic	  discourse	  in	  enrollment	  discussion	  
is	  provided	  by	  physicians	  and	  not	  by	  patients	  or	  parents.17	  Conflicts	  of	  interest	  on	  the	  part	  of	  
researchers	  also	  hinder	  the	  provision	  of	  clear	  and	  reliable	  information.	  Physicians	  may	  have	  
a	   personal	   agenda	   in	   enrolling	   minors	   in	   clinical	   trials,	   such	   as	   enriching	   their	   personal	  
career,	  obtaining	  research	  funding,	  or	  pleasing	  colleagues.	  Bias	  and	  conflicts	  of	  interests	  can	  
also	   influence	   parental	   decisions,	   especially	   when	   financial	   incentives	   are	   involved.	  
Recognizing	   this	   problem,	   laws	   prohibit	   excessive	   compensation	   for	   inconvenience	   and	  
hardship.	  
Dependency	  	  
In	  making	  the	  decision	  to	  participate	  in	  a	  clinical	  trial,	  the	  autonomous	  judgment	  of	  both	  
minors	   and	   their	   parents	   can	   be	   impaired	   by	   relationships	   of	   dependency.	   In	  most	   cases	  
minors	  and	  their	  parents	  are	  highly	  dependent	  on	  medical	  staff	  to	  provide	  and	  interpret	  the	  
data	   relevant	   to	   their	   decision.	   The	   considerable	   asymmetry	   in	   information	   and	  
interpretative	  skills	  between	  researchers	  and	  research	  subjects	  forces	  minors	  and	  parents	  to	  
rely	  upon	  medically	  qualified	  staff	  to	  clarify	  the	  relevant	  data.18	  
Similarly,	   minors	   must	   depend	   on	   their	   parents	   to	   obtain	   authentic	   involvement	   in	  
decisions.	   The	   decision	   to	   enroll	   a	  minor	   in	   a	   clinical	   study	   and	   the	   degree	   of	   the	   child’s	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involvement	   in	   the	   decision	  making	   process	   are	   largely	   left	   to	   the	   parents.	   Although	   the	  
active	   involvement	  of	  minors	   in	   the	  decision	   is	   highly	   valued	   in	  ethics	   and	   law,	   the	  actual	  
decision	  about	  enrollment	  of	  a	  minor	  in	  a	  clinical	  study	  occurs	   in	  the	  privacy	  of	  the	  family.	  
Parents	  are	  trusted	  to	  make	  decisions	  on	  behalf	  of	  their	  children	  and	  to	  balance	  the	  interests	  
of	   the	   minor	   to	   be	   enrolled	   and	   those	   of	   other	   family	   members.19	   Interventions	   in	   the	  
privacy	   of	   the	   family	   are	   very	   rare.	   On	   occasion	   (depending	   on	   domestic	   legislation),	   the	  
autonomy	  of	  parents	  may	  be	   limited	  by	   the	  obligation	   to	   respect	   the	  express	  dissent	  of	  a	  
minor.	  
The	  contingencies	  and	  the	  unavoidable	  dependency	  associated	  with	  the	  research	  setting	  
increase	  the	  vulnerability	  of	  both	  minors	  and	  their	  parents,	  forcing	  them	  to	  rely	  on	  others	  to	  
obtain	  the	  information	  they	  need	  to	  make	  rational	  and	  responsible	  decisions.	  
Handling	  patient	  concerns	  in	  relationships	  of	  trust	  
In	  absence	  of	  trust,	  research	  participation	  is	  unlikely.20	  Because	  the	  concerns	  of	  parents	  
and	  children	  are	  very	  personal	  and	  strongly	  related	  to	  the	  medical	  history	  of	  the	  minor,	  they	  
are	   difficult	   to	   address	   in	   impersonal	   relationships.	   Hence,	   it	   is	   not	   surprising	   that	  
impersonal	  recruitment	  strategies	  are	  generally	  unsuccessful.21	  Concerns	  about	  clinical	  trial	  
participation—be	   they	   the	   child’s	   or	   the	   parents’—are	   best	   situated	   in	   personal	  
relationships,	  such	  as	  established	  relationships	  of	  trust	  between	  physicians,	  minor	  patients,	  
and	   their	   parents.	   The	   handling	   of	   these	   concerns	  within	   personal	   relationships	   does	   not,	  
however,	   relieve	  minors	   and	   their	   parents	   from	   the	   challenging	   task	   of	   deciding	  who	   and	  
what	  to	  trust.	  
Trustworthiness	  	  
Trustworthiness	   refers	   to	   the	   truthful,	   competent,	   sincere,	   and	  honest	   character	  of	   the	  
trustee.22	  When	  clinicians,	  minors,	  and	  their	  parents	  negotiate	  the	  participation	  of	  a	  minor	  in	  
a	   clinical	   trial,	   the	   interests	   of	   the	   child	   must	   be	   reconciled	   with	   the	   opportunities	   and	  
hardship	  involved.	  In	  this	  process,	  minors	  and	  their	  parents	  are	  bound	  to	  rely	  on	  clinicians	  to	  
close	  the	  gap	  in	  expertise	  and	  knowledge.	  Because	  misconception,	  manipulation,	  deception,	  
and	  coercion	  cannot	  be	  precluded	  in	  the	  provision	  of	  information,	  the	  trustworthiness	  of	  the	  
clinician	   who	   invites	   the	   child	   to	   participate	   is	   of	   great	   importance.	   Trust	   is	   required	   for	  
minors	   and	   their	   parents	   to	   rely	   on	   the	   future	   and	   contingent	   actions	  of	   researchers.22	   In	  
addition	  to	  trust	  in	  the	  person	  of	  the	  researcher,	  a	  child	  and	  his	  or	  her	  parents	  must	  trust	  the	  
aims	  and	  methods	  of	  the	  proposed	  research.	  
Just	  as	  trust	  cannot	  be	  ignored,	  there	  is	  no	  suitable	  substitute	  for	  trust.	  O’Neill23	  argues	  
that	   mere	   transparency,	   autonomy,	   or	   accountability—although	   each	   is	   of	   great	   value—
cannot	  compensate	  for	  trust.	  Therefore,	  and	  even	  in	  the	  face	  of	  its	  possible	  abuse,	  we	  must	  
find	  a	  way	  to	  promote	  and	  enhance	  trust.	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Trust	  issues	  in	  the	  European	  clinical	  trials	  directive	  
Entrusting	  issues	  
Trust	  is,	  as	  we	  have	  shown,	  essential	  to	  address	  the	  major	  concerns	  of	  minors	  and	  their	  
parents	  with	  regard	  to	  clinical	  trial	  participation.	  While	  ‘‘trust’’	  is	  not	  an	  explicit	  part	  of	  the	  
regulations	  governing	  the	  use	  of	  minors	  in	  research,	  by	  assigning	  tasks	  and	  responsibilities	  to	  
various	   trustees,	   European	   legislation	   implicitly	   recognizes	   the	   importance	   of	   trust.	  More	  
specifically,	   the	   Clinical	   Trials	   Directive	   of	   the	   European	   Commission	   and	   the	   European	  
Parliament	   (2001/20/EC,	   further:	   the	   Directive)24	   serves	   to	   organize	   and	   distribute	   trust	  
among	  specific	  persons	  and	  institutional	  bodies.	  
The	   Directive	   is	   not	   explicit	   in	   this	   regard.	   Rather,	   the	   legislation	   simply	   formulates	  
general	   principles	   and	   leaves	   the	   interpretation	   of	   these	   principles	   to	   those	   charged	  with	  
implementation.	  The	  provision	  of	   information	  and	  the	  active	   involvement	  of	  minors	   in	   the	  
decision	  making	  process,	  are,	  for	  example,	  left	  to	  the	  field	  of	  pediatric	  research	  practice,	  as	  
is	  the	  determination	  of	  what	  counts	  as	  successful	  accomplishment	  of	  these	  tasks.	  Clinicians,	  
minors,	   and	   their	   parents	   must	   determine	   what	   constitutes	   appropriate	   information	   or	  
suitable	   involvement	  of	  minors	   in	  decision	  making.	  Other	  decisions,	  however,	  are	  explicitly	  
removed	   from	   pediatric	   researchers	   and	   given	   to	   external	   bodies,	   such	   as	   the	   national	  
legislator,	  the	  EMEA	  (European	  Medicines	  Agency),	  or	  Research	  Ethics	  Committees.	  
European	  concerns	  	  
At	   the	   European	   level,	   the	   main	   concern	   is	   to	   promote	   the	   European	   Union	   as	   a	  
competitive	  research	  environment.	  The	  interventions	  intended	  to	  make	  Europe	  an	  attractive	  
destination	   for	   research	   include	   the	   simplification	   of	   REC-­‐approval	   in	  multi-­‐centre	   clinical	  
trials,	   the	   introduction	   of	   strict	   time	   limits	   for	   the	   provision	   of	   REC	   approval,	   and	   the	  
provision	  of	  harmonized	  REC-­‐	  procedures	  by	  means	  of	  detailed	  guidance	  issued	  by	  EMEA.	  
The	  desire	   to	  be	  competitive,	  however,	  does	  not	  overrule	   the	  need	  to	  protect	   research	  
subjects.	   In	   this	   respect,	   the	   Directive	   explicitly	   states	   that	   the	   interests	   of	   the	   research	  
subject	  always	  prevail	  over	  those	  of	  science	  and	  society.	  The	  Directive	  specifies	  a	  wide	  range	  
of	   subject	   protection	  measures,	   calling	   on	   several	   existing	   ethical	   and	   legal	   documents—
including	   the	   International	   Conference	   on	  Harmonisation	   (ICH)	   guideline	   for	   Good	   Clinical	  
Practice,25	   the	   Declaration	   of	   Helsinki,	   and	   the	   Convention	   on	   Human	   Rights	   and	  
Biomedicine26—to	   provide	   a	   general	   framework	   for	   these	   measures.	   However,	   the	  
interpretation,	   implementation,	   and	   control	   of	   the	   issues	   related	   to	   research	   subject	  
protection	  (both	  adults	  and	  children)	  are	  entrusted	  to	  the	  individual	  Member	  States	  and/or	  
those	  in	  the	  field	  of	  research.	  
Public	  concerns	  	  
Two	   major	   tasks	   in	   arranging	   responsible	   scientific	   progress—the	   assessment	   of	   the	  
necessity	   of	   research	   and	   the	   safety	   of	   clinical	   trials—are	   given	   to	   the	   individual	  Member	  
States	   and	  handled	  by	   a	  Research	  Ethics	  Committee	  and/or	   the	   competent	   authority.	   The	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Directive	  specifies	  that	  in	  the	  assessment	  of	  pediatric	  research,	  RECs	  must	  call	  on	  pediatric	  
expertise	   or	   get	   other	   expert	   advice	   on	   the	   clinical,	   ethical,	   and	   psychosocial	   problems	  
associated	  with	  the	  participation	  of	  children	  in	  research.	  
With	  regard	  to	  the	  necessity	  of	  a	  clinical	  trial,	  RECs	  must	  assess	  whether	  the	  clinical	  trial	  
generates	  some	  direct	  benefit	  to	  the	  group	  of	  patients	  and	  whether	  research	  is	  essential	  and	  
cannot	  be	  done	  using	  adults	  or	  other	  research	  methods.	  RECs	  also	  must	  assess	  the	  safety	  of	  
the	   clinical	   trials	   and	   determine	   whether	   the	   expected	   risks	   are	   proportionate	   to	   the	  
anticipated	  benefits,	  whether	  the	  staff	  conducting	  the	  research	  is	  qualified,	  whether	  written	  
information	   for	   informed	   consent	   is	   of	   sufficient	   quality,	   whether	   the	   provisions	   for	  
indemnity	  or	  compensation	  are	  satisfactory,	  and	  whether	  pain,	  fear,	  discomfort,	  and	  other	  
risks	   are	   accurately	   minimized.	   RECs	   are	   also	   charged	   with	   creating	   a	   system	   to	   monitor	  
serious	  adverse	  reactions.	  
Private	  concerns	  	  
The	   Directive	   provides	   only	   general	   guidelines	   governing	   the	   opportunity	   to	   be	   in	  
research,	   the	   decisional	   freedom	   of	   minor	   subjects	   and	   parents,	   and	   the	   feasibility	   of	  
participation.	   This	   means	   that	   researchers,	   minors,	   and	   parents	   must	   negotiate	   concerns	  
about	  these	  issues	  within	  the	  general	  framework	  set	  down	  in	  European	  law.	  There	  is	  wisdom	  
in	   this	   lack	   of	   regulation.	   The	   fact	   that	   these	   ‘‘private	   concerns’’	   are	   left	   to	   the	   field	   of	  
pediatric	   research	   allows	   them	   to	   be	   addressed	   within	   the	   existing	   relationships	   of	   trust	  
between	  researchers,	  minors,	  and	  their	  parents.	  Overregulation	  would	  move	  these	  concerns	  
from	  the	  relationships	  of	  trust	  to	  an	  inflexible	  bureaucracy.	  
The	  way	  forward	  
At	   first	  glance,	   the	  European	  Clinical	  Trials	  Directive	  seems	  to	  provide	  a	  comprehensive	  
and	   complete	   framework	   for	   protecting	   research	   subjects.	   The	   interests	   of	   the	   European	  
Union	  are	  dealt	  with	  served	  at	  the	  European	  level,	  public	  interests	  are	  given	  to	  the	  domestic	  
sphere	  of	  competent	  authorities	  and	  Research	  Ethics	  Committees,	  and	  private	  concerns	  of	  
clinicians,	  minors,	  and	  their	  parents	  are	  left	  to	  pediatric	  research	  practice	  to	  be	  worked	  out	  
within	  relationships	  of	  trust.	  There	  are,	  however,	  important	  gaps	  in	  the	  system.	  
The	   problems	   associated	   with	   the	   contingencies	   and	   dependencies	   found	   in	   clinical	  
research	  with	  children	  are	  poorly	  addressed	  in	  the	  Directive.	  
Discussion:	  coping	  with	  the	  downside	  of	  trust	  
To	  some,	  the	  act	  of	  trusting	  can	  seem	  naïve,	  opening	  research	  subjects	  to	  the	  possibility	  
of	  abuse.	  What	  can	  we	  do	  when	  trust	  fails?	  How	  can	  we	  deal	  with	  the	  deception,	  coercion,	  
or	   harm	   associated	   with	   the	   contingencies	   and	   dependencies	   involved	   in	   research	  
participation?	  In	  order	  to	  improve	  the	  process	  of	  recruiting,	  informing,	  and	  including	  minors	  
in	  clinical	  trials	  we	  must	  acknowledge	  the	  downside	  of	  trust.	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Informed	  consent,	  assent,	  and	  dissent	  
The	  doctrine	  of	  informed	  consent	  plays	  an	  important	  function	  in	  the	  pediatric	  setting	  by	  
specifying	   liability	   and	   confirming	   (symbolically)	   enrollment	   in	  a	   clinical	   trial.	  On	   the	  other	  
hand,	  informed	  consent	  in	  pediatric	  clinical	  trials	  fails	  to	  address	  several	  concerns	  of	  minors	  
and	  their	  parents	  in	  the	  decisional	  process.	  This	  is	  especially	  true	  in	  decisions	  where	  parents	  
have	   no	   choice	   e.g.,	   when	   the	   only	   medical	   interventions	   for	   their	   child’s	   illness	   are	  
experimental.27	  The	  problems	  of	  informed	  consent	  for	  pediatric	  research	  are	  not	  relieved	  by	  
the	  use	  of	  assent.	  Because	  minors	  are	  not	  capable	  of	  settling	  liability	  issues,	  the	  only	  added	  
value	  of	  assent	  is	  as	  a	  formal	  affirmation	  of	  willingness	  to	  participate	  in	  research.	  While	  this	  
affirmation	  is	  important	  (it	  provides	  tangible	  evidence	  of	  the	  commitment	  of	  the	  minor),	  the	  
signature	   on	   the	   assent	   document	   puts	   too	   much	   weight	   on	   the	   role	   of	   formal	  
documentation.	  
Focus	  on	   the	  documentary	  evidence	  of	   consent	  and	  assent	   turns	  ethical	   standards	   into	  
bureaucratic	   ones	   and	  distracts	   from	   important	   and	  ongoing	   relationships	   of	   trust.	   It	   is	   in	  
these	   relationships	   where	   the	   true	   concerns	   of	   research	   participation	   are	   addressed.	  We	  
believe	   that	   the	  best	  way	   to	   involve	  minors	   in	  decisions	  about	   research	  participation	   is	   to	  
embed	  those	  decisions	  in	  an	  ongoing	  patient–physician	  relationship	  characterized	  by	  mutual	  
trust.	  It	  is	  in	  these	  relationships	  that	  children	  and	  parents	  can	  freely	  express	  their	  concerns	  
about	  the	  research	  and	  about	  the	  decisional	  capacity	  of	  the	  child	  subject.	  
Recruitment	  
Impersonal	  recruitment	  strategies,	  including	  recruitment	  by	  an	  independent	  person	  who	  
does	  not	  know	  the	  details	  of	  a	  child’s	  medical	  condition	  and	  history,	  do	  not	  work.21	  Not	  only	  
do	  they	  yield	  few	  participants,	  they	  have	  little	  potential	  to	  address	  the	  concerns	  of	  minors	  
and	  parents	  contemplating	  enrollment	  in	  a	  clinical	  study.	  
As	  with	  consent/assent,	  relationships	  of	  trust	  are	  a	  good	  locus	  to	  negotiate	  the	  inclusion	  
of	  a	  minor	  in	  a	  clinical	  trial.	  
There	  are,	  however,	   important	   caveats	  about	   this	   recruitment	   strategy:	   (a)	  even	  within	  
relationships	   of	   trust	   there	   is	   the	   potential	   for	   bias	   and	   (b)	   not	   all	   physicians	   are	   able	   to	  
address	   the	   concerns	   of	  minors	   and	   parents	   about	   clinical	   trial	   participation.	  Minors	   and	  
parents	  must	  be	  empowered	  to	  identify	  and	  discuss	  their	  concerns,	  and	  physicians	  must	  be	  
instructed	  in	  responding	  to	  the	  issues	  of	  pediatric	  research.	  
Empowering	  minors	  and	  their	  parents	  	  
In	   our	   opinion,	   the	   best	  way	   to	   overcome	   the	   problems	   associated	  with	   using	   existing	  
relationships	  of	  trust	  as	  the	  location	  of	  informed	  consent	  discussions	  is	  the	  appointment	  of	  
an	   independent	   counselor.	   This	   counselor	   will	   inform	   minors	   and	   parents	   about	   their	  
fundamental	   rights	   as	   research	   participants,	   help	   them	   to	   identify	   and	   discuss	   their	  
concerns,	  and	  make	  them	  aware	  of	  the	  potential	  biases	  of	  the	  physicians	  who	  are	  recruiting	  
them	  for	  a	  clinical	  study.	  The	  counselor	  must	  be	  able	  to	  explain	  the	  consent	  documents,	  and	  
aspects	   of	   the	   clinical	   trial,	   and	   to	   answer	   questions	   that	   minors	   and	   parents	   may	   be	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reluctant	   to	   ask	   the	   physician.	   The	   counselor	  must	   have	   sufficient	   expertise	   to	   assess	   the	  
information	  provided	  to	  minors	  and	  their	  parents	  and	  to	  examine	  whether	  the	  concerns	  of	  
minors	   and	   their	   parents	   have	   been	   adequately	   addressed.	   The	   availability	   of	   an	  
independent	  counselor—one	  who	  is	  capable	  of	  providing	  advice	  and	  judging	  whether	  minors	  
and	   their	   parents	   were	   correctly	   invited	   and	   well	   informed—will	   strengthen	   the	  
trustworthiness	  of	  research	  and	  help	  minors	  and	  their	  parents	  to	  decide	  where	  to	  place	  their	  
trust.23	  
Creating	  expertise	  in	  physicians	  	  
The	  delicate	  task	  of	  informing	  minors	  and	  their	  parents	  about	  why	  it	  would	  be	  good	  for	  a	  
minor	   to	   participate	   in	   research	   requires:	   (1)	   knowing	   the	   child	   and	   his	   or	   her	   medical	  
background	   well,	   (2)	   being	   aware	   of	   the	   child’s	   ability	   to	   cope	   with	   the	   hardship	   of	  
participation	  in	  a	  clinical	  trial,	  and	  (3)	  being	  familiar	  with	  decisional	  styles	  characteristic	  for	  a	  
family.	  Physicians	  who	  know	  the	  family	  well	  are	  well	  positioned	  to	  do	  this.	  Dealing	  with	  the	  
concerns	  of	  minors	  and	  their	  parents	  about	  participation	  in	  a	  clinical	  trial,	  however,	  requires	  
more	  than	  knowledge	  of	  the	  medical	  and	  social	  situation	  of	  the	  child.	  
In	   order	   to	   promote	   the	   ethical	   inclusion	   of	   minors	   in	   clinical	   trials,	   physicians	   must	  
enhance	   their	   communication	   and	   information	   skills.	   Although	   studies	   suggest	   that	   few	  
physicians	   actively	   ask	   for	   such	   measures,15	   we	   are	   convinced	   that	   such	   a	   measure	   is	   a	  
necessary	   step	   for	   the	   implementation	  of	   a	  normative	   framework	   that	   addresses	   the	   true	  
concerns	  minors	  and	  parents.	  
Laws,	   directives,	   and	   guidelines	   provide	   the	   framework	   for	   the	   protection	   of	   the	  
subjects—both	  adults	  and	  children—of	  medical	   research.	  But	  these	   ‘‘paper	  rules’’	  must	  be	  
affirmed	  by	   the	   ‘‘real	   rules’’	   that	   govern	  what	  occurs	   in	   research	  practice.	  With	   regard	   to	  
pediatric	  clinical	  research,	  the	  real	  rules	  of	  research—and	  real	  protections	  for	  minors—are	  
found	  in	  relationships	  of	  trust	  between	  physician-­‐	  researchers,	  children,	  and	  parents.	  These	  
relationships	  have	  a	  high	  yet	  under-­‐employed	  potential	  to	  address	  subjects’	  concerns	  about	  
research	   participation.	   By	   creating	   know-­‐	   how	   in	   physicians	   and	   empowering	  minors	   and	  
their	   parents,	   relationships	   of	   trust	   can	   become	   the	   place	   where	   patient	   concerns	   are	  
effectively	   discussed	   and	  addressed,	  where	  minors	   truly	   can	  be	   involved	   in	  decisions,	   and	  
where	  ethical	  and	  legal	  standards	  are	  effectively	  implemented	  in	  pediatric	  research	  practice.	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Abstract	  	  
	  
In	  the	  course	  of	  the	  past	  decades,	  considerable	  effort	  has	  been	  expended	  on	  the	  ethical	  
guidance	  and	  legal	  regulation	  of	  pediatric	  clinical	  trials	  in	  Europe.	  Nonetheless,	  the	  conduct	  
of	   clinical	   research	   in	   the	   population	   of	  minors	   continues	   to	   generate	  myriad	   ethical	   and	  
regulatory	   issues.	   This	   paper	   explores	   seven	   bottlenecks	   in	   the	   ethical	   guidance	   and	   legal	  
regulation	  that	  currently	  govern	  pediatric	  clinical	  research:	  (1)	  the	  integration	  of	  research	  in	  
therapy,	   (2)	   the	   education	   of	   clinicians,	   (3)	   the	   empowerment	   of	   families,	   (4)	   the	  
harmonization	   of	   protocol	   review,	   (5)	   the	   assessment	   non-­‐clinical	   research	   objectives,	   (6)	  
the	   control	   of	   placebo	   use,	   and	   (7)	   the	   provision	   of	   fair	   incentives	   for	   pediatric	   research	  
conduct.	   For	   all	   of	   these	   issues,	   a	   clear	   view	  on	   the	  way	   forward	   is	   largely	   lacking,	   either	  
because	   these	   issues	   have	   not	   been	   discussed	   in	   depth	   to	   date	   or	   because	   the	   existing	  
debates	  have	  failed	  to	  generate	  a	  generally	  supported	  consensus.	  
Introduction	  
In	  the	  course	  of	  the	  past	  decades,	  considerable	  effort	  has	  been	  expended	  on	  the	  ethical	  
guidance	  and	  legal	  regulation	  of	  pediatric	  clinical	  trials	  in	  Europe.	  Nonetheless,	  the	  conduct	  
of	   clinical	   research	   in	   the	   population	   of	  minors	   continues	   to	   generate	  myriad	   ethical	   and	  
regulatory	  issues.	  
This	   paper	   explores	   seven	  bottlenecks	   in	   the	   ethical	   guidance	   and	   legal	   regulation	   that	  
are	  currently	  governing	  pediatric	  clinical	  research:	  (1)	  the	  integration	  of	  research	  in	  therapy,	  
(2)	   the	  education	  of	   clinicians,	   (3)	   the	  empowerment	  of	   families,	   (4)	   the	  harmonization	  of	  
protocol	   review,	   (5)	   the	   assessment	   of	   non-­‐clinical	   research	   objectives,	   (6)	   the	   control	   of	  
placebo	  use,	  and	  (7)	  the	  provision	  of	  fair	  incentives	  for	  pediatric	  research	  conduct.	  For	  all	  of	  
these	  issues,	  a	  clear	  view	  on	  the	  way	  forward	  is	  largely	  lacking,	  either	  because	  these	  issues	  
have	   not	   been	   discussed	   in	   depth	   to	   date	   or	   because	   the	   existing	   debates	   have	   failed	   to	  
generate	  a	  generally	  supported	  consensus.	  
Most	   of	   the	   issues	   that	   are	   explored	   in	   this	   paper	   are	   not	   exclusively	   associated	   with	  
pediatric	   research;	   they	   also	   apply	   to	   a	   certain	   extent	   to	   research	   in	   other	   populations.	  
Nonetheless,	  this	  collection	  of	  issues	  is	  particularly	  relevant	  from	  the	  viewpoint	  of	  pediatric	  
clinical	  research,	  as	  it	  provides	  an	  overview	  of	  the	  major	  ethical	  concerns	  in	  current	  pediatric	  
research	  practice.	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Integrating	  research	  in	  therapy	  
A	  first	  challenge	  to	  the	  current	  ethical	  and	  regulatory	  framework	  guiding	  pediatric	  clinical	  
trials	   is	   to	   clarify	   the	   ambiguous	   distinction	   between	   research	   and	   therapy.	   Traditionally,	  
clinical	  research	  is	  explicitly	  distinguished	  from	  therapy,	  discerning	  therapeutic	  interventions	  
with	  validated	  medicines	  from	  research	  interventions.1	  2	  Because	  the	  therapeutic	  nature	  of	  
research	  always	  remains	  ambiguous	  and	  uncertain—even	  when	  research	  is	  expected	  to	  yield	  
therapeutic	  benefits—research	  interventions	  are	  associated	  with	  increased	  uncertainty	  and	  
risks.	   Therefore,	   in	   a	   sense,	   research	   starts	  where	   therapy	   ends.	   In	   pediatrics,	   however,	   a	  
rigid	  distinction	  between	  research	  and	  therapy	  is	  untenable.	  
Due	  to	  stringent	   lack	  of	  medicines	  that	  are	   labeled	  for	  pediatric	  use,	  a	   large	  part	  of	  the	  
medicines	   used	   in	   pediatric	   practice	   are	   prescribed	   off-­‐label.3-­‐7	   As	   a	   consequence,	   the	  
dividing	  line	  between	  research	  and	  therapy	  may	  at	  times	  be	  very	  thin,	  as	  both	  the	  off-­‐label	  
prescription	   of	   drugs	   and	   the	   conduct	   of	   clinical	   trials	   introduce	   the	   experimental	   use	   of	  
medicines	   in	   pediatric	   practice.	   Therefore,	   research	   interventions	   in	   a	   clinical	   trial	   do	   not	  
necessarily	  subject	  the	  minor	  subject	  to	  additional	  risks	  or	  to	  a	  more	  contingent	  therapeutic	  
course	  than	  the	  (off-­‐label)	  standard	  of	  care.8	  Quite	  the	  reverse,	  participating	  in	  a	  clinical	  trial	  
may	   entail	   several	   advantages	   in	   comparison	   with	   being	   treated	   off-­‐label.	   First,	   research	  
interventions	  in	  clinical	  trials	  are	  administered	  in	  a	  controlled	  fashion,	  which	  includes	  a	  close	  
follow-­‐up	  of	  adverse	  reactions	  and	  adverse	  events.	  Second,	  European	  law	  requires	  that	  the	  
sponsor’s	   insurance	   or	   indemnity	   guarantees	   an	   adequate	   compensation	   in	   case	   research	  
subjects	  would	   be	   harmed	  while	   participating	   in	   the	   trial.9	   Third,	   research	   is	   governed	   by	  
ethical	  and	  regulatory	  requirements	  that	  are	  to	  positively	  affect	  the	  quality	  of	  research	  (e.g.,	  
the	  European	  Clinical	  Trial	  Directive	  specifically	  addresses	  research	   in	  minors).9	  Finally,	   the	  
development	   of	   safe	   and	   efficacious	   drugs	   for	   those	   in	   need	   of	   a	   (better)	   treatment	   is	  
intrinsically	  valuable.	  
Thus,	   in	  pediatrics,	  research	  not	  necessarily	  starts	  where	  therapy	  ends	  and,	  by	  contrast,	  
may	  present	  itself	  as	  a	  therapeutic	  option.	  Therefore,	  the	  rigid	  distinction	  between	  research	  
and	  therapy	  should	  be	  abandoned	  in	  the	  pediatric	  setting,	  and	  invitations	  to	  enroll	  subjects	  
in	   a	   pediatric	   clinical	   trial	   should	   be	   framed	   in	   the	   therapeutic	   context	   of	   the	   individual	  
minor	  concerned.	  
As	   the	   recruitment	   of	  minor	   research	   subjects	   is	   a	   highly	   personal	   enterprise,10	  minors	  
and	   their	   parents	  want	   to	   know	  why	   it	  would	  be	  worthwhile	   for	   the	   individual	   subject	   to	  
participate	   in	   a	   trial,	   rather	   than	  merely	   being	   informed	   about	   the	   trial,	   the	   risks	   and	   the	  
benefits	   according	   to	   the	   specificities	   described	   in	   the	   study	   protocol.	   Discussing	   clinical	  
trials	   against	   the	   background	   of	   a	   patient’s	   course	   of	   disease,	   medical	   history,	   current	  
treatment,	   and	  prognosis	   creates	  opportunities	   to	  provide	   correct	  and	  personally	   relevant	  
information	   on	   the	   risks,	   burdens,	   and	   benefits	   related	   to	   clinical	   trial	   participation.	   As	   a	  
consequence,	   framing	  research	   in	   the	  therapeutic	  context	  of	   individual	  patients	   is	   likely	   to	  
serve	   clinicians,	   minors,	   and	   their	   parents	   in	   making	   honest,	   realistic,	   and	   well-­‐informed	  
commitments	  with	  regard	  to	  the	  clinical	  trial	  participation.	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Notwithstanding	   these	   significant	   opportunities,	   the	   integration	   of	   research	   in	   the	  
therapeutic	   context	   also	   has	   important	   drawbacks.	   The	   asymmetry	   in	   expertise	   between	  
clinicians	  and	  minors	  and	   their	  parents	  and	   the	  contingency	  of	  both	   therapy	  and	   research	  
must	  render	  one	  vigilant	  with	  regard	  to	  biased	  information,	  conflicts	  of	  interest,	  therapeutic	  
misconception,	   dependency,	   or	   uncritical	   loyalty	   of	  minors	   and	   their	   parents	   toward	   their	  
physicians.11-­‐16	   Nonetheless,	   none	   of	   these	   threats	   need	   to	   be	   insuperable,	   provided	   that	  
appropriate	   safeguards	   are	   set	   up.	   To	   a	   large	   extent,	   this	   can	   be	   achieved	   through	   the	  
education	   of	   clinicians	   and	   the	   empowerment	   of	   families	   deciding	   upon	   research	  
participation	  (cf.	  infra).	  
Educating	  clinicians	  
Many	  of	  the	  ample,	  complex	  and	  diverse	  tasks	  in	  the	  implementation	  of	  the	  ethical	  and	  
legal	  frameworks	  governing	  pediatric	  clinical	  research	  are	  left	  to	  the	  clinicians	  who	  conduct	  
clinical	   research	   in	  minor	   subjects.17	   To	   permit	   these	   clinicians	   to	   acquit	   themselves	   from	  
their	   tasks	   successfully,	   they	   are	   granted	   considerable	   latitude	   in	   interpreting	   and	  
implementing	   the	   applicable	   ethical	   and	   regulatory	   requirements.	   This	   discretion	   in	   the	  
interpretation	   and	   implementation	   of	   essential	   aspects	   of	   good	   clinical	   practice	   (GCP),	  
however,	   is	   a	   double-­‐edged	   sword.	   On	   the	   one	   hand,	   it	   facilitates	   the	   successful	  
implementation	   of	   ethical	   and	   regulatory	   requirements	   for	   several	   reasons.	   First,	   it	   is	  
respectful	   of	   the	  established	   routine	  of	  making	  medical	   decisions	  on	  a	   case-­‐by-­‐case	  basis.	  
Second,	   granting	   both	   latitude	   and	   responsibility	   to	   clinicians	   counters	   the	   sometimes	  
serious	  workability	  problems	  that	  are	  characteristic	  to	  top–down	  implementation	  strategies.	  
Third,	  this	  approach	  thwarts	  overregulation	  and	  is	  therefore	  likely	  to	  prevent	  that	  ethics	  are	  
transformed	   into	   a	  meaningless	   bureaucratic	   burden.18	  On	   the	   other	   hand,	   there	   are	   also	  
important	   drawbacks	   to	   the	   discretion	   of	   clinicians.	   A	   lack	   of	   communication	   skills,	   poor	  
knowledge	   of	   the	   relevant	   ethical	   and	   regulatory	   requirements,	   conflicts	   of	   interest,	   and	  
time	   constraints	   all	   can	   be	   serious	   hurdles	   to	   a	   successful	   implementation	   of	   GCP	  
standards.19-­‐22	  Therefore,	  providing	  support	  to	  clinicians	  who	   implement	  GCP	  standards	  on	  
the	  floor	  is	  essential	  for	  guarding	  the	  quality	  of	  GCP.	  
To	   prevent	   that	   the	   quality	   of	   the	   implementation	   of	   ethical	   and	   legal	   requirements	  
depends	   upon	   the	   capacities,	   skills	   and	   experience	   that	   individual	   clinicians	   developed	  
fortuitously,	  proper	  education	  in	  medical	  ethics	  and	  law	  is	  essential.	  By	  preference,	  training	  
in	   ethics	   and	   law	   exceeds	   theoretical	   courses	   in	   the	   curriculum	  of	  medical	   education	   and	  
also	  entails	  the	  coaching	  of	  junior	  researchers	  by	  experienced	  researchers	  and	  by	  experts	  in	  
medical	   ethics	   and	   health	   law.	   Just	   like	   medical	   students	   who	   study	   medicine	   in	   the	  
classroom	   and	   become	   doctors	   as	   they	   walk	   the	   hospital	   wards,23	   also	   the	   capacities	  
required	  to	  implement	  GCP	  standards	  in	  pediatric	  research	  practice	  should	  be	  nurtured	  both	  
in	  the	  classroom	  and	  on	  the	  floor.	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Empowering	  families	  
Like	   clinicians,	   also	   families	   face	   complex	   and	   diverse	   tasks	  with	   regard	   to	   clinical	   trial	  
participation.	   First	   of	   all,	   families	   have	   to	   deal	   with	   invitations	   to	   enroll	   a	   minor	   family	  
member	  in	  a	  clinical	  trial.	  Due	  to	  several	  factors,	  this	  may	  be	  a	  complex	  and	  confusing	  task.	  
For	   example,	   invitations	   to	   enroll	   a	   minor	   in	   a	   clinical	   trial	   may	   come	   unexpected	   and	  
prompt	  minors	   and	   their	   parents	   to	   deal	   with	   their	   emotions,	   assess	   their	   interests,	   and	  
decide	   upon	   clinical	   trial	   participation,	   often	   in	   complete	   absence	   of	   relevant	   decision-­‐
making	   experience.	   They	   may	   feel	   like	   anything	   in	   between	   being	   elected	   as	   the	   first	  
beneficiaries	  of	  exclusive	  and	  marvelous	  novel	  technologies	  that	  are	  not	  yet	  available	  on	  the	  
market	  and	  being	  exploited	  as	  a	  guinea	  pig.24	  25	  In	  addition,	  decisions	  on	  study	  participation	  
are	   often	   subjected	   to	   serious	   time	   constraints,	   as	   participation	   may	   have	   to	   start	   very	  
shortly	   after	   a	   new	   diagnosis,	   a	   particular	   event	   (e.g.,	   a	   crisis),	   or	   a	   certain	   stage	   in	   the	  
course	  of	  a	  disease.	  
Second,	   minors	   and	   their	   parents	   face	   the	   difficult	   task	   of	   making	   decisions	   based	   on	  
difficult,	   voluminous,	   and	   contingent	   information.	   Obviously,	   feeling	   overloaded	   with	  
information	  that	  is	  too	  complex	  to	  comprehend	  may	  render	  it	  difficult	  or	  even	  impossible	  for	  
minors	  and	  their	  parents	  to	  make	  a	  well-­‐considered	  decision	  and	  even	  tempt	  them	  to	  leave	  
the	   decision	   to	   someone	   else	   altogether.26	   Studies	   have	   pointed	   out	   that	   it	   is	   difficult	   to	  
understand	  and	  remember	  the	  contingencies	  intrinsic	  to	  pediatric	  clinical	  trials,	  such	  as	  the	  
concept	  of	  randomization.27-­‐31	  Furthermore,	  the	  distinction	  between	  research	  and	  therapy	  is	  
often	   hard	   to	   grasp,	   as	   is	   suggested	   by	   the	   widespread	   phenomenon	   of	   “therapeutic	  
misconception”,11	   12	   15	   16	   which	   indicates	   that	   research	   interventions	   may	   be	   attributed	  
therapeutic	  qualities	  erroneously.	  Finally,	  also	  the	  risks	  inherent	  to	  clinical	  trials	  may	  confuse	  
minors	  and	  their	  parents,	  as	  consenting	  to	  procedures	  that	  may	  negatively	  affect	  the	  health	  
and	  welfare	  of	  a	  minor	  can	  be	  disturbing.	  
Third,	   families	   have	   an	   extensive	   discretion	   in	   the	   distribution	   of	   decisional	   power	   and	  
responsibilities	   among	   the	  minor	   and	   his	   parents.	   As	  most	  minors	   cannot	   provide	   legally	  
valid	   informed	   consent,	   they	   are	   represented	   by	   their	   parents	   in	   informed	   consent	  
discussions.	   However,	   this	   involvement	   of	   parents	   as	   proxy	   decision	   maker	   does	   not	  
preclude	   minors	   from	   active	   involvement	   in	   the	   decision.	   Quite	   the	   reverse,	   the	   ethical	  
principle	   of	   respect	   for	   persons	   requires	   that	  minors	   are	   involved	   in	   the	   decision-­‐making	  
process,	   to	   the	   extent	   possible	   and	   in	   function	   of	   their	   age	   and	   maturity.32-­‐35	   Research	  
pointed	  out	   that	   families	  handle	  different	   strategies	   to	  distribute	  decisional	  power	  among	  
their	  members.36	  As	  a	  consequence,	  decision-­‐making	  is	  first	  and	  foremost	  a	  family	  affair.	  
Fourth,	  families	  must	  weigh	  the	  enrollment	  of	  a	  child	  in	  a	  trial	  to	  other	  family	  concerns.	  In	  
this	   respect,	   the	   practical	   burden	   of	   having	   a	   child	   participating	   in	   a	   clinical	   trial	   (e.g.,	  
administrative	   requirements,	   additional	   hospital	   visits)	  may	   be	   hard	   to	   reconcile	  with	   the	  
interests	  of	  other	  family	  members,	  as	  all	  parents	  are	  limited	  in	  time	  and	  abilities.37	  
Fifth,	   the	   considerable	   differentiation	   in	   expertise,	   tasks,	   and	   responsibilities	   among	  
minors,	   their	   parents,	   and	   clinicians	   constitutes	   asymmetric	   relationships	   that	   complicate	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decisions	   on	   clinical	   trial	   participation.14	   This	   asymmetry	   creates	   a	   dependency	   of	  minors	  
and	   their	   parents	   upon	   each	   other	   and	   upon	   clinicians	   to	   provide,	   explain,	   and	   frame	  
information,	   which	   raises	   serious	   ethical	   concerns	   about	   conflicts	   of	   interests,	   uncritical	  
loyalty	   towards	   physicians,	   and	   information	   bias.	   Nonetheless,	   all	   of	   these	   issues	   can	   be	  
addressed	   adequately	   and	   need	   not	   be	   a	   hurdle	   to	   the	   establishment	   of	   relationships	   of	  
mutual	  trust	  between	  all	  individuals	  involved	  in	  the	  decision.17	  38	  
It	  would	  be	  unreasonable	  to	  expect	  from	  family	  members	  to	  just	  own	  the	  skills	  and	  know-­‐
how	   that	   are	   required	   to	   make	   well-­‐considered	   decisions	   on	   the	   enrollment	   of	   a	   minor	  
family	  member	   in	  a	  clinical	   trial.	  However,	  at	  present,	  easily	  accessible	  support	   for	  minors	  
and	  their	  parents	   in	  deciding	  on	  research	  participation	   is	   largely	   lacking.	  Therefore,	  efforts	  
should	  be	  made	  to	  employ	  the	  vast	  and	  unexplored	  potential	  of	  empowering	  families	  for	  the	  
advancement	  of	  ethical	  conduct	  in	  pediatric	  clinical	  research.	  
Streamlining	  protocol	  review	  
Competent	   authorities	   and	   ethics	   committees	   have	   a	   leading	   role	   in	   guiding	   sponsors,	  
clinicians,	   minors,	   and	   their	   parents	   through	   the	   complex	   landscape	   of	   GCP	   in	   pediatric	  
research	   conduct.	   To	   procure	   a	   safe	   and	   successful	   journey	   for	   all	   involved,	   competent	  
authorities	   and	   ethics	   committees	   endeavor	   to	   identify	   and	   address	   various	   foreseeable	  
obstacles	  to	  GCP	  in	  the	  protocols	  that	  they	  review.	  
However	   valuable	   the	   efforts	   of	   competent	   authorities	   and	   ethics	   committees	   in	  
embedding	   GCP	   in	   pediatric	   research	   are,	   the	   protocol	   review	   they	   perform	   is	   often	  
experienced	   as	   problematic	   by	   sponsors	   and	   investigators	   for	   several	   reasons.	   First,	  
applications	   for	   protocol	   review	   most	   often	   generate	   a	   considerable	   administrative	  
burden.39-­‐43	   Second,	   the	   diversity	   of	   the	   legal	   requirements	   protocols	   that	   have	   to	   be	  
complied	  with	   is	  often	  experienced	  as	   a	  hurdle.44	  Depending	  on	   the	  geographical	   location	  
where	   the	   research	   is	   conducted,	   compliance	   with	   specific	   domestic	   regulation	   may	   be	  
required.45	   This	  may	   result	   in	   a	   differentiation	   of	   the	   study	   protocol,	   as	   each	   review	  may	  
induce	  specific	  changes	  or	  amendments	  to	  the	  protocol,	  which	  may	  complicate	  the	  central	  
coordination	  of	  the	  study.	  Third,	  multiple	  assessments	  of	  the	  same	  research	  protocol,	  which	  
for	   example	   occurs	   in	   the	   case	   of	   multinational	   trials,	   may	   result	   in	   diverging	   or	   even	  
contradictory	   assessment	   outcomes.45-­‐48	   This	   renders	   the	   process	   of	   protocol	   review	  
unpredictable,	   as	   the	   same	   protocol	   may	   be	   accepted	   in	   one	   country	   and	   rejected	   in	  
another,	  or	  even	  be	  accepted	  at	  one	  site	  and	  rejected	  at	  another	  within	  the	  same	  country.49	  
The	  consequences	  of	  these	  variations	  in	  outcome	  for	  sponsors	  and	  investigators	  are	  harsh,	  
as	  the	  timing	  of	  clinical	  trials	  may	  get	  disrupted	  seriously,	  and	  delays	  at	  individual	  sites	  are	  
likely	   to	   drive	   up	   the	   costs	   of	   a	   clinical	   trial.	   For	   investigator-­‐initiated	   trials	  with	   a	   clearly	  
marked	  start	  and	  end,	  delays	   in	  getting	  ethics	  approval	   in	  all	   trial	  sites	  may	  put	  success	  of	  
the	  entire	  project	  at	  risk.50	  
The	   unpredictable	   outcome	   of	   protocol	   review	   by	   competent	   authorities	   and	   ethics	  
committees	   is	   a	   recurrent	   source	   of	   frustration.	   Ultimately,	   the	   considerable	   variations	   in	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outcome	   may	   create	   even	   a	   wrongful	   impression	   of	   arbitrariness	   to	   sponsors	   and	  
researchers	   who	   organize	   multicenter	   pediatric	   clinical	   trials.	   However,	   protocol	   review	  
cannot	  be	  streamlined	  easily,	  as	  the	  large	  number	  of	  ethics	  committees	  works	  against	  a	  truly	  
harmonized	   approach.	   Reducing	   the	   number	   of	   committees	   involved,	   however,	   is	   not	   an	  
acceptable	   quick	   fix	   for	   this	   issue,	   as	   the	   assessment	   of	   specific	   issues	   related	   to	   the	   site	  
where	  the	  research	  is	  conducted	  (e.g.,	  a	  local	  hospital	  or	  research	  team)	  is	  vital	  in	  the	  review	  
of	   research	  protocols.	   Location	   thus	  matters,	   and	   to	  date,	   local	   concerns	   tend	   to	  overrule	  
the	   quest	   for	   a	   harmonized	   and	   unified	   protocol	   review.	   In	   addition,	   a	   far	   going	  
harmonization	   of	   the	   ethical	   criteria	   for	   protocol	   review	   simply	   is	   no	   panacea	   because	  
applying	   the	   same	   set	   of	   criteria	   by	   no	  means	   guarantees	   a	   standardized	   and	   predictable	  
outcome.	  Obviously,	  different	  individuals	  or	  committees	  may	  decide	  differently,	  even	  when	  
they	  use	  the	  same	  criteria.	  
In	   the	   absence	   of	   a	   complete	   harmonization	   of	   regulatory	   requirements,	   however,	  
important	   efforts	   to	   streamline	   protocol	   review	   can	   still	   be	  made.	   In	   this	   respect,	   among	  
many	  other	   things,	   increasing	   the	   transparency	  of	  protocol	   review,	  ameliorating	   the	  direct	  
communication	  between	  research	  sponsors	  and	  protocol	  reviewers,	  and	  having	  members	  of	  
reviewing	   bodies	   sharing	   expertise	   across	   national	   borders	   all	   could	   contribute	   to	   this	  
process.	  
Non-­‐clinical	  research	  objectives	  
Biomedicine	   is	  a	  rapidly	  developing	  enterprise	  that	   is	  capable	  of	  silently	  outgrowing	  the	  
ethical	   and	   regulatory	   frameworks	   that	   guide	   scientific	   innovations	   through	   our	   complex	  
society.	  Sometimes,	  scientific	  breakthroughs	  significantly	  alter	  the	  objectives	  and	  outcomes	  
of	  medical	   interventions,	   calling	  bioethics	   and	  health	   regulation	   to	   enquire	  new	   issues,	   or	  
even	  to	  move	  to	  a	  new	  paradigm.	  A	  contemporary,	  paradigmatic	  illustration	  of	  this	  process	  
can	  be	  found	  in	  pediatric	  magnetic	  resonance	  imaging	  (fMRI)	  research.	  
Apart	  from	  the	  obvious	  clinical	  interest	  in	  pediatric	  fMRI,	  like	  the	  support	  of	  brain	  surgery	  
or	  the	  diagnosis	  of	  conditions	  and	  diseases,	  the	  technique	  of	  fMRI	  has	  a	  great	  potential	  for	  
developing	   non-­‐clinical	   applications,	   for	   example	   in	   the	   field	   of	   jurisprudence	   (e.g.,	   lie	  
detection,	  moral	  decision	  making,	  accountability),	  education	   (e.g.,	  memory	  enhancement),	  
or	  marketing	   (e.g.,	   consumer	   brand	   attachment,	   persuasion),	   several	   of	   which	   have	   been	  
registered	  already.51	  
Fostering	   the	  pursuit	  of	  non-­‐clinical	  objectives	  within	  pediatric	  clinical	   research	  practice	  
challenges	   the	   established	   procedures	   of	   protocol	   review	   by	   ethics	   committees	   and	  
generates	   profound	   ethical	   questions	   regarding	   the	   acceptability	   of	   involving	   minors	   in	  
clinical	   research,	   the	   assessment	   of	   research	   risks,	   the	   fair	   compensation	   of	   research	  
participation,	  and	  research	  sponsorship.52	  
First,	   hosting	   the	   development	   of	   non-­‐clinical	   applications	   of	   medical	   technologies	   in	  
clinical	   trials	   threatens	   to	  erode	   the	  basic	   grounds	   for	   involving	  human	   subjects	   in	   clinical	  
studies	  because	  such	  research	  no	  longer	  ultimately	  aims	  at	   improving	  the	  health	  or	  quality	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of	   life	   of	   minors.	   Even	   worse,	   there	   is	   no	   single	   guarantee	   that	   such	   studies	   serve	   the	  
interests	  of	  minors	   in	  any	  way	  at	  all.	  Therefore,	  the	  acceptability	  of	  such	  research	  is	  highly	  
questionable.	  
Second,	   it	   is	   questionable	  whether	   research	   risks,	   even	   the	   slightest,	   can	  be	   justified	   if	  
research	  merely	   is	   conducted	   for	   the	   realization	   of	   research	   objectives	   in	   which	   children	  
have	   no	   intrinsic	   interest.	   However,	   in	   the	   current	   system	   of	   protocol	   assessment,	   most	  
protocols	   of	   pediatric	   fMRI	   research	   will	   smoothly	   comply	   with	   even	   the	   lowest	   risk	  
threshold	  due	  to	  the	  very	  low	  risks	  and	  noninvasive	  character	  of	  the	  research	  interventions	  
concerned.	   In	   addition,	   risk	   assessments	   tend	   to	   largely	   ignore	   the	   considerable	  
socioeconomical	  risks	  of	  pediatric	  fMRI	  research.51	  
Third,	   the	   resistiveness	   to	   financial	   incentives	   to	   reward	   research	   loses	   its	   significance	  
when	  pediatric	   research	   pursues	   non-­‐clinical	   objectives	   because	   the	   development	   of	   non-­‐
clinical	  applications	  of	  medical	  technologies	   is	  essentially	  a	  commercial,	  non-­‐health-­‐related	  
enterprise	  in	  which	  restrictions	  on	  compensation	  no	  longer	  seem	  to	  be	  rational.	  
Fourth,	   hosting	   the	   development	   of	   non-­‐clinical	   applications	   of	   medical	   technologies	  
within	   pediatric	   clinical	   research	   is	   likely	   to	   attract	   sponsors	   from	   outside	   the	   biomedical	  
setting.	   Such	   an	   introduction	   of	   new	   sponsors	   generates	   specific	   ethical	   and	   regulatory	  
issues,	  as	  new	  players	  in	  the	  field	  may	  lack	  familiarity	  with	  clinical	  research	  and	  expertise	  in	  
dealing	  with	  research	  subjects	  in	  an	  ethical	  way.51	  
To	   date,	   many	   questions	   with	   regard	   to	   the	   objectives	   of	   pediatric	   clinical	   research	  
remain	  unanswered.	  Is	  clinical	  research	  the	  setting	  were	  non-­‐clinical	  applications	  of	  medical	  
technologies	  should	  be	  developed?	  Is	  the	  involvement	  of	  minor	  subjects	  in	  clinical	  research	  
supporting	   the	   development	   of	   non-­‐clinical	   objectives	   ethically	   acceptable?	   Can	   the	  
technology	  transfer	  from	  medicine	  to	  broader	  society	  be	  guided	  and	  regulated?	  Should	  the	  
ethics	   committees	   that	   review	   research	   protocols	   act	   as	   a	   gatekeeper	   that	   guides	   the	  
technology	   transfer	   from	   biomedicine	   to	   society?	   Obviously,	   these	   questions	   need	   to	   be	  
addressed	  urgently.	  
Controlled	  placebo	  use	  
A	  radical	  dissimilarity	  between	  experimental	  therapy	  and	  clinical	  research	  is	  that	  research	  
is	   controlled.	   Among	   other	   things,	   this	   control	   entails	   that,	   within	   a	   trial,	   the	   safety	   and	  
efficacy	  of	   investigational	   interventions	  are	  measured	  against	  a	  comparator.	   In	   the	  case	  of	  
drug	  trials,	  the	  comparator	  may	  be	  another	  medicinal	  product,	  a	  different	  dose	  of	  the	  same	  
medicinal	   product,	   another	   combination	   of	   medicines	   than	   the	   tested	   combination	   of	  
medicines,	  or	  a	  placebo.	  
Double-­‐blind	   randomized	   controlled	   trials	   (RCT)	   are	   widely	   regarded	   as	   the	   golden	  
standard	  in	  testing	  treatment	  efficacy.53	  Particularly,	  RCTs	  in	  which	  the	  control	  is	  a	  placebo	  
are	   a	   highly	   efficient	   way	   to	   test	   the	   efficacy	   of	   medicinal	   products.	   However,	   there	   is	  
something	  profoundly	  ambiguous	  about	  using	  placebos	  as	  a	  control	  in	  pediatric	  RCTs.	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On	   the	   one	   hand,	   placebo	   controlled	   trials	   offer	   the	   considerable	   advantage	   that	   the	  
sample	   size	   of	   research	   subjects	   that	   is	   required	   to	   generate	   relevant	   results	   can	   be	  
downsized	  significantly	  in	  comparison	  with	  other	  research	  designs.54	  55	  This	  advantage	  is	  of	  
great	  value,	  as	  various	  scientific,	  practical,	  and	  ethical	  considerations	  argue	  a	  case	  for	  small	  
sample	   sizes.	   Scientifically,	   placebo-­‐controlled	   RCTs	   generate	   the	  most	   reliable	   data,	   as	   in	  
absence	  of	  placebo-­‐controlled	  studies	   investigational	  medicinal	  products	   that	  are	  no	  more	  
effective	   than	   a	   placebo	   might	   gain	   approval	   based	   on	   the	   data	   derived	   from	   active	  
controlled	  equivalence	  investigations.	  In	  addition,	  it	  may	  be	  hard	  to	  find	  an	  acceptable	  active	  
comparator	   in	   pediatric	   clinical	   trials	   because,	   in	   many	   cases,	   the	   standard	   of	   care	   in	  
pediatric	   practice	   is	   off-­‐label	   and	   therefore	   cannot	   always	   be	   used	   as	   a	   comparator.	  
Practically,	  it	  must	  be	  acknowledged	  that,	  by	  nature,	  the	  pediatric	  population	  is	  quite	  small,	  
which	  renders	  the	  recruitment	  of	  a	  sample	  of	  minor	  research	  subjects	  that	  is	  large	  enough	  to	  
generate	   relevant	   data	   difficult.56	   57	   As	   a	   result,	   complex	   and	   expensive	   multicentre	   or	  
multinational	   trials	  may	  be	  the	  only	  way	  to	  conduct	  a	  scientifically	  sound	  clinical	   trial,	  and	  
decreasing	   the	   sample	   size	   of	   research	   subjects	   in	   pediatric	   clinical	   trials	   generates	   a	  
substantial	  practical	  advantage.	  Ethically,	  at	  least	  two	  principles	  argue	  in	  favor	  of	  downsizing	  
the	   sample	  of	   research	   subjects	   in	  pediatric	   clinical	   trials.	   First,	   the	  principle	   that	   children	  
should	   only	   be	   involved	   in	   clinical	   research,	   in	   so	   far	   that	   there	   are	   no	   alternatives	   to	  
generate	  the	  required	  data,	  is	  widely	  alleged	  in	  ethical	  guidelines	  and	  legal	  regulations.	  This	  
premise	   is	   often	   interpreted	   as	   a	   prohibition	   to	   conduct	   research	   in	   minors	   whenever	  
relevant	   data	   can	   also	   be	   obtained	   by	   laboratory	   research,	   animal	   trials,	   or	   research	   in	  
competent	   adults,	   rather	   than	   an	   obligation	   to	   minimize	   sample	   sizes.	   Nonetheless,	  
endeavors	  to	  minimize	  the	  sample	  size	  of	  pediatric	  clinical	  trials	  would	  certainly	  square	  with	  
this	   ethical	   principle,	   and	   involving	   more	   minors	   than	   necessary	   in	   burdensome	   or	   risky	  
clinical	   trials	   will	   be	   especially	   hard	   to	   justify	   ethically.	   Second,	   there	   exists	   a	   general	  
consensus	  that	  the	  risks	  in	  pediatric	  clinical	  research	  should	  be	  minimized.	  In	  this	  respect,	  it	  
has	   been	   demonstrated	   that	   using	   a	   placebo	   may	   decrease	   the	   incidence	   of	   harm	   in	  
pediatric	   clinical	   trials	  and,	  as	  a	   consequence,	  decrease	   the	   risk	  of	  harm.	  Even	   though	   the	  
relative	  risk	  of	  enduring	  a	  therapeutic	  disadvantage	  from	  research	  participation	  is	  higher	  in	  
placebo-­‐controlled	   trials	   than	   in	   trials	  with	   an	   active	   comparator,	   the	   absolute	  number	  of	  
disadvantaged	  research	  participants	  may	  still	  be	  smaller	  in	  placebo-­‐	  controlled	  trials	  because	  
due	  to	  the	  decreased	  sample	  size,	  fewer	  subjects	  are	  at	  risk.58	  
Regardless	  of	  the	  scientific,	  practical,	  and	  ethical	  advantages,	  placebo-­‐controlled	  RCTs	  are	  
often	  ethically	  contested	  for	  several	  reasons.	  First,	  the	  concept	  of	  randomization	  is	  proven	  
to	  be	  hard	  to	  understand	  for	  the	  subjects	  participating	  in	  research	  and	  their	  proxy	  decision	  
makers.27-­‐31	   Second,	   desperate	   patients	   who	   face	   all	   validated	   treatment	   options	   being	  
exhausted	  may	  be	  reluctant	  to	  participate	  in	  placebo-­‐controlled	  RCTs,	  as	  they	  are	  reluctant	  
to	  settle	  with	  anything	  other	  than	  the	  active	  substance.	  Third,	  placebo	  use	  may	  result	   in	  a	  
wash	  out	  of	   the	   current	   treatment,	   resulting	   in	  additional	   risks,	   a	  decreased	   level	  of	   care,	  
and	   a	   violation	   of	   the	   principle	   of	   equipoise,	   which	   requires	   that	   all	   arms	   of	   a	   study	   are	  
reasonably	  believed	  to	  have	  a	  comparable	  chance	  of	  being	  the	  “better	  arm”.	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To	  date,	  the	  ethical	  controversy	  surrounding	  placebo-­‐	  controlled	  trials	   in	  minor	  subjects	  
has	  not	   been	   cleared	  out,	   and	   the	   considerable	   advantages	   and	  disadvantages	  of	   placebo	  
use	   in	   pediatric	   RCTs	   render	   it	   particularly	   hard	   to	   take	   an	   appropriate	   ethical	   stance.	  
Polarizing	   the	   discussion	   as	   an	   ethics	   versus	   science	   discussion,	   however,	   is	   not	   an	  
appropriate	   way	   forward,	   as	   banning	   placebo	   use	   in	   pediatric	   clinical	   research	   practice	  
altogether	  is	  not	  a	  realistic	  option.	  By	  contrast,	  suggesting	  that	  placebo	  use	  in	  pediatric	  trials	  
is	  to	  be	  eliminated	  obscures	  the	  devastating	  impact	  of	  banning	  placebo	  on	  the	  quantity	  and	  
quality	  of	  pediatric	  trials,	  pushing	  minors	  back	  into	  “therapeutic	  orphanage”.59	  Nonetheless,	  
it	  must	  be	  acknowledged	  that	  placebo-­‐controlled	  trials	  are	  not	  always	  the	  best,	  not	  to	  say	  
the	  only	  way	  to	  conduct	  clinical	  trials	  in	  minors.	  Therefore,	  prudence	  is	  ethically	  imperative,	  
since	   the	  high	  efficiency	  of	  placebo-­‐controlled	  RCTs	  may	  bias	   researchers	  and	   sponsors	   to	  
opt	  for	  this	  strategy.	  The	  true	  challenge	  in	  front	  of	  us	  is	  thus	  to	  find	  a	  feasible	  way	  to	  control	  
the	  use	  of	  placebo	   in	  pediatric	  clinical	   trials.	   In	  our	  opinion,	   this	   should	  not	  be	  realized	  by	  
defining	   a	   “golden	   rule”	   for	   the	   use	   of	   placebo	   in	   pediatric	   research,	   as	   such	   rule	   would	  
ignore	   the	   complexities	   and	   needs	   of	   individual	   cases.	   Rather,	   efforts	   should	   be	  made	   to	  
inform	  and	  optimize	  the	  assessment	  of	  placebo	  use	  on	  a	  case-­‐by-­‐case	  basis.	  
Rewarding	  research	  
Due	  to	  several	  constraints,	  research	  in	  minors	  is	  by	  and	  large	  commercially	  less	  attractive	  
than	   research	   in	  competent	  adults.	  First,	   the	  small	   size	  of	   the	  pediatric	  public	  generates	  a	  
geographical	   spread	   of	   eligible	   minor	   research	   subjects,	   often	   rendering	   recruitment	   and	  
follow-­‐up	  difficult	  and	  costly.	   In	  addition,	  due	  to	  the	  small	  size	  of	  the	  group	  of	  minors,	  the	  
market	  for	  drugs	  for	  pediatric	  use	  is	  relatively	  small.	  Jointly,	  the	  small	  market	  and	  the	  high	  
development	   costs	   of	   medicines	   for	   the	   young	   tend	   to	   tumble	   the	   profits	   involved	   in	  
pediatric	  drug	  development.	  
Second,	   the	   pediatric	   population	   is	   very	   heterogeneous,	   as	   is	   clearly	   illustrated	   by	   the	  
well-­‐known	  age	  classification	  of	  International	  Conference	  on	  Harmonization	  guideline	  E1160	  
dividing	   minors	   in	   the	   subsets	   of	   preterm	   newborn	   infants,	   term	   newborn	   infants	   (0–27	  
days),	   infants	  and	  toddlers	   (28	  days	   to	  23	  months),	  children	   (2–11	  years),	  and	  adolescents	  
(12	   to	   16–18	   years,	   depending	   on	   the	   region).	   Because	   subjects	   categorized	   in	   different	  
subsets	   of	   the	   pediatric	   population	   tend	   to	   differ	   significantly	   in	   body	   composition	   and	  
functioning,	   sometimes,	   specific	   research	   needs	   exist	   for	   different	   subgroups	   of	   minors.	  
Obviously,	  handling	  this	  heterogeneity	  comes	  at	  a	  price	  and	  drives	  up	  the	  costs	  of	  pediatric	  
research.	  
Third,	  because	  the	  dosage	  prescribed	  is	  often	  determinate	  for	  the	  retail	  price,	  the	  small	  
dosages	   that	  are	   typical	   for	  many	  pediatric	  drug	  prescriptions	  weigh	  on	  profits	   involved	   in	  
pediatric	  drug	  development.	  
The	   high	   costs	   and	   relatively	   low	   yields	   in	   pediatric	   clinical	   research	   make	   that	   a	   fair	  
return	  on	   investment	   is	  often	  highly	  uncertain.61	  Therefore,	   the	  pharmaceutical	   industry	   is	  
not	   likely	   to	   show	   much	   enthusiasm	   in	   developing	   drugs	   for	   the	   young.	   To	   counter	   this	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commercial	  disinterest,	  regulatory	  efforts	  have	  been	  made	  in	  the	  USA	  and	  the	  EU,	  granting	  
companies	  that	  invest	  in	  the	  development	  of	  drugs	  for	  pediatric	  use	  a	  considerable	  reward	  
in	  the	  form	  of	  an	  extension	  of	  the	  market	  exclusivity	  of	  the	  drug	  in	  question	  for	  example,	  the	  
FDA	   modernization	   act	   in	   the	   USA,62	   and	   the	   pediatric	   regulation	   in	   the	   EU.63	   However,	  
despite	  this	   incentive,	  the	  financial	  outcome	  of	  pediatric	  drug	  development	  remains	  highly	  
variable.61	  
For	  some	  medicinal	  products,	  the	  incentives	  will	  hardly,	  or	  even	  not	  at	  all,	  cover	  the	  costs	  
of	   the	   trial.61	   In	   this	  case,	   the	   incentive	  does	  not	  suffice	   to	  win	  pharmaceutical	  companies	  
over	  to	  test	  a	  drug	  in	  minors.	  For	  other	  medicinal	  products,	  peculiarly	  for	  blockbuster	  drugs,	  
the	  profits	  involved	  in	  testing	  the	  substance	  in	  minors	  can	  be	  very	  lucrative	  as	  a	  result	  of	  the	  
provided	  incentive,	  prompting	  the	  industry	  to	  test	  these	  drugs	  in	  minors,	  regardless	  of	  any	  
priorities	  in	  pediatric	  drug	  development.	  Therefore,	  it	  is	  questionable	  whether	  such	  rewards	  
are	  rational	  at	  all.	  
The	  outcome	  of	  the	  extended	  market	  exclusivity	  as	  an	  incentive	  for	  developing	  drugs	  for	  
the	  young	   is	   thus	  as	  uncertain	  as	   troublesome	  and	  may	  generate	  numerous	  ethical	   issues.	  
We	  suggest	  that	  three	  issues	  are	  addressed	  in	  this	  regard.	  
First,	   this	   type	   of	   incentive	   turns	   science-­‐driven	   priorities	   into	  market-­‐driven	   priorities,	  
which	  may	  only	  respond	  accidentally	  to	  the	  real	  needs	  of	  minor	  patients.	  As	  a	  result,	  minors	  
participating	   in	   clinical	   research	   rather	   serve	   the	   interests	   of	   the	   industry	   than	   their	   own	  
medical	  interests	  or	  those	  of	  related	  beneficiaries.	  
Second,	   extending	   market	   exclusivity	   as	   a	   reward	   for	   conducting	   pediatric	   research	  
regardless	   of	   the	   outcome	   of	   the	   investigation—as	   is	   the	   case	   in	   the	   EU—it	   is	   likely	   to	  
negatively	  affect	  the	  quality	  of	  clinical	  research.	  If	  the	  conduct	  of	  pediatric	  research	  as	  such	  
becomes	  more	   important	   than	   the	   successful	   pursuit	   of	   specific	   research	   objectives,	   “the	  
cheaper,	   the	   better”	   tends	   to	   become	   a	   basic	   principle	   of	   pediatric	   drug	   development.	  
Conversely,	  making	  the	  outcome	  of	  pediatric	  trials	  a	  requirement	  for	  obtaining	  the	  extension	  
of	   market	   exclusivity	   will	   make	   companies	   even	   more	   suspicious	   toward	   the	   economic	  
profitability	  of	  pediatric	  clinical	  trials.	  
Third,	   it	   is	  highly	  questionable	  whether	   the	  extension	  of	  market	  exclusivity	   is	  a	   rational	  
and	  efficient	  investment	  of	  taxpayers’	  money	  in	  the	  development	  of	  pediatric	  drugs.	  Just	  as	  
unpredictable	  as	  the	  profits	  that	  a	  pediatric	  trial	  will	  yield	  for	  the	  sponsor	  are	  the	  costs	  to	  
society	  for	  providing	  the	  incentive.	  As	  a	  result,	  the	  current	  incentives	  are	  out	  of	  control.	  
Redrawing	   the	   present	   incentives	   could	   enable	   to	   control	   budgets	  more	   rationally	   and	  
efficiently	  and	  to	  set	  clear	  priorities	  in	  pediatric	  research.	  This	  would	  certainly	  advance	  the	  
interests	  of	  minor	  patients	   in	  drug	  development	  while	  still	  encouraging	  that	  new	  drugs	  for	  
the	  young	  are	  marketed.	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Conclusion	  
In	   this	   article,	   seven	   ethical	   controversies	   in	   the	   current	   practice	   of	   pediatric	   clinical	  
research	  have	  been	  explored:	  (1)	  the	  integration	  of	  research	  in	  therapy,	  (2)	  the	  education	  of	  
clinicians,	   (3)	   the	   empowerment	   of	   families,	   (4)	   the	   harmonization	  of	   protocol	   review,	   (5)	  
the	  assessment	  of	  non-­‐clinical	  research	  objectives,	  (6)	  the	  control	  of	  placebo	  use,	  and	  (7)	  the	  
provision	  of	  fair	  incentives	  for	  pediatric	  research	  conduct.	  For	  all	  of	  these	  issues,	  a	  clear	  view	  
on	  the	  way	  forward	  is	  largely	  lacking,	  either	  because	  these	  issues	  have	  not	  been	  discussed	  in	  
depth	  to	  date	  or	  because	  the	  existing	  debates	  have	  failed	  to	  generate	  a	  generally	  supported	  
consensus.	  Nonetheless,	  these	  issues	  need	  to	  be	  addressed	  to	  facilitate	  the	  ethical	  conduct	  
of	   pediatric	   research,	   the	   practical	   implementation	   of	   the	   ethical	   and	   legal	   frameworks	  
governing	   pediatric	   clinical	   research,	   and	   the	   streamlined,	   transparent,	   and	   exhaustive	  
protocol	  review.	  As	  a	  consequence,	  the	  establishment	  of	  a	  working	  consensus	  in	  these	  issues	  
and	   the	   operational	   implementation	   of	   this	   consensus	   are	   of	   major	   importance	   for	   the	  
ethical	  quality	  of	  pediatric	  clinical	  research	  conduct.	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Abstract	  
Patients	  who	  search	  for	  a	  better	  treatment,	  an	  increased	  quality	  of	  life,	  or	  even	  a	  chance	  
to	   preserve	   life	   itself	  may	   claim	   to	   have	   an	   interest	   in	   accessing	   investigational	  medicinal	  
products	   (IMP),	   particularly	   when	   no	   validated	   treatment	   for	   their	   disease	   or	   condition	  
exists.	  For	  many,	  awaiting	  the	  uncertain	  and	  time-­‐consuming	  process	  of	  converting	  an	  IMP	  
into	  an	  approved	  drug	  may	  not	  appear	  a	  realistic	  option,	  as	  prognoses	  may	  be	  grim	  and	  a	  
dramatic	  outcome	  may	  seem	  hard	  to	  avert.	  Gaining	  access	  to	  an	  IMP,	  however,	  often	  proves	  
to	   be	   a	   difficult	   enterprise	   with	   a	   highly	   uncertain	   outcome.	   In	   addition,	   the	   process	   of	  
seeking	   access	   to	   IMP	   is	   surrounded	  by	   various	   ethical	   issues	   that	  will	   be	  explored	   in	   this	  
article.	  This	  paper	  explores	  the	  ethical	  concerns	  in	  two	  potential	  tracks	  of	  seeking	  access	  to	  
IMP	   for	   minors:	   on	   an	   individual	   basis,	   or	   collectively,	   as	   a	   patient	   organization.	   In	   this	  
discourse,	  several	  unique	  ethical	  and	  regulatory	  concerns	  related	  to	  the	  direct	  negotiation	  of	  
access	   to	   IMP	   for	   minor	   patients	   are	   identified,	   with	   a	   focus	   on	   product	   safety,	   the	  
recruitment	   of	   research	   subjects,	   the	   unnoticed	   entry	   of	   market	   mechanisms	   in	   the	  
recruitment	   of	   research	   subjects,	   and	   the	   sidelining	   of	   third	   parties	   in	   the	   recruitment	  
process.	  The	  paper	  concludes	  with	  a	  concise	   reflection	  on	   the	  way	   forward.	  The	  quest	   for	  
access	   to	   investigational	   drugs	   is	   particularly	   relevant	   to	   pediatric	   practice,	   in	   which	   a	  
significant	  share	  of	  the	  drugs	  prescribed	  has	  never	  been	  tested	  in	  children	  or	  labeled	  for	  use	  
in	  the	  pediatric	  population.	  
Introduction	  
Patients	  who	  search	  for	  a	  better	  treatment,	  an	  increased	  quality	  of	  life,	  or	  even	  a	  chance	  
to	   preserve	   life	   itself	  may	   claim	   to	   have	   an	   interest	   in	   accessing	   investigational	  medicinal	  
products	   (IMP),	   particularly	   when	   no	   validated	   treatment	   for	   their	   disease	   or	   condition	  
exists.1	  For	  many,	  awaiting	  the	  uncertain	  and	  time-­‐consuming	  process	  of	  converting	  an	  IMP	  
into	  an	  approved	  drug	  may	  not	  appear	  a	  realistic	  option,	  as	  prognoses	  may	  be	  grim	  and	  a	  
dramatic	  outcome	  may	  seem	  hard	  to	  avert.	  Therefore,	  patients	  have	  been	  actively	  seeking	  
access	   to	   IMP	  ever	  since	   the	  AIDS	  crisis	   in	   the	  1980s.2	  Gaining	  access	   to	  an	   IMP,	  however,	  
often	  proves	  to	  be	  a	  difficult	  enterprise	  with	  a	  highly	  uncertain	  outcome.	  
In	   general,	   there	   are	   two	  ways	   to	   obtain	   access	   to	   an	   IMP,	   of	  which	   participation	   in	   a	  
clinical	   trial	   is	   the	   most	   obvious.	   Unfortunately,	   many	   patients	   will	   be	   denied	   access	   to	  
clinical	   trials	   as	   they	   fail	   to	   comply	   with	   the	   eligibility	   criteria	   or	   because	   the	   sample	   of	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research	  subjects	  is	  limited	  in	  number,	  time,	  or	  location.	  Alternatively,	  terminally	  ill	  patients	  
can	   be	   granted	   access	   to	   IMP	   exceptionally	   under	   different	   types	   of	   compassionate	   use	  
programs,	  several	  of	  which	  exist	  in	  the	  USA,	  the	  EU	  and	  Canada.	  For	  patients	  failing	  to	  access	  
IMP	   through	   participation	   in	   a	   clinical	   trial	   or	   under	   a	   compassionate	   use	   program,	   there	  
appears	   to	   be	   no	   systematic	   opportunity,	   not	   to	  mention	   a	   generally	   recognized	   right	   to	  
access	   IMP,	   as	   is	   for	   example	   suggested	   in	   the	   paradigmatic	   case	   Abigail	   Alliance	   v	   von	  
Eschenbach.3	  4	  	  	  
The	  quest	  for	  access	  to	  investigational	  drugs	  is	  particularly	  relevant	  to	  pediatric	  practice,	  
in	  which	   a	   significant	   share	   of	   the	   drugs	   prescribed	   has	   never	   been	   tested	   in	   children	   or	  
labeled	   for	   use	   in	   the	  pediatric	   population.5-­‐7	   As	   a	   result,	   the	   line	  between	  using	   IMP	  and	  
prescribing	  medicines	  off-­‐	   label	  may	  at	  times	  be	  very	  thin,	  and	  therefore	  in	  pediatrics,	   IMP	  
may	  be	  appear	  appealing	  as	  any	  non-­‐validated	  treatment	  prescribed	  off-­‐label.	  However,	  as	  
off-­‐label	   prescriptions	   are	   part	   of	   therapeutic	   practice	   and	   using	   IMP	   is	   part	   of	   drug	  
development	  processes,	  there	  is	  a	  profound	  difference	  between	  prescribing	  treatments	  off-­‐
label	  and	  opening	  up	  the	  access	  to	  IMP.	  As	  a	  result,	  strategies	  to	  open	  up	  access	  to	  IMP	  for	  
children	   create	  unique	  and	  profound	  ethical	   and	   legal	   issues.	  As	   creating	   access	   to	   IMP	   is	  
clearly	   perceived	   as	   an	   interest	   of	   some	   pediatric	   patients,	   these	   issues	   need	   to	   be	  
addressed	  urgently.	  
In	  this	  paper,	  we	  explore	  the	  ethical	  concerns	  in	  two	  potential	  tracks	  of	  seeking	  access	  to	  
IMP	   for	   minors:	   on	   individual	   basis,	   or	   collectively,	   as	   a	   patient	   organization.	   In	   our	  
discourse,	  we	   identify	   several	  unique	  ethical	  and	   regulatory	  concerns	   related	   to	   the	  direct	  
negotiation	   of	   access	   to	   IMP	   for	   minor	   patients,	   with	   a	   focus	   on	   product	   safety,	   the	  
recruitment	   of	   research	   subjects,	   the	   unnoticed	   entry	   of	   market	   mechanisms	   in	   the	  
recruitment	   of	   research	   subjects	   and	   the	   sidelining	   of	   third	   parties	   in	   the	   recruitment	  
process.	  	  
Individual	  patients	  seeking	  access	  to	  IMP:	  an	  illustratory	  case	  
Sandra	  Massart,	  a	  Belgian	  girl	  aged	  7	  years	  with	  from	  metachromatic	   leukodystrophy,	   is	  
rapidly	   declining	   in	   the	   absence	   of	   a	   validated	   treatment	   for	   her	   disease.	   Her	   parents	  
devoted	   themselves	   indefatigably	   to	  provide	  her	  with	  Metazym,	  an	   IMP	  developed	  by	   the	  
Danish	   firm	  Zymenex.	   Sandra	  could	  not	  obtain	  Metazym	  through	  participation	   in	  a	   clinical	  
trial	   because	   –exceeding	   the	   upper	   age	   limit	   of	   60	  months-­‐	   she	   did	   not	   comply	  with	   the	  
eligibility	  criteria	  of	  the	  running	  trial.	  Therefore,	  the	  parents	  searched	  for	  an	  alternative	  way	  
to	  obtain	  Metazym	  and	  claim	  to	  have	  negotiated	  that	  Zymenex	  would	  provide	  Sandra	  with	  
Metazym	   under	   the	   named	   patient	   program	   on	   payment	   of	   approximately	   €45	   000	   per	  
month,	   or	   €1	   000	   000	   for	   2	   years	   of	   administration.	   Because	   the	   Belgian	   public	   health	  
insurance	   rejected	   the	  parents’	   request	   to	   refund	  Metazym,	  an	  extensive	  media	  campaign	  
was	   set	   up	   to	   raise	   the	   necessary	   funds.	   This	   campaign	   peaked	   when	   Belgium’s	   largest	  
commercial	   channel	   reported	   on	   Sandra’s	   cruel	   fate	   during	   Christmas	   day’s	   prime	   time	  
newscast.	   In	   the	   following	   days,	   public	   indignation	   was	   nurtured	   and	   in	   no	   time	   the	  
necessary	  funds	  were	  raised.	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However,	  in	  sheer	  contrast	  to	  the	  rapid	  and	  easy	  fundraising,	  the	  family	  did	  not	  succeed	  
in	  gaining	  access	  to	  Metazym.	  Shire,	  the	  British	  firm	  that	  had	  acquired	  Metazym	  by	  the	  time	  
funds	  were	  raised,	  stated	  that	  they	  were	  unable	  to	  provide	  the	  family	  with	  Metazym,	  due	  to	  
supply	  constraints.8	  Even	  when	  production	  restrictions	  are	  not	  applicable,	  litigation	  fears	  and	  
public	  relations	  concerns	  may	  constitute	  a	  hurdle	  to	  the	  provision	  of	  an	  IMP	  at	  the	  request	  
of	  an	  individual	  patient.1	  2	  
Recently,	  Shire	  announced	  that	  they	  were	  stopping	  the	  trials	  of	  Metazym	  because	  of	  the	  
low	  efficacy.	  	  
Obviously,	  this	  complex	  case	  raises	  many	  more	  ethical	   issues	  than	  that	  of	  access	  to	  IMP	  
alone.	  However,	  in	  this	  paper,	  we	  will	  limit	  the	  scope	  of	  the	  ethical	  assessment	  of	  this	  case	  
to	  the	  issue	  of	  access	  to	  IMP.	  
Negotiating	   access	   collectively:	   the	   collective	   claim	   of	   patient	  
populations	  
The	  case	  of	  Sandra	  Massart	  clearly	   illustrates	   the	   interest	   in	  accessing	   IMP	  that	  may	  be	  
attributed	   to	   individual	   patients.	   Similar	   to	   this	   individual	   interest	   in	   accessing	   IMP	   of	  
individual	  patients,	  a	  collective	  interest	  in	  accessing	  IMP	  can	  be	  claimed	  by	  patients	  with	  the	  
same	  disease.	  As	  a	  consequence,	  it	  is	  worthwhile	  to	  extend	  the	  scope	  of	  ethical	  reflection	  on	  
the	  direct	  negotiation	  of	  access	  to	  IMP	  from	  the	  individual	  level	  to	  a	  group	  level.	  As	  patient	  
organizations	  serve	  the	  collective	  interests	  of	  patients	  at	  such	  a	  group	  level,	  it	  is	  worthwhile	  
to	  explore	  their	  potential	  role	  in	  negotiating	  the	  access	  to	  IMP	  collectively.	  	  
Theoretically,	  patient	  organizations	  are	  well	  placed	  to	  discuss	  and	  negotiate	  the	  access	  to	  
IMP	  for	  the	  collective	  of	  their	  members.	  Not	  only	  do	  they	  increasingly	  present	  themselves	  as	  
partners	   of	   the	   pharmaceutical	   industry	   in	   drug	   development,9	   their	   role	   in	   the	   field	   of	  
clinical	  research	  also	  well	  exceeds	  that	  of	  individual	  research	  subjects,10	  providing	  them	  with	  
a	   wide	   repertory	   of	   assets	   that	   may	   appeal	   to	   the	   producers	   of	   IMP.	   First,	   patient	  
organizations	   are	   a	   major	   source	   of	   information	   to	   their	   members,	   and	   may	   raise	  
enthusiasm	   as	   well	   as	   suspicion	   about	   clinical	   trials	   among	   them.	   Second,	   patient	  
organizations	   may	   actively	   contribute	   to	   the	   success	   of	   clinical	   trials	   by	   facilitating	   the	  
recruitment	   of	   research	   subjects,	   which	   is	   often	   difficult	   for	   pediatric	   clinical	   trials.	   In	  
addition,	  patient	  organizations	  are	  well	  placed	  to	  create	  patient	  registries,	  which	  are	  of	  great	  
importance	   to	   clinical	   research.	   Third,	   patient	   organizations	   may	   be	   willing	   to	   provide	  
financial	  support	  to	  clinical	  research,	  which	  enables	  them	  to	  press	  on	  the	  research	  agenda	  
and	  direct	  clinical	  research	  towards	  the	  experienced	  needs	  of	  the	  patients	  they	  represent.	  In	  
addition,	  to	  a	  certain	  extent,	  acting	  as	  a	  research	  funder	  grants	  patient	  organizations	  a	  say	  in	  
the	   design	   of	   clinical	   trials,	   including	   the	   eligibility	   criteria	   for	   trial	   participation.	   Holding	  
these	  assets,	  patient	  organizations	  enjoy	  a	  privileged	  position	  in	  the	  negotiation	  of	  access	  to	  
IMP,	  particularly	  with	  regard	  to	  IMP	  provided	  to	  research	  subjects	  in	  clinical	  trials.	  
114	  ⏐	  Chapter	  6	  
Ethical	  and	  regulatory	  concerns	  
The	  negotiation	  of	  access	  to	  IMP,	  either	  by	  individuals	  or	  patient	  organizations,	  generates	  
various	  ethical	  and	  regulatory	  issues	  that	  need	  to	  be	  addressed.	  In	  particular	  product	  safety,	  
the	  recruitment	  of	  a	  sufficient	  number	  of	  research	  subjects,	  the	  unnoticed	  entry	  of	  market	  
mechanisms	   in	   the	   recruitment	   of	   research	   subjects,	   and	   the	   sidelining	   of	   third	   parties	  
involved	  in	  the	  recruitment	  process	  deserve	  specific	  attention	  in	  this	  respect.	  
Product	  safety	  
Obviously,	  the	  therapeutic	  nature	  of	  an	  IMP	  is	  contingent	  until	  its	  safety	  and	  efficacy	  have	  
been	   tested,	   appropriate	   dosages	   and	   administration	   forms	   have	   been	   determined,	   and	  
adverse	  effects	  have	  been	   identified.	  Therefore,	   the	  control	  of	  product	  safety	  of	  medicinal	  
products	  is	  a	  time-­‐consuming	  process,11	  and	  hastening	  access	  to	  these	  products	  will	  expose	  
patients	  to	  considerable	  risks,	  as	  serious	  toxicities	  are	  often	  only	  detected	  in	  late	  stage	  drug	  
development.12	   13	  Nonetheless,	   the	  benefits	  of	  using	   IMP	  may	  appear	  plentiful	   to	  patients,	  
and	  the	  odds	  are	   that	   for	  many	  patients	   the	  risks	  and	  therapeutic	  contingency	  of	   IMP	  will	  
easily	  be	  overruled	  by	  their	  presumed	  benefits,	  particularly	  when	  no	  validated	  drugs	  exist,	  
and	  time	  is	  pressing	  because	  patients	  deteriorate	  rapidly.11	  	  
However,	  in	  pediatric	  clinical	  research,	  product	  safety	  is	  of	  special	  importance	  as	  minors,	  
in	   contrast	   to	   their	   adult	   counterparts,	   are	  most	   often	   considered	   incapable	   of	   taking	   full	  
responsibility	  for	  voluntary	  risk	  taking.	  This	  renders	  it	  unethical	  to	  expose	  minors	  to	  research	  
risks	  unnecessarily,	  not	  only	  in	  the	  sense	  that	  minors	  should	  not	  be	  exposed	  to	  unnecessary	  
research	  risks,	  but	  also	  in	  the	  sense	  that	  no	  more	  minors	  than	  necessary	  should	  be	  exposed	  
to	   research	   risks,	   regardless	  of	   their	   severity	  or	   acceptability.	   In	   this	   regard,	  based	  on	   the	  
ethical	  principle	  of	  non-­‐	  maleficence,14	  many	  ethical	  codes	  and	  legal	  regulations	  require	  that	  
clinical	   trials	   of	   IMP	   are	   only	   conducted	   in	   as	   few	  minor	   subjects	   as	   necessary	   to	   obtain	  
relevant	   research	   results.	   Therefore,	   opening	  up	   the	   access	   to	   IMP	   to	  more	  patients	   than	  
required	   to	   gather	   relevant	   data	   raises	   serious	   ethical	   concerns,	   also	   when	   access	   is	  
facilitated	  outside	  the	  setting	  of	  clinical	  trials.	  	  
The	  requirement	  to	  limit	  the	  number	  of	  subjects	  in	  clinical	  trials	  to	  a	  minimum,	  however,	  
does	  not	  automatically	  rule	  out	  the	  compassionate	  use	  of	   IMP	  when	  patients	  enter	  a	  case	  
beyond	   aid	   and	   no	   more	   therapeutic	   options	   are	   available.	   However,	   here,	   vulnerable	  
parents	  who	  may	  be	  willing	  to	  spend	  fortunes	  on	   ill-­‐founded	  hopes	  and	  despair	  should	  be	  
protected	   against	   the	   drawbacks	   of	   an	   unregulated	   market.	   As	   medicinal	   products	   are	  
subjected	   to	   strict	   licensing	   and	   marketing	   requirements	   for	   very	   sound	   reasons,	   any	  
commercial	   supply	   of	   products	   -­‐most	   often	   at	   an	   excessively	   high	   cost-­‐	   appears	   ethically	  
questionable.	  Therefore,	  we	  suggest	  that	  the	  provision	  of	  IMP	  for	  compassionate	  use	  should	  
never	  be	  organized	  as	  a	   free	  market	  or	  by	  direct	  negotiation	  between	  the	  beneficiary	  and	  
the	   producer.	   Quite	   the	   reverse,	   society	   should	   take	   the	   important	   responsibility	   of	  
protecting	  all	  who	  have	  outreached	  the	  scope	  of	  therapeutic	  options	  against	  the	  devastating	  
consequences	  that	  ill-­‐founded	  hopes	  and	  despair	  may	  have.	  As	  IMP	  are	  to	  be	  situated	  at	  the	  
frontline	  of	  medical	  innovation,	  one	  must	  question	  whether	  it	  is	  acceptable	  to	  send	  minors	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to	   the	   front,	  acknowledging	  that	   the	  majority	  of	   IMP	  will	  not	  make	   it	   to	  validated	  drugs,11	  
and	  the	  use	  of	  IMP	  is	  likely	  to	  expose	  more	  minors	  than	  necessary	  to	  considerable	  research	  
risks.	  
The	  recruitment	  of	  a	  sufficient	  number	  of	  minor	  research	  subjects	  
The	   conduct	   of	   clinical	   studies	   in	   a	   sufficient	   number	   of	   eligible	   research	   subjects	   is	  
indispensible	  to	  develop	  safe	  and	  efficacious	  drugs.2	  13	  However,	  opportunities	  to	  access	  IMP	  
outside	  of	  clinical	  trials	  are	  likely	  to	  interfere	  gravely	  with	  the	  already	  difficult	  recruitment	  of	  
minor	   research	   subjects.1	   15	   In	   particular,	   the	   many	   patients	   who	   seek	   to	   avoid	   random	  
assignment	   will	   seek	   access	   to	   IMP	   outside	   of	   clinical	   trials,	   and	  may	   even	   try	   to	   render	  
themselves	  ineligible	  for	  trial	  participation.1	  
Apart	   from	   these	   recruitment	  difficulties,	   permitting	   companies	   to	  provide	  unapproved	  
IMP	   against	   payment	   contrasts	   sharply	   with	   the	   extensive	   efforts	   to	   encourage	   the	  
pharmaceutical	   industry	   to	   invest	   in	   complex	   and	   expensive	   clinical	   trials,2	   	   including	   the	  
provision	  of	  considerable	  incentives	  to	  compensate	  	  the	  poor	  profitability	  of	  pediatric	  drug	  
development.16	  17	  
Preserving	  recruitment	  from	  market	  mechanisms	  	  
Ever	  since	  the	  involvement	  of	  human	  subjects	  in	  clinical	  research	  has	  become	  the	  subject	  
of	  extensive	  ethical	  guidance	  and	  legal	  regulation,	  considerable	  efforts	  have	  been	  made	  to	  
preclude	  market	   rationales	   from	   becoming	   involved	   in	   the	   recruitment	   of	  minor	   research	  
subjects.	   For	   example,	   in	   Europe,	   the	   provision	   of	   payments	   or	   other	   incentives	   to	  
researchers,	  minors,	  and/or	  their	  parents	  has	  been	  regarded	  with	  great	  suspicion	  because	  of	  
the	   bias	   and	   conflicts	   of	   interests	   such	   incentives	  may	   generate.	   However,	  when	   patients	  
negotiate	  their	  access	  to	  IMP	  outside	  of	  clinical	  trial	  participation,	  market	  rationales	  tend	  to	  
enter	  unnoticed.	  	  
For	   example,	   obtaining	   IMP	   outside	   of	   clinical	   trials	   comes	   at	   a	   price,	   which	   can	   be	  
excessively	  high.1	  Also	  when	  patient	  organizations	  negotiate	   their	  members’	  access	   to	   IMP	  
within	  clinical	  trials,	  market	  rationales	  tend	  to	  become	  involved.	  The	  fact	  that	  the	  owners	  of	  
IMP	  have	  something	  of	  great	  interest	  to	  the	  members	  of	  the	  patient	  organization	  and	  that	  
patient	  organizations	  own	  several	  assets	  of	  interest	  to	  the	  producers	  of	  IMP	  provides	  all	  the	  
ingredients	  for	  market-­‐driven	  exchanges.	  	  The	  unnoticed	  entrance	  of	  market	  mechanisms	  in	  
pediatric	   clinical	   research	   cannot	   be	   reconciled	   with	   the	   ethical	   premises	   and	   legal	  
requirements	  that	  have	  been	  governing	  pediatric	  research	  for	  decades	  now.	  Therefore,	  care	  
should	   be	   taken	   that	  market	   rationales	   do	   not	   erode	   the	   voluntariness	   and	   altruism	   that	  
traditionally	  underpin	  research	  participation.	  	  
Keeping	  third	  parties	  involved	  	  
Third	   parties,	   such	   as	   competent	   authorities,	   regulatory	   bodies,	   ethics	   committees	   and	  
physicians	  who	  operate	  independently	  from	  the	  sponsor	  play	  an	  essential	  role	  in	  the	  design	  
and	   conduct	   of	   clinical	   trials.	   However,	   the	   direct	   negotiation	   of	   access	   to	   IMP	   between	  
patients	   and	   companies	   willing	   to	   provide	   IMP	   to	   them	   tends	   to	   bypass	   the	   timely	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involvement	   of	   such	   third	   parties,	   releasing	   this	   form	   of	   experimental	   drug	   use	   from	  
substantive	  scientific	  and	  ethical	  assessment.	  	  
While	  it	   is	  obvious	  that	  competent	  authorities,	  regulatory	  bodies	  and	  ethics	  committees	  
will	   always	   have	   entry	   points	   in	   the	   development	   and	   supply	   of	   IMP,	   the	   involvement	   of	  
physicians	   operating	   independently	   of	   the	   sponsor	   (e.g.,	   hospital	   physicians	   agreeing	   to	  
cooperate	  with	  a	  clinical	  trial	  and	  to	  recruit	  among	  their	  patients)	  tends	  to	  fade	  away	  when	  
access	   to	   IMP	   is	   negotiated	   directly	   between	   patients	   and	   sponsors.	   Nonetheless,	   such	  
physicians	  have	  several	  important	  opportunities	  to	  implement	  ethical	  standards	  in	  practice.	  	  
First,	  being	   committed	   to	   the	   treatment	  of	   their	  patients,	  physicians	  are	  well	  placed	   to	  
assess	   whether	   an	   IMP,	   administered	   either	   within	   or	   outside	   a	   clinical	   trial,	   suits	   an	  
individual	  patient	  against	  the	  background	  of	  the	  medical	  history,	  the	  current	  condition	  and	  
the	  prognosis	  of	  the	  patient	  concerned.	  In	  consequence,	  physicians	  are	  well	  placed	  to	  inform	  
their	  patients	  about	  all	  relevant	  aspects	  of	  using	  an	  IMP,	  which	  is	  likely	  to	  counter	  misplaced	  
enthusiasm	  about	  IMP,	  similar	  to	  therapeutic	  misconceptions	   in	  clinical	  research.18	  Second,	  
the	   relationship	   of	   trust	   that	   physicians	   have	   established	   with	   their	   patients	   over	   time	  
appears	  to	  be	  an	  excellent	  situation	  in	  which	  to	  discuss	  the	  use	  of	  an	  IMP.	  Third,	  operating	  
independently	  from	  the	  sponsor,	  physicians	  can	  easily	  refuse	  to	  recruit	  subjects	  among	  their	  
patients	  when	  they	   judge	  that	  a	  study	  protocol	   is	  ethically	  unacceptable	  or	  does	  not	  serve	  
the	   interests	   of	   their	   patients,	   even	   when	   the	   protocol	   has	   been	   approved	   by	   an	   ethics	  
committee	   and	   the	   competent	   authority.19	   In	   this	   way	   physicians	   personally	   provide	   an	  
additional	  ethical	  assessment	  of	  study	  protocols.	  
Conclusion	  and	  discussion	  
It	  is	  encouraging	  that	  new	  innovations	  in	  clinical	  research	  are	  considered	  to	  be	  of	  interest	  
to	  minor	  patients,	  that	  hope	  in	  future	  scientific	  developments	  is	  cherished,	  that	  enthusiasm	  
about	  new	  IMP	  is	  raised,	  and	  that	  minor	  subjects	  find	  themselves	  prepared	  to	  participate	  in	  
clinical	   trials.	   Enthusiasm	   and	   hope,	   however,	   should	   not	   push	   the	   desire	   for	   health	  
innovation	  beyond	  the	  ethical	  and	  regulatory	  safeguards	  that	  have	  been	  integrated	  into	  the	  
procedures	  of	  clinical	  trials	  and	  alternatively	  in	  systems	  of	  compassionate	  use.	  However,	  in	  a	  
setting	   in	  which	  a	   relatively	   large	  share	  of	   the	  drugs	  used	  have	  not	  been	   tested	   for	   safety	  
and	   efficacy,	   such	   as	   pediatric	   health	   care,	   patients	   who	   seek	   a	   better	   treatment,	   an	  
increased	  quality	  of	  life,	  or	  even	  a	  chance	  to	  preserve	  life	  itself	  may	  claim	  to	  have	  an	  interest	  
in	   accessing	   IMP,	   and	   actively	   seek	   access	   to	   IMP,	   either	   individually,	   or	   collectively	   as	   a	  
patient	  organization.	   In	  this	  article,	   four	  serious	  ethical	  concerns	   in	  the	  quest	  for	  access	  to	  
IMP	  have	  been	  explored:	  (1)	  product	  safety;	  (2)	  the	  recruitment	  of	  research	  subjects;	  (3)	  the	  
unnoticed	   entry	   of	  market	  mechanisms	   into	   the	   recruitment	   of	   research	   subjects;	   and	   (4)	  
the	   sidelining	   of	   third	   parties	   in	   the	   recruitment	   process.	   These	   ethical	   concerns	   indicate	  
that	  broadening	  the	  access	  to	  IMP	  is	  a	  very	  precarious	  enterprise	  that	  appears	  hard	  to	  align	  
with	  existing	  ethical	  and	  regulatory	  frameworks.	  In	  addition,	  it	  is	  strongly	  to	  be	  discouraged	  
that	  vulnerable	  parents	  are	  tempted	  to	  spend	  large	  amounts	  of	  money	  on	  ill-­‐founded	  hopes	  
and	  despair.	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On	  the	  other	  hand,	  access	  to	  IMP	  can	  be	  provided	  legitimately,	  as	  is	  currently	  done	  within	  
clinical	  trials	  and	  compassionate	  use	  programs.	  However,	  these	  ways	  of	  providing	  IMP	  have	  
a	   number	   of	   constraints	   that	   are	   open	   to	   discussion.	   First,	   both	   clinical	   trials	   and	  
compassionate	  use	  programs	  have	  no	   truly	   systematic	  way	  of	   determining	  which	  patients	  
can	   be	   provided	   with	   IMP.	   This	   may	   appear	   manifestly	   unjust	   to	   the	   parents	   of	   children	  
whose	   lives	   are	   at	   stake,	   and	   is	   therefore	   very	   likely	   to	   be	   hard	   to	   accept.	   Against	   this	  
background,	   families	   may	   actively	   seek	   access	   to	   IMP,	   even	   outside	   of	   clinical	   trials	   and	  
compassionate	  use	  programs,	  and	  backed	  by	  massive	  support	  from	  the	  media	  and	  the	  public	  
at	   large,	   as	   the	   case	   of	   Sandra	   Massart	   indicated.	   Second,	   any	   determination	   of	   who	   is	  
eligible	  for	  clinical	  trial	  participation	  is	  a	  result	  of	  scientific	  or	  policy	  choices,	  which	  are	  open	  
to	   discussion	   and	   change.	   Therefore,	   notwithstanding	   the	   profound	   ethical	   concerns	  
described	   in	   this	   article,	   patients,	   individually	   or	   collectively,	   may	   feel	   they	   have	   strong	  
reasons	  actively	  to	  seek	  access	  to	  IMP.	  
Responding	   to	   the	  phenomenon	  of	   the	  direct	  negotiation	  of	   access	   to	   IMP	  adequately,	  
however,	   is	  a	  complex	  challenge.	  A	  mere	  prohibition	  of	  access	  to	  IMP	  outside	  clinical	  trials	  
and	   compassionate	   use	   programs	   is	   not	   sufficient	   in	   this	   respect,	   because	   the	   direct	  
negotiation	  of	  access	  to	  IMP	  between	  patients	  and	  drug	  developers	  may	  also	  affect	  access	  
within	  clinical	  trials	  or	  compassionate	  use	  programs.	  Three	  additional	  concerns	  are	  in	  need	  
of	  ethical	  attention.	  	  
First,	  firm	  and	  realistic	  understanding	  about	  what	  is	  to	  be	  expected	  from	  healthcare	  and	  
drug	   development	   should	   be	   nurtured	   in	   all	   actors	   involved.	   No	   matter	   how	   tragic	   the	  
situation	  or	  how	  strong	  and	  emotional	  appeal	  to	  a	  last	  resort,	  it	  should	  always	  be	  recognized	  
that	  IMP	  are	  no	  panacea.	  Opening	  up	  access	  to	  IMP	  will	  not	  discharge	  patients	  in	  need	  from	  
irreversible,	  and	  at	  times	  cruel	  and	  fatal	  disease.	  Also,	  the	  fact	  that	  time	  may	  work	  against	  
cure	   will	   not	   be	   resolved	   by	   opening	   up	   access	   to	   IMP	   (unless	   maybe	   in	   an	   extremely	  
exceptional	  case).	  The	  recognition	  that	  disease	  can	  come	  as	  an	  inevitable	  tragedy	  is	  not	  to	  
result	   in	   skepticism	   towards	   drug	   development	   but	   merely	   serves	   to	   show	   that	   the	  
disadvantages	  of	   rushing	  a	  process	  as	   complex,	   contingent	  and	   risky	  as	  drug	  development	  
are	   likely	   to	  outweigh	   the	  benefits.	  Against	   this	   background,	  one	   should	  be	   vigilant	   about	  
what	   claims	   to	   health	   care	   we	   support	   as	   clinicians,	   patient	   organizations	   and	   society	   at	  
large	  (including	  popular	  media,	  as	  the	  case	  of	  the	  family	  Massart	  clearly	  illustrates).	  
Second,	  ethical	  and	   regulatory	  guidance	  should	  enter	   the	  drug	  development	  process	  as	  
early	  as	  possible,	  preventing	  direct	  partnerships	  between	  patients	  or	  patient	  organizations	  
and	  drug	  developers	  from	  taking	  place	  in	  an	  underregulated	  environment.	  In	  contrast	  to	  the	  
provision	   of	   IMP	   in	   clinical	   trials	   or	   compassionate	   use	   programs,	   partnership	   between	  
patient	   organizations	   and	   drug	   developers	   as	   such	   is	   not	   specifically	   regulated	   or	   guided.	  
This	  does	  not	  imply	  that	  such	  partnerships	  are	  to	  be	  avoided,	  but	  raises	  concerns	  about	  how	  
ethical	  and	  regulatory	  issues	  are	  to	  be	  addressed,	  for	  example	  when	  such	  partnerships	  result	  
in	   agreements	   that	   shape	   the	   research	   agenda	   or	   the	   design	   of	   future	   clinical	   trials.	   In	  
particular,	   concerns	   related	   to	   the	   unnoticed	   entry	   of	   market	   mechanisms	   should	   be	  
detected	  and	  addressed	  as	  soon	  as	  possible.	  Therefore,	  a	  timely	  involvement	  of	  third	  parties	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in	  the	  partnership	  between	  patient	  organizations	  and	  drug	  developers,	   including	  experts	  in	  
treatment,	  ethics	  and	  law	  is	  strongly	  recommended.	  
Third,	   it	   is	  both	  prudent	  and	  responsible	  to	  rely	  on	  important	  efforts	  to	  supply	  safe	  and	  
efficacious	  drugs	   for	   the	  young	  that	  are	  currently	  being	  made.	   In	   the	  European	  Union	  and	  
elsewhere,	  important	  efforts	  have	  been	  made	  to	  encourage	  and	  reward	  the	  development	  of	  
safe	   and	   efficacious	   drugs	   for	   minors.	   Against	   this	   background,	   one	   must	   be	   particularly	  
vigilant	  that	  recruitment	  for	  clinical	  trials	   is	  not	  hampered	  by	  efforts	  to	  facilitate	  or	  extend	  
access	   to	   IMP.	   Although	   time	   consuming,	   the	   quest	   for	   better	   treatments	   and	   increased	  
quality	  of	  life	  should	  obviously	  focus	  no	  regular	  processes	  of	  drug	  development	  in	  controlled	  
clinical	  trials.	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Abstract	  
Over	  the	  past	  decades,	  important	  efforts	  have	  been	  made	  to	  regulate	  the	  involvement	  of	  
children	  in	  clinical	  trials.	  However,	  current	  ethical	  and	  legal	  procedures	  surrounding	  clinical	  
trials	   in	   minors	   (US/EU)	   are	   not	   designed	   to	   consider	   and	   assess	   the	   non-­‐clinical	   use	   of	  
medical	   technologies	  such	  as	   fMRI,	  while	  non-­‐clinical	  applications	  of	  pediatric	   fMRI	  cannot	  
be	  developed	  without	  conducting	  clinical	  trials	  in	  children.	  In	  our	  comment,	  we	  discuss	  the	  
diverse	  ethical	  issues	  related	  to	  the	  non-­‐clinical	  applications	  of	  fMRI	  from	  the	  perspective	  of	  
pediatric	  clinical	  trial	  regulation	  	  
Ethical	   and	  Regulatory	   Issues	   in	  Pediatric	  Research	  Supporting	   the	  
Non-­‐Clinical	  Application	  of	  fMR	  Imaging	  
Clinical	  research	  using	  fMRI	  enables	  to	  correlate	  brain	  activity	  to	  highly	   intimate	  human	  
capacities	  and	  functions	  such	  as	  memory,	  character,	  or	  (anti-­‐)	  social	  behavior.	  The	  results	  of	  
such	  research	  offer	  a	  large	  potential	  for	  non-­‐clinical	  applications,	  as	  Fenton	  and	  colleagues1	  
point	  out	  in	  the	  target	  article.	  Pediatric	  fMRI	  is	  surrounded	  by	  myriad	  ethical	  issues2	  that	  are	  
intensified	   in	   developing	   non-­‐clinical	   applications	   of	   the	   technology,	   as	   such	   applications	  
may	   introduce	   new	   paradigms	   in	   important	   social	   institutions,	   including	   education	   and	  
jurisprudence.	   In	   this	   context,	   Illes	  and	  colleagues3	   rightly	   indicate	   that,	  even	   though	   such	  
non-­‐clinical	  applications	  are	  not	  validated,	  reliable	  or	  standardized	  to	  date,	  the	  time	  is	  right	  
for	  a	  proactive	  ethical	  approach.	  
In	   addition	   to	   discussing	   the	   ethical	   issues	   related	   to	   the	   non-­‐clinical	   application	   of	  
pediatric	  fMRI,	  a	  proactive	  ethical	  approach	  should	  also	  reflect	  on	  the	  development	  of	  these	  
non-­‐clinical	   applications.	   As	   non-­‐clinical	   applications	   of	   pediatric	   fMRI	   do	   not	   just	   emerge	  
outside	   the	   clinical	   setting	   and	   their	   development	   requires	   the	   conduct	   of	   research	   in	  
children,	  the	  ethical	  issues	  related	  to	  involving	  children	  in	  research	  are	  also	  highly	  relevant	  in	  
this	  discussion.	  
In	   the	  US4	  and	   the	  EU5,	   the	  conduct	  of	  pediatric	   research	   is	  guided	  by	  extensive	  ethical	  
and	  legal	  frameworks	  that	  have	  been	  developed	  over	  the	  past	  decades.	  These	  frameworks	  
consist	  of	  a	  large	  variety	  of	  ethical	  guidelines	  and	  national	  and	  international	  laws	  and	  share	  
various	  ethical	  concerns	  that	  underpin	  them.	   In	  this	  commentary,	  we	  will	  explore	  how	  the	  
ethical	   and	   regulatory	   frameworks	   that	   guide	   pediatric	   research	   are	   challenged	   by	   the	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development	  of	  non-­‐clinical	  applications	  of	  pediatric	  fMRI.	   In	  doing	  so,	  we	  will	  not	  provide	  
an	   exhaustive	   overview	   or	   analysis	   of	   applicable	   regulation,	   but	   reflect	   on	   ethical	   values	  
addressed	  in	  ethical	  guidance	  and	  legal	  regulation.	  
Ethical	  Issues	  Related	  to	  the	  Scientific	  Design	  of	  Pediatric	  Research	  
Two	   issues	   related	   to	   the	   scientific	   design	   of	   pediatric	   research	   raise	   serious	   ethical	  
concerns:	  research	  objectives	  and	  research	  sponsorship.	  
First,	  clearly	  formulated	  and	  scientifically	  sound	  objectives	  are	  essential	  for	  research	  to	  be	  
ethically	   acceptable.	   While	   at	   first	   sight	   it	   may	   seem	   obvious	   that	   research	   serves	   the	  
advancement	  of	  biomedicine	  by	  generating	  progress	   in	  scientific	  knowledge	  or	  therapeutic	  
options,	   this	  may	  not	  be	  the	  case	   in	  pediatric	  studies	  supporting	  the	  development	  of	  non-­‐
clinical	   applications	   of	   pediatric	   fMRI.	  We	  explicitly	   acknowledge	   that	   research	   supporting	  
non-­‐clinical	  applications	  of	  medical	  technology	  may	  not	  be	  clearly	  and	  easily	  distinguishable	  
from	  research	  serving	  biomedical	  objectives.	  However,	  in	  our	  opinion,	  the	  direct	  biomedical	  
relevance	   of	   certain	   studies,	   such	   as	   research	   gaining	   insight	   in	   religious	   experiences	   or	  
moral	  deliberation,	  is	  open	  to	  discussion.	  
The	   large	   variety	   of	   research	   objectives—including	   therapeutic,	   non-­‐therapeutic,	   and	  
non-­‐clinical	  objectives—that	  are	  pursued	  within	  the	  clinical	  setting	  may	  obscure	  the	  clinical	  
relevance	  of	   research	  and	   the	   interests	  underlying	   research.	   In	   this	   respect,	   distinguishing	  
clinical	   from	   non-­‐clinical	   applications	   of	   pediatric	   fMRI	   may	   be	   helpful	   in	   searching	   for	   a	  
moral	  justification	  of	  involving	  minors	  in	  research.	  
Second,	  and	  closely	  related	  to	  the	  issue	  of	  setting	  clear	  research	  objectives,	  is	  the	  issue	  of	  
research	   sponsorship.	   Conducting	   research	   that	   serves	  non-­‐clinical	   applications	  of	  medical	  
technologies	   is	   likely	   to	   broaden	   the	   scope	   of	   interest	   in	   pediatric	   research	   from	   the	  
scientific	   community	   and	   pharmaceutical	   industry	   to	   a	   large	   variety	   of	   commercial	  
stakeholders	   searching	   for	   commercial	   applications	   of	   pediatric	   fMRI,	   such	   as	   reliable	  
techniques	  for	  lie	  detection	  or	  methods	  to	  increase	  brand	  attachment.	  However,	  attracting	  
investors	  who	   lack	   biomedical	   interest	   in	   research	   to	   fund	   pediatric	   studies	  will	   generate	  
various	   ethical	   challenges,	   including	   dealing	   with	   conflicts	   of	   interests	   and	   creating	  
appropriate	  professional	  standards.	  
Issues	  in	  Involving	  Minor	  Subjects	  in	  Research	  
Three	  major	  issues	  in	  involving	  minor	  subjects	  in	  research	  are	  intensified	  in	  the	  conduct	  
of	  pediatric	  studies	  supporting	  non-­‐clinical	  applications	  of	  fMRI:	  research	  risks,	  the	  impact	  of	  
research	  on	  the	  well-­‐being	  of	  minor	  research	  subjects,	  and	  informed	  consent	  and	  assent.	  
First,	   pediatric	   research	   supporting	   the	   realization	   of	   non-­‐clinical	   objectives	   entails	  
research	   risks,	   including	   physical	   and	   psychological	   risks6	   and	   social	   risks,	   such	   as	  
medicalization,	  stigmatization,	  or	  neurodeterminism.7	  
As	   a	   general	   rule,	   risk-­‐taking	   in	   pediatric	   research	   is	   strongly	   restricted	   by	   law.	   Most	  
regulations	   require	   that	   research	   risks	   are	   either	   very	   low	   or	   justified	   convincingly	   by	   a	  
benefit	  that	  counterbalances	  the	  risks.	  First,	  risks	  may	  be	  acceptable	  because	  the	  potential	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to	   harm	   is	   very	   low.	   In	   U.S.	   federal	   regulation	   (45	   CFR	   46	   subpart	   D,	   §46.404)8	   and	   the	  
European	  Convention	  on	  Human	  Rights	  and	  Biomedicine	  (Art.	  17),9	  minimal	  risk	  is	  explicitly	  
defined	  as	  a	  risk	  threshold.	  Second,	  also	  risks	  exceeding	  this	  minimal	   level	  can	  be	  justified.	  
The	   most	   common	   justification	   is	   proportionality	   between	   research	   risks	   and	   expected	  
benefits.	  According	  to	  this	  rule	  of	  proportionality,	  the	  level	  of	  acceptable	  risks	  will	   increase	  
as	  research	  generates	  more	  significant	  benefits.	  Benefits	  are	  valued	  higher	  in	  function	  of	  the	  
therapeutic	   nature	   of	   research	   (therapeutic	   research	   is	   often	   distinguished	   from	   non-­‐
therapeutic	  research),	  and	  in	  function	  of	  the	  direct	  character	  of	  the	  benefit	  (a	  direct	  benefit	  
to	  the	  research	  participant	  is	  generally	  preferred	  over	  benefits	  to	  more	  remote	  beneficiaries,	  
such	  as	  the	  group	  of	  patients	  to	  which	  a	  minor	  belongs,	  the	  population	  of	  minors,	  or	  future	  
patients	  or	  minors).	  
The	  risks	  assessed	  during	  the	  ethics	  review	  of	  research	  protocols,	  are	  strongly	  focused	  on	  
the	   risks	   imposed	  on	   individual	   research	   subjects	   during	   research	  participation.	   The	   social	  
implications	   of	   medical	   technologies—although	   very	   relevant	   in	   the	   case	   of	   pediatric	  
research	  supporting	  non-­‐clinical	  applications	  of	  pediatric	  fMRI—are	  not	  explicitly	  taken	  into	  
account.	  Being	  non-­‐invasive	  and	  overall	  low	  risk	  research	  (if	  fMRI	  devices	  are	  used	  correctly),	  
pediatric	   fMRI	   tends	   to	   fall	   outside	   the	   scope	   of	  most	   risk	   parameters	   assessed	   by	   ethics	  
committees.	  
Second,	   and	   closely	   related	   to	   the	   social	   risks	   of	   non-­‐clinical	   applications	   of	   pediatric	  
fMRI,	   is	   the	   ethical	   concern	   for	   the	  well-­‐being	   of	   children.	   Pediatric	   fMRI—although	   non-­‐
invasive	  in	  clinical	  terms—has	  the	  potential	  of	  deeply	  entering	  the	  most	  private	  areas	  of	  the	  
self,	  and	  therefore	  may	  have	  a	  serious	  impact	  on	  the	  lives	  of	  individual	  minors	  and	  of	  minors	  
as	  a	  group.	  Most	  minors	  are	  unable	  to	  serve	  their	  own	  interests	  or	  to	  provide	   legally	  valid	  
informed	   consent	   and	   are	   therefore	   protected	   against	   deception,	   abuse,	   or	   exploitation	  
when	  participating	   in	   research.	  While	   the	   current	  protection	  of	  minor	   research	   subjects	   is	  
focused	  on	  harms	  that	  are	  directly	  related	  to	  participation	  in	  research,	  the	  potential	  threats	  
of	  non-­‐clinical	  applications	  of	  pediatric	  fMRI	  well	  exceed	  the	  current	  scope	  of	  protection.	  In	  
our	   opinion,	   serious	   efforts	   should	   be	   made	   to	   serve	   children’s	   rights	   in	   the	   conduct	   of	  
pediatric	  research	  supporting	  the	  development	  of	  non-­‐clinical	  applications	  of	  pediatric	  fMRI.	  
The	  collection	  of	  children’s	  rights	  captured	  in	  the	  UN	  Convention	  on	  the	  Rights	  of	  the	  Child	  
provides	   several	   interesting	   principles	   that	   can	   be	   used	   as	   a	   solid	   starting	   point	   in	   this	  
respect.	  
Third,	  the	  conduct	  of	  research	  that	  supports	  the	  development	  of	  non-­‐clinical	  applications	  
of	   fMRI	   affects	   the	   process	   of	   obtaining	   informed	   consent	   and	   assent	   for	   participation	   in	  
pediatric	  research.	  In	  particular	  the	  issue	  of	  providing	  clear	  disclosure	  of	  research	  sponsors	  
and	   research	   objectives	   is	   intensified	   when	   research	   serves	   non-­‐clinical	   applications.	  
Nonetheless,	   clarity	   about	   conflicts	   of	   interests	   is	   essential	   for	   obtaining	   valid	   consent.	   In	  
addition,	   important	   tacit	   processes	   in	   consent	   discussions,	   such	   as	   placing	   trust	   in	   the	  
research	   and	   in	   researchers,	   may	   be	   compromised	   in	   absence	   of	   a	   clear	   disclosure	   of	  
research	  objectives	  and	  sponsors.10	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Conclusion	  
Non-­‐clinical	   applications	   of	   pediatric	   fMRI	   entail	   both	   opportunities	   and	   threats	   in	  
relation	   to	   the	   conduct	   of	   pediatric	   research	   and	   the	   interests	   of	   children.	   In	   a	   proactive	  
ethical	   approach,	   the	   fact	   that	   non-­‐clinical	   applications	   of	   pediatric	   fMRI	   challenge	   the	  
current	  ethical	  and	  regulatory	  framework	  should	  not	  result	  inevitably	  in	  skepticism	  towards	  
the	  development	  of	  such	  applications.	  Nonetheless,	  the	  conduct	  of	  pediatric	  research	  should	  
be	   approached	   with	   caution,	   and	   various	   essential	   questions	   need	   to	   be	   addressed,	  
preferably	  within	  the	  current	  legal	  frameworks	  regulating	  pediatric	  research.	  
First,	   it	  must	  be	  discussed	  how	  non-­‐clinical	  objectives	  in	  pediatric	  research	  can	  be	  taken	  
into	   account	   and	   ethically	   assessed.	   Current	   review	   procedures	   are	   ill-­‐suited	   to	   take	   into	  
account	  and	  assess	  non-­‐clinical	   applications	  of	  pediatric	   fMRI,	   and	   it	   is	  open	   to	  discussion	  
whether	  the	  biomedical	  scientific	  community	  should	  act	  as	  a	  gatekeeper	  guarding	  potential	  
threats	  in	  the	  non-­‐clinical	  application	  of	  medical	  technology.	  Nonetheless,	  explicit	  attention	  
for	  non-­‐clinical	  applications	  of	  pediatric	  fMRI	  in	  protocol	  review	  would	  certainly	  raise	  ethical	  
sensitivity	  towards	  the	   individual	  and	  social	   threats	  that	  such	  non-­‐clinical	  applications	  may	  
entail.	  
Second,	  it	  must	  be	  cleared	  out	  whether	  the	  involvement	  of	  minors	  in	  research	  serving	  the	  
development	  of	  non-­‐clinical	  applications	  is	  acceptable	  and	  in	  which	  cases.	  Pediatric	  research	  
is	  a	  precarious	  enterprise,	  and	  important	  efforts	  have	  been	  made	  to	  restrict	  the	  involvement	  
of	  minors	  in	  research	  wherever	  possible.	  Pediatric	  research	  supporting	  the	  development	  of	  
non-­‐clinical	  applications	  of	  fMRI	  tends	  to	  bypass	  these	  restrictions,	  and	  therefore	  should	  be	  
the	  subject	  of	  new	  regulatory	  efforts	  that	  can	  be	  established	  within	  the	  existing	  ethical	  and	  
legal	  frameworks.	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Abstract	  	  
For	  a	  significant	  number	  of	  patients,	  no	  or	  only	  poor	   interest	   in	  developing	  a	  treatment	  
for	   their	   disease	   or	   condition	   exists.	   Especially	   with	   regard	   to	   rare	   diseases,	   the	   lack	   of	  
commercial	  interest	  in	  drug	  development	  is	  a	  burning	  issue.	  	  
Several	  regulatory	  interventions	  have	  been	  made	  in	  to	  address	  the	  commercial	  disinterest	  
in	  rare	  diseases.	  However,	  existing	  regulations	  mainly	  focus	  on	  the	  provision	  of	  incentives	  to	  
the	   sponsors	   of	   clinical	   trials	   of	   orphan	   drugs,	   and	   leave	   the	   overarching	   question	   on	   the	  
righteous	  place	  of	  orphan	  drugs	  in	  resource	  allocation	  systems	  unanswered.	  	  
In	  this	  article,	  we	  analyze	  major	  ethical	  issues	  in	  the	  development	  and	  supply	  of	  drugs	  for	  
rare	   conditions.	   Subsequently,	   we	   propose	   an	   ethical	   framework,	   which	   can	   help	   health	  
policy	  makers	   in	  moving	   forward	   in	   the	   difficult	   issue	   of	   justly	   allocating	   resources	   to	   the	  
prevention	  and	  treatment	  of	  rare	  diseases.	  	  
Introduction	  	  
Orphan	   drugs	   are	   developed	   for	   the	   diagnosis,	   prevention,	   or	   treatment	   of	   life-­‐
threatening	   or	   chronically	   debilitating	   rare	   diseases,	   a	   significant	   share	   of	   which	   affects	  
neonates	  and	  children.	  As	  for	  known	  causes,	  these	  diseases	  vary	  from	  genetic	  diseases,	  very	  
rare	  infectious	  diseases,	  to	  auto-­‐immune	  diseases	  and	  very	  rare	  poisonings.1	  2	  It	  is	  estimated	  
that	  20	  to	  35	  percent	  of	  all	  recognized	  diseases	  are	  rare	  diseases,	  the	  prevalence	  of	  which	  is	  
below	  or	  equal	  to	  five	  in	  10	  thousand	  persons	  or	  less.3	  4	  	  
Although	  the	  prevalence	  of	  individual	  rare	  diseases	  is	  by	  definition	  very	  low,	  rare	  diseases	  
are	   a	   widespread	   phenomenon.	   At	   present,	   the	   worldwide	   number	   of	   rare	   diseases	   is	  
estimated	   between	   5	   and	   8000,	   affecting	   about	   250.000	   patients	   in	   the	   European	  Union.	  
Notwithstanding	  the	  frequent	  occurrence	  of	  rare	  diseases	  among	  the	  European	  population,	  
a	  significant	  share	  of	  these	  diseases	  has	  been	  relegated	  to	  therapeutic	  orphanage.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i The	  first	  and	  second	  author	  equally	  contributed	  to	  this	  manuscript 
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Several	   issues	   render	   the	   development	   and	   provision	   of	   drugs	   for	   the	   diagnosis,	  
prevention,	  or	  treatment	  of	  rare	  diseases	  a	  precarious	  enterprise.	  For	  example,	  the	  scarcity	  
and	   geographical	   dispersal	   of	   eligible	   research	   subjects	   make	   clinical	   research	   in	   rare	  
diseases	   complex	   and	   expensive.	   In	   addition,	   the	   combination	   of	   the	   high	   cost	   of	   clinical	  
trials	   and	   the	   small	  market	   for	   newly	   developed	   treatments	   often	   results	   in	   an	   uncertain	  
return	  on	  investment	  under	  the	  regular	  market	  conditions.	  	  
Because	   the	   usual	   conditions	   for	   marketing	   drugs	   are	   likely	   to	   work	   against	   the	  
development	  and	  manufacturing	  of	  drugs	  for	  the	  diagnosis,	  prevention,	  or	  treatment	  of	  rare	  
diseases,	   this	   predicament	   needs	   specific	   attention	   in	   ethics	   and	   policy.	   In	   this	   respect,	  
important	  efforts	  to	  provide	  adequate	  political	  support	  and	  scientific	  research	  programs	  in	  
the	   field	   of	   rare	   diseases	   have	   been	   made	   worldwideii	   over	   the	   past	   two	   decades.	   For	  
example,	   in	   the	   EU,	   a	   specific	   regulatory	   framework	   has	   been	   created	   to	   encourage	   the	  
development	   of	   “orphan	   drugs”	   (including	   the	   provision	   of	   financial	   incentives)	   for	   the	  
diagnosis,	   prevention,	   or	   treatment	   of	   rare	   diseases.	   At	   the	   supranational	   level,	   this	  
regulatory	   framework	   consists	   of	   two	   regulations	   (Regulation	   (EC)	   No	   141/2000	   and	  
Regulation	   (EC)	   No	   847/2000),	   that	   are	   directly	   applicable	   to	   all	   EU	   Member	   States.	   In	  
addition,	  specific	  domestic	  laws	  of	  individual	  EU	  member	  states	  may	  also	  be	  applicable.	  	  
Article	   3.1	   of	   regulation	   141/2000	   stipulates	   that	   orphan	   designation	   is	   granted	   if	   the	  
sponsor	  can	  establish:	  
(a) that	  it	  is	  intended	  for	  the	  diagnosis,	  prevention	  or	  treatment	  of	  a	  life-­‐threatening	  or	  
chronically	  debilitating	  condition	  affecting	  not	  more	  than	  five	  in	  10	  thousand	  persons	  
in	   the	   Community	   when	   the	   application	   is	   made,	   or	   that	   it	   is	   intended	   for	   the	  
diagnosis,	   prevention	   or	   treatment	   of	   a	   life-­‐threatening,	   seriously	   debilitating	   or	  
serious	   and	   chronic	   condition	   in	   the	   Community	   and	   that	   without	   incentives	   it	   is	  
unlikely	   that	   the	   marketing	   of	   the	   medicinal	   product	   in	   the	   Community	   would	  
generate	  sufficient	  return	  to	  justify	  the	  necessary	  investment;	  and	  
(b) that	  there	  exists	  no	  satisfactory	  method	  of	  diagnosis,	  prevention	  or	  treatment	  of	  the	  
condition	  in	  question	  that	  has	  been	  authorized	  in	  the	  Community	  or,	  if	  such	  method	  
exists,	   that	   the	  medicinal	  product	  will	  be	  of	   significant	  benefit	   to	   those	  affected	  by	  
that	  condition.	  
The	  success	  of	  the	  regulatory	  interventions	  in	  the	  EU	  has	  been	  widely	  recognized,2	  5	  6	  and	  
in	  the	  past	  decade,	  the	  European	  Medicines	  Agency	  has	  received	  over	  1100	  applications	  for	  
orphan	  designation.	  Since	  the	  entry	  into	  force	  of	  the	  European	  Orphan	  Regulation	  in	  2000,	  
more	   than	   700	   orphan	   designations	   were	   granted,	   and	  more	   than	   60	   orphan	   designated	  
medicines	  have	  been	  approved,	  offering	  new	  treatment	  options	  for	  over	  50	  rare	  diseases.iii	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ii	  Specific	  programs	  exist	  for	  example	  in	  the	  US,	  Japan,	  Australia,	  Taiwan,	  and	  the	  EU	  
iii http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/05/WC500090820.pdf	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However,	   this	   success	   in	   encouraging	   the	   development	   of	   drugs	   for	   rare	   diseases	   did	   not	  
discharge	  rare	  diseases	  from	  all	  the	  forces	  that	  drive	  them	  into	  orphanage.	  Apart	  from	  the	  
well-­‐known	  scientific	  and	  economical	  difficulties,	  a	  fundamental	  challenge	  resides	   in	  facing	  
the	  opportunity	  cost	  of	   funding	  orphan	  drug	  development.	  Like	  Gericke	  et	  al.7	  have	  put	   it,	  
the	  discussion	  of	  how	  much	  a	   society	   should	   spend	  on	   research	  and	  development	  of	   rare	  
diseases	   represents	   a	   fundamental	  moral	   dilemma.	   On	   the	   one	   hand,	   each	   rare	   disease	  
represents	   only	   a	   small	   number	   of	   individual	   patients	   within	   a	   particular	   society.	   Hence,	  
investing	  substantial	  amounts	  of	  resources	  in	  rare	  conditions	  could	  be	  considered	  unethical	  
from	  a	  utilitarian	  point	  of	  view,	  since	  this	  would	  not	  maximize	  the	  benefits	  of	  society.	  The	  
opportunity	   cost,	   understood	   in	   terms	   of	   benefits	   foregone	   for	   others,	   of	   such	   a	   policy	  
would	   be	   very	   high.	  On	   the	  other	   hand,	   it	   is	   reasonable	   to	   question	   the	   abandonment	   of	  
individual	  patients	  who	  are	  affected	  by	  a	  serious	  but	  rare	  condition	  for	  which	  no	  treatment	  
exists.	   Is	   it	   fair	   to	   simply	   deny	   support	   for	   research	   and	   development	   on	   the	   basis	   of	   a	  
condition	   being	   rare?	   Many	   would	   disagree	   and	   uphold	   that	   (1)	   society	   has	   a	   moral	  
obligation	  not	  to	  abandon	  the	  patients	  suffering	  from	  a	  rare	  disease,	  and	  that	  (2)	  medicine	  
has	  a	  professional	  obligation	  to	  advance	  scientific	  knowledge	  in	  pursuing	  new	  therapies.	   In	  
this	   paper,	   we	   analyze	   this	   dilemma	   by	   focusing	   on	   the	   following	   question:	   How	   can	  
sufficient	  attention	  be	  paid	  to	  orphan	  drug	  research	  and	  development	  in	  a	  fair	  and	  equitable	  
way	   (that	   is,	   in	   a	  way	   that	   it	   does	   not	   drain	   away	   all	   the	   resources	   from	  other	   important	  
health	   care	   goals)?	   Starting	   from	   a	   normative	   reflection	   on	   the	   biomedical	   and	   ethical	  
relevance	   of	   allocating	   limited	   resources	   to	   the	   development	   and	   supply	   of	   orphan	   drugs	  
(Part	  1),	  we	  design	  a	  framework,	  which	  serves	  as	  the	  ethical	  basis	  to	  provide	  a	  fair	  share	  of	  
resources	  for	  the	  development	  and	  supply	  of	  orphan	  drugs	  (Part	  2).	  The	  framework	  consists	  
of	   a	   lexicographical	   structure	   of	   three	   principles,	   namely	   (1)	   fair	   budgetary	   insulation,	  	  
(2)	  certain	  access	  for	  some,	  based	  on	  rational	  priorities,	  and	  (3)	  possible	  access	  for	  all,	  based	  
on	  random	  selection.	  Figure	  1	  provides	  an	  overview	  of	  the	  various	  questions	  and	  tracks	  that	  
we	  explore	  in	  this	  framework.	  
Part	  1:	  Why	  we	  should	  care	  about	  the	  orphans	  
In	   all	   health	   care	   systems,	   there	   is	   a	   struggle	   to	   decide	  which	   health	   care	   services	   and	  
technologies	   should	   be	   provided	   for	   patients	   within	   the	   system.8	   These	   struggles	   are	  
particularly	   acute	   when	   considering	   pharmaceuticals.	   Which	   drugs	   are	   eligible	   for	  
investment	   in	   research	   and	   development,	   as	   well	   as	   for	   reimbursement	   later	   on?	   In	   this	  
discussion,	  criteria	  such	  as	  efficacy,	  need,	  prevalence,	  and	  cost-­‐effectiveness	  are	  used	  in	  the	  
assessment	  process,	  which	  makes	  orphan	  drugs	  not	  easily	   eligible	   for	   selection.2	   So,	   if	  we	  
want	  to	  make	  out	  a	  case	  for	  the	  patients	  who	  suffer	  from	  a	  rare	  disease,	  we	  have	  to	  answer	  
to	   the	   first	   and	   most	   basic	   normative	   question	   in	   this	   field:	   why	   should	   resources	   be	  
allocated	  to	  the	  diagnosis,	  prevention,	  and	  treatment	  of	  rare	  diseases?	  
	  
	  




















Does	  the	  development	  and	  supply	  of	  orphan	  drugs	  	  
fit	  the	  objectives	  of	  health	  and	  healthcare?	  
Yes!	  	  
The	  diagnosis,	  prevention,	  or	  treatment	  of	  rare	  diseases	  	  






Is	  the	  development	  and	  supply	  of	  orphan	  drugs	  	  
compliant	  with	  our	  concepts	  of	  justice?	  
Yes!	  
The	  development	  and	  supply	  of	  orphan	  drugs	  is	  compatible	  with	  our	  
concepts	  of	  justice	  
	  
Answer	  1:	  Yes	  we	  should	  fund	  the	  development	  and	  supply	  of	  orphan	  drugs.	  
	  














Hurdles:	  Practical	  modalities	  of	  allocating	  resources	  to	  orphan	  drugs	  
	  	  	  -­‐	  prevalence	  
	  	  	  -­‐	  efficiency	  	  
	  	  	  -­‐	  efficacy	  	  
	  	  	  -­‐	  opportunity	  cost	  	  




Is	  the	  opportunity	  cost	  of	  orphan	  drugs	  ethically	  acceptable?	  
No!	  	  
In	  so	  far	  that	  the	  
interests	  of	  the	  
individual	  erode	  the	  







Can	  this	  be	  avoided?	  
	   Yes!	  
If	  limits	  are	  set	  to	  the	  
number	  of	  
beneficiaries	  	  
Track	  1:	  	  
Rational	  Priorities	  
Certainty	  for	  some	  
-­‐-­‐-­‐conditional-­‐-­‐-­‐	  	  	  
If	  limits	  are	  set	  to	  the	  
chance	  of	  acquiring	  
funds	  
Track	  2:	  	  
Anne	  of	  Green	  Gables	  
Possibility	  for	  all	  
-­‐-­‐-­‐unconditional-­‐-­‐-­‐	  
Moral	  qualities:	  






Answer	  2:	  Yes	  we	  can	  fund	  the	  development	  and	  supply	  of	  orphan	  drugs	  
While	  limited	  resources	  do	  not	  allow	  to	  abundantly	  provide	  resources	  to	  all,	  the	  	  
opportunity	  cost	  of	  orphan	  drugs	  can	  be	  kept	  within	  rational	  boundaries,	  and	  the	  	  
principle	  of	  non-­‐abandonment	  can	  be	  fully	  implemented	  in	  resource	  allocation	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Biomedical	  considerations	  
From	   a	   biomedical	   perspective,	   the	   development	   and	   supply	   of	   orphan	   drugs	  must	   be	  
situated	  within	  the	  realm	  of	  the	  objectives	  of	  healthcare	  and	  medicine.	  	  
Contemporary	   health	   care	   is	   a	   complex	   and	   heterogeneous	   framework	   of	   institutions,	  
services	   and	  policy	  measures	   that	   are	   generally	  organized	   in	   accordance	  with	   three	  goals:	  
prevention,	   cure	   and	   care.8	   In	   general,	   public	   health	   measures	   contain	   the	   categories	   of	  
services	   that	   promote	   the	   collective	   health	   status	   by	  means	   of	   prevention	   of	   disease	   and	  
disability.	   Besides	   prevention,	   health	   care	   also	   includes	   the	   familiar	   personal	   medical	  
services	  of	  cure	  and	  the	  social	  support	  services	  of	  care	  for	  the	  chronically	  ill	  or	  disabled.	  At	  
first	   sight,	   these	   three	   pillars	   of	   health	   care	   are	   hierarchically	   structured:	   prevention	   is	  
preferred	  to	  cure,	  and	  cure	  is	  preferred	  to	  care.	  	  
By	  preserving	  health,	  by	  restoring	  it	  when	  possible,	  and	  by	  caring	  for	  the	  patients	  when	  
cure	   is	   not	   possible,	   offering	   them	   support	   and	   easing	   their	   suffering,	   health	   care	  
institutions,	  services,	  and	  measures	  have	  a	  great	  impact	  on	  people’s	  well-­‐being.	  That	  is,	  they	  
determine	   “the	   level	   and	   distribution	   of	   the	   risk	   of	   our	   getting	   sick,	   the	   likelihood	   of	   our	  
being	   cured	   and	   the	   degree	   to	   which	   others	   will	   help	   us	   when	   we	   become	   impaired	   or	  
dysfunctional”.9	  Off	  course,	  a	   lot	  depends	  on	  the	  way	   in	  which	  health	  and	  disease	  –	  and	  a	  
fortiori	  the	  principle	  aim	  of	  medicine	  -­‐	  are	  being	  understood.	  Here,	  we	  can	  distinguish	  two	  
representative	   theories.10	   The	   first	   is	   the	  narrow,	  biomedical	  model	   of	   health	   and	  disease	  
according	  to	  which	  health	  is	  the	  absence	  of	  disease	  and	  disease	  is	  a	  deviation	  from	  normal,	  
natural,	  species-­‐typical	  functioning	  as	  human	  beings.11-­‐13	  Health	  refers	  to	  normal	  functional	  
capacity,	   whereas	   disease	   reduces	   this	   capacity	   to	   a	   level	   that	   is	   lower	   than	   the	   typical	  
efficiency	   levels.	   The	   task	  of	  objectively	   characterizing	  normal	   functioning	   capacity	   falls	   to	  
the	  biomedical	   sciences	  and	   is	   calculated	   statistically	  by	   comparison	  with	  an	  age	  group	  or	  
sex	  within	   the	  human	  species.	  The	   second	   is	   the	  broad	  and	  more	  holistic	  model,	   in	  which	  
cultural,	   historical	   and	   social	   factors	   are	   taken	   up	   in	   addition	   to	   factors	   of	   species-­‐typical	  
functioning.	  According	  to	  the	  holistic	  approach,	  health	  always	  has	  to	  do	  with	  the	  functioning	  
of	  a	  person	  as	  a	  whole,	  as	  a	   social	  being,	  part	  of	  a	  network	  of	   relations.	  According	   to	   this	  
theory,	  health	  is	  the	  ability	  of	  a	  person	  to	  attain	  vital	  goals	  under	  standard	  circumstances.14	  
In	   both	   theories,	   health	   is	   a	   broad	   concept	   that	   lacks	   inherent	  boundaries.	   This	   lack	  of	  
boundaries	   is	   saliently	   illustrated	  by	   the	   	  World	  Health	  Organization’s	   (WHO)	  definition	  of	  
health.	  According	  to	  this	  definition,	  health	  can	  be	  defined	  as	  “a	  state	  of	  complete	  physical,	  
mental	  and	  social	  well-­‐being	  and	  not	  merely	  the	  absence	  of	  disease	  or	  infirmity.”	  Obviously,	  
concepts	   as	   broad	   as	   the	  WHO	   definition	   of	   health	   have	   been	   fiercely	   criticized	   for	   their	  
potential	   to	   outstrip	   the	   limited	   resources	   a	   society	   can	   devote	   to	   healthcare	   in	   an	  
uncontrolled	   fashion.	   The	   tension	   between	   indefinite	   health	   aspirations	   and	   exhaustible	  
resources	   prompts	   allocation	   policies	   to	   pursue	   justice	   and	   fairness	   in	   the	   distribution	   of	  
available	   resources.	   In	   this	   respect,	   Daniel	   Callahan	   pointed	   out	   the	   absolute	   necessity	   to	  
limit	  the	  aspirations	  that	  a	  society	  pursues	  in	  the	  public	  provision	  of	  healthcare,	  based	  on	  a	  
132	  ⏐	  Chapter	  8	  
clear	  concept	  of	   the	  kind	  of	   life	  we	  want	  to	   live	  and	  what	  efforts	  a	  society	  can	  reasonably	  
make	  to	  support	  the	  realization	  thereof.15	  16	  
Obviously,	   setting	   limits	   to	  what	  we	   pursue	   in	   health	   does	   not	   leave	   the	   objectives	   of	  
healthcare	   unreflected.	   While	   broad	   concepts	   of	   health	   may	   comprise	   myriad	   objectives	  
(ranging	   from	   diagnosis,	   prevention	   and	   therapy	   to	   bodily	   aesthetics	   and	   human	  
enhancement),	  safeguarding	  the	  fair	  and	  rational	  allocation	  of	  resources	  by	  setting	  limits	  to	  
what	  health	  society	  supports	  for	  all	  does	  not	  seem	  compatible	  with	  such	  unbounded	  pursuit	  
of	   health	   objectives.	   Therefore,	   it	   is	   important	   to	   situate	   the	   diagnosis,	   prevention,	   and	  
treatment	  of	  rare	  diseases	  in	  relation	  to	  other	  health	  objectives.	  	  
The	   general	   objectives	   of	   prevention,	   cure	   and	   care	   are	   cornerstones	   of	   contemporary	  
healthcare.	  Particularly	  with	  regard	  to	  life	  threatening	  or	  chronically	  debilitating	  conditions	  
or	  diseases,	  diagnosis,	  prevention	  or	  treatment	  are	  to	  be	  considered	  as	  core	  businesses	  of	  
healthcare,	  for	  their	  responsiveness	  to	  basic	  medical	  needs,	  as	  preserving	  life	  itself.	  This	  is	  by	  
definition	   the	   case	   for	   the	   development	   of	   orphan	   drugs,	   and	   the	   low	   prevalence	   of	   rare	  
diseases	  does	  not	  affect	  this	  compliance	  with	  the	  core	  objectives	  of	  healthcare	  in	  any	  way.	  
By	   consequence,	   there	   appear	   to	   be	   no	   valid	   reasons	   to	   exclude	   rare	   diseases	   from	   the	  
scope	  health	  objectives	  when	  limits	  are	  set	  to	  what	  is	  pursued	  in	  publicly	  funded	  healthcare.	  	  
Ethical	  considerations	  
Now	  that	  the	  diagnosis,	  prevention,	  and	  treatment	  of	  rare	  diseases	  have	  been	  situated	  at	  
the	   core	  of	  biomedicines	  activities,	   the	  development	  and	   supply	  of	  orphan	  drugs	  must	  be	  
aligned	  with	  our	  concepts	  of	  justice.	  	  
Theoretically,	   the	   share	   of	   available	   resources	   that	   is	   allocated	   to	   the	   diagnosis,	  
prevention,	   and	   treatment	   of	   rare	   diseases	   can	   range	   from	   zero	   to	   unlimited	   expenses.	  
However,	  both	  ends	  of	  this	  spectrum	  are	  clearly	  unethical.	  On	  the	  one	  hand,	  it	  is	  manifestly	  
unethical	  to	  preclude	  rare	  diseases	  from	  public	  healthcare	  resources	  for	  its	  violation	  of	  the	  
principle	  of	  non-­‐abandonment.7	  17	  Ignoring	  the	  healthcare	  needs	  of	  a	  population	  as	  large	  as	  
that	   of	   all	   patients	   suffering	   from	   rare	   diseases	   simply	   cannot	   be	   ethically	   justified.	   In	  
addition,	  orphan	  drugs	  can	  be	  regarded	  as	  essential	  medicines,2	  18	  19	  which	  are	  described	  by	  
the	  WHO	  as:	  	  
The	   medicines	   that	   address	   the	   priority	   health	   care	   requirements	   of	   a	   given	  
population.	   These	  medicines	   are	   selected	   through	  an	   evidence-­‐based	  process	  with	  
due	  regard	  to	  public	  health	  relevance,	  quality,	  safety,	  efficacy	  and	  comparative	  cost-­‐
effectiveness.	  	  
A	  fundamental	  criterion	  for	  essential	  medicines	  is	  that	  they	  must	  be	  available	  within	  
the	   context	   of	   functioning	   health	   systems,	   and	   always	   in	   suitable	   amounts	   and	  
dosage	   forms.	   The	   selection	   of	   essential	   medicines	   is	   a	   cornerstone	   of	   national	  
medicine	  policies	  and	  supports	  the	  smooth	  functioning	  of	  the	  entire	  pharmaceutical	  
system.20	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On	   the	  other	  hand,	  unlimited	  expenses	  are	  out	  of	   the	  question,	   since	   the	  development	  
and	  supply	  of	  orphan	  drugs	  –due	  to	  the	   limited	  nature	  of	  public	  healthcare	  resources,	   the	  
high	   price	   of	   treatments	   and	   large	   number	   of	   diseases-­‐	   clearly	   comes	   at	   the	   risk	   of	  
outstripping	   the	   available	   healthcare	   budgets	   in	   an	   uncontrolled	   manner.	   While	   both	  
unlimited	   funding	   and	   overall	   abandonment	   do	   not	   offer	   acceptable	   grounds	   for	   the	  
allocation	  of	  resources,	  it	  is	  possible	  and	  necessary	  to	  adopt	  a	  middle	  course.	  On	  this	  track,	  
the	  major	  challenge	   is	   to	  address	   the	  moral	  dilemma	  of	  opportunity	  cost.	  This	  entails	   that	  
the	  resources	  that	  are	  devoted	  to	  the	  diagnosis,	  prevention,	  or	   treatment	  of	   rare	  diseases	  
cannot	   be	   spent	   on	   the	   realization	   of	   other	   healthcare	   objectives.	   Thus,	   the	   allocation	   of	  
resources	  to	  orphan	  drugs	  excludes	  other	  claims	  to	  the	  limited	  resources	  available.	  McCabe	  
et	  al21	  illustrate	  this	  issue	  strikingly:	  “a	  drug	  costing	  £50.000	  per	  patient	  per	  year,	  would	  only	  
cost	  £2.5m	  a	  year	  of	  there	  were	  only	  50	  patients	  to	  be	  treated.	  However,	  the	  cost	  should	  not	  
be	  considered	  without	  reference	  to	  the	  value	  of	  what	  is	  foregone.	  £2.5m	  would	  pay	  for	  over	  
520	  hip	  replacements.”	  Exactly	  this	  opportunity	  cost	  necessitates	  us	  to	  enquire	  whether	  the	  
development	  and	  supply	  of	  orphan	  drugs	  can	  be	  reconciled	  with	   the	  different	  concepts	  of	  
distributive	   justice	   that	  govern	  healthcare	  policies.	   In	   this	   respect,	   several	   traits	  of	  orphan	  
drugs	  challenge	  the	  utilitarian	  and	  right-­‐based	  approaches	  of	  justice	  that	  are	  commonly	  used	  
in	   allocation	   policies.7	   First,	   several	   traits	   of	   rare	   diseases	   and	   orphan	   drugs	  work	   against	  
efforts	   to	   maximize	   the	   benefit	   that	   is	   generated	   from	   limited	   resources.	   For	   example,	  
research	  and	  development	  is	  hampered	  by	  a	  shortage	  of	  (reliable)	  data	  on	  various	  aspects	  of	  
rare	  diseases,2	  5	  19	  difficulties	  in	  recruiting	  sufficiently	  large	  samples	  of	  research	  subjects.22	  In	  
addition,	   serious	  concerns	  with	   regard	   to	   the	  cost	  efficiency	  of	  orphan	  drugs	  exist.	   Jointly,	  
the	   low	  prevalence	  of	   rare	  diseases,	   the	  high	  costs	  of	  developing	  a	  drug,	  and	  the	  practical	  
complexity	  of	  developing	  efficacious	  orphan	  drugs	  work	  against	  cost-­‐efficiency.	  Nonetheless,	  
cost-­‐efficiency	  will	  play	  an	   important	   role	   in	  various	  accounts	  of	  distributive	   justice	  and	   in	  
the	  way	  a	  health	  policy	  deals	  with	  opportunity	  costs.	  Because	  evidence	  base	  to	  assess	  cost-­‐
efficiency	  is	  lacking	  for	  many	  rare	  conditions,	  the	  allocation	  of	  resources	  to	  the	  development	  
and	   supply	   of	   orphan	   drugs	   is	   practically	   complicated	   (but	   therefore	   not	   impossible)	   to	  
reconcile	  with	  utilitarian	  concept	  of	  distributive	  justice.	  Here,	  the	  challenge	  in	  front	  of	  us	  is	  
thus	  balance	   the	  undocumented	  and	  uncertain	  process	  of	   orphan	  drug	  development	  with	  
the	   concerns	   efficiency	   and	   efficacy	   that	   play	   a	   prominent	   role	   in	   utilitarian	   accounts	   of	  
justice.	   Second,	   the	  development	   and	   supply	  of	   orphan	  drugs	   cannot	   fully	   respond	   to	   the	  
high	   claims	   rights	   based	   approaches	   make	   in	   the	   name	   of	   equity.	   While	   the	   mere	   low	  
prevalence	  of	  a	  disease	  does	  not	  provide	  a	  valid	  ground	  to	  deny	  patients	  suffering	  from	  rare	  
diseases	  from	  the	  benefits	  of	  medical	  progress,23	  non-­‐abandonment	  does	  not	  automatically	  
entail	  a	   full	   realization	  of	  equity	   in	  all	  of	   its	  different	  concepts	   (including	  equitable	  access,	  
equitable	  resources,	  and	  equitable	  outcomes).21	  Even	  though	  patients	  who	  suffer	  from	  rare	  
diseases	  are	  theoretically	  entitled	  to	  an	  equal	  claim	  to	  high	  quality	  healthcare	  as	  any	  other	  
patient,7	   17	   the	   limited	   nature	   of	   healthcare	   resources	   simply	   does	   not	   enable	   to	   provide	  
every	  available	  or	  possible	  healthcare	  for	  all.	  Here,	  the	  challenge	   is	  to	  balance	  concerns	  of	  
equity	  with	  the	  natural	  and	  artificial	  limits	  of	  the	  resources	  society	  devotes	  to	  rare	  diseases.	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The	  fact	  that	  the	  allocation	  of	  resources	  to	  orphan	  drugs	  comes	  at	  an	  opportunity	  cost,	  
obviously	  does	  not	  demonstrate	   the	   injustice	   thereof.	  Quite	   the	   reverse,	   any	  allocation	  of	  
resources	   comes	   at	   an	   opportunity	   cost.	   In	   the	   specific	   case	   of	   rare	   diseases,	   several	  
rationales	  may	  argue	  in	  favor	  of	  meeting	  the	  opportunity	  cost	  of	  developing	  and	  providing	  
orphan	  drugs,	  provided	  that	  the	  resources	  expended	  on	  orphan	  drugs	  do	  not	  outshine	  other	  
rational	   priorities	   in	   healthcare.	   Allocation	   policies	   thus	   face	   the	   challenging	   task	   to	   serve	  
justice	  by	  providing	  a	  fair	  share	  of	  resources	  to	  the	  development	  and	  supply	  of	  orphan	  drugs	  
without	  generating	  an	  unreasonably	  high	   (opportunity)	   cost.	   In	   support	  of	   this	   challenging	  
task,	  we	  will	  now	  explore	  different	  strategies	  to	  allocate	  resources	  to	  the	  development	  and	  
supply	  of	  orphan	  drugs	  in	  a	  responsible	  manner.	  	  
Part	  2:	  Toward	  a	  Fair	  Share	  for	  the	  Orphans	  
	  Finding	   orphan	   drugs	   compatible	   with	   the	   core	   objectives	   of	   healthcare	   and	   with	   the	  
concepts	  of	  justice	  that	  govern	  our	  allocation	  policies,	  does	  not	  offer	  a	  clear	  cut	  way	  to	  fund	  
the	   development	   and	   supply	   of	   orphan	   drugs	   a	   controlled	  way.	   In	   response	   to	   the	  moral	  
dilemmas	   in	   resources	   allocation	   to	   orphan	   drugs	   described	   in	   this	   paper,	   we	   therefore	  
suggest	   three	   interventions	   to	   keep	   the	   allocation	   of	   resources	   to	   the	   development	   and	  
supply	   of	   orphan	   drugs	   under	   control:	   (1)	   budgetary	   insulation,	   (2)	   certain	   access	   to	  
resources	  for	  some	  (according	  to	  rational	  priorities),	  and	  (3)	  potential	  access	  to	  healthcare	  
resources	  for	  all	  (at	  random).	  	  
Budgetary	  insulation	  
The	   designation	   of	   an	   orphan	   status	   to	   drugs	   for	   rare	   diseases	   has	   important	  
consequences,	   as	   it	   turns	   the	   relatively	   weak	   claim	   to	   limited	   healthcare	   resources	   that	  
individual	   rare	   disease	   have	   into	   a	   massive	   cumulative	   claim	   representing	   5000	   to	   8000	  
diseases	  and	  over	  250.000	  patients	  in	  the	  EU.	  As	  a	  result,	  orphanage	  is	  turned	  from	  tragedy	  
into	   opportunity,	   since	   the	   cumulative	   claim	   to	   resources	   of	   all	   rare	   diseases	   that	   obtain	  
orphan	  designation	  is	  clearly	  too	  strong	  to	  be	  ignored	  in	  public	  policy.	  Opportunity,	  in	  turn,	  
can	   even	   result	   in	   considerable	   success,	   as	   some	   drugs	   that	   were	   initially	   designated	   as	  
orphan	   drugs	   in	   the	   U.S.	   eventually	   found	   a	   more	   common	   (e.g.,	   AZT	   to	   block	   HIV	  
replication)	  or	   also	  proved	  effective	   against	  more	   common	  disorders	   (e.g.,	   EPO),24	   turning	  
them	  in	  top-­‐seller	  products.	  
The	  cumulative	  claim	  of	  rare	  diseases	  to	  limited	  healthcare	  resources	  also	  has	  important	  
drawbacks	   that	   prompt	   public	   policy	   to	   balance	   rare	   diseases	   as	   a	   common	  phenomenon	  
with	   rare	   diseases	   as	   rare	   conditions.	   Obviously,	   the	   strong	   cumulative	   claim	   of	   all	   rare	  
diseases	   cannot	   just	   be	   extrapolated	   to	   every	   individual	   rare	   disease,	   as	   this	   would	   put	  
unreasonable	  constraints	  to	  the	  allocation	  of	  limited	  public	  resources.	  Conversely,	  a	  budget	  
comparable	  to	  that	  of	  a	  more	  common	  disease	  will	  not	  suffice	  to	  cover	  for	  the	  expenses	  of	  
developing	  and	  supplying	  a	  drug	  for	  an	  individual	  rare	  disease.	  Therefore,	  the	  only	  rational	  
response	   cumulative	   claim	   of	   all	   rare	   diseases	   is	   directed	   to	   the	   integer	   of	   rare	   diseases,	  
rather	   than	   to	   individual	   rare	   diseases.	   This	   can	   be	   achieved	   by	  means	   of	   the	   budgetary	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insulation	  of	  a	  share	  of	  resources	  to	  be	  dedicated	  to	  the	  development	  and	  supply	  of	  orphan	  
drugs.	   In	   this	  way,	   an	  equitable	   share	  of	   resources	   can	  be	  provided	   to	   the	   integer	  of	   rare	  
diseases	   in	   comparison	   with	   the	   integer	   of	   more	   common	   diseases,	   and	   equals	   can	   be	  
treated	  equally.	  At	  the	  same	  time,	  diversity	  can	  be	  valued,	  as	  incentives	  can	  be	  provided	  to	  
correct	   –to	   the	   extent	   possible-­‐	   for	   of	   the	  dissimilarities	   between	   rare	   diseases	   and	  more	  
common	  diseases.	  In	  addition,	  budgetary	  insulation	  will	  enable	  to	  generate	  progress	  in	  rare	  
diseases,	  while	  firm	  limits	  can	  be	  set	  to	  prevent	  that	  the	  rare	  diseases	  outstrip	  the	  available	  
healthcare	  budget.	  
While	   budgetary	   insulation	   can	   prevent	   the	   global	   healthcare	   budget	   from	   being	  
disrupted	   by	   disproportionate	   cumulative	   claims	   and	   opens	   up	   real	   opportunities	   for	  
allocating	  a	  fair	  share	  of	  resources	  to	  rare	  diseases,	  it	  does	  not	  solve	  the	  fundamental	  moral	  
dilemmas	  in	  resource	  allocation.	  Inevitably,	  the	  insulated	  share	  of	  resources	  -­‐regardless	  the	  
available	  budget-­‐	  is	  bound	  to	  be	  too	  limited	  to	  provide	  all	  for	  every	  individual.	  Therefore,	  the	  
insulated	  budget	  rather	  relocates	  difficult	  choices	  on	  the	  allocation	  of	  resources	  to	  individual	  
orphan	  drugs	  and	  rare	  diseases	  to	  a	  separate	  policy	  domain,	  than	  truly	  addressing	  the	  moral	  
dilemmas	   underlying	   these	   choices.	   Therefore,	   budgetary	   insulation	   as	   such	  will	   prove	   an	  
insufficient	   measure	   to	   handle	   profound	   ethical	   issues	   such	   as	   distributive	   justice,	   non-­‐
abandonment,	  and	  opportunity,	  and	  is	  only	  a	  prerequisite	  for	  an	  allocation	  mechanism,	  and	  
not	  an	  allocation	  mechanism	  in	  itself.	  	  
Therefore,	   once	  a	  budget	  has	  been	   insulated,	   specific	   allocation	  mechanisms	  must	   find	  
their	  entrance	  into	  health	  policy.	  We	  suggest	  two	  tracks	  of	  research	  allocation	  in	  this	  respect	  
(1)	  certain	  access	  to	  resources	   for	  some	  (according	  to	  rational	  priorities),	  and	  (2)	  potential	  
access	  to	  healthcare	  resources	  for	  all	  (at	  random).	  	  
Certainty	  for	  some:	  rational	  priorities	  among	  individual	  rare	  diseases	  	  
First,	  among	  comparable	  claims,	  rational	  priorities	  can	  be	  set.	  In	  this	  regard,	  Heemstra	  et	  
al.	  have	  identified	  several	  predictors	  for	  the	  authorization	  of	  orphan	  drugs,	  related	  to	  (1)	  the	  
company	   that	   develops	   the	   drug,	   (2)	   the	   pharmaceutical	   innovation	   performance,	   and	   (3)	  
disease	  specific	  factors,	  including	  the	  prevalence,	  disease	  class,	  and	  disease-­‐specific	  scientific	  
output.25	  Also	  the	  well	  known	  NICE	  proposal	  for	  the	  appraisal	  of	  orphan	  drugs	  for	  very	  rare	  
diseases	   is	  exemplary	   in	   this	   respect.26	  According	  to	  this	  proposal,	   three	  criteria	  can	  direct	  
the	   allocation	   of	   limited	   resources:	   (1)	   the	   severity	   of	   the	   disease,	   (2)	   evidence	   of	   health	  
gain,	   and	   (3)	   the	   life-­‐threatening	   nature	   of	   the	   disease.	   Although	   it	   is	   open	   to	   discussion	  
what	  criteria	  should	  be	  used	  to	  set	  rational	  priorities	  among	  the	  claims	  to	  resources	  within	  
the	  bulk	  of	  orphan	  drugs,	   it	   is	  beyond	  doubt	  that	  (imperfect)	  criteria	  can	  and	  must	  be	  set,	  
because	  clear	  priorities	  are	   indispensible	  to	  establish	  a	  rational,	  controlled,	  and	  efficacious	  
use	   of	   limited	   resources.	   On	   the	   other	   hand,	   however,	   setting	   priorities	   in	   resource	  
allocation	  also	  incorporates	  important	  drawbacks.	  In	  any	  set	  of	  priorities,	  certain	  diseases	  or	  
conditions	  will	  fail	  to	  move	  up	  on	  the	  priority	  scale,	  rendering	  them	  practically	  untreatable.	  
In	  addition,	  setting	  priorities	  also	  entails	  a	  considerable	  opportunity	  cost,	  as	  giving	  priority	  to	  
one	   rare	   disease,	  will	   block	   the	   claim	   to	   recourses	   of	   another.	   To	   a	   large	   extent,	   rational	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priorities	  are	  an	  efficient	  way	   to	  arrange	   the	  distribution	  of	   the	   limited	   resources	   that	  are	  
allocated	   to	   rare	   diseases.	   Nonetheless,	   they	   do	   not	   suffice	   to	   constitute	   an	   overall	   fair	  
distribution	   of	   resources.	   In	   any	   set	   of	   rational	   priorities,	   certain	   conditions	   will	   lack	   the	  
assets	   required	   to	  move	   up	   on	   the	   priority	   list,	   and	  would	   therefore	   face	   eternal	   exile	   to	  
orphanage,	   and	   by	   extension,	   non-­‐explicit	   abandonment.	   Therefore,	  we	   suggest	   a	   second	  
track	  of	  resource	  allocation	  to	  correct	  for	  this	  downside.	  	  
Possibility	  for	  all:	  the	  non	  abandonment	  of	  Anne	  of	  Green	  Gables-­‐track	  
Since	  there	  are	  no	  valid	  reasons	  to	  principally	  preclude	  any	  patient	  suffering	  from	  a	  rare	  
disease	   from	   having	   a	   rightful	   claim	   to	   the	   available	   resources	   (cf.	   principle	   of	   non-­‐
abandonment),	  also	  the	  rare	  diseases	  that	  fall	  outside	  the	  scope	  of	  rational	  priorities	  should	  
be	  granted	  opportunities	  to	  acquire	  a	  share	  of	  the	  available	  resources.	  Keeping	  the	  access	  to	  
limited	   resources	   open	   to	   all	   patients,	   however,	   cannot	   be	   done	   by	   means	   of	   rational	  
priorities.	  Therefore,	  a	  complementary	  system	  of	  resource	  allocation,	  in	  which	  every	  orphan	  
has	   a	   real	   -­‐be	   it	   uncertain-­‐	   chance	   to	   adoption,	   is	   necessary.	   In	   addition	   to	   allocation	  
according	  to	  rational	  priorities,	  we	  therefore	  suggest	  a	  second	  track	  of	  resource	  allocation	  in	  
which	   all	   patients	   suffering	   from	   rare	   diseases	   are	   granted	   a	   real	   (and	   not	   a	   merely	  
theoretical)	  chance	  to	  obtain	  a	  share	  of	  limited	  resources	  for	  the	  diagnosis,	  prevention,	  and	  
treatment	  of	  their	  disease.	  In	  this	  way,	  even	  the	  orphans	  that	  no	  one	  would	  rationally	  want	  
to	  adopt	  –the	  Anne	  of	  Green	  Gables-­‐like	  orphansiv-­‐	  acquire	  a	  realistic,	  be	  it	  small,	  possibility	  
of	  adoption.	  	  
To	  prevent	  this	  second	  track	  from	  outstripping	  the	  first	  track	  of	  resource	  allocation	  (i.e.	  
allocation	  according	  to	  rational	  priorities),	  also	  here,	  budgetary	  insulation	  is	  indispensible.	  In	  
addition,	   allocation	   in	   the	   second	   track	   should	   be	   organized	   ‘at	   random’,	   to	  move	   to	   the	  
unrecalled	   territory	   beyond	   opportunity	   cost	   considerations	   and	   rational	   priorities	   (which	  
generate	  new	  forms	  of	  abandonment).	  Such	  random	  allocation	  is	  analogous	  to	  the	  lowering	  
a	  lifeboat	  at	  a	  random	  place	  among	  a	  group	  of	  drowning	  persons,	  while	  the	  boat	  is	  to	  small	  
to	   carry	   all	   of	   them:	   nor	   does	   it	   preliminarily	   excludes	   anyone	   form	   being	   saved,	   neither	  
does	  it	  decide	  in	  a	  rational	  way	  upon	  who	  should	  get	  priority.	  It	  is	  a	  rescue	  addressed	  to	  all,	  
even	   though	   tragically,	   all	   can	   never	   be	   rescued	   with	   the	   resources	   at	   our	   disposal.	   By	  
consequence,	  the	  random	  allocation	  of	  a	  minor	  share	  of	  resources	  is	  potentially	  more	  than	  
just	  an	  inefficient	  and	  irrational	  system	  of	  resource	  allocation,	  since	  if	  used	  complementary	  
to	   rational	   priority	   setting,	   it	   may	   turn	   rationality	   (which	   in	   itself	   is	   not	   necessarily	  
compassionate)	   and	   compassion	   (which	  needs	  not	   to	  be	   rational)	   into	  a	  perfect	  match.	   In	  
this	   sense,	   criticism	   on	   both	   setting	   rational	   priorities	   and	   random	   allocation	   can	   be	  
addressed	  adequately.27	  28	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
iv Cf. the novel of Lucy Maud Montgomery. Anne of Green Gables is the orphan that does not match 
the profile that the adoption parents had in mind. 	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Summarized,	   the	   second	   track	   of	   resource	   allocation	   (Anne	  of	  Green	  Gables)	   grants	   all	  
patients	  suffering	  from	  an	  rare	  disease,	  even	  those	  who	  would	  never	  attract	  the	  attention	  in	  
rational	   priority	   lists,	   a	   limited	   though	   real	   chance	   to	   be	   adopted	   in	   funding	   policies.	   This	  
track	   is	   complementary	   to	   our	   first	   track	   (rational	   priorities),	   which	   ascertains	   that	   the	  
efficient	  use	  of	  resources	  is	  to	  large	  extent	  pursues,	  as	  any	  rational	  and	  just	  healthcare	  policy	  
would	  require.	  Combined,	  these	  two	  tracks	  respond	  adequately	  to	  the	  main	  moral	  dilemmas	  
that	  underlie	  the	  allocation	  of	  resources	  to	  orphan	  drugs	  (cf.	  infra).	  	  
Conclusion	  	  
The	   provision	   of	   public	   healthcare	   depends	   upon	   limited	   resources	   to	   which	   many	  
patients	  apply.	  No	  matter	  what	  efforts	  are	  made	  to	  dedicate	  public	  resources	  to	  healthcare,	  
any	   share	  of	   resources	  a	   society	   can	  devote	   to	  health	  will	   prove	   to	  be	   insufficient	   to	   fully	  
realize	   the	   open-­‐ended	   objectives	   of	   healthcare.	   This	   has	   profound	   implications	   for	   rare	  
diseases,	  many	  of	   them	  tend	   to	  have	  a	   rather	  weak	  claim	  to	  public	   resources,	   for	   reasons	  
that	  include	  the	  limited	  availability	  of	  data	  about	  the	  disease,	  the	  opportunity	  cost,	  and	  the	  
high	  price	  and	  the	  low	  cost-­‐efficiency	  of	  drugs	  for	  the	  diagnosis,	  prevention,	  and	  treatment	  
of	  rare	  diseases.	  Nonetheless,	  orphan	  designation	  has	  transformed	  the	  weak	  claim	  individual	  
rare	   diseases	   could	  make	   to	   limited	   public	   resources	   into	   a	   strong,	   cumulative	   claim	   that	  
cannot	  be	  ignored	  in	  European	  health	  policy.	  	  
In	  this	  paper,	  we	  have	  suggested	  a	  conceptual	  framework	  for	  the	  allocation	  of	  a	  fair	  share	  
of	  limited	  healthcare	  resources	  to	  the	  diagnosis,	  prevention	  and	  treatment	  of	  rare	  diseases.	  
This	   framework	   consists	   of	   three	   complementary	   parts.	   First,	   budgetary	   insulation	   of	  
resources	   devoted	   to	   orphan	   drugs	   is	   a	   prerequisite,	   both	   to	   avoid	   that	   the	   strong	  
cumulative	   claim	   of	   rare	   diseases	   to	   limited	   healthcare	   resources	   would	   outstrip	   the	  
available	  budgets,	  and	  to	  enable	  that	  resources	  can	  be	  allocated	  in	  a	  controlled	  way.	  Second,	  
the	   fair	   distribution	  of	   an	   insulated	  budget	   for	   the	  development	   and	   supply	  orphan	  drugs	  
among	   the	   competing	   claims	   of	   individual	   patients	   and	   diseases,	  will	   clearly	   benefit	   form	  
clear	  and	  rational	  criteria	  for	  priority	  setting.	  Notwithstanding	  the	  absolute	  need	  and	  clear	  
advantages	  of	  setting	  rational	  priorities,	  however,	  priority	  setting	  does	  not	  suffice	  to	  provide	  
all	   patients	   suffering	   from	   rare	   diseases	   with	   a	   real	   chance	   to	   attract	   funds	   for	   drug	  
development	  and	  supply.	  Therefore,	  a	  second	  track	  of	  resource	  allocation,	  embedded	  in	  an	  
insulated	   part	   of	   the	   budget	   allocated	   to	   orphan	   drugs,	   should	   grant	   all	   patients	   a	   real,	  
though	   limited	   chance	   to	   see	   their	   claim	   to	   resources	   granted.	   This	   can	   only	   be	   achieved	  
through	  a	   form	  of	   random	  allocation	  of	  a	  very	  small	  part	  of	   resources	  among	  the	  patients	  
and	  diseases	  with	  the	  weakest	  claim	  to	  resources.	  	  
Allocating	   resources	   over	   two	   asymmetrical	   trails	   (rational	   priorities	   and	   random	  
allocation)	  enables	  our	  public	  healthcare	  systems	  to	  afford	  “common	  rarity”.	  While	  it	  must	  
be	   recognized	   that	   not	   all	   can	   be	   done	   for	   everyone	   –a	   premise	   the	   application	   scope	   of	  
which	   is	   not	   limited	   to	   the	   rare	   diseases-­‐	   something	   can	   possibly	   be	   done	   for	   all,	   and	  
certainly	  for	  some.	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Abstract	  	  
Objectives:	   In	   this	   chapter,	   practical	   issues	   in	   implementing	   ethical	   and	   legal	  
requirements	   in	  pediatric	   research	  practice	  are	  empirically	   explored.	   The	   findings	   that	   are	  
presented	   serve	   as	   a	   first	   illustration	   of	   how	   empirical	   enquiry	   can	   be	   integrated	   in	   the	  
analysis	   of	   ethical,	   legal,	   and	   social	   aspects	   of	   pediatric	   clinical	   research,	   using	   the	  
conceptual	   framework	   that	   has	   been	   developed	   in	   this	   doctoral	   thesis	   (cf.	   chapter	   1).	   In	  
addition,	   the	   findings	   that	   are	   presented	   in	   this	   chapter	   aim	   at	   informing	   the	   normative	  
discussion	   of	   major	   tensions	   in	   pediatric	   research	   practice	   empirically	   (cf.	   general	  
discussion).	  The	  analysis	  in	  this	  chapter	  focuses	  on	  the	  implementation	  of	  the	  national	  and	  
supranational	   legal	   frameworks	   governing	   pediatric	   clinical	   research	   in	   informed	   consent	  
discussions.	  	  
Methods:	   	   Practical	   issues	   in	   the	   operational	   implementation	   of	   ethical	   and	   legal	  
requirements	   in	   pediatric	   research	   practice	   are	   empirically	   explored	   by	   means	   of	   an	  
observational	  study	  of	  23	  informed	  consent	  discussions.	  Recognizing	  that	  the	  European	  legal	  
framework	  imposes	  a	  single	  set	  of	  legal	  requirements	  to	  a	  large	  diversity	  of	  pediatric	  clinical	  
trials,	  consent	  discussions	  were	  observed	   for	  a	   large	  variety	  of	  studies,	  diseases,	  sponsors,	  
and	   study	   designs.	   The	   discussions	   were	   audio	   taped,	   transcribed,	   coded	   and	   analyzed	  
qualitatively,	   linking	   the	   content	   of	   the	   informed	   consent	   discussions	   to	   three	   major	  
concerns	   in	   the	   European	   legal	   framework.	   Only	   oral	   communication	   was	   taken	   account,	  
even	   though	   additional	   written	   information	   was	   provided	   to	   the	   parents	   and/or	   minor	  
subjects.	  	  
Against	  the	  background	  of	  the	  modest	  objectives	  of	  this	  empirical	  exploration,	  the	  limited	  
sample	  size,	   the	  explicit	  choice	   to	  study	  pediatric	  clinical	   research	   in	   its	   full	  heterogeneity,	  
and	  concerns	  to	  protect	  the	  anonymity	  of	  the	  clinicians,	  minors,	  and	  their	  parents	  involved,	  
some	  types	  of	  analysis	  have	  been	  abandoned.	  In	  this	  respect,	  no	  links	  between	  observations	  
and	   specific	   studies	   have	   been	   made,	   and	   no	   counts	   of	   the	   number	   of	   cases	   in	   which	  
particular	  observations	  were	  present	  	  are	  given,	  since	  this	  type	  of	  analysis	  is	  likely	  to	  create	  a	  
deceptive	  view.	  	  
It	  is	  fully	  acknowledged	  that	  the	  analysis	  does	  not	  generate	  any	  generalizable	  knowledge,	  
and	   that	   the	   findings	  presented	   in	   this	  chapter	  could	  not	  be	  saturated	  within	   the	   limits	  of	  
this	   empirical	   exploration.	   Nonetheless,	   the	   findings	   in	   this	   chapter	   suggest	   a	   number	   of	  
issues	   that	   are	   highly	   relevant	   to	   analyze	   and	   discuss	   the	   operational	   implementation	   of	  
ethical	  and	  legal	  requirements	  in	  pediatric	  research	  practice.	  As	  such,	  this	  analysis	  serves	  as	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a	  first	  inventory	  of	  practical	  issues	  that	  can	  inform	  (1)	  pragmatic	  decision-­‐making	  and	  (2)	  the	  
design	  of	  further,	  more	  comprehensive	  clinical	  research.	  
Results:	  From	  the	  observed	  consent	  discussions,	  there	  are	  few	  indications	  that	  European	  
legal	   good	  clinical	  practice	   (GCP)	   requirements	  are	   systematically	   implemented.	  We	   found	  
no	  indications	  that	  the	  European	  legal	  framework	  offers	  strong	  impetuses	  for	  the	  realization	  
of	  legal	  GCP-­‐requirements	  at	  the	  interpersonal	  level	  of	  addressing	  ethical	  issues.	  	  
In	   addition,	   our	   analysis	   sheds	   a	   new	   light	   on	   five	   important	   ethical	   tensions:	   (1)	  
harmonization	  versus	  heterogeneity	   (2)	   informed	  consent	  versus	  documented	  consent,	   (3)	  
assent	  versus	  procedure	  compliance,	  (4)	  direct	  benefit	  versus	  valid	  research	  results,	  and	  (5)	  
risk-­‐benefit	  ratio	  versus	  risk-­‐risk	  ratio.	  	  
Conclusion:	  It	  is	  both	  relevant	  and	  important	  to	  define	  and	  support	  the	  tasks,	  roles,	  and	  
interests	   of	   minors,	   parents,	   and	   researchers	   in	   the	   informed	   consent	   process.	   Our	  
observations	   draft	   a	   background	   against	   which	   these	   tasks,	   roles,	   and	   interests	   can	   be	  
explored.	  Furthermore,	  our	  analysis	  sheds	  a	  new	  light	  on	  five	  important	  ethical	  tensions:	  (1)	  
harmonization	  versus	  heterogeneity	   (2)	   informed	  consent	  versus	  documented	  consent,	   (3)	  
assent	  versus	  procedure	  compliance,	  (4)	  direct	  benefit	  versus	  valid	  research	  results,	  and	  (5)	  
risk-­‐benefit	  ratio	  versus	  risk-­‐risk	  ratio.	  In	  the	  general	  discussion,	  these	  tensions	  are	  discussed	  
against	  the	  background	  of	  this	  observational	  study	  and	  other	  studies	  of	  informed	  consent	  for	  
(pediatric)	  clinical	  research.	  	  
Introduction:	   Ethical	   and	   regulatory	   guidance	   of	   pediatric	   clinical	  
research	  conduct	  
In	   the	   European	   Union	   (EU),	   pediatric	   clinical	   research	   is	   governed	   by	   a	   supranational	  
legal	   framework	   that	   mainly	   consists	   of	   three	   landmark	   documents:1	   the	   Clinical	   Trial	  
Directive2,	  the	  Pediatric	  Regulation3,	  and	  the	  Convention	  on	  Human	  Rights	  and	  Biomedicine4	  
(and	   its	   additional	   protocol	   on	   biomedical	   research5).	   In	   addition,	   domestic	   legislation	   of	  
individual	  member	  states	  may	  be	  applicable.6	  7	  
The	   supranational	   legal	   framework	   regulates	   ethical	   issues	   at	   two	   levels.	   Issues	   with	  
regard	   to	   the	   research	   design,	   the	   quality	   of	   research,	   and	   the	   practical	   modalities	   of	  
research	  conduct	  are	  handled	  at	   the	   institutional	   level,	  where	   institutional	  bodies	   (such	  as	  
the	   European	   Medicines	   Agency	   (EMA),	   competent	   authorities,	   and/or	   research	   ethics	  
committees)	  are	  charged	  with	  the	  assessment	  of	  several	  aspects	  of	  research	  protocols.	  The	  
urgency	  to	  deal	  with	  ethical	  requirements	  at	  the	  institutional	  level	  is	  very	  high,	  since	  this	  is	  a	  
prerequisite	  to	  start	  any	  clinical	   trial.	  Once	  a	  protocol	  has	  been	  approved	  and	  recruitment	  
starts,	  ethical	  issues	  move	  from	  the	  institutional	  level	  to	  the	  interpersonal	  level	  and	  present	  
themselves	  on	  a	  case-­‐by-­‐case	  basis.	  At	  this	  level	  practitioners	  must	  deal	  with	  ethical	  issues	  in	  
practice	   while	   interpreting	   and	   implementing	   generally	   formulated	   legal	   requirements.	   In	  
contrast	   to	   the	   institutional	   level,	   compliance	   with	   regulatory	   requirements	   at	   the	  
interpersonal	  level	  is	  hardly	  monitored	  or	  documented,	  except	  for	  the	  collection	  of	  written	  
consent	  documents.	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In	  this	  paper,	  the	  main	  legal	  requirements	  at	  the	  interpersonal	  level,	  which	  are	  set	  down	  
in	   article	   4	   of	   the	   Clinical	   Trial	   Directive,	   are	   used	   as	   a	   starting	   point	   for	   the	   analysis	   of	  
observed	  consent	  discussions.	  
	  
BOX	  1:	  
Clinical	  Trial	  Directive	  (Directive	  2001/20/EC)	  
Article	  4	  –	  Clinical	  trials	  on	  minors	  
In	  addition	  to	  any	  other	  relevant	  restriction,	  a	  clinical	  trial	  on	  minors	  may	  be	  undertaken	  only	  if:	  
(a)	  the	  informed	  consent	  of	  the	  parents	  or	  legal	  representative	  has	  been	  obtained;	  consent	  must	  represent	  the	  
minor's	  presumed	  will	  and	  may	  be	  revoked	  at	  any	  time,	  without	  detriment	  to	  the	  minor;	  
(b)	  the	  minor	  has	  received	  information	  according	  to	  its	  capacity	  of	  understanding,	  from	  staff	  with	  experience	  
with	  minors,	  regarding	  the	  trial,	  the	  risks	  and	  the	  benefits;	  
(c)	  the	  explicit	  wish	  of	  a	  minor	  who	  is	  capable	  of	  forming	  an	  opinion	  and	  assessing	  this	   information	  to	  refuse	  
participation	  or	  to	  be	  withdrawn	  from	  the	  clinical	  trial	  at	  any	  time	  is	  considered	  by	  the	  investigator	  or	  where	  
appropriate	  the	  principal	  investigator;	  
(d)	  no	  incentives	  or	  financial	  inducements	  are	  given	  except	  compensation;	  
(e)	  some	  direct	  benefit	  for	  the	  group	  of	  patients	  is	  obtained	  from	  the	  clinical	  trial	  and	  only	  where	  such	  research	  
is	   essential	   to	   validate	   data	   obtained	   in	   clinical	   trials	   on	   persons	   able	   to	   give	   informed	   consent	   or	   by	   other	  
research	  methods;	  additionally,	   such	   research	  should	  either	   relate	  directly	   to	  a	  clinical	   condition	   from	  which	  
the	  minor	  concerned	  suffers	  or	  be	  of	  such	  a	  nature	  that	  it	  can	  only	  be	  carried	  out	  on	  minors;	  
(f)	  the	  corresponding	  scientific	  guidelines	  of	  the	  Agency	  have	  been	  followed;	  
(g)	   clinical	   trials	   have	   been	   designed	   to	   minimise	   pain,	   discomfort,	   fear	   and	   any	   other	   foreseeable	   risk	   in	  
relation	  to	  the	  disease	  and	  developmental	  stage;	  both	  the	  risk	  threshold	  and	  the	  degree	  of	  distress	  have	  to	  be	  
specially	  defined	  and	  constantly	  monitored;	  
(h)	   the	  Ethics	  Committee,	  with	  paediatric	  expertise	  or	  after	   taking	  advice	   in	  clinical,	  ethical	  and	  psychosocial	  
problems	  in	  the	  field	  of	  paediatrics,	  has	  endorsed	  the	  protocol;	  and	  
(i)	  the	  interests	  of	  the	  patient	  always	  prevail	  over	  those	  of	  science	  and	  society.	  
comparative	  overview	  of	  ethical	  and	  legal	  guidance	  at	  the	  institutional	  and	  interpersonal	  level	  
	  	   Institutional	  level	  	   Interpersonal	  level	  	  
Ethical	  Issues	  	   research	  design	  
the	  quality	  of	  research	  
the	   practical	   modalities	   of	   research	  
conduct	  
personal	   concerns	   and	   values	   of	   the	  
actors	  involved	  	  
Assessor	   institutional	   bodies,	   such	   as	   the	   EMA,	  





prior	  to	  the	  start	  of	  the	  trial	  	  
specific	   issues	  are	  monitored	  during	   the	  
trial	  	  
from	   recruitment	   until	   termination	   of	  
the	  trial	  
Response	  to	  
ethical	  issues	  	  
meticulous	  
well	  documented	  
subjective	  and	  unsystematic	  
undocumented	  (except	  for	  the	  collection	  
of	  signed	  consent	  forms)	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Legal	  requirements	  at	  the	  interpersonal	  level	  
Article	  4	  of	  the	  Clinical	  Trial	  Directive	  regulates	  three	  main	  ethical	  concerns:	  (1)	  voluntary	  
informed	  consent,	  (2)	  the	  provision	  of	  incentives,	  and	  (3)	  the	  benefits,	  risks	  and	  burdens	  of	  a	  
pediatric	  clinical	  study.	  	  
Informed	  consent	  	  
As	  a	  legal	  doctrine,	  informed	  consent	  formally	  settles	  the	  agreement	  to	  enroll	  a	  research	  
subject	   in	   a	   specific	   research	   protocol.	   In	   this	   respect,	   the	   Clinical	   Trial	   Directive	   requires	  
that:	  
(1) the	   parents	   or	   another	   legal	   representative	   grant	   informed	   consent	   prior	   to	   the	  
inclusion	  of	  a	  minor	  subject	  in	  a	  clinical	  study.	  This	  proxy	  consent	  is	  subjected	  to	  all	  
legal	  standards	  for	  consent	  applicable	  to	  the	  consent	  of	  competent	  adults	  and	  must	  
represent	  the	  presumed	  will	  of	  the	  minor	  concerned;	  
(2) minors	  are	  informed	  by	  a	  qualified	  person	  about	  the	  trial,	  the	  risks,	  and	  the	  benefits,	  
at	  a	  level	  appropriate	  to	  their	  understanding;	  
(3) dissent	  -­‐the	  explicit	  wish	  of	  a	  minor	  to	  refuse	  participation	  or	  to	  be	  withdrawn	  from	  
the	  clinical	  trial-­‐	  is	  considered	  by	  the	  (principal)	  investigator,	  in	  so	  far	  that	  a	  minor	  is	  
capable	  of	  assessing	  information	  and	  forming	  an	  opinion.	  	  
The	  voluntariness	  of	  research	  participation	  is	  emphasized,	  since	  article	  4(a)	  of	  the	  Clinical	  
Trial	   Directive	   states	   that	   consent	   can	   be	   revoked	   at	   any	   time,	   without	   negative	  
consequences	  for	  the	  minor.	  	  
Incentives	  	  
The	  Clinical	  Trial	  Directive	  does	  not	  allow	  any	  incentives	  or	  financial	  inducements	  except	  
for	  compensation.	  Unfortunately,	  this	  clear	  prohibition	  of	  payment	  does	  not	  provide	  clarity	  
in	   the	   sensitive	   area	   of	   compensation.	  While	   it	   is	   obvious	   that	   refunding	   a	   train	   ticket	   is	  
unproblematic,	  the	  acceptability	  of	  offering	  a	  symbolic	  compensation	  for	  sacrificing	  several	  
hours	  of	  (spare)	  time	  to	  a	  clinical	  study	  remains	  a	  source	  of	  controversy.8-­‐11	  
Benefits,	  risks,	  and	  burdens	  	  
Requiring	  that	  “some	  direct	  benefit	  for	  the	  group	  of	  patients	  is	  obtained	  from	  the	  clinical	  
trial”,	   article	   4(e)	   introduces	   the	   enigmatic	   concept	   of	   a	   “direct	   group	   benefit”.	   While	  
traditionally,	  a	  group	  benefit	  indicates	  that	  research	  is	  expected	  to	  generate	  a	  benefit	  other	  
than	   a	   direct	   benefit	   to	   the	   individual	   subject	   concerned,	   the	   formulation	   in	   the	   directive	  
mixes	   up	   direct	   benefit	   and	   group	   benefit.	   In	   a	  minimalistic	   interpretation,	   this	   provision	  
would	  at	  least	  require	  that	  research	  results	  are	  of	  some	  interest	  to	  the	  population	  of	  minors	  
or	   another	   group	   to	  which	   the	  minor	   subject	   belongs	   (such	   as	   the	   population	   of	   patients	  
with	  the	  same	  disease,	  or	  the	  group	  of	  minors).	  The	  requirement	  that	  research	  must	  either	  
relate	  directly	  to	  a	  clinical	  condition	  from	  which	  the	  minor	  concerned	  suffers	  or	  be	  of	  such	  a	  
nature	  that	  it	  can	  only	  be	  carried	  out	  on	  minors,	  is	  consistent	  with	  such	  interpretation.	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In	   addition,	   article	   4	   (g)	   stipulates	   that	   clinical	   trials	   be	   designed	   to	   minimize	   pain,	  
discomfort,	  fear	  and	  any	  other	  foreseeable	  risk.	  	  
Scope	  and	  methodology	  
23	  consent	  discussions	  concerning	  the	  enrollment	  minors	  in	  clinical	  trials	  were	  observed	  
in	  a	  Belgian	  academic	  hospital.	  Because	  the	  European	  and	  Belgian	  legal	  frameworks	  impose	  
the	   same	   sets	  of	   legal	   requirements	   to	   a	   large	  diversity	  of	  pediatric	   clinical	   trials,	   consent	  
discussions	  were	  observed	  for	  a	  large	  variety	  of	  studies	  (n=12),	  diseases	  (acute	  and	  chronic,	  
common	   and	   rare),	   sponsors	   (academic	   and	   industrial),	   and	   study	   designs	   (drug	   trials,	  
diagnostic	   trials,	   placebo	   controlled	   and	   active	   controlled	   etc.).	   The	   duration	   of	   the	  
discussions	   ranged	   from	   3’43”	   to	   74’46”.	   In	   two	   consent	   discussions,	   an	   interpreter	  
translated	  the	  conversation.	  The	  age	  of	  the	  minor	  subjects	  concerned	  ranged	  from	  2	  to	  15	  
years.	  	  
All	  research	  subjects	  except	  for	  the	  healthy	  volunteers	  entered	  the	  research	  setting	  while	  
seeking	  to	  deal	  with	  their	  disease	  or	  condition,	  either	  at	  their	  own	  initiative	  (in	  the	  follow-­‐up	  
of	   a	   chronic	   condition	   or	   prompted	   by	   an	   unexpected	   disease),	   or	   in	   response	   to	   a	  
researcher’s	  invitation	  to	  consider	  participation	  in	  a	  trial.	  The	  healthy	  volunteers	  in	  the	  study	  
were	  recruited	  as	  a	  sibling	  or	  friend	  of	  diseased	  patients.	  	  
The	  discussions	  were	  audio-­‐taped,	  transcribed	   ,coded	  and	  analyzed	  qualitatively,	   linking	  
the	   	  content	  of	  the	   informed	  consent	  discussions	  to	  three	  major	  concerns	   in	  the	  European	  
legal	   framework.	   Only	   oral	   communication	   was	   taken	   account,	   even	   though	   additional	  
written	  information	  was	  provided	  to	  the	  parents	  and/or	  minor	  subjects.	  	  
Against	  the	  background	  of	  the	  modest	  objectives	  of	  this	  empirical	  exploration,	  the	  limited	  
sample	  size,	   the	  explicit	  choice	   to	  study	  pediatric	  clinical	   research	   in	   its	   full	  heterogeneity,	  
and	  concerns	  to	  protect	  the	  anonymity	  of	  the	  clinicians,	  minors,	  and	  their	  parents	  involved,	  
some	  types	  of	  analysis	  have	  been	  abandoned.	  In	  this	  respect,	  no	  links	  between	  observations	  
and	   specific	   studies	   have	   been	   made,	   and	   no	   counts	   of	   the	   number	   of	   cases	   in	   which	  
particular	  observations	  were	  present	  have	  are	  given,	   since	   this	   type	  of	  analysis	   is	   likely	   to	  
create	  a	  deceptive	  view.	  
It	  is	  fully	  acknowledged	  that	  the	  analysis	  does	  not	  generate	  any	  generalizable	  knowledge,	  
and	  that	  the	  findings	  presented	  in	  this	  chapter	  could	  not	  be	  saturated	  in	  within	  the	  limits	  of	  
this	  empirical	  exploration.	  Nonetheless,	   the	   findings	  presented	  suggest	  a	  number	  of	   issues	  
that	  are	  highly	  relevant	  to	  analyze	  and	  discuss	  the	  operational	  implementation	  of	  ethical	  and	  
legal	   requirements	   in	   pediatric	   research	   practice.	   As	   such,	   this	   analysis	   serves	   as	   a	   first	  
inventory	   of	   practical	   issues	   that	   can	   inform	   (1)	   pragmatic	   decision-­‐making	   and	   (2)	   the	  
design	  of	  further,	  more	  comprehensive	  clinical	  research.	  
The	   protocol	   for	   this	   observational	   study	   was	   approved	   by	   the	   competent	   Ethics	  
Committee,	   and	   oral	   informed	   consent	  was	   obtained	   form	   all	   the	   parents	   after	   providing	  
them	  written	   information	   about	   the	   study.	   Assent	  was	   obtained	   from	  minors	   unless	   they	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were	   incapable	   of	   providing	   it.	   All	   researchers	   who	   participated	   in	   the	   study	   provided	  
written	  consent	  for	  their	  participation	  in	  the	  study.	  
Implementation	  of	  legal	  standards	  	  
Informed	  Consent	  	  
Motivated	  participation	  	  
While	  legally,	  willingness	  to	  participate	  in	  a	  trial	  is	  a	  matter	  of	  voluntariness,	  in	  practice,	  
the	  motivated	  commitment	  of	  minors	  and	   their	  parents	   is	  essential	   for	  any	  clinical	   trial	   to	  
succeed.	  During	  the	  observations,	  minors	  did	  not	  explicitate	  any	  motives	  to	  participate	  in	  a	  
clinical	  study.	  Notwithstanding	  their	  overall	  willingness	  to	  discuss	  research	  participation	  and	  
to	  grant	   informed	  consent,	   also	   the	  parents	  did	  not	  explicitate	  much	  of	  what	  drives	   them	  
towards	  research	  participation.	  Still,	  three	  interrelated	  parental	  motives	  for	  participation	  in	  
research	  were	  identified:	  	  
(1) pursuing	  an	  improved	  management	  of	  the	  disease,	  by	  increasing	  scientific	  knowledge	  
and	  creating	  new	  therapeutic	  options	  
(2) addressing	   personal	   questions	   and	   uncertainties	   (for	   example,	   in	   one	   case	   	   the	  
parents	   clearly	   regretted	   that	   some	   questions	   they	   had	   about	   the	   disease	   would	  
remain	  unanswered	  in	  the	  study);	  
(3) creating	  a	  direct	  benefit	  for	  the	  child	  (as	  one	  parent	  explicitated:	  “I’m	  only	  interested	  
in	  what’s	  best	  for	  her	  [the	  patient].	  Whatever	  you	  say	  is	  good	  for	  the	  child,	  we’ll	  do	  
it”).	  	  
Apart	  from	  these	  parental	  motives,	  six	  motives	  for	  research	  participation	  were	  provided	  
by	  the	  medical	  practitioners	  we	  observed,	  four	  of	  which	  are	  functional	  motivations:	  	  
(1) acquire	   access	   to	   medicinal	   products	   that	   are	   otherwise	   not	   available	   (during	   the	  
trial,	  and	  sometimes	  also	  after	  the	  termination	  of	  the	  trial);	  
(2) increase	  the	  clinician’s	  knowledge	  about	  various	  aspects	  of	  the	  disease;	  
(3) improve	   the	   management	   of	   the	   disease,	   maybe	   even	   generate	   a	   therapeutical	  
breakthrough;	  
(4) help	  others,	  such	  as	  the	  next	  generation	  of	  patients	  suffering	  from	  the	  same	  disease.	  
In	  addition,	  two	  factual	  motivations	  indicated	  the	  low	  threshold	  to	  move	  from	  the	  current	  
therapeutic	  scheme	  to	  research	  participation:	  	  
(5) opting	  for	  off-­‐label	  treatment	  or	  a	  clinical	  study	  was	  largely	  a	  matter	  of	  the	  parent’s	  
preference	   since	   in	   practice,	   research	   participation	   would	   hardly	   be	   experienced	  
different	  than	  off-­‐label	  treatment;	  
(6) research	  participation	  is	  a	  common	  option	  since	  (nearly)	  all	  children	  (with	  the	  same	  
condition)	  at	  the	  (i.c.	  pediatric	  oncology)	  ward	  were	  enrolled	  in	  a	  clinical	  trial.	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Obviously,	   these	   motives	   were	   introduced	   on	   a	   case-­‐by-­‐case-­‐basis	   and	   cannot	   just	   be	  
extrapolated	  to	  informed	  consent	  discussions	  in	  general.	  	  
Information	  	  
In	   the	   observed	   consent	   discussions,	   information	  was	   not	   limited	   to	   information	   about	  
the	  study	  concerned.	  Quite	  the	  reverse,	  in	  the	  majority	  of	  observed	  discussions	  the	  share	  of	  
information	   about	   the	   trial	  was	   considerably	   small	   compared	   to	   the	   share	   of	   information	  
about	  the	  disease,	  the	  condition	  of	  the	  individual	  minor,	  how	  the	  disease	  is	  to	  be	  managed,	  
and	  miscellaneous	  practical	  and	  social	  issues.	  	  
Depending	  on	  the	  case,	  consent	  discussions	  served	  multiple	  purposes,	  a	  first	  set	  of	  which	  
is	  related	  to	  research,	  addressing:	  	  
(1) a	  specific	  trial,	  for	  which	  informed	  consent	  was	  requested,	  or;	  	  
(2) research	  in	  general	  (for	  example	  when	  clinicians	  requested	  informed	  consent	  to	  take	  
a	  blood	  sample	  for	  undefined	  research	  purposes),	  or;	  
(3) upcoming	   trials,	   to	   raise	  enthusiasm	  about	  upcoming	  research	   (for	  example,	   in	  one	  
case,	  we	  observed	   four	  different	  upcoming	  protocols	   being	  explained	   to	   the	  minor	  
and	  the	  parents),	  or;	  
(4) trials	  in	  which	  the	  minor	  cannot	  participate,	  because	  he	  or	  she	  does	  not	  comply	  with	  
the	  eligibility	  criteria	  or	  because	  no	  more	  patients	  are	  being	  enrolled	  in	  the	  study	  (for	  
example,	  one	  clinician	  explicitated:	  “If	  you	  here	  talking	  about	  this	  trial,	  you	  know	  why	  
you’re	  not	  in…”).	  	  
Apart	   from	   research-­‐related	   issues,	   a	   large	   variety	   of	   other	   health-­‐related	   issues	   was	  
discussed.	  For	  example,	  consent	  discussions	  that	  were	  held	  shortly	  after	  the	  diagnosis	  were	  
employed	   to	   initiate	  minors	   and	   parents	   to	   the	   disease	   and	   how	   it	   is	   being	  managed.	   In	  
addition,	   miscellaneous	   practical	   and	   social	   issues	   were	   discussed	   during	   the	   informed	  
consent	   discussions,	   including	   educational	   issues,	   parenting,	   work-­‐life	   balance,	   travel,	   the	  
need	  for	  information	  and	  support	  for	  siblings,	  and	  even	  haircuts.	  	  
Often,	   information	   about	   the	   clinical	   trial	   was	   clearly	   embedded	   in	   the	   therapeutic	  
context	  of	  the	  minor	  subject.	  In	  this	  respect,	  we	  observed:	  
(1) information	   about	   research	   participation	   being	   framed	   in	   the	   diagnosis	   and/or	  
therapeutic	  context	  of	  the	  minor	  concerned;	  	  
(2) 	  research	  protocols	  being	  used	  to	  explain	  regular	  therapy	  (for	  example,	  the	  standard	  
of	  care	  was	  explained	  as	  the	  execution	  of	  the	  protocol	  without	  being	  registered	  in	  the	  
trial,	  or	  as	  one	  particular	  arm	  of	  a	   randomized	  study;	   in	  one	  case,	  a	   study	  protocol	  
was	   used	   to	   explain	   the	   standard	   of	   care,	   even	   though	   no	   more	   patients	   were	  
included	  in	  the	  study);.	  	  
(3) parents‘	  questions	  about	  the	  disease	  and	  its	  treatment	  being	  answered	  in	  reference	  
to	  current	  or	  future	  research;	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(4) parents	   enquiring	   whether	   their	   particular	   concerns	   (e.g.,	   gaining	   insight	   in	   the	  
etiology	  of	  the	  disease)	  were	  being	  investigated,	  as	  part	  of	  the	  protocol	  discussed	  or	  
elsewhere.	  
Administration	  	  
The	   clinicians,	   parents,	   and	   where	   applicable	   minors	   that	   we	   observed	   expended	  
considerable	  effort	   to	   comply	  meticulously	  with	   the	  administrative	  dimension	  of	   informed	  
consent.	  Several	  issues	  needed	  to	  be	  cleared	  out,	  such	  as	  who	  had	  to	  sign	  where,	  what	  was	  
the	  exact	  date,	  how	  many	  signed	  copies	  were	  needed,	  or	  what	  minors	  should	  do	  when	  they	  
are	  asked	  to	  sign	  but	  had	  no	  signature.	  	  
In	   one	   study	   in	   which	   friends	   of	   patients	   were	   recruited	   as	   healthy	   volunteers,	   the	  
recruitment	  strategy	  challenged	  the	  documentation	  of	  consent,	  since	  the	  healthy	  volunteers	  
joined	  the	  patient	  and	  its	  parents	  to	  the	  hospital	  in	  absence	  of	  their	  –own	  parents.	  	  
Timing	  	  
The	   timing	   of	   the	   informed	   consent	   process	   clearly	   exceeded	   that	   of	   the	   observed	  
discussions.	   Frequently	   ,reference	   was	   made	   to	   previous	   communication	   or	   to	   future	  
opportunities	   to	   discuss	   research	   participation,	   and	   in	   general,	   parents	  were	   given	   ample	  
time	  to	  consider	  the	  protocol	  before	  signing.	  	  
Also	   information	  was	  spread	   in	  time.	   In	  complex	  protocols,	   the	   information	  provided	  at	  
the	  time	  of	   the	  observed	  discussion	  was	  most	  often	   limited	  to	   (1)	  a	  general	  outline	  of	   the	  
trial	   and	   (2)	   detailed	   information	   on	   a	   first	   set	   of	   interventions	   in	   the	   near	   future.	   Here,	  
clinicians	   explicitly	   indicated	   that	   they	   provided	   a	   lot	   of	   information	   in	   a	   very	   short	   time.	  
Parents,	  in	  turn,	  did	  not	  request	  any	  further	  details.	  
Participation	  of	  the	  minor	  	  
In	   the	   observed	   consent	   discussions,	   the	   communication	   between	   minors	   and	   the	  
researchers	  clearly	  focused	  on	  the	  disease	  and	  its	  management.	  When	  researcher	  explicitly	  
addressed	   minors	   about	   the	   clinical	   trial,	   the	   interaction	   focused	   on	   the	   minors’	  
understanding	  of	  what	  had	  been	  explained	  and	  his	  or	  her	  willingness	   to	  participate	   in	   the	  
trial.	   Rare	   efforts	   to	   increase	   the	   minors’	   involvement	   in	   the	   consent	   discussion	   were	  
unsuccessful,	  due	  to	  a	  clear	  lack	  of	  response	  from	  the	  minors’	  part.	  Overall,	  minors	  showed	  
little	  interest	  in	  discussing	  research	  participation.	  	  
Apart	   from	   a	   few	   healthy	   volunteers	   who	   enquired	   how	   much	   time	   the	   investigation	  
would	  take	  and	  whether	  it	  would	  entail	  the	  use	  of	  needles,	  no	  questions	  about	  the	  research	  
were	  asked	  by	   the	  minors	   in	   this	   study.	   In	  addition,	  minors	   responded	   to	  questions	  about	  
their	  participation	  in	  research	  a	  very	  concise	  and	  affirmative	  way,	  and	  showed	  no	  interest	  in	  
discussing	  specific	  concerns	  in	  research	  participation.	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Four	  types	  of	  observations	  indicated	  a	  low	  level	  of	  involvement	  in	  the	  discussion:	  	  
(1) the	  minor	  did	  not	  attend	  the	  informed	  consent	  discussion	  (all	  minors	  in	  this	  situation	  
were	  younger	  than	  6	  years	  old	  and	  hospitalized);	  	  
(2) the	  minor	  was	  clearly	  too	  young	  to	  have	  an	  active	  role	  in	  the	  discussion;	  
(3) exhausted	  by	  the	  illness,	  therapy	  and/or	  emotions,	  the	  minor	  showed	  no	  interest	  in	  
(full)	  participation	  in	  the	  discussion,	  even	  though	  maturity	  and	  age	  would	  not	  be	  an	  
obstacle	  
(4) the	  minor	  did	  not	  demonstrate	  any	  interest	  in	  discussing	  participation	  in	  a	  trial.	  	  
When	  minors	  were	  asked	  to	  read	  an	  information	  leaflet,	  they	  always	  did	  so.	  Most	  of	  them	  
took	  ample	  time	  to	  read	  the	  document.	  	  
Parental	  concerns	  	  
Most	  parents	  did	  not	  discuss	   specific	   research-­‐related	  concerns.	  Nonetheless,	  based	  on	  
the	  questions	   that	  parents	  asked	  during	  the	  observed	  consent	  discussions	   (the	  majority	  of	  
which	  was	   formulated	   in	  only	   two	  cases),	   a	   considerable	  variety	  of	  parental	   concerns	  was	  
identified,	  related	  to	  the:	  	  
(1) access	  to	  the	  study	  drug	  after	  the	  trial	  (also	  in	  the	  in	  the	  case	  that	  the	  minor	  would	  
have	  been	  given	  a	  placebo):	  
(2) research	  design,	  more	  specifically:	  
(3) the	  way	  in	  which	  knowledge	  is	  created;	  	  
(4) specific	  research	  designs	  (e.g.,	  randomization,	  wash	  out,	  placebo	  control);	  	  
(5) uncertainty	  about	  the	  best	  intervention	  (e.g.,	  in	  the	  case	  of	  randomization);	  
(6) the	  role	  of	  the	  child	  (e.g.,	  one	  parent	  checked:	  “it’s	  not	  that	  my	  child	  is	  going	  to	  be	  a	  
guinea	  pig,	  right?”);	  
(7) benefits	  (e.g.,	  advantages	  of	  the	  study	  drug	  compared	  to	  the	  current	  therapy);	  
(8) burdens	   (particularly	  practical	   issues,	   including	   the	   scheduling	  of	   follow-­‐up	  visits	  or	  
the	  frequency	  of	  collecting	  blood	  samples);	  	  
(9) risk	  to	  harm	  (including	  the	  risk	  of	  not	  being	  in	  the	  study);	  
(10) compatibility	   with	   other	   treatments	   (e.g.,	   interaction	   between	   the	   study	   drug	   and	  
other	  drugs	  a	  minor	  takes)	  	  
(11) adverse	   effects	   (e.g.,	   how	   adverse	   effects	   can	   be	   recognized,	   whether	   potential	  
adverse	   effects	   are	   reversible,	   and	  what	   intervention	  will	   be	  made	   in	   case	   adverse	  
effects	  would	  occur).	  	  	  
152	  ⏐Chapter	  9	  
Incentives	  
In	   one	   study,	   cinema	   gift	   vouchers	   were	   provided	   to	   the	   participating	   minors.	   This	  
incentive	  was	  not	  discussed	  during	  the	  consent	  discussion,	  even	  though	  in	  two	  instances,	  the	  
vouchers	   were	   handed	   during	   this	   discussion.	   The	   incentive	   has	   never	   been	   mentioned	  
before	  consent	  was	  given,	  and	  has	  not	  been	  used	  during	  the	  discussion	  to	  persuade	  minors	  
to	   consent	   (we	   have	   not	   studied	   the	   recruitment	   process,	   where	   the	   provision	   of	   this	  
incentive	  may	  have	  played	  a	  role…).	  	  
In	   one	   case,	   the	  mother	   of	   a	   research	   subject	   provided	   an	   incentive	   for	   her	   son,	   as	   a	  
reward	  for	  giving	  a	  blood	  sample.	  	  
Risks,	  burdens,	  and	  benefits	  	  
Benefit	  	  
In	  the	  observed	  consent	  discussions,	  hardly	  any	  explicit	  attention	  was	  paid	  to	  the	  (direct)	  
benefits	   that	   the	   research	   was	   expected	   to	   generate.	   Most	   often,	   the	   topic	   was	   ignored	  
altogether,	   and	  when	   benefit	   was	   discussed,	   its	   contingency	  was	   strongly	   emphasized.	   In	  
one	  study,	  however,	  the	  potential	  benefits	  were	  related	  to	  the	  individual	  research	  subjects,	  
linking	  the	  trial	  to	  a	  decrease	  of	  the	  “problems”	  that	  the	  patient	  experienced.	  Also	  the	  long	  
time	  required	  to	  get	  a	  clear	  view	  on	  the	  true	  benefits	  was	  emphasized	  at	  several	  instances.	  	  
Notwithstanding	   this	   reticence	   to	   discus	   the	   potential	   benefits	   of	   a	   specific	   trial,	   the	  
benefits	   of	   clinical	   research	   in	   general	   were	   discussed	   regularly.	   For	   example,	   clinicians	  
suggested	   that	   research	   enables	   them	   to	   help	   children	   better,	   and	   can	   result	   in	   an	  
amelioration	   of	   the	   current	   therapeutic	   standards.	   Similarly,	   reference	   was	   made	   to	   the	  
positive	  impact	  of	  previous	  research	  on	  the	  current	  prognosis.	  	  
Risk	  to	  harm	  	  
Like	  it	  was	  frequently	  emphasized	  that	  the	  trial	  would	  not	  necessarily	  generate	  a	  benefit,	  
it	   was	   equally	   emphasized	   that	   the	   harm,	   no	   matter	   how	   rare	   the	   incidence,	   might	   be	  
inflicted	  to	  the	  subject	  concerned.	  At	  the	  same	  time,	  parents	  were	  often	  reassured	  that	   in	  
the	   personal	   experience	   of	   the	   clinicians,	   no	   problems	   were	   experienced	   to	   date,	   even	  
though	  many	   children	   had	   already	   used	   the	   drug.	  Where	   applicable,	   the	   risks	   of	   the	   trial	  
were	   explained	   extensively,	   often	   in	   reference	   to	   the	   written	   information	   provided	   to	  
research	  subjects.	  In	  the	  majority	  of	  observed	  studies,	  however,	  the	  risks	  of	  being	  in	  a	  trial	  
were	   either	   very	   low	   (and	   comparable	   to	   the	   risks	   of	   the	   (off-­‐label)	   standard	   of	   care)	   or	  
similar	  to	  the	  risks	  of	  non-­‐treatment.	  	  
Only	  in	  one	  case,	   it	  was	  explicitly	  stated	  that	  the	  study	  was	  designed	  to	  minimize	  harm.	  
However,	  the	  topic	  of	  minimizing	  harm	  was	  frequently	  discussed	  when	  clinicians	  stated	  that	  
the	  potential	  risks	  would	  be	  monitored	  carefully	  and	  that	  the	  adverse	  effects	  would	  be	  kept	  
under	  control	  in	  case	  they	  would	  occur.	  	  
Minors	   did	   not	   interact	   in	   the	   presentation	   of	   risks.	   The	   concerns	   discussed	   by	   the	  
parents	  related	  to	  the	  reversibility	  of	  harm,	  rather	  than	  the	  risk	  to	  harm	  as	  such.	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Burdens	  	  
In	  the	  consent	  discussions	  we	  observed,	  the	  following	  burdens	  were	  discussed:	  	  
(1) additional	  visits	  to	  the	  hospital;	  
(2) having	  blood	  samples	  taken;	  	  
(3) fasting;	  	  
(4) missing	   school	   (or	  waking	   up	   early	   on	   a	   holiday	   to	   get	   to	   the	   hospital	   if	   you	   don’t	  
want	  to	  miss	  school);	  	  
(5) 	  spending	  time	  in	  the	  waiting	  room;	  
(6) the	  frequency	  and	  duration	  of	  the	  procedures;	  
(7) the	   difficult	   compatibility	  with	   family	   life	   (for	   example	   the	   planned	   activities	   of	   all	  
family	  members	  or	  the	  religious	  calendar).	  	  
At	   several	   instances,	   the	   minors	   in	   this	   study	   asked	   questions	   about	   burden-­‐related	  
issues,	  such	  as	  the	  number	  of	  interventions	  that	  would	  be	  done,	  the	  duration	  of	  the	  research	  
or	   of	   a	   particular	   intervention,	   or	   the	   use	   of	   needles	   in	   a	   test.	   Most	   of	   all,	   however,	  
observations	  revealed	  that	  minor	  experienced	  their	  task	  to	  deal	  with	  a	  disease,	  including	  the	  
unpleasant	  aspects	  thereof,	  as	  a	  fait	  accompli.	  In	  addition,	  we	  did	  not	  observe	  any	  indication	  
that	   minors	   make	   a	   distinction	   between	   research	   interventions	   and	   therapeutic	  
interventions	  in	  this	  respect.	  
A	   significant	   part	   of	   the	   discourse	   on	  burdens	   focused	  on	   the	  practicalities	   of	   research	  
participation,	  and	  clearly	  provoked	  more	  interaction	  of	  parents	  than	  any	  other	  topic.	  This	  is	  
not	   surprising,	   given	   that	   parents	   have	   a	   key	   role	   in	   handling	   the	   practical	   burdens	   of	  
research	  participation,	  including	  hospital	  visits,	  log	  keeping,	  and	  reporting	  potential	  adverse	  
effects	  or	  adverse	  events.	  	  
Conclusion	  
The	  European	  legal	  framework	  sets	  down	  several	  requirements	  for	  Good	  Clinical	  Practice	  
at	   the	   interpersonal	   level.	   In	   the	   oral	   communication	   during	   the	   consent	   discussions	   we	  
observed,	   little	   demonstrated	   a	   true	   implementation	   or	   interpretation	   of	   these	   legal	  
requirements.	  In	  addition,	  we	  found	  no	  indications	  that	  the	  European	  legal	  framework	  offers	  
strong	  impetuses	  for	  the	  realization	  of	  legal	  GCP-­‐requirements	  at	  the	  interpersonal	  level.	  	  
Therefore,	   it	   is	  both	   relevant	  and	   important	   to	  define	  and	  support	   the	   tasks,	   roles,	  and	  
interests	   of	   minors,	   parents,	   and	   researchers	   in	   the	   informed	   consent	   process.	   Our	  
observations	   draft	   a	   background	   against	   which	   these	   tasks,	   roles,	   and	   interests	   can	   be	  
explored.	  	  
Furthermore,	   our	   analysis	   sheds	   a	   new	   light	   on	   five	   important	   ethical	   tensions:	  	  
(1)	  harmonization	  versus	  heterogeneity	   (2)	   informed	  consent	  versus	  documented	  consent,	  
(3)	  assent	  versus	  procedure	  compliance,	  (4)	  direct	  benefit	  versus	  valid	  research	  results,	  and	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(5)	   risk-­‐benefit	   ratio	   versus	   risk-­‐risk	   ratio.	   In	   the	   general	   discussion,	   these	   tensions	   are	  
discussed	  against	  the	  background	  of	  this	  observational	  study	  and	  other	  studies	  of	  informed	  
consent	  for	  (pediatric)	  clinical	  research.	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General	  Discussion	  
Against	  the	  background	  of	  our	  analysis	  of	  ethical	  literature,	  health	  law,	  and	  empirical	  data	  
we	   will	   now	   discuss	   seven	   ethical	   tensions:	   (1)	   standard	   of	   care	   versus	   state	   of	   the	   art	  
disease	   management,	   (2)	   protection	   versus	   trust,	   (3)	   regulation	   versus	   discretion,	   (4)	  
harmonization	   versus	   heterogeneity,	   (5)	   informed	   consent	   versus	   documented	   consent,	  	  
(6)	  assent	  versus	  procedure	  compliance,	  and	  (7)	  direct	  benefit	  versus	  valid	  research	  results.	  
The	  discussion	  of	  these	  seven	  tensions	  is	  illustratory	  for	  the	  contribution	  of	  this	  dissertation	  
to	  the	  elucidation	  of	  ethical	  issues	  by	  means	  of	  contextual	  analysis,	  normative	  qualification,	  
and	  practical	  guidance.	  	  
It	  needs	  to	  be	  emphasized	  that	  the	  formulation	  of	  ethical	  tensions	  in	  terms	  of	  conflicting	  
concerns	   is	   by	   no	  means	   intended	   to	   suggest	   a	   polarization	   of	   ethical	   stances.	   Quite	   the	  
reverse,	  as	  explicitated	  in	  the	  discussion	  of	  each	  tension,	  a	  well-­‐considered	  middle	  ground	  is	  
endorsed.	  
Standard	  of	  care	  versus	  state	  of	  the	  art	  disease	  management	  	  
In	   a	   human	   experience	   as	   striking	   and	   intimate	   as	   disease,	   uncertainty	  may	   come	   as	   a	  
highly	  disturbing	  reality.	  Nonetheless,	  in	  pediatrics	  (much	  more	  explicit	  than	  in	  many	  other	  
healthcare	   settings),	   uncertainty	   is	   everywhere.	   For	   example,	   the	   high	   rate	   off-­‐label	  
prescriptions1-­‐4	  clearly	  illustrates	  that	  uncertainty	  about	  the	  effects	  of	  medicinal	  products	  is	  
a	  common	  phenomenon.	  Consequently,	  a	  significant	  number	  of	  therapeutic	  interventions	  in	  
pediatric	  practice	  essentially	  tend	  to	  be	  “an	  educated	  guess”,	  consisting	  of	  unsystematic	  and	  
uncontrolled	  medical	  experimentation.	  	  
Although	  pediatric	  clinical	   trials	  are	  clearly	  the	  way	  forward	   in	  reducing	  the	  widespread	  
uncertainty	  in	  pediatric	  practice,5	  the	  focus	  of	  ethical	  attention	  has	  traditionally	  been	  on	  the	  
uncertainties	  in	  clinical	  research	  rather	  than	  on	  the	  reduction	  of	  uncertainties	  in	  therapeutic	  
practice.	  For	  example,	  the	  expected	  direct	  benefit	  to	  the	  subject,	  the	  risk	  to	  harm,	  and	  the	  
potential	  burdens	  have	  all	  acquired	  a	  central	  position	  in	  the	  assessment	  of	  the	  ethical	  nature	  
of	   clinical	   research.	  Accordingly,	   therapeutic	  practice	  has	  been	  qualified	  as	   ‘standard’	   (the	  
standard	   of	   care),	   while	   clinical	   research	   has	   been	   qualified	   as	   ‘exception’.6	   Given	   the	  
stringent	   lack	  of	  validated	  medicines	   in	  pediatric	  research,	  however,	   it	   is	  not	  clear	  to	  what	  
extent	  such	  research	  exceptionalism	  serves	  the	  interests	  of	  minors	  who	  are	  in	  search	  of	  safe	  
and	   efficacious	   therapy.	   For	   example,	   it	   is	   not	   clear	   whether	   patients	   are	   better	   served	  
outside	  of	  clinical	  trials.5	  7	  Quite	  the	  reverse,	  several	  important	  arguments	  make	  out	  the	  case	  
for	  a	  better	  management	  of	  diseases	  within	  clinical	  trials:	  clinical	  trials	  (1)	  are	  conducted	  in	  a	  
controlled	   setting,	   (2)	   entail	   a	   closer	   follow	   up	   of	   the	   patient,	   and	   (3)	   are	   conducted	   by	  
clinicians	   who	   work	   at	   the	   state	   of	   the	   art	   of	   science	   and	   have	   primary	   access	   to	   newly	  
generated	   evidence.	   An	   adequate	   management	   of	   a	   disease	   may	   therefore	   encompass	  
clinical	   research	   and,	   from	   a	   scientific	   point	   of	   view	   and	   dependent	   on	   the	   specific	   case	  
concerned,	  even	  give	  preference	  to	  participation	  in	  a	  clinical	  trial	  over	  the	  standard	  of	  care.	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While	   clinical	   research	  must	  obviously	   remain	   subjected	   to	  extensive	   scientific	   and	  ethical	  
assessment,	  aspiring	  a	  state	  of	  the	  art	  disease	  management	   in	  stead	  of	  the	  provision	  of	  an	  
established	  standard	  of	  care,	  will	  rather	  broaden	  the	  scope	  of	  ethical	  attention	  (to	  the	  entire	  
healthcare	  process)	  than	  decrease	  the	  level	  of	  protection	  of	  minors.	  However,	  if	  research	  is	  
not	  considered	  to	  be	  an	  exceptionalist	  track	  in	  comparison	  to	  a	  validated	  standard	  of	  care,	  
this	  has	  profound	  implications	  for	  the	  ethical	  assessment	  of	  research	  protocols,	  particularly	  
with	  regard	  to	  the	  widely	  endorsed	  requirement	  to	  generate	  a	  direct	  benefit	   to	  the	  minor	  
research	  subject	  concerned,	  and	  by	  extension	  also	   for	   the	  distinction	  between	  therapeutic	  
and	  non-­‐therapeutic	  research	  (cf.	  infra).	  
Protection	  versus	  trust	  	  
Minors	   are	   a	   vulnerable	   population	   and	   therefore	   deserve	   extensive	   protection.	   This	  
protection,	  however,	  can	  be	  established	  in	  different	  ways.	  On	  the	  one	  hand,	  efforts	  can	  be	  
made	   to	   shut	  minors	   off	   from	  what	   is	   deemed	  unethical.	   For	   example,	   research	   imposing	  
significant	  risks	  to	  minors	  may	  be	  prohibited.	  Or,	  to	  guarantee	  a	  fully	  adequate	  protection	  of	  
minors,	   the	   population	   can	   be	   excluded	   from	   clinical	   research	   altogether.	   However,	   this	  
cannot	  be	  done	  without	  devastating	  drawbacks,	  since	  such	  an	  ethical	  stance	  is	  likely	  to	  block	  
the	   access	   of	   minors	   to	   clinical	   research,	   denying	   them	   the	   benefits	   from	   medical	  	  
progress.8-­‐10	   The	   consequences	   of	   such	   a	   stance	   have	   become	   clear	   throughout	   recent	  
history,	  and	  are	  tangible	  to	  date	  in	  the	  stringent	  lack	  of	   licensed	  drugs	  that	  are	  labeled	  for	  
pediatric	  use.1	  2	  4	  On	  the	  other	  hand,	  minors	  can	  be	  protected	  by	  means	  of	  ethical	  safeguards	  
that	  seek	  to	  deal	  with	  the	  drawbacks	  of	  medical	  progress	  without	  avoiding	  this	  drawbacks	  
altogether.	  Doing	  so,	  the	  pursuit	  of	  medical	  progress	  can	  be	  balanced	  with	  the	  protection	  of	  
minors.	  	  
When	  access	  and	  protection	  need	  to	  be	  balanced,	  however,	  trust	  will	  be	  essential.	  While	  
at	  first	  glace,	  the	  act	  of	  trusting	  may	  seem	  naive	  to	  some,	  relationships	  of	  trust	  have	  great	  
potential	   for	   negotiating	   the	   participation	   of	   a	   minor	   in	   a	   clinical	   trial	   (cf.	   chapter	   4).11	  
Nonetheless,	   relationships	   of	   trust	   also	   have	   important	   weaknesses,	   that	   should	   not	   be	  
underestimated	  or	  ignored.	  Indeed,	  trust	  may	  increase	  the	  vulnerability	  of	  minors	  and	  their	  
parents	  for	  deception,	  coercion,	  or	  harm.12-­‐15	  	  
Given	  the	  devastating	  consequences	  of	  blocking	  the	  access	  of	  minors	  to	  clinical	  research,	  
it	   is	  better	   to	  deal	  with	  drawbacks	   than	  to	  avoid	  them	  altogether.	  Therefore,	   the	  accurate	  
protection	  of	  minors	  in	  clinical	  research	  should	  not	  lead	  to	  an	  overall	  skepticism	  or	  mistrust	  
in	  research.	  Taking	  the	  drawbacks	  of	  trust	  seriously,	  however,	  criticism	  should	  be	  nurtured	  in	  
minors	   and	   their	   parents,	   ethical	   expertise	   need	   to	   be	   created	   in	   clinicians,	   (sufficiently)	  
independent	  sources	  of	  information	  should	  be	  provided	  to	  minors	  and	  their	  parents,	  and	  an	  
adequate	  level	  of	  transparency	  should	  be	  guaranteed	  in	  research	  conduct.	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Regulation	  versus	  discretion	  	  
Pediatric	  clinical	  research	  hosts	  a	  wide	  variety	  of	  research	  projects	  and	  research	  designs	  
and	   brings	   together	   a	   large	   diversity	   of	   professional	   and	   lay	   actors,	   each	   with	   their	   own	  
experience,	  values,	  skills,	   interests,	  personality,	  etc.	  By	  consequence,	  ethical	  issues	  and	  the	  
way	   they	   are	   dealt	   with	   may	   vary	   substantially	   on	   a	   case-­‐by-­‐case	   basis.	   This	   research	  
heterogeneity,	   however,	   is	   not	   addressed	   directly	   in	   the	   legal	   frameworks	   that	   govern	  
pediatric	  clinical	  research	  in	  the	  EU.16	  Quite	  the	  reverse,	  important	  efforts	  have	  been	  made	  
to	  harmonize	  European	  regulation,	   for	  the	  sake	  of	  encouraging	  and	  facilitating	  multicentre	  
pediatric	  clinical	  research	  across	  the	  borders	  of	  EU	  member	  states.17	  18	  
In	   this	   respect,	   the	   question	   whether	   a	   harmonized	   legal	   framework	   can	   adequately	  
respond	   to	   the	   diverse	   specificities	   of	   individual	   cases	   is	   relevant.	   In	   the	   empirical	  
observations	   made	   in	   this	   project,	   no	   indications	   were	   found	   that	   the	   legal	   framework	  
proves	   hard	   to	   apply	   to	   specific	   situations.	   This	   is	   not	   surprising,	   since	   the	   general	  
formulation	   of	   legal	   requirements	   leaves	   ample	   latitude	   to	   tailor	   their	   interpretation	   and	  
implementation	  to	  the	  specificities	  of	  an	  individual	  case.	  Indeed,	  not	  everything	  in	  the	  law	  is	  
arranged	  by	  law.	  Therefore,	  in	  principle,	  the	  legal	  framework	  appears	  to	  be	  adequate	  to	  deal	  
with	  research	  heterogeneity.	  However,	  it	  is	  exactly	  the	  generality	  of	  legal	  requirements	  that	  
also	   puts	   strong	   boundaries	   on	   their	   vigor.	   While	   nothing	   in	   the	   legal	   framework	   is	  
redundant	  as	  such,	  nothing	  seems	  to	  be	  a	   true	   impetus	   for	  GCP	  either.	   In	   this	   respect,	  no	  
indications	   that	   the	   European	   legal	   framework	   is	   inspiring	   for	   those	   committed	   to	   ethical	  
issues	  on	  the	  interpersonal	  level	  were	  found	  this	  project.	  	  
Thus,	  while	   at	   the	   institutional	   level,	   a	   considerable	  urgency	   to	  deal	  with	   ethical	   issues	  
exists	   (cf.	   chapter	  9),	   at	   the	   interpersonal	   level,	   the	   realization	  of	  GCP-­‐standards	   seems	   to	  
depend	   largely	   on	   the	   individual	   qualities	   that	   the	   actors	   involved	  developed	   fortuitously.	  
Since	  the	  individual	  patient	  only	  enters	  the	  scene	  at	  the	  impersonal	  level,	  omitting	  structural	  
efforts	   to	   monitor	   and	   improve	   the	   quality	   of	   GCP	   at	   the	   interpersonal	   level	   is	   ethically	  
negligent.	  Unfortunately,	   to	   date,	   no	   systematic	  mechanisms	   to	  monitor	   and	   improve	   the	  
quality	  of	  GCP	  exist	  at	  the	  interpersonal	  level	  of	  trial	  conduct.	  	  
Informed	  consent	  versus	  documented	  consent	  	  
According	   to	   article	   2(j)	   of	   the	   Clinical	   Trial	   Directive,	   informed	   consent	   is	   a	   “decision,	  
which	  must	  be	  written,	  dated	  and	   signed,	   to	   take	  part	   in	  a	   clinical	   trial,	   taken	   freely	  after	  
being	   duly	   informed	   of	   its	   nature,	   significance,	   implications	   and	   risks	   and	   appropriately	  
documented,	  by	  any	  person	  capable	  of	  giving	  consent	  or,	  where	  the	  person	  is	  not	  capable	  of	  
giving	   consent,	   by	   his	   or	   her	   legal	   representative	   […]”.17	   To	   a	   considerable	   extent,	   this	  
formulation	  has	  an	  administrative	  focus,	  requiring	  that	  consent	  be	  documented	  (as	  a	  written	  
and	   dated	   document,	   signed	   by	   a	   competent	   person).	   Three	   elements,	   however,	   push	  
informed	  consent	  beyond	  the	  administrative	  level:	  (1)	  decision	  making,	  (2)	  being	  informed,	  
and	  (3)	  voluntariness.	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Decision	  making	  
The	  definition	  in	  the	  Clinical	  Trial	  Directive	  states	  that	  informed	  consent	  is	  a	  decision.	  The	  
outcome	  of	   the	  decision	   (the	  signature	  of	  a	  consent	  document),	  however,	  does	  not	   reveal	  
much	  about	  what	  reasoning	  –if	  any-­‐	  precedes	  the	  decisional	  outcome.	  	  
The	  observations	  of	  informed	  consent	  discussions	  in	  this	  project	  revealed	  no	  indications	  
that	   -­‐paradigmatically-­‐	   informed	   consent	   is	   grounded	   in	   a	   well-­‐considered	   and	   rational	  
decision.	  In	  addition,	  several	  factors	  challenge	  the	  premise	  that	  written	  consent	  is	  preceded	  
by	  a	  duly	  informed,	  well-­‐considered,	  rational	  decision.	  First,	  the	  fact	  that	  informed	  consent	  
is	  granted	  by	  competent	  persons	  does	  not	  imply	  that	  competences	  are	  actually	  used	  to	  take	  
a	  stance	  towards	  a	  study	  protocol.	  Rationality	   is	  not	  necessarily	   the	  golden	  standard	  of	  all	  
important	  decisions	  we	  make	  in	  life,	  and	  other	  factors	  (particularly	  tacit	  elements	  like	  hope,	  
trust,	  or	  dependency)	  may	  shape	  decisions	  to	  grant	   informed	  consent.	   In	  this	  respect,	  one	  
parent	  in	  our	  empirical	  study	  clearly	  stated	  to	  the	  researcher:	  “whatever	  you	  say	  is	  good	  for	  
the	  child,	  we’ll	  do	  it”.	  Also	  other	  studies	  indicated	  several	   issues	  that	  work	  against	  rational	  
decision	   making,	   such	   as	   inadequacies	   in	   understanding	   the	   research,19-­‐22	   and	   emotional	  
distress.23t	  	  One	  study	  even	  indicated	  that	  10	  out	  of	  68	  parents	  did	  not	  remember	  that	  they	  
had	   signed	   up	   for	   a	   research	   protocol.20	   Second,	   several	   clinicians	   in	   our	   study	   suggested	  
that	   granting	   informed	   consent	   is	   (nearly)	   customary,	   since	   (almost)	   all	   patients	   with	   the	  
same	  disease	  are	  enrolled	  in	  a	  clinical	  trial.	  In	  this	  respect,	  consent	  appears	  as	  a	  customary	  
commitment	  to	  the	  joint	  efforts	  of	  clinicians,	  parents	  and	  the	  minor	  to	  manage	  the	  disease	  
in	  all	  available	  manners,	  rather	  than	  a	  commitment	  to	  a	  specific	  study	  protocol.	  	  
Although	   obviously,	   consent	   discussions	   can	   be	  well-­‐considered	   and	   rational	   decisions,	  
they	   might	   be	   a	   priori	   decisions	   as	   well,	   representing	   and	   confirming	   a	   positive	   stance	  
towards	   research	   that	   parents	   already	  had	  before	   recruitment.	   This	   hypothesis	   of	  a	  priori	  
decision-­‐making	  would	  be	  consistent	  with	  three	  other	  observations	  in	  this	  project.	  First,	  two	  
planned	  observations	  were	  canceled	  because	  the	  parents	  were	  considered	  to	  be	  too	  unlikely	  
to	   consent.	   This	   suggests	   the	   researcher	   concerned	   traced	   an	   unfavorable	  a	   priori	   stance	  
towards	   research.	   Second,	   most	   parents	   did	   not	   show	   any	   criticism	   towards	   research	  
participation,	  for	  example	  by	  asking	  questions	  or	  discuss	  specific	  aspects	  of	  the	  study	  more	  
thoroughly.	   In	   fact,	   only	   two	   parents,	   who	   clearly	   had	   a	   critical	   stance	   towards	   clinical	  
research,	  accounted	  for	  nearly	  all	   the	  questions	  that	  parents	  formulated	  in	  our	  study.	  Also	  
this	  critical	  stance	  is	  consistent	  with	  the	  idea	  of	  a	  priori	  decision-­‐making.	  Third,	  we	  observed	  
an	  overall	  willingness	  to	  grant	  informed	  consent.	  Also	  corridor	  chat	  with	  the	  clinicians	  in	  our	  
study	   confirmed	   that	   refusal	   to	   participate	   in	   research	  was	   rather	   exceptional.	   Given	   the	  
uncritical	   attitude	   of	  most	   parents,	   this	  willingness	   to	   consent	  might	   suggest	   a	   positive	  a	  
priori	  stance	  towards	  research	  in	  general,	  rather	  than	  a	  duly	   informed	  endorsement	  of	  the	  
study	  protocol.	  	  
Because	  several	  indications	  in	  our	  observations	  suggest	  that	  parents	  create	  little	  basis	  for	  
making	   rational	   and	  well	   considered	   decisions,	  we	   suggest	   that	   the	   hypothesis	   of	   a	   priori	  
decision	  making	  is	  to	  taken	  seriously	  and	  investigated	  further.	  	  
General	  Discussion	  ⏐	  159	  
Being	  informed	  	  
Being	  informed	  is	  not	  the	  same	  as	  merely	  receiving	  information.	  It	  suggests	  a	  certain	  level	  
of	  understanding.	  And	  understanding	  is	  not	  the	  same	  as	  memory.	  This,	  however,	  needs	  not	  
to	  be	  a	  tragedy,	  since	  the	  major	  problems	  in	  the	  provision	  and	  understanding	  of	  information	  
that	   have	   been	   reported	   in	   literature20-­‐22	   24	   25	   need	   not	   necessarily	   to	   prevent,	   or	   even	  
bother	  parents	  from	  making	  a	  determined	  decision	  on	  research	  participation.	  
From	   our	   observations,	   we	   have	   no	   indications	   that	   paradigmatically,	   parents	   were	  
systematically	  provided	  with	   legally	  required	  (or	  other)	   information.	  Quite	  the	  reverse,	  the	  
information	  provided	  varied	  significantly	  on	  a	  case-­‐by-­‐case	  basis.	   In	  addition,	  most	  parents	  
clearly	  did	  not	  seek	  to	  get	  to	  the	  bottom	  of	  the	  research	  project	  and,	  as	  already	  has	  been	  
pointed	   out,	   the	   parents	   in	   our	   study	   formulated	   remarkably	   few	   questions	   about	   the	  
research.	  	  
Voluntariness	  
The	   potential	   for	   a	   priori	   and	   customary	   decision-­‐making,	   makes	   that	   research	  
participation	  is	  neither	  obligatory,	  nor	  unusual.	  In	  this	  regard,	  informed	  consent	  may	  rather	  
be	  a	  decision	  not	   to	  drop	  out	  of	  certain	  practices	   that	  surround	  the	  minor	   in	   the	  hospital,	  
than	   a	   decision	   to	   sign	   in	   into	   a	   research	   project.	   Against	   this	   background,	   however,	  
voluntariness	   and	   the	   right	   to	  withdraw	   are	   of	   primordial	   importance.	  We	  have	   observed	  
that	   this	   right	   was	   frequently	   emphasized,	   and	   we	   strongly	   suggest	   that	   researchers	   be	  
extremely	   clear	   on	   the	   voluntariness	   of	   research	   participation,	   and	   the	   right	   to	  withdraw	  
from	  the	  project	  at	  any	  time,	  without	  detriment	  to	  the	  minor.	  	  
Informed	  consent	  versus	  documented	  consent	  	  
On	   the	   one	   hand,	   informed	   consent	   presents	   itself	   as	   a	   formal	   permission	   to	   enroll	   a	  
minor	   in	   the	   protocol,	   and	   can	   be	   regarded	   as	   documented	   consent.	  On	   the	   other	   hand,	  
informed	  consent	  can	  be	  a	  duly	  informed	  and	  well-­‐considered	  decision	  to	  enroll	  a	  minor	  in	  a	  
clinical	  trial,	  and	  can	  be	  regarded	  as	  informed	  consent.	  	  
Documented	   consent	   and	   informed	   consent	   can	   be	   regarded	   the	   one	   ends	   of	   a	   broad	  
spectrum.	  Where	  consent	  is	  currently	  situated	  in	  the	  spectrum,	  will	  vary	  from	  case	  to	  case.	  
Where	   consent	   should	   be	   situated	   in	   this	   spectrum,	   is	   an	   important	  moral	   question	   that	  
needs	   further	   normative	   reflection.	   Should	   we	   truly	   respect	   a	   family’s	   culture	   of	   making	  
poorly	   informed	   and	   ill-­‐reflected	   decisions?	  Or	   should	  we	   nurture	  well-­‐informed	   and	   ripe	  
decision-­‐making?	  	  
Assent	  versus	  compliant	  behavior	  
The	   difficulties	   in	   turning	   the	   procedure	   of	   granting	   consent	   into	   a	   truly	   informed	   and	  
well-­‐considered	  decision	  are	  also	  applicable	  to	  assent.	  Assent,	  the	  affirmative	  agreement	  of	  
a	  minor	  to	  participate	  in	  a	  clinical	  trial,	  is	  not	  explicitly	  required	  by	  the	  Clinical	  Trial	  Directive.	  
Nonetheless,	   the	   concept	   has	   been	   debated	   extensively	   in	   literature25-­‐33	   and	   has	   been	  
adopted	  in	  the	  guidelines	  on	  the	  implementation	  of	  the	  Directive	  provided	  by	  the	  EMA.34	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In	  the	  consent	  discussions	  that	  were	  observed	  in	  this	  study,	  written	  assent	  was	  requested	  
from	   the	  minor	   at	   several	   instances.	   All	  minors	   agreed	   to	   assent.	   From	   our	   observations,	  
however,	  it	  is	  not	  clear	  whether	  this	  assent	  is	  grounded	  in	  a	  solid	  commitment	  to	  the	  trial,	  or	  
in	  the	  compliant	  attitude	  that	  most	  minors	  in	  our	  study	  conveyed.	  	  
In	   contrast	   to	   the	   clear	   willingness	   to	   provide	   written	   assent,	   our	   observations	   also	  
indicate	  that	  minors	  may	  lack	  interest	  and	  willingness	  to	  take	  part	  in	  decisions	  on	  research	  
participation,	  even	  when	  their	  age	  and	  maturity	  enables	  them	  to	  do	  so.	  To	  our	  opinion,	  such	  
disinterest	   or	   unwillingness	   to	   take	   part	   in	   the	   decision	   should	   be	   respected,	   and	   assent	  
should	  not	   force	  minors	   to	   form	  an	  opinion	  on	  decisions	   they	  prefer	   to	   leave	   to	   someone	  
else	  altogether.	  	  
Direct	  benefits	  versus	  valid	  research	  results	  	  
Since	   the	   benefit	   of	   clinical	   research	   is	   by	   nature	   contingent	   and	   the	   very	   purpose	   of	  
clinical	   research	   is	   to	   find	   out	   whether	   additional	   benefit	   will	   be	   generated,	   speaking	   of	  
benefit	  at	  the	  time	  of	  the	  consent	  discussion	  may	  be	  jumping	  to	  conclusions	  that	  still	  need	  
to	  be	  drawn.	   In	  addition,	  also	   the	   fact	   that	  many	  trials	  eventually	  do	  not	   result	   in	  a	  direct	  
therapeutic	   benefit	   for	   the	   subject	   should	   be	   recognized.	   Claiming	   a	   direct	   benefit	   to	   the	  
individual	  patient	  as	  the	  outcome	  of	  a	  contingent	  scientific	  process	  yet	  to	  conduct	  therefore	  
seems	  particularly	  imprudent.	  Reasons	  enough	  to	  be	  careful	  in	  discussing	  research	  benefits	  
with	  parents	  and	  the	  practitioners	  in	  our	  empirical	  study	  of	  consent	  discussions	  seemed	  to	  
be	  very	  much	  aware	  of	  that.	  In	  addition,	  the	  parents	  and	  minors	  in	  our	  study	  did	  not	  indicate	  
that	   (direct)	   benefit	   was	   a	   prerequisite	   for	   research	   participation	   anywhere	   in	   our	  
observations.	  	  
The	  mere	  fact	  that	  reliable	  predictions	  about	  benefit	  cannot	  be	  made,	  however,	  does	  not	  
render	   the	   concept	   of	   benefit	   worthless.	   Obviously,	   when	   researchers	   conduct	   research,	  
they	  pursue	  a	  benefit,	  be	  it	  rather	  in	  a	  process-­‐oriented	  than	  a	  result-­‐oriented	  fashion.	  Here,	  
valid	   data	   seem	   to	   be	   the	   true	   benefit	   of	   research,	   rather	   than	   any	   direct	   benefit	   to	   the	  
individual.5	   Nonetheless,	   the	   concept	   of	   direct	   benefit	   has	   earned	   a	   prominent	   place	   in	  
medical	   ethics	   and	   health	   law,	   particularly	   as	   a	   counterweight	   to	   the	   risks	   involved	   in	   a	  
clinical	  trial.	  In	  our	  opinion,	  however,	  direct	  benefit	  seems	  to	  be	  a	  very	  limited	  standard	  to	  
assess	  the	  ethical	  acceptability	  of	  pediatric	  clinical	  research	  in	  comparison	  to	  valid	  results,	  as	  
this	  standard	  enables	  to	  value	  both	  positive	  and	  negative	  research	  outcomes.	  	  
Nonetheless,	   direct	   benefit	   enjoys	   a	   prominent	   position	   in	   the	   assessment	   of	   research	  
protocols	   by	   ethics	   committees.	   The	   standard	   is	   used	   to	   weigh	   the	   acceptability	   of	   risks,	  
based	   on	   the	   rationale	   that	   the	   greater	   the	   potential	   benefit	   involved,	   the	   lower	   the	   risk	  
threshold	   should	   be.	   For	   example,	   major	   legal	   regulation	   requires	   that	   basically,	   non-­‐
beneficial	   research	   does	   not	   exceed	   stringent	   minimal-­‐risk	   and	   minimal-­‐burden	  	  
thresholds.35	   36	   Also	   the	   Clinical	   Trial	   Directive	   requires	   proportionality	   between	   risks	   and	  
benefits,	   as	   article	   3,2(a)	   stipulated	   that	   “a	   clinical	   trial	   may	   be	   undertaken	   only	   if	   the	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foreseeable	  risks	  and	  inconveniences	  have	  been	  weighed	  against	  the	  anticipated	  benefit	  for	  
the	  individual	  trial	  subject	  and	  other	  present	  and	  future	  patients.”17	  
As	   has	   been	   demonstrated,	   however,	   in	   pediatric	   research	   the	   expected	   benefits	   do	   not	  
provide	   a	   convincing	   ground	   to	   assess	   whether	   potential	   risks	   are	   justified	   in	   pediatric	  
research	  for	  at	  least	  two	  reasons.	  First,	  in	  a	  setting	  with	  a	  share	  of	  off-­‐license	  and	  off-­‐label	  
treatments	   as	   high	   in	   pediatrics,	   the	   risks	   characteristic	   to	   medical	   experimentation	   are	  
never	   far	  away.	  While	  clinical	   trials	  are	  conducted	   in	  controlled	  conditions,	  off-­‐license	  and	  
off-­‐label	   treatments	   entail	   medical	   experimentation	   in	   an	   uncontrolled	   fashion.	   Thus,	   in	  
many	  instances,	  it	  might	  be	  advantageous	  to	  be	  in	  a	  trial	  compared	  to	  off-­‐label	  treatments,	  
at	   least	   for	  what	   is	   concerned	   the	   risks.	  Second,	  due	   to	   the	  contingent	  nature	  of	  benefits,	  
predictions	  about	  expected	  (direct)	  benefits	  come	  at	  risk	  of	  being	  highly	  speculative.	  	  
In	  our	  observations	  of	  consent	  discussions,	  we	  found	  no	  discussion	  of	  risk-­‐benefit	  ratios.	  
In	   fact,	   hardly	   any	   explicit	   attention	   was	   paid	   to	   the	   (direct)	   benefits	   of	   research	  
participation.	  Therefore,	  the	  risk	  to	  harm	  when	  not	  participating	  in	  the	  trial	  (i.e.	  the	  risks	  of	  
the	  standard	  of	  care,	  of	  off-­‐label	  or	  off-­‐license	  treatment,	  or	  of	  non-­‐treatment)	  may	  provide	  
a	  better	  basis	  to	  assess	  the	  acceptability	  of	  the	  risks	  to	  harm	  that	  a	  trial	  entails.	  
Harmonization	  versus	  Diversification	  
Given	  the	  generally	  recognized	  priority	  to	  catch	  up	  with	  the	  development	  of	  drugs	  for	  use	  
in	   the	  pediatric	   population,	   one	  would	   logically	   expect	   that	   the	   recently	   issued	   regulation	  
rather	   simplifies	   the	   conduct	   of	   clinical	   research	   in	   minors	   than	   complicates	   it.	  
Unfortunately,	  the	  reverse	  may	  be	  the	  case.	  While	  in	  the	  EU	  	  drugs	  are	  being	  licensed	  for	  the	  
bulk	  of	  the	  27	  member	  states	  in	  one	  single	  marketing	  authorization	  procedure,	  the	  process	  
leading	  to	  marketing	  authorization	   is	  much	  more	  diversified.	  The	  main	  cause	  of	   regulatory	  
diversity	  is	  the	  coexistence	  of	  several	  regulatory	  frameworks,	  both	  at	  the	  supranational	  level	  
and	  the	  level	  of	  individual	  EU	  Member	  states.37	  38	  Due	  to	  this	  regulatory	  diversity,	  a	  number	  
of	  contradictory	  provisions	  exist	  at	   the	  supranational	   level,	  and	  a	  considerable	  diversity	  of	  
legal	   requirements	  must	   be	   complied	  with	   at	   the	  national	   level,	   dependent	  on	  where	   the	  
research	  takes	  place.	  Obviously,	   it	  would	  be	  of	  clear	   interest	  to	  sponsors,	  researchers,	  and	  
probably	  also	  research	  subjects	  and	  their	  parents	  if	  this	  diversity	  were	  reduced	  to	  the	  extent	  
possible.	   Such	   reduction,	   however,	   should	   not	   work	   against	   the	   particular	   identity	   of	  
individual	   member	   states.	   Nonetheless,	   it	   is	   questionable	   to	   what	   extent	   the	   current	  
diversity	   of	   legal	   provisions	   actually	   serves	   the	   specific	   identity	   and	   needs	   of	   individual	  
member	   states.	   Therefore,	   in	  my	   opinion,	   there	   is	   still	   a	   substantial	   potential	   for	   further	  
harmonization.	  	  
In	  addition,	  the	  harmonization	  process	  should	  not	  be	  limited	  to	  harmonization	  of	  relevant	  
legal	   provisions,	   but	   also	   cover	   the	   operational	   implementation	   of	   legal	   requirements.	  
Particularly	  the	  work	  of	  ethics	  committees	  is	  open	  to	  further	  streamlining	  in	  this	  respect.39	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The	  way	  forward	  
The	   seven	   ethical	   tensions	   that	   have	   been	   discussed	   in	   this	   general	   conclusion	   all	  
challenge	   the	   current	   reflection	   on	   the	   ethical,	   legal,	   and	   social	   issues	   in	   pediatric	   clinical	  
research.	   In	   addition,	   this	  discussion	   confronts	   clinical	   practice,	  medical	   ethics,	   and	  health	  
law	  with	  many	  important	  and	  yet	  unanswered	  questions.	  	  
In	  the	  integrative	  approach	  of	  ethical,	   legal,	  and	  social	   issues	  that	  has	  been	  proposed	  in	  
this	  dissertation	   it	   is	  neither	   the	   intention,	  nor	   the	  objective	   to	  address	   such	  questions	  by	  
resolving	  them,	  for	  example	  by	  proposing	  clear-­‐cut,	  ready	  to	  implement	  recommendations.	  
Rather,	   this	   integrative	   approach	   suggests	   that	   adequate	   contextual	   analysis,	   normative	  
qualification,	  and	  practical	  guidance	  will	  enable	  all	  parties	  involved	  to	  make	  better	  and	  more	  
ethical	  decisions.	  In	  this	  way,	  medical	  ethicists	  or	  legislators	  do	  not	  pinch	  the	  pith	  of	  ethical	  
decision-­‐making,	   but	   leave	   it	   to	   those	   who	   are	   actually	   charged	   with	   these	   decisions	   in	  
practice.	   At	   the	   same	   time,	   the	   integrative	   approach	   enables	   ethical	   reflection	   and	   legal	  
analysis	  to	  make	  legitimate	  use	  of	  large	  scopes	  of	  data,	  methodologies,	  and	  ethical	  theories,	  
regardless	   their	   problem-­‐solving	   capacities	  with	   regard	   to	   specific	   cases.	   For	   sure,	   limiting	  
ethical	   and	   legal	   reflection	   to	   problem	   solving	   would	   be	   a	   very	   reductionist	   approach	   to	  
medical	  ethics	  and	  health	  law.	  	  
The	  discussion	  of	  seven	  ethical	  tensions	  in	  this	  general	  conclusion	  is	  thus	  not	  an	  endpoint	  
of	  ethical	  and	  legal	  analysis,	  and	  the	  results	  of	  ethical	  and	  legal	  analysis	  are	  not	  function	  as	  
an	  ethical	  oracle.	  Rather,	   they	  are	  a	   catalyst	   for	  ethical	  decision	  making,	   supporting	   those	  
who	  are	  charged	  with	   the	  core	  decisions	   in	  pediatric	   clinical	   research	  conduct.	  To	  support	  
ethical	  decision	  making,	  however,	  continuous	  enquiry	  of	  the	  ethical,	  legal,	  and	  social	  issues	  
in	  pediatric	  research	  conduct	  will	  remain	  necessary,	  to	  adequately	  respond	  to	  new	  scientific	  
evolutions	  and	  changing	  social	  contexts.	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Although	   Harry	   Shirkey	   reported	   already	   in	   1968	   that	   in	   absence	   of	   pediatric	   clinical	  
research	  minors	  would	  be	   turned	   into	   ‘therapeutic	  orphans’,	   pediatric	  patients	  have	  been	  
ignored	   in	   clinical	   research	   for	   long,	   and	   systematic	   efforts	   to	   encourage	   the	   inclusion	   of	  
minors	   in	   clinical	   studies	   only	   came	   decades	   later.	   Today,	   the	   urgent	   need	   for	   pediatric	  
clinical	   research	   in	   the	   population	   of	  minors	   continues	   to	   exist,	   even	   though	   it	   has	   been	  
generally	  recognized	  that	  pediatric	  clinical	  trials	  are	  indispensible	  to	  provide	  minors	  with	  an	  
equitable	  gamut	  of	  safe	  and	  efficacious	  drugs	  as	  their	  adult	  counterparts.	  	  
Because	  of	  the	  important	  differences	  between	  adults	  and	  minors	  –both	  as	  persons	  and	  as	  
populations-­‐	  paradigms	  of	  clinical	  research,	  research	  ethics	  and	  research	  regulation	  that	  are	  
grafted	   on	   the	   competent	   adult	   do	   not	   adequately	   respond	   to	   the	   specifics	   of	   pediatric	  
clinical	  research.	  Therefore,	  specific	  attention	  must	  be	  paid	  to	  the	  ethical,	   legal,	  and	  social	  
issues	  in	  pediatric	  clinical	  research.	  In	  other	  words:	  One	  size	  does	  not	  fit	  all.	  
Objectives	  	  
Four	   research	   objectives	   are	   central	   to	   this	   dissertation:	   the	   (1)	   enhancement	   of	   the	  
access	   to	   and	   insight	   in	   the	   European	   legal	   frameworks	   that	   govern	   pediatric	   clinical	  
research;	   (2)	   comparative	   analysis	   of	   relevant	   regulation	   at	   the	   supranational	   level	   and	  at	  
the	   national	   level;	   (3)	   enquiry	   of	   the	   operational	   implementation	   of	   ethical	   and	   legal	  
requirements	  in	  informed	  consent	  discussion	  in	  clinical	  research;	  and	  (4)	  ethical	  analysis	  of	  
specific	  issues	  in	  pediatric	  clinical	  research.	  	  
Research	  results	  
In	   chapter	   1,	   the	   European	   legal	   framework	   (supranational	   level)	   governing	   pediatric	  
clinical	   trials	   is	   analyzed	   from	   the	   perspective	   of	   the	   major	   ethical	   concerns	   in	   pediatric	  
research.	  The	  four	  principles	  of	  biomedical	  ethics	  are	  used	  as	  a	  conceptual	  framework	  (1)	  to	  
map	  the	  ethical	   issues	  addressed	   in	  the	  European	  legal	  framework,	  (2)	  to	  study	  how	  these	  
issues	   are	   commonly	   handled	   in	   competent	   adults,	   (3)	   to	   detect	   workability	   problems	   of	  
these	   paradigmatic	   approaches	   in	   the	   specific	   setting	   of	   pediatric	   research,	   and	   (4)	   to	  
illustrate	  the	  strong	  urge	  to	  differentiate,	  specify,	  or	  adjust	  these	  paradigmatic	  approaches	  
to	   guarantee	   their	   successful	   operation	   in	   pediatric	   research.	   In	   addition,	   a	   concise	  
comparative	   analysis	   of	   the	   European	   regulation	   is	   made.	   To	   conclude	   the	   analysis,	   our	  
findings	   are	   discussed	   against	   the	   background	   of	   existing	   ethical	   discussions	   on	   issues	  
specific	  to	  pediatric	  clinical	  research.	  
In	   chapter	   2,	   the	   regulation	   of	   pediatric	   clinical	   research	   at	   the	   level	   of	   individual	   EU	  
member	   states	   is	   mapped	   and	   analyzed.	   The	   analysis	   focuses	   on	   the	   way	   in	   which	   the	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national	  and	  supranational	   legal	   frameworks	  address	   five	  ethical	   issues	  that	  are	  specific	   to	  
pediatric	   clinical	   research:	   (a)	   informed	   consent,	   (b)	   the	   necessity	   to	   conduct	   research	   in	  
minor	  subjects,	  (c)	  the	  interests	  of	  the	  subject	  concerned,	  (d)	  the	  risks	  and	  burdens	  involved,	  
and	  (e)	  the	  pediatric	  expertise	  of	  protocol	  review	  committees.	  The	  chapter	  is	  concluded	  by	  a	  
discussion	   of	   the	   harmonization	   and	   diversification	   of	   the	   legal	   requirements	   that	   govern	  
pediatric	  clinical	  research	  in	  the	  EU.	  
Chapter	   3	   provides	   an	   overview	   of	   the	   requirements	   for	   involving	   minors	   in	   medical	  
experiments	  in	  Belgium.	  In	  this	  chapter,	  the	  Law	  of	  7	  May	  2004	  concerning	  experiments	  on	  
the	  human	  person	  (LEH)	  is	  analyzed,	  and	  dissimilarities	  between	  the	  LEH	  and	  the	  European	  
Directive	  are	  discussed.	  
In	   chapter	   4,	   it	   is	   analyzed	  how	   the	  enrollment	  of	  minors	   in	   clinical	   trials	   is	   negotiated	  
within	   relationships	   of	  mutual	   trust	   between	   clinicians,	  minors,	   and	   their	   parents.	   After	   a	  
brief	  description	  of	   the	  problems	  associated	  with	   involving	  minors	   in	  clinical	   research,	   it	   is	  
considered	  how	  existing	  ‘‘relationships	  of	  trust’’	  can	  be	  used	  as	  a	  place	  where	  the	  concerns	  
of	   research	   subjects	   can	   be	   more	   fully	   discussed	   and	   addressed.	   Building	   on	   the	   tacit	  
recognition	  of	  trust	  found	  in	  The	  European	  Clinical	  Trials	  Directive,	  policy	  recommendations	  
for	   clearer,	  more	  ethically	   informed	  guidelines	   for	  enrolling	  minors	   in	   clinical	   research	  are	  
made.	  
Chapter	   5	   explores	   seven	   bottlenecks	   in	   the	   ethical	   guidance	   and	   legal	   regulation	   that	  
currently	  govern	  pediatric	  clinical	  research:	  (1)	  the	  integration	  of	  research	  in	  therapy,	  (2)	  the	  
education	  of	  clinicians,	  (3)	  the	  empowerment	  of	  families,	  (4)	  the	  harmonization	  of	  protocol	  
review,	  (5)	  the	  assessment	  of	  non-­‐clinical	  research	  objectives,	  (6)	  the	  control	  of	  placebo	  use,	  
and	  (7)	  the	  provision	  of	  fair	  incentives	  for	  pediatric	  research	  conduct.	  For	  all	  of	  these	  issues,	  
a	  clear	  view	  on	  the	  way	  forward	  is	  largely	  lacking,	  either	  because	  these	  issues	  have	  not	  been	  
discussed	   in	   depth	   to	   date,	   or	   because	   the	   existing	   debates	   have	   failed	   to	   generate	   a	  
generally	  supported	  consensus.	  
	  In	   chapter	   6,	   the	   ethical	   concerns	   in	   two	   potential	   tracks	   of	   seeking	   access	   to	  
investigational	  medicinal	  products	  for	  minors	  are	  explored:	  access	  on	  an	  individual	  basis,	  or	  
collective	   access	   via	   patient	   organizations.	   In	   the	   discourse,	   several	   unique	   ethical	   and	  
regulatory	  concerns	  related	  to	  the	  direct	  negotiation	  of	  access	  to	  IMP	  for	  minor	  patients	  are	  
identified,	   focusing	  on	  product	  safety,	   the	   recruitment	  of	   research	  subjects,	   the	  unnoticed	  
entry	  of	  market	  mechanisms	   in	   the	   recruitment	  of	   research	  subjects,	  and	   the	  sidelining	  of	  
third	  parties	  in	  the	  recruitment	  process.	  	  
Chapter	   7	   focuses	   on	   the	  pursuit	   of	   non-­‐clinical	   research	  objectives	   in	   pediatric	   clinical	  
research.	  While	   over	   the	   past	   decades	   important	   efforts	   have	   been	  made	   to	   regulate	   the	  
involvement	   of	   children	   in	   clinical	   trials,	   current	   ethical	   and	   legal	   procedures	   surrounding	  
clinical	  trials	  in	  minors	  (US/EU)	  are	  not	  designed	  to	  consider	  and	  assess	  the	  non-­‐clinical	  use	  
of	   medical	   technologies	   such	   as	   fMRI.	   Nonetheless,	   non-­‐clinical	   applications	   of	   pediatric	  
fMRI	   cannot	   be	   developed	   without	   conducting	   clinical	   trials	   in	   children.	   In	   this	   chapter,	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diverse	  ethical	  issues	  related	  to	  the	  non-­‐clinical	  applications	  of	  fMRI	  are	  discussed	  from	  the	  
perspective	  of	  pediatric	  clinical	  trial	  regulation.	  	  
In	   chapter	   8,	  major	   ethical	   issues	   in	   the	   development	   and	   supply	   of	   orphan	   drugs	   are	  
discussed.	   This	   chapter	   focuses	   on	   addressing	   the	   commercial	   disinterest	   in	   developing	  
drugs	   for	   rare	   conditions.	   While	   several	   interventions	   have	   been	   made	   in	   the	   regulatory	  
field,	  existing	   regulations	   leave	   the	  overarching	  question	  on	   the	   righteous	  place	  of	  orphan	  
drugs	  in	  resource	  allocation	  systems	  unanswered.	  In	  this	  chapter,	  major	  ethical	  issues	  in	  the	  
development	  and	   supply	  of	   treatments	   for	   rare	   conditions	  are	  analyzed.	   Subsequently,	   an	  
ethical	  framework	  is	  proposed,	  aiming	  at	  helping	  health	  policy	  makers	  in	  moving	  forward	  in	  
the	   difficult	   issue	   of	   justly	   allocating	   resources	   to	   the	   prevention	   and	   treatment	   of	   rare	  
diseases.	  	  
In	  chapter	  9,	  it	  is	  explored	  how	  the	  legal	  framework	  governing	  pediatric	  clinical	  research	  
is	   implemented	   in	   informed	   consent	   discussions.	   In	   this	   chapter,	   the	   results	   of	   an	  
observational	  study	  of	  informed	  consent	  discussions	  are	  discussed.	  	  
Conclusion	  
In	  this	  dissertation,	  the	  ethical,	  legal	  and	  social	  aspects	  of	  clinical	  research	  in	  the	  EU	  have	  
been	  investigated	  from	  a	  multidisciplinary	  perspective.	  In	  the	  first	  four	  chapters,	  the	  access	  
to	  and	   insight	   in	  the	  European	   legal	   frameworks	  that	  govern	  pediatric	  clinical	  research	  has	  
been	   increased,	   by	   mapping	   and	   analyzing	   national	   and	   supranational	   legislation.	   The	  
analysis	  of	  legal	  requirements	  in	  chapters	  1-­‐3	  also	  covers	  a	  comparative	  analysis	  of	  relevant	  
regulation	  at	   the	   supranational	   level	  and	  at	   the	  national	   level.	   Specific	  attention	  has	  been	  
paid	   to	   the	   Belgian	   situation.	   In	   addition,	   the	   regulation	   of	   trust	   in	   the	   European	   legal	  
framework	  surrounding	  pediatric	  clinical	  research	  has	  been	  analyzed,	  as	  an	  illustration	  of	  the	  
tacit	  elements	  that	  are	  essential	  to	  the	  operational	  implementation	  of	  legal	  requirements.	  	  
Chapters	   5-­‐8	   have	   focused	   on	   the	   ethical	   analysis	   of	   specific	   issues	   in	   pediatric	   clinical	  
research,	  including	  (1)	  the	  integration	  of	  research	  in	  therapy,	  (2)	  the	  education	  of	  clinicians,	  
(3)	   the	   empowerment	   of	   families,	   (4)	   the	   harmonization	   of	   protocol	   review,	   (5)	   the	  
assessment	   of	   non-­‐clinical	   research	   objectives,	   (6)	   placebo	   use,	   (7)	   the	   provision	   of	   fair	  
incentives	   for	   pediatric	   research	   conduct,	   (8)	   access	   to	   investigational	  medicinal	   products,	  
and	  (9)	  the	  development	  and	  supply	  of	  orphan	  drugs.	  	  
An	   enquiry	   of	   the	   operational	   implementation	   of	   ethical	   and	   legal	   	   requirements	   in	  
informed	  consent	  discussion	  has	  been	  presented	  in	  chapter	  9.	  	  
To	   conclude	   the	   analysis	   in	   this	   dissertation,	   seven	   controversies	   in	   contemporary	  
pediatric	  clinical	  research	  are	  discussed:	  (1)	  standard	  of	  care	  versus	  state	  of	  the	  art	  disease	  
management,	  (2)	  protection	  versus	  trust,	  (3)	  regulation	  versus	  discretion,	  (4)	  harmonization	  
versus	  heterogeneity,	   (5)	   informed	   consent	   versus	  documented	   consent,	   (6)	   assent	   versus	  





Hoewel	  Harry	  Shirkey	  reeds	  in	  1968	  opmerkte	  dat	  minderjarigen	  bij	  gebrek	  aan	  klinische	  
proeven	   “therapeutische	   wezen”	   zouden	   worden,	   werden	   kinderen	   tot	   voor	   kort	   sterk	  
genegeerd	  in	  het	  klinisch	  onderzoek.	  Systematische	  inspanningen	  om	  klinisch	  onderzoek	  bij	  
minderjarigen	  aan	  te	  moedigen,	  kwamen	  zelfs	  pas	  decennia	  later.	  	  
Vandaag	   de	   dag	   bestaat	   deze	   nood	   aan	   klinisch	   onderzoek	   bij	   minderjarigen	  
onverminderd	   voort,	   ook	   al	   wordt	   de	   nood	   om	   minderjarigen	   in	   klinische	   proeven	   te	  
includeren	  nu	  algemeen	  erkend.	  	  
Omwille	   van	   de	   significante	   verschillen	   tussen	   kinderen	   en	   volwassenen	   (zowel	   op	   het	  
niveau	   van	   het	   individu	   als	   op	   het	   niveau	   van	   de	   populatie)	   kunnen	   de	   paradigmata	   van	  
wetenschappelijk	   onderzoek,	   medische	   ethiek	   en	   gezondheidsrecht	   die	   gebruikt	   worden	  
voor	  de	   regulering	   van	  klinische	  proeven	  met	   competente	  volwassenen,	  niet	   zonder	  meer	  
voor	   de	   regeling	   van	   klinische	   proeven	   met	   kinderen	   worden	   ingezet.	   Daarom	   moet	  
specifieke	   aandacht	   besteed	   worden	   aan	   de	   ethische,	   juridische	   en	   sociale	   aspecten	   van	  
klinische	  proeven	  met	  minderjarige	  proefpersonen.	  Met	  andere	  woorden:	  “one	  size	  doesn’t	  
fit	  all”.	  	  
Doelstellingen	  	  
Centraal	   in	  deze	  dissertatie	  staan	  de	  volgende	  vier	  doelstellingen:	  (1)	  de	  toegang	  tot	  de	  
regelgeving	  die	  klinische	  proeven	  met	  kinderen	   in	  Europa	  regelt	  verbeteren,	  en	  het	   inzicht	  
erin	   vergroten;	   (2)	   een	   rechtsvergelijkende	   analyse	   van	   supranationale	   (Europese)	   en	  
nationale	   regelgeving	   die	   van	   toepassing	   is	   op	   klinisch	   onderzoek	   met	   minderjarigen	  
opstellen	   ;	   (3)	   de	   implementering	   van	  wettelijke	   vereisten	   inzake	   goede	   klinische	   praktijk	  
onderzoeken;	  en	  (4)	  specifieke	  ethische	  kwesties	  met	  betrekking	  tot	  klinisch	  onderzoek	  met	  
minderjarige	  proefpersonen	  analyseren.	  	  
Resultaten	  	  
In	   het	   eerste	   hoofdstuk	  wordt	   het	   Europese	   regelgevende	   kader	   dat	   klinische	   proeven	  
met	   minderjarigen	   regelt	   kritisch	   beschouwd	   tegen	   de	   achtergrond	   van	   vier	   centrale	  
ethische	   bekommernissen.	   De	   vier	   principes	   van	   biomedische	   ethiek	   worden	   in	   dit	  
hoofdstuk	  gebruikt	  als	  conceptueel	  kader	  om	  (1)	  ethische	  kwesties	  in	  het	  regelgevend	  kader	  
in	  kaart	  te	  brengen,	  (2)	  te	  bestuderen	  hoe	  deze	  kwesties	  worden	  aangepakt	  in	  de	  sturing	  van	  
klinische	  proeven	  met	  competente	  volwassenen,	  (3)	  de	  problemen	  die	  deze	  paradigmatische	  
aanpak	  vertoont	  in	  de	  specifieke	  context	  van	  onderzoek	  met	  kinderen	  te	  detecteren	  en	  (4)	  
de	  drang	  om	  bestaande	  paradigmata	  toch	  te	  doen	  functioneren	  voor	  klinisch	  onderzoek	  bij	  
kinderen	  (bv.	  door	  differentiatie,	  specificatie,	  of	  aanpassing)	  te	  illustreren.	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In	  hoofdstuk	   twee	  wordt	  de	   regelgeving	  waaraan	  klinische	  proeven	  bij	  minderjarigen	   in	  
de	  verschillende	  Europese	  lidstaten	  moet	  voldoen	  in	  kaart	  gebracht	  en	  geanalyseerd.	  In	  dit	  
hoofdstuk	  wordt	  de	  regeling	  van	  vijf	  ethische	  kwesties	  die	  specifiek	  zijn	  voor	  onderzoek	  met	  
minderjarigen	   onderzocht:	   (1)	   geïnformeerde	   toestemming,	   (2)	   de	   noodzaak	   om	   het	  
onderzoek	  te	  verrichten	  bij	  minderjarigen,	  (3)	  de	  belangen	  van	  de	  betrokken	  minderjarigen,	  
(4)	  de	  risico’s	  en	  belastingen	  die	  eigen	  zijn	  aan	  het	  onderzoek,	  en	  (5)	  de	  specifieke	  expertise	  
van	  ethische	  commissies	  inzake	  het	  betrekken	  van	  minderjarigen	  in	  klinisch	  onderzoek.	  Het	  
hoofdstuk	  eindigt	  met	  een	  kritische	  beschouwing	  van	  de	  harmonisering	  en	  diversificatie	  van	  
wettelijke	  vereisten	  die	  binnen	  de	  EU	  gelden.	  	  
In	   het	   derde	   hoofdstuk	   worden	   de	   wettelijke	   vereisten	   voor	   klinisch	   onderzoek	   met	  
minderjarigen	   in	   België	   in	   kaart	   gebracht.	   In	   dit	   hoofdstuk	  wordt	   de	  wet	   van	   7	  mei	   2004	  
inzake	  experimenten	  op	  de	  menselijke	  persoon	  besproken,	  met	  bijzondere	  aandacht	  voor	  de	  
punten	  van	  verschil	   tussen	  deze	  wet	  en	  de	  Europese	  Richtlijn	  met	  betrekking	   tot	  klinische	  
proeven.	  	  
In	   het	   vierde	   hoofdstuk	   wordt	   onderzocht	   hoe	   de	   deelname	   van	   minderjarigen	   aan	  
klinische	   proeven	   wordt	   besproken	   binnen	   de	   vertrouwensrelaties	   tussen	   artsen,	  
minderjarigen	   en	   hun	   ouders.	   In	   dit	   hoofdstuk	   wordt	   bekeken	   hoe	   bestaande	  
vertrouwensrelaties	   aangewend	   kunnen	   worden	   om	   de	   specifieke	   belangen	   van	  
minderjarige	  proefpersonen	  te	  bespreken	  en	  behartigen.	  Vertrekkende	  vanuit	  de	  impliciete	  
erkenning	  van	  het	  belang	  van	  de	  vertrouwensrelatie	  in	  de	  Europese	  wetgeving	  die	  klinische	  
proeven	   met	   minderjarigen	   regelt,	   worden	   aanbevelingen	   voor	   de	   rekrutering	   van	  
minderjarigen	  voor	  klinisch	  onderzoek	  geformuleerd.	  	  
In	  hoofdstuk	  vijf	  worden	  zeven	  actuele	  knelpunten	  in	  het	  hedendaagse	  klinisch	  onderzoek	  
met	  minderjarigen	  besproken:	  (1)	  de	  integratie	  van	  onderzoek	  in	  de	  therapeutische	  praktijk,	  
(2)	  de	  ethische	  vorming	  van	  clinici,	  (3)	  de	  emancipatie	  van	  families,	  (4)	  het	  stroomlijnen	  van	  
de	   ethische	   evaluatie	   van	   onderzoeksprotocols,	   (5)	   de	   evaluatie	   van	   niet-­‐klinische	  
onderzoeksdoelstellingen,	   (6)	   gecontroleerd	   placebo	   gebruik	   en	   (7)	   het	   voorzien	   van	  
rechtvaardige	   financiële	   stimuli.	   De	   ethische	   reflectie	   inzake	   deze	   zeven	   kwesties	   is	   van	  
bijzonder	  belang,	  omdat	  er	  geen	  consensus	  bestaat	  over	  hoe	  ze	  aangepakt	  moeten	  worden,	  
of	  omdat	  ze	  tot	  op	  heden	  onvoldoende	  onderzocht	  werden.	  	  
In	   het	   zesde	   hoofdstuk	   worden	   de	   ethische	   kwesties	   met	   betrekking	   tot	   de	  
toegankelijkheid	   van	   experimentele	   geneesmiddelen	   onderzocht,	   zowel	   in	   het	   geval	   dat	  
individuen	   experimentele	   geneesmiddelen	   proberen	   te	   bekomen,	   als	   in	   het	   geval	   dat	  
patiëntenverenigingen	   voor	   het	   collectief	   van	   hun	   leden	   toegang	   tot	   experimentele	  
geneesmiddelen	   zouden	   zoeken.	   Hierbij	   worden	   specifieke	   ethische	   en	   regelgevende	  
kwesties	   in	   kaart	   gebracht,	   met	   bijzondere	   aandacht	   voor	   (1)	   productveiligheid,	   (2)	   de	  
rekrutering	  van	  proefpersonen,	  (3)	  de	  vermarkting	  van	  deelname	  aan	  klinisch	  onderzoek,	  en	  
(4)	  het	  uitsluiten	  van	  externe	  partijen	  in	  het	  rekruteringsproces.	  	  
In	   het	   zevende	   hoofdstuk	   wordt	   de	   problematiek	   van	   niet-­‐klinische	  
onderzoeksdoelstellingen	   beschouwd.	   Ondanks	   het	   feit	   dat	   de	   voorbije	   decennia	   werd	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geïnvesteerd	   in	   de	   regeling	   van	   klinisch	   onderzoek	   met	   kinderen,	   ontsnappen	   bepaalde	  
types	   van	   onderzoek	   –zoals	   klinisch	   onderzoek	   met	   niet-­‐klinische	   doelstellingen-­‐	   aan	  
daadwerkelijke	  ethische	  evaluatie	  van	  de	  inherente	  risico’s	  voor	  het	  kind	  en	  de	  samenleving.	  
In	   dit	   hoofdstuk	   worden	   daarom	   verscheidene	   ethische	   kwesties	   met	   betrekking	   tot	  
klinische	  proeven	  met	  niet-­‐klinische	  doelstellingen	  in	  kaart	  gebracht	  en	  geanalyseerd.	  	  
In	  het	  achtste	  hoofdstuk	  worden	  de	  ethische	  kwesties	  in	  de	  ontwikkeling	  en	  verstrekking	  
van	  medicijnen	  voor	   zeldzame	   ziektes	  geanalyseerd.	   In	  dit	  hoofdstuk	  wordt	  nagegaan	  hoe	  
kan	  worden	  omgegaan	  met	  het	   gebrek	   aan	   commerciële	   interesse	   in	   de	  ontwikkeling	   van	  
medicijnen	   voor	   zeldzame	   ziekten,	   vanuit	   de	   vraag	   naar	   de	   rechtmatige	   plaats	   van	  
weesgeneesmiddelen	  in	  de	  publieke	  gezondheidszorg.	  	  
In	   het	   negende	   hoofdstuk	   wordt	   in	   kaart	   gebracht	   hoe	   de	   geldende	   regelgeving	   met	  
betrekking	  tot	  goede	  klinische	  praktijk	  wordt	  geïmplementeerd	  in	  oudergesprekken	  waarin	  
de	  deelname	  van	  minderjarigen	  aan	  klinische	  proeven	  wordt	  besproken.	  	  
Besluit	  
In	   deze	   dissertatie	   werden	   de	   ethische,	   juridische	   en	   sociale	   kwesties	   in	   klinisch	  
onderzoek	  met	  minderjarigen	   in	  de	  Europese	  Unie	  onderzocht	   vanuit	   een	  multidisciplinair	  
perspectief.	  De	  eerste	  vier	  hoofdstukken	  creëerden	  toegang	  tot	  en	   inzicht	   in	  de	  bestaande	  
regelgeving,	   door	   de	   geldende	   wetten	   in	   kaart	   te	   brengen	   en	   te	   analyseren.	   Daarnaast	  
omvatten	   hoofdstuk	   1-­‐3	   ook	   een	   rechtsvergelijkende	   analyse.	   Bijzondere	   aandacht	   werd	  
besteed	  aan	  de	  Belgische	  regelgeving.	  Tot	  slot	  werd	  ook	  het	  belang	  van	  vertrouwensrelaties	  
voor	  de	  succesvolle	  implementering	  van	  wettelijke	  vereisten	  geanalyseerd.	  	  
In	   het	   vijfde	   tot	   en	  met	   achtste	   hoofdstuk	   werden	   specifieke	   ethische	   kwesties	   in	   het	  
klinisch	  onderzoek	  met	  minderjarige	  proefpersonen	  belicht,	  waaronder	  (1)	  de	  integratie	  van	  
onderzoek	   in	   de	   therapeutische	   praktijk,	   (2)	   de	   ethische	   vorming	   van	   clinici,	   (3)	   de	  
emancipatie	   van	   families,	   (4)	   het	   stroomlijnen	   van	   de	   ethische	   evaluatie	   van	  
onderzoeksprotocols,	   (5)	   de	   evaluatie	   van	   niet-­‐klinische	   onderzoeksdoelstellingen,	   (6)	  
gecontroleerd	  placebo	  gebruik,	  (7)	  het	  voorzien	  van	  rechtvaardige	  financiële	  stimuli,	  (8)	  de	  
toegankelijkheid	   van	   experimentele	   geneesmiddelen,	   en	   (9)	   de	   omgang	   met	  
weesgeneesmiddelen	  voor	  zeldzame	  ziekten.	  
In	  het	  negende	  hoofdstuk	  werden	  de	  resultaten	  van	  ons	  observationeel	  onderzoek	  naar	  
de	   implementering	   van	   wettelijke	   vereisten	   tijdens	   oudergesprekken	   betreffende	   de	  
deelname	  van	  een	  minderjarige	  proefpersoon	  aan	  een	  klinische	  proef	  voorgesteld.	  	  
Tot	   slot	  werden	  zeven	  ethische	  spanningen	   in	  het	  hedendaagse	  klinisch	  onderzoek	  met	  
minderjarigen	  belicht:	  (1)	  standaardtherapie	  versus	  vernieuwende	  aanpak,	  (2)	  bescherming	  
versus	  vertrouwen,	  (3)	  regelgeving	  versus	  oordeelkunde,	  (4)	  harmonisatie	  versus	  diversiteit,	  
(5)	  geïnformeerde	  toestemming	  versus	  gedocumenteerde	  toestemming,	   (6)	  geïnformeerde	  
instemming	   versus	   medewerking	   en	   (7)	   therapeutisch	   voordeel	   versus	   kwaliteitsvolle	  
resultaten.	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